{"PMC3884606": [["IntroductionSarcoidosis is a multisystem, granulomatous disease whose aetiology is obscure and controversial.", [["IntroductionSarcoidosis", "DISEASE", 0, 23], ["granulomatous disease", "DISEASE", 42, 63], ["IntroductionSarcoidosis", "PROBLEM", 0, 23], ["a multisystem, granulomatous disease", "PROBLEM", 27, 63], ["multisystem", "OBSERVATION_MODIFIER", 29, 40], ["granulomatous", "OBSERVATION", 42, 55]]], ["An estimated one million people in the USA have this disease.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["this disease", "PROBLEM", 48, 60], ["one", "OBSERVATION_MODIFIER", 13, 16], ["million", "OBSERVATION", 17, 24], ["disease", "OBSERVATION", 53, 60]]], ["Based on the current US population of 315 556 000, there will be approximately 38 605 new cases of sarcoidosis this year and just over 1000 (2.6%) will die of the illness.12IntroductionThe fundamental pathological abnormality in the disease is the formation of non-caseating epithelioid granulomas, which usually confine poorly soluble foreign material that simply cannot be removed by a single phagocytic cell.", [["epithelioid granulomas", "ANATOMY", 275, 297], ["phagocytic cell", "ANATOMY", 395, 410], ["sarcoidosis", "DISEASE", 99, 110], ["illness", "DISEASE", 163, 170], ["granulomas", "DISEASE", 287, 297], ["epithelioid granulomas", "PATHOLOGICAL_FORMATION", 275, 297], ["phagocytic cell", "CELL", 395, 410], ["phagocytic cell", "CELL_TYPE", 395, 410], ["the current US population", "TEST", 9, 34], ["sarcoidosis", "PROBLEM", 99, 110], ["the illness", "PROBLEM", 159, 170], ["The fundamental pathological abnormality", "PROBLEM", 185, 225], ["the disease", "PROBLEM", 229, 240], ["non-caseating epithelioid granulomas", "PROBLEM", 261, 297], ["poorly soluble foreign material", "PROBLEM", 321, 352], ["sarcoidosis", "OBSERVATION", 99, 110], ["illness", "OBSERVATION", 163, 170], ["fundamental", "OBSERVATION_MODIFIER", 189, 200], ["pathological", "OBSERVATION_MODIFIER", 201, 213], ["abnormality", "OBSERVATION", 214, 225], ["disease", "OBSERVATION", 233, 240], ["non-caseating", "OBSERVATION_MODIFIER", 261, 274], ["epithelioid granulomas", "OBSERVATION", 275, 297], ["poorly soluble", "OBSERVATION_MODIFIER", 321, 335], ["foreign material", "OBSERVATION", 336, 352], ["phagocytic cell", "OBSERVATION", 395, 410]]], ["The key feature in sarcoidosis is activated CD4 T cells which differentiate into type 1 helper T cells, secreting interleukin 2 and interferon \u03b3, augmenting macrophage tumour necrosis factor-\u03b1 and amplifying the local cellular immune response.34 This granulomatous inflammation interferes with local tissue homeostasis leading to organ impairment.IntroductionSince sarcoidosis primarily involves the lungs, eyes and skin, attention has focused on airborne environmental antigens that might trigger this presumed hypersensitivity response with its T cell-mediated cellular immune response.3 Similar granulomatous responses can be seen from a variety of infectious agents including mycobacteria, parasites (schistosoma) and fungi (coccidiomycosis).", [["CD4 T cells", "ANATOMY", 44, 55], ["type 1 helper T cells", "ANATOMY", 81, 102], ["cellular", "ANATOMY", 218, 226], ["granulomatous", "ANATOMY", 251, 264], ["tissue", "ANATOMY", 300, 306], ["organ", "ANATOMY", 330, 335], ["lungs", "ANATOMY", 400, 405], ["eyes", "ANATOMY", 407, 411], ["skin", "ANATOMY", 416, 420], ["T cell", "ANATOMY", 547, 553], ["cellular", "ANATOMY", 563, 571], ["granulomatous", "ANATOMY", 598, 611], ["sarcoidosis", "DISEASE", 19, 30], ["necrosis", "DISEASE", 175, 183], ["inflammation", "DISEASE", 265, 277], ["organ impairment", "DISEASE", 330, 346], ["sarcoidosis", "DISEASE", 365, 376], ["hypersensitivity", "DISEASE", 512, 528], ["mycobacteria, parasites (schistosoma) and fungi", "DISEASE", 680, 727], ["coccidiomycosis", "DISEASE", 729, 744], ["CD4 T cells", "CELL", 44, 55], ["T cells", "CELL", 95, 102], ["interleukin 2", "GENE_OR_GENE_PRODUCT", 114, 127], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 132, 144], ["macrophage tumour necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 157, 192], ["cellular", "CELL", 218, 226], ["tissue", "TISSUE", 300, 306], ["organ", "ORGAN", 330, 335], ["lungs", "ORGAN", 400, 405], ["eyes", "ORGAN", 407, 411], ["skin", "ORGAN", 416, 420], ["T cell", "CELL", 547, 553], ["cellular", "CELL", 563, 571], ["coccidiomycosis", "CANCER", 729, 744], ["CD4 T cells", "CELL_TYPE", 44, 55], ["type 1 helper T cells", "CELL_TYPE", 81, 102], ["interleukin 2", "PROTEIN", 114, 127], ["interferon \u03b3", "PROTEIN", 132, 144], ["macrophage tumour necrosis factor-\u03b1", "PROTEIN", 157, 192], ["sarcoidosis", "PROBLEM", 19, 30], ["activated CD4 T cells", "PROBLEM", 34, 55], ["secreting interleukin 2", "TREATMENT", 104, 127], ["interferon \u03b3", "TREATMENT", 132, 144], ["augmenting macrophage tumour necrosis factor", "PROBLEM", 146, 190], ["This granulomatous inflammation", "PROBLEM", 246, 277], ["local tissue homeostasis", "PROBLEM", 294, 318], ["organ impairment", "PROBLEM", 330, 346], ["sarcoidosis", "PROBLEM", 365, 376], ["hypersensitivity response", "PROBLEM", 512, 537], ["Similar granulomatous responses", "PROBLEM", 590, 621], ["infectious agents", "TREATMENT", 652, 669], ["mycobacteria", "PROBLEM", 680, 692], ["parasites (schistosoma)", "PROBLEM", 694, 717], ["fungi (coccidiomycosis)", "PROBLEM", 722, 745], ["sarcoidosis", "OBSERVATION", 19, 30], ["macrophage", "OBSERVATION_MODIFIER", 157, 167], ["tumour necrosis", "OBSERVATION", 168, 183], ["cellular immune response", "OBSERVATION", 218, 242], ["granulomatous", "OBSERVATION_MODIFIER", 251, 264], ["inflammation", "OBSERVATION", 265, 277], ["local tissue homeostasis", "OBSERVATION", 294, 318], ["sarcoidosis", "OBSERVATION", 365, 376], ["lungs", "ANATOMY", 400, 405], ["eyes", "ANATOMY", 407, 411], ["skin", "ANATOMY", 416, 420], ["cellular immune response", "OBSERVATION", 563, 587], ["Similar", "OBSERVATION_MODIFIER", 590, 597], ["granulomatous", "OBSERVATION", 598, 611], ["infectious", "OBSERVATION", 652, 662], ["mycobacteria", "OBSERVATION", 680, 692], ["schistosoma", "OBSERVATION_MODIFIER", 705, 716]]], ["Early studies reported associations with non-infective agents including beryllium, zirconium, aluminium, wood-burning stoves, tree pollen, clay soil, talc, insecticides, inorganic particles and moldy environments, but none of these theoretical causes has endured.356 There is also a several-fold increased incidence of sarcoidosis occurring in siblings and parents, as well as a consistent strong association with specific gene products such as class I and class II human leukocyte antigens, which may add to the familial connection.IntroductionAlthough no infectious agent has been cultured directly from sarcoidosis tissues, clinical and immunological characteristics of the disorder provide the strongest support for a microbial aetiology, at least in some patients.5\u20137 To explore a possible infectious cause in patients seen at the Moffitt Cancer Center, we correlated the clinical presentation and long-term follow-up of patients with sarcoidosis with the presence of bacterial DNA in archived, surgically resected mediastinal lymph nodes.", [["sarcoidosis tissues", "ANATOMY", 606, 625], ["mediastinal lymph nodes", "ANATOMY", 1020, 1043], ["beryllium", "CHEMICAL", 72, 81], ["zirconium", "CHEMICAL", 83, 92], ["aluminium", "CHEMICAL", 94, 103], ["talc", "CHEMICAL", 150, 154], ["sarcoidosis", "DISEASE", 319, 330], ["sarcoidosis", "DISEASE", 606, 617], ["Cancer", "DISEASE", 844, 850], ["sarcoidosis", "DISEASE", 940, 951], ["beryllium", "CHEMICAL", 72, 81], ["zirconium", "CHEMICAL", 83, 92], ["aluminium", "CHEMICAL", 94, 103], ["beryllium", "SIMPLE_CHEMICAL", 72, 81], ["zirconium", "SIMPLE_CHEMICAL", 83, 92], ["aluminium", "SIMPLE_CHEMICAL", 94, 103], ["inorganic particles", "SIMPLE_CHEMICAL", 170, 189], ["class II human leukocyte antigens", "GENE_OR_GENE_PRODUCT", 457, 490], ["sarcoidosis tissues", "TISSUE", 606, 625], ["patients", "ORGANISM", 760, 768], ["patients", "ORGANISM", 815, 823], ["patients", "ORGANISM", 926, 934], ["DNA", "CELLULAR_COMPONENT", 983, 986], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 1032, 1043], ["class I and class II human leukocyte antigens", "PROTEIN", 445, 490], ["bacterial DNA", "DNA", 973, 986], ["human", "SPECIES", 466, 471], ["patients", "SPECIES", 760, 768], ["patients", "SPECIES", 815, 823], ["patients", "SPECIES", 926, 934], ["class II human", "SPECIES", 457, 471], ["Early studies", "TEST", 0, 13], ["non-infective agents", "TREATMENT", 41, 61], ["beryllium", "TREATMENT", 72, 81], ["zirconium", "TREATMENT", 83, 92], ["aluminium", "TREATMENT", 94, 103], ["tree pollen", "PROBLEM", 126, 137], ["talc", "TREATMENT", 150, 154], ["sarcoidosis", "PROBLEM", 319, 330], ["class II human leukocyte antigens", "PROBLEM", 457, 490], ["infectious agent", "PROBLEM", 557, 573], ["sarcoidosis tissues", "PROBLEM", 606, 625], ["the disorder", "PROBLEM", 673, 685], ["infectious cause", "PROBLEM", 795, 811], ["sarcoidosis", "PROBLEM", 940, 951], ["bacterial DNA in archived, surgically resected mediastinal lymph nodes", "PROBLEM", 973, 1043], ["burning stoves", "OBSERVATION", 110, 124], ["several", "OBSERVATION_MODIFIER", 283, 290], ["-fold", "OBSERVATION_MODIFIER", 290, 295], ["increased", "OBSERVATION_MODIFIER", 296, 305], ["incidence", "OBSERVATION_MODIFIER", 306, 315], ["sarcoidosis", "OBSERVATION", 319, 330], ["no", "UNCERTAINTY", 554, 556], ["infectious", "OBSERVATION", 557, 567], ["sarcoidosis", "OBSERVATION", 606, 617], ["possible", "UNCERTAINTY", 786, 794], ["infectious", "OBSERVATION_MODIFIER", 795, 805], ["sarcoidosis", "OBSERVATION", 940, 951], ["bacterial DNA", "OBSERVATION", 973, 986], ["surgically", "OBSERVATION_MODIFIER", 1000, 1010], ["resected", "OBSERVATION_MODIFIER", 1011, 1019], ["mediastinal", "ANATOMY", 1020, 1031], ["lymph nodes", "OBSERVATION", 1032, 1043]]], ["Results from sarcoidosis nodes were compared with control lymph nodes resected at the time of lung surgery in node-negative, stage I non-small cell lung cancer patients.Regulatory oversight ::: MethodsTissue and clinical data in this case\u2013control study was obtained after approval by the Moffitt Cancer Center Scientific Review Committee Protocol MCC #16131 and the University of South Florida IRB Protocol #108656.Study design ::: MethodsBy searching the Moffitt Cancer Center surgical pathology database between 1 January 2000 and 1 April 2010, we retrospectively identified 30 randomly chosen patients who were diagnosed with sarcoidosis based on the typical radiographic and clinical presentation, and the histological finding of non-caseating epithelioid granulomata in lymph nodes obtained sterilely only by mediastinoscopy, to avoid possible microorganism contamination by endoscopic biopsies.", [["sarcoidosis nodes", "ANATOMY", 13, 30], ["lymph nodes", "ANATOMY", 58, 69], ["lung", "ANATOMY", 94, 98], ["node", "ANATOMY", 110, 114], ["non-small cell lung cancer", "ANATOMY", 133, 159], ["epithelioid granulomata", "ANATOMY", 748, 771], ["lymph nodes", "ANATOMY", 775, 786], ["sarcoidosis", "DISEASE", 13, 24], ["non-small cell lung cancer", "DISEASE", 133, 159], ["Cancer", "DISEASE", 296, 302], ["Cancer", "DISEASE", 464, 470], ["sarcoidosis", "DISEASE", 629, 640], ["granulomata", "DISEASE", 760, 771], ["sarcoidosis nodes", "MULTI-TISSUE_STRUCTURE", 13, 30], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 58, 69], ["lung", "ORGAN", 94, 98], ["node", "MULTI-TISSUE_STRUCTURE", 110, 114], ["non-small cell lung cancer", "CANCER", 133, 159], ["patients", "ORGANISM", 160, 168], ["Moffitt Cancer", "CANCER", 456, 470], ["patients", "ORGANISM", 596, 604], ["epithelioid granulomata", "CANCER", 748, 771], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 775, 786], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 596, 604], ["sarcoidosis nodes", "PROBLEM", 13, 30], ["control lymph nodes", "PROBLEM", 50, 69], ["lung surgery", "TREATMENT", 94, 106], ["node", "TEST", 110, 114], ["stage I non-small cell lung cancer", "PROBLEM", 125, 159], ["clinical data", "TEST", 212, 225], ["this case\u2013control study", "TEST", 229, 252], ["sarcoidosis", "PROBLEM", 629, 640], ["non-caseating epithelioid granulomata in lymph nodes", "PROBLEM", 734, 786], ["mediastinoscopy", "TEST", 814, 829], ["microorganism contamination", "PROBLEM", 849, 876], ["endoscopic biopsies", "TEST", 880, 899], ["sarcoidosis nodes", "OBSERVATION", 13, 30], ["lymph nodes", "OBSERVATION", 58, 69], ["lung", "ANATOMY", 94, 98], ["surgery", "OBSERVATION", 99, 106], ["node", "OBSERVATION", 110, 114], ["stage I", "OBSERVATION_MODIFIER", 125, 132], ["non-small cell", "OBSERVATION", 133, 147], ["lung", "ANATOMY", 148, 152], ["cancer", "OBSERVATION", 153, 159], ["sarcoidosis", "OBSERVATION", 629, 640], ["non-caseating", "OBSERVATION_MODIFIER", 734, 747], ["epithelioid granulomata", "OBSERVATION", 748, 771], ["lymph nodes", "OBSERVATION", 775, 786]]], ["Special stains for microorganisms were negative on the specimens.", [["specimens", "ANATOMY", 55, 64], ["Special stains", "TEST", 0, 14], ["microorganisms", "PROBLEM", 19, 33], ["the specimens", "TEST", 51, 64]]], ["For inclusion in this group, the following criteria were used to make the diagnosis of sarcoidosis: (1) chest radiograph and chest CT findings of symmetrical mediastinal and hilar adenopathy with or without reticulonodular infiltrates in the lung fields (see figure 1); (2) positron emission tomography (PET) scans demonstrated glucose avidity in the enlarged lymph nodes (see figure 2); (3) asymptomatic presentation or typical symptoms of dyspnoea, cough, chest tightness/pain, night sweats, fevers, fatigue, malaise, skin rash or weight loss; (4) lymph nodes showing histological features of confluent, non-caseating granulomata and (5) any known microorganism causes of granulomata were excluded by history or culture.", [["chest", "ANATOMY", 104, 109], ["mediastinal", "ANATOMY", 158, 169], ["hilar adenopathy", "ANATOMY", 174, 190], ["reticulonodular infiltrates", "ANATOMY", 207, 234], ["lung", "ANATOMY", 242, 246], ["lymph nodes", "ANATOMY", 360, 371], ["chest", "ANATOMY", 458, 463], ["skin", "ANATOMY", 520, 524], ["lymph nodes", "ANATOMY", 550, 561], ["granulomata", "ANATOMY", 620, 631], ["granulomata", "ANATOMY", 674, 685], ["sarcoidosis", "DISEASE", 87, 98], ["adenopathy", "DISEASE", 180, 190], ["glucose", "CHEMICAL", 328, 335], ["dyspnoea", "DISEASE", 441, 449], ["cough", "DISEASE", 451, 456], ["chest tightness", "DISEASE", 458, 473], ["pain", "DISEASE", 474, 478], ["night sweats", "DISEASE", 480, 492], ["fevers", "DISEASE", 494, 500], ["fatigue", "DISEASE", 502, 509], ["skin rash", "DISEASE", 520, 529], ["weight loss", "DISEASE", 533, 544], ["granulomata", "DISEASE", 620, 631], ["granulomata", "DISEASE", 674, 685], ["glucose", "CHEMICAL", 328, 335], ["chest", "ORGAN", 104, 109], ["hilar adenopathy", "CANCER", 174, 190], ["lung", "ORGAN", 242, 246], ["glucose", "SIMPLE_CHEMICAL", 328, 335], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 360, 371], ["chest", "ORGANISM_SUBDIVISION", 458, 463], ["skin", "ORGAN", 520, 524], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 550, 561], ["granulomata", "PATHOLOGICAL_FORMATION", 620, 631], ["granulomata", "PATHOLOGICAL_FORMATION", 674, 685], ["sarcoidosis", "PROBLEM", 87, 98], ["chest radiograph", "TEST", 104, 120], ["chest CT", "TEST", 125, 133], ["symmetrical mediastinal and hilar adenopathy", "PROBLEM", 146, 190], ["reticulonodular infiltrates in the lung fields", "PROBLEM", 207, 253], ["positron emission tomography", "TEST", 274, 302], ["PET) scans", "TEST", 304, 314], ["glucose avidity", "PROBLEM", 328, 343], ["the enlarged lymph nodes", "PROBLEM", 347, 371], ["asymptomatic presentation", "PROBLEM", 392, 417], ["typical symptoms", "PROBLEM", 421, 437], ["dyspnoea", "PROBLEM", 441, 449], ["cough", "PROBLEM", 451, 456], ["chest tightness", "PROBLEM", 458, 473], ["pain", "PROBLEM", 474, 478], ["night sweats", "PROBLEM", 480, 492], ["fevers", "PROBLEM", 494, 500], ["fatigue", "PROBLEM", 502, 509], ["malaise", "PROBLEM", 511, 518], ["skin rash", "PROBLEM", 520, 529], ["weight loss", "PROBLEM", 533, 544], ["(4) lymph nodes", "PROBLEM", 546, 561], ["confluent, non-caseating granulomata", "PROBLEM", 595, 631], ["any known microorganism", "PROBLEM", 640, 663], ["granulomata", "PROBLEM", 674, 685], ["culture", "TEST", 714, 721], ["sarcoidosis", "OBSERVATION", 87, 98], ["chest", "ANATOMY", 104, 109], ["chest", "ANATOMY", 125, 130], ["symmetrical", "OBSERVATION_MODIFIER", 146, 157], ["mediastinal", "ANATOMY", 158, 169], ["hilar", "ANATOMY", 174, 179], ["adenopathy", "OBSERVATION", 180, 190], ["without", "UNCERTAINTY", 199, 206], ["reticulonodular", "OBSERVATION_MODIFIER", 207, 222], ["infiltrates", "OBSERVATION", 223, 234], ["lung", "ANATOMY", 242, 246], ["fields", "ANATOMY_MODIFIER", 247, 253], ["glucose avidity", "OBSERVATION", 328, 343], ["enlarged", "OBSERVATION_MODIFIER", 351, 359], ["lymph nodes", "OBSERVATION", 360, 371], ["chest", "ANATOMY", 458, 463], ["skin", "ANATOMY", 520, 524], ["rash", "OBSERVATION", 525, 529], ["lymph nodes", "OBSERVATION", 550, 561], ["confluent", "OBSERVATION_MODIFIER", 595, 604], ["non-caseating", "OBSERVATION_MODIFIER", 606, 619], ["granulomata", "OBSERVATION", 620, 631], ["microorganism", "OBSERVATION", 650, 663], ["granulomata", "OBSERVATION", 674, 685]]], ["All histopathological specimens were reviewed by one of the authors (PS) to reconfirm the diagnosis made originally by departmental pathologists at Moffitt.Study design ::: MethodsTo insure sterile collection, all control specimens were taken from lymph nodes removed at open thoracotomy by one of the authors (LAR) in 30 (1:1 match with cases) randomly chosen patients with stage IA non-small lung cancer.", [["specimens", "ANATOMY", 22, 31], ["specimens", "ANATOMY", 222, 231], ["lymph nodes", "ANATOMY", 248, 259], ["non-small lung cancer", "ANATOMY", 384, 405], ["non-small lung cancer", "DISEASE", 384, 405], ["histopathological specimens", "CANCER", 4, 31], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 248, 259], ["patients", "ORGANISM", 361, 369], ["stage IA non-small lung cancer", "CANCER", 375, 405], ["patients", "SPECIES", 361, 369], ["All histopathological specimens", "TEST", 0, 31], ["Methods", "TREATMENT", 173, 180], ["sterile collection", "TREATMENT", 190, 208], ["all control specimens", "TEST", 210, 231], ["lymph nodes", "TREATMENT", 248, 259], ["open thoracotomy", "TREATMENT", 271, 287], ["stage IA non-small lung cancer", "PROBLEM", 375, 405], ["lymph nodes", "OBSERVATION", 248, 259], ["thoracotomy", "OBSERVATION", 276, 287], ["non-small", "OBSERVATION", 384, 393], ["lung", "ANATOMY", 394, 398], ["cancer", "OBSERVATION", 399, 405]]], ["Lymph nodes were selected only from patients with small peripheral tumours, no obstructive atelectasis and no evidence of active infection.", [["Lymph nodes", "ANATOMY", 0, 11], ["peripheral tumours", "ANATOMY", 56, 74], ["peripheral tumours", "DISEASE", 56, 74], ["atelectasis", "DISEASE", 91, 102], ["infection", "DISEASE", 129, 138], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["patients", "ORGANISM", 36, 44], ["peripheral tumours", "CANCER", 56, 74], ["patients", "SPECIES", 36, 44], ["Lymph nodes", "PROBLEM", 0, 11], ["small peripheral tumours", "PROBLEM", 50, 74], ["obstructive atelectasis", "PROBLEM", 79, 102], ["active infection", "PROBLEM", 122, 138], ["Lymph nodes", "OBSERVATION", 0, 11], ["small", "OBSERVATION_MODIFIER", 50, 55], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["tumours", "OBSERVATION", 67, 74], ["no", "UNCERTAINTY", 76, 78], ["obstructive", "OBSERVATION_MODIFIER", 79, 90], ["atelectasis", "OBSERVATION", 91, 102], ["no evidence of", "UNCERTAINTY", 107, 121], ["active", "OBSERVATION_MODIFIER", 122, 128], ["infection", "OBSERVATION", 129, 138]]], ["One of the authors (PS) reviewed all control lymph node histology to verify whether there were any metastases, acute inflammation or granulomata.Clinical data ::: MethodsThe clinical data on the patient demographics, initial presenting symptoms and objective findings were extracted from the electronic medical record on all patients with sarcoidosis by one of the authors (LAR).", [["lymph node", "ANATOMY", 45, 55], ["metastases", "ANATOMY", 99, 109], ["granulomata", "ANATOMY", 133, 144], ["metastases", "DISEASE", 99, 109], ["inflammation", "DISEASE", 117, 129], ["granulomata", "DISEASE", 133, 144], ["sarcoidosis", "DISEASE", 339, 350], ["lymph node", "MULTI-TISSUE_STRUCTURE", 45, 55], ["granulomata", "PATHOLOGICAL_FORMATION", 133, 144], ["patient", "ORGANISM", 195, 202], ["patients", "ORGANISM", 325, 333], ["patient", "SPECIES", 195, 202], ["patients", "SPECIES", 325, 333], ["all control lymph node histology", "TEST", 33, 65], ["any metastases", "PROBLEM", 95, 109], ["acute inflammation", "PROBLEM", 111, 129], ["granulomata", "PROBLEM", 133, 144], ["Methods", "TREATMENT", 163, 170], ["initial presenting symptoms", "PROBLEM", 217, 244], ["sarcoidosis", "PROBLEM", 339, 350], ["lymph node", "OBSERVATION", 45, 55], ["metastases", "OBSERVATION", 99, 109], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["inflammation", "OBSERVATION", 117, 129], ["granulomata", "OBSERVATION", 133, 144], ["sarcoidosis", "OBSERVATION", 339, 350]]], ["Patients were staged using the modified Scadding radiographic staging system: stage 0 normal chest X-ray; stage 1 hilar and mediastinal adenopathy alone; stage 2 adenopathy and pulmonary infiltrates; stage 3 pulmonary infiltrates alone and stage 4 pulmonary fibrosis.4 Long-term follow-up clinical status and subsequent treatment regimens for all patients with sarcoidosis were obtained from the electronic medical record and telephone calls placed to the patients or their immediate family.DNA extraction ::: MethodsDe-identified, formalin-fixed, paraffin-embedded blocks of lymph nodes from sarcoidosis and control patients were sent to the Departments of Laboratory Medicine and Microbiology at the University of Washington (Seattle, Washington, USA), where investigators were blinded as to the identity of the specimens.", [["hilar", "ANATOMY", 114, 119], ["mediastinal adenopathy", "ANATOMY", 124, 146], ["pulmonary infiltrates", "ANATOMY", 177, 198], ["pulmonary", "ANATOMY", 208, 217], ["pulmonary", "ANATOMY", 248, 257], ["lymph nodes", "ANATOMY", 576, 587], ["specimens", "ANATOMY", 814, 823], ["adenopathy", "DISEASE", 136, 146], ["adenopathy", "DISEASE", 162, 172], ["pulmonary fibrosis", "DISEASE", 248, 266], ["sarcoidosis", "DISEASE", 361, 372], ["sarcoidosis", "DISEASE", 593, 604], ["formalin", "CHEMICAL", 532, 540], ["paraffin", "CHEMICAL", 548, 556], ["Patients", "ORGANISM", 0, 8], ["hilar", "MULTI-TISSUE_STRUCTURE", 114, 119], ["pulmonary", "ORGAN", 248, 257], ["patients", "ORGANISM", 347, 355], ["patients", "ORGANISM", 456, 464], ["DNA", "CELLULAR_COMPONENT", 491, 494], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 576, 587], ["patients", "ORGANISM", 617, 625], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 347, 355], ["patients", "SPECIES", 456, 464], ["patients", "SPECIES", 617, 625], ["stage 1 hilar and mediastinal adenopathy", "PROBLEM", 106, 146], ["stage 2 adenopathy", "PROBLEM", 154, 172], ["pulmonary infiltrates", "PROBLEM", 177, 198], ["stage 3 pulmonary infiltrates", "PROBLEM", 200, 229], ["stage 4 pulmonary fibrosis", "PROBLEM", 240, 266], ["subsequent treatment regimens", "TREATMENT", 309, 338], ["sarcoidosis", "PROBLEM", 361, 372], ["MethodsDe", "TEST", 510, 519], ["formalin", "TEST", 532, 540], ["lymph nodes", "PROBLEM", 576, 587], ["sarcoidosis", "PROBLEM", 593, 604], ["chest", "ANATOMY", 93, 98], ["hilar", "ANATOMY", 114, 119], ["mediastinal", "ANATOMY", 124, 135], ["adenopathy", "OBSERVATION", 136, 146], ["stage 2", "OBSERVATION_MODIFIER", 154, 161], ["adenopathy", "OBSERVATION", 162, 172], ["pulmonary", "ANATOMY", 177, 186], ["infiltrates", "OBSERVATION", 187, 198], ["stage 3", "OBSERVATION_MODIFIER", 200, 207], ["pulmonary", "ANATOMY", 208, 217], ["infiltrates", "OBSERVATION", 218, 229], ["stage 4", "OBSERVATION_MODIFIER", 240, 247], ["pulmonary", "ANATOMY", 248, 257], ["fibrosis", "OBSERVATION", 258, 266], ["lymph nodes", "OBSERVATION", 576, 587], ["sarcoidosis", "OBSERVATION", 593, 604]]], ["The DNA extraction from paraffin-embedded blocks was performed after paraffin was removed by incubation in xylene using the Roche HighPure PCR template purification kit (Roche Diagnostics GmbH, Mannheim, Germany).8 Several negative patient samples (unrelated to the present study) were included in each batch to rule out any contamination.", [["paraffin", "CHEMICAL", 24, 32], ["paraffin", "CHEMICAL", 69, 77], ["xylene", "CHEMICAL", 107, 113], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["xylene", "SIMPLE_CHEMICAL", 107, 113], ["patient", "ORGANISM", 232, 239], ["patient", "SPECIES", 232, 239], ["The DNA extraction", "TREATMENT", 0, 18], ["paraffin-embedded blocks", "TREATMENT", 24, 48], ["paraffin", "TREATMENT", 69, 77], ["the present study", "TEST", 262, 279], ["any contamination", "PROBLEM", 321, 338]]], ["Inhibition was ruled out by checking the ability of exogenously added target DNA to be amplified in the same PCR mix that contained DNA extracted from clinical specimen.", [["specimen", "ANATOMY", 160, 168], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["target DNA", "DNA", 70, 80], ["PCR mix", "DNA", 109, 116], ["exogenously added target DNA", "TREATMENT", 52, 80], ["the same PCR mix", "TREATMENT", 100, 116], ["DNA", "PROBLEM", 132, 135], ["clinical specimen", "TEST", 151, 168]]], ["Mycobacterium tuberculosis and Bartonella henselae have been detected multiple times in the past using these PCR assays.", [["Mycobacterium tuberculosis", "DISEASE", 0, 26], ["Bartonella henselae", "DISEASE", 31, 50], ["Mycobacterium tuberculosis", "ORGANISM", 0, 26], ["Bartonella henselae", "ORGANISM", 31, 50], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Bartonella henselae", "SPECIES", 31, 50], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Bartonella henselae", "SPECIES", 31, 50], ["Mycobacterium tuberculosis", "PROBLEM", 0, 26], ["Bartonella henselae", "PROBLEM", 31, 50], ["these PCR assays", "TEST", 103, 119], ["Bartonella henselae", "OBSERVATION", 31, 50]]], ["16S primers used were of broad range for all bacteria. hsp65 and rpoB were of broad range for Mycobacteria spp only.", [["hsp65", "GENE_OR_GENE_PRODUCT", 55, 60], ["rpoB", "GENE_OR_GENE_PRODUCT", 65, 69], ["16S primers", "DNA", 0, 11], ["hsp65", "DNA", 55, 60], ["rpoB", "DNA", 65, 69], ["16S primers", "TEST", 0, 11], ["all bacteria", "PROBLEM", 41, 53], ["hsp65", "TEST", 55, 60], ["rpoB", "TEST", 65, 69], ["broad range", "TEST", 78, 89], ["Mycobacteria spp", "PROBLEM", 94, 110], ["Mycobacteria spp", "OBSERVATION", 94, 110]]], ["16S PCR detected non-Mycobacterium spp DNA such as Propionibacterium acnes.", [["Propionibacterium acnes", "DISEASE", 51, 74], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["Propionibacterium acnes", "GENE_OR_GENE_PRODUCT", 51, 74], ["Propionibacterium acnes", "SPECIES", 51, 74], ["Propionibacterium acnes", "SPECIES", 51, 74], ["16S PCR", "TEST", 0, 7], ["non-Mycobacterium spp DNA", "PROBLEM", 17, 42], ["Propionibacterium acnes", "PROBLEM", 51, 74]]], ["Mycobacterium spp DNA were detected by hsp65 and/or rpoB primers.", [["DNA", "CELLULAR_COMPONENT", 18, 21], ["hsp65", "GENE_OR_GENE_PRODUCT", 39, 44], ["Mycobacterium spp DNA", "DNA", 0, 21], ["hsp65 and/or rpoB primers", "DNA", 39, 64], ["Mycobacterium spp DNA", "PROBLEM", 0, 21], ["hsp65", "TEST", 39, 44], ["rpoB primers", "PROBLEM", 52, 64]]], ["Primers used for amplification were also used for amplicon sequencing.", [["Primers", "TREATMENT", 0, 7], ["amplification", "TREATMENT", 17, 30], ["amplicon sequencing", "TREATMENT", 50, 69]]], ["The PCR amplicon was directly sequenced; no cloning was performed.", [["PCR amplicon", "DNA", 4, 16], ["The PCR amplicon", "TREATMENT", 0, 16]]], ["Mixed infection was not detected in this set of specimens.", [["specimens", "ANATOMY", 48, 57], ["infection", "DISEASE", 6, 15], ["Mixed infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15]]], ["For alignment, BLASTN was used.", [["BLASTN", "TEST", 15, 21]]], ["No sequence that could not be linked to a microbe was detected.DNA extraction ::: MethodsP acnes was detected by 16S primers and Mycobacterium avium was detected by hsp65 primers.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["MethodsP acnes", "GENE_OR_GENE_PRODUCT", 82, 96], ["Mycobacterium avium", "ORGANISM", 129, 148], ["hsp65", "GENE_OR_GENE_PRODUCT", 165, 170], ["16S primers", "DNA", 113, 124], ["hsp65 primers", "DNA", 165, 178], ["Mycobacterium avium", "SPECIES", 129, 148], ["Mycobacterium avium", "SPECIES", 129, 148], ["MethodsP acnes", "PROBLEM", 82, 96], ["Mycobacterium avium", "PROBLEM", 129, 148]]], ["M avium was detected and identified by sequence analysis.PCR analysis for 16S ribosomal DNA, heat shock protein 65 (hsp65), RNA polymerase subunit (rpoB) ::: MethodsThe 16S gene fragment was amplified as previously described.8 The hsp65 gene was amplified using TB11 and TB12 primers, and the RNA polymerase subunit gene (rpoB) was amplified using MF and MR primers.9 The amplified products were then sequenced using the Big Dye Sequencing kit (Applied Biosystems, Foster City, California, USA) as per the vendor's recommended protocol.", [["M avium", "GENE_OR_GENE_PRODUCT", 0, 7], ["16S", "GENE_OR_GENE_PRODUCT", 74, 77], ["ribosomal", "CELLULAR_COMPONENT", 78, 87], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["heat shock protein 65", "GENE_OR_GENE_PRODUCT", 93, 114], ["hsp65", "GENE_OR_GENE_PRODUCT", 116, 121], ["RNA polymerase subunit", "GENE_OR_GENE_PRODUCT", 124, 146], ["rpoB", "GENE_OR_GENE_PRODUCT", 148, 152], ["hsp65", "GENE_OR_GENE_PRODUCT", 231, 236], ["TB11", "GENE_OR_GENE_PRODUCT", 262, 266], ["TB12", "GENE_OR_GENE_PRODUCT", 271, 275], ["RNA polymerase subunit", "GENE_OR_GENE_PRODUCT", 293, 315], ["rpoB", "GENE_OR_GENE_PRODUCT", 322, 326], ["16S ribosomal DNA", "DNA", 74, 91], ["heat shock protein 65", "PROTEIN", 93, 114], ["hsp65", "PROTEIN", 116, 121], ["RNA polymerase subunit", "PROTEIN", 124, 146], ["rpoB", "PROTEIN", 148, 152], ["16S gene fragment", "DNA", 169, 186], ["hsp65 gene", "DNA", 231, 241], ["TB11 and TB12 primers", "DNA", 262, 283], ["RNA polymerase subunit gene", "DNA", 293, 320], ["rpoB", "DNA", 322, 326], ["MF and MR primers", "DNA", 348, 365], ["M avium", "SPECIES", 0, 7], ["M avium", "SPECIES", 0, 7], ["sequence analysis", "TEST", 39, 56], ["PCR analysis", "TEST", 57, 69], ["16S ribosomal DNA", "TEST", 74, 91], ["heat shock protein", "TEST", 93, 111], ["hsp", "TEST", 116, 119], ["RNA polymerase subunit", "TEST", 124, 146], ["Methods", "TREATMENT", 158, 165], ["The 16S gene fragment", "PROBLEM", 165, 186], ["The hsp65 gene", "TEST", 227, 241], ["TB11 and TB12 primers", "TREATMENT", 262, 283], ["the RNA polymerase", "TREATMENT", 289, 307], ["MR primers", "TEST", 355, 365], ["The amplified products", "TREATMENT", 368, 390], ["the Big Dye Sequencing kit", "TREATMENT", 417, 443], ["fragment", "OBSERVATION_MODIFIER", 178, 186]]], ["The sequences of two strands were assembled into double-stranded contig using Sequencher software (Gene Codes, Ann Arbor, Michigan, USA).", [["double-stranded contig", "DNA", 49, 71]]], ["The final sequences were used to search the National Center for Biotechnology Information (National Institutes of Health) database using the Basic Local Alignment Search Tool (BLAST) to identify the amplified DNA.Quantitative variables ::: MethodsThe primary variable to be compared between the sarcoidosis and controls patients is the number of patients in each group with bacterial DNA found in lymph nodes.", [["lymph nodes", "ANATOMY", 397, 408], ["sarcoidosis", "DISEASE", 295, 306], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["patients", "ORGANISM", 320, 328], ["patients", "ORGANISM", 346, 354], ["DNA", "CELLULAR_COMPONENT", 384, 387], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 397, 408], ["amplified DNA", "DNA", 199, 212], ["patients", "SPECIES", 320, 328], ["patients", "SPECIES", 346, 354], ["the amplified DNA", "PROBLEM", 195, 212], ["Methods", "TREATMENT", 240, 247], ["the sarcoidosis", "PROBLEM", 291, 306], ["bacterial DNA", "PROBLEM", 374, 387], ["lymph nodes", "PROBLEM", 397, 408], ["sarcoidosis", "OBSERVATION", 295, 306], ["bacterial DNA", "OBSERVATION", 374, 387], ["lymph nodes", "OBSERVATION", 397, 408]]], ["The N-1 Two Proportion test for comparing independent proportions for small sample size is used to compare the results between the two groups.10 In addition, ORs with 95% CIs were calculated.11 All numerical data are expressed as the mean\u00b1SD.Demographics ::: ResultsPatient ages are mean 52.5\u00b112.3 years (median 53 years, range 30\u201375 years).", [["SD", "DISEASE", 239, 241], ["small sample size", "PROBLEM", 70, 87], ["All numerical data", "TEST", 194, 212]]], ["The male:female ratio is 14:16.", [["female", "ORGANISM", 9, 15]]], ["The ethnicity includes Caucasian 73.3% (22), African-American 16.7% (5) and Hispanic 10% (3).", [["Caucasian", "TEST", 23, 32], ["Hispanic", "TEST", 76, 84]]], ["Most of the patients were overweight: mean body mass index is 31.4\u00b16.9, median 28.5 and range 18.8\u201347.3.Clinical presentation ::: ResultsAt the time of initial presentation, 19 of 30 patients (63.3%) were symptomatic, usually with multiple symptoms.", [["body", "ANATOMY", 43, 47], ["overweight", "DISEASE", 26, 36], ["patients", "ORGANISM", 12, 20], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 183, 191], ["mean body mass index", "TEST", 38, 58], ["median", "TEST", 72, 78], ["range", "TEST", 88, 93], ["symptomatic", "PROBLEM", 205, 216], ["multiple symptoms", "PROBLEM", 231, 248]]], ["Of these 19 patients, the duration of symptoms before diagnosis was a mean of 22.1\u00b130.0 months (median 12 months, range 1\u2013120 months).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["symptoms", "PROBLEM", 38, 46]]], ["The most common symptoms were night sweats 9 (30.0%), dyspnoea 8 (26.7%), chest pain 7 (23.3%), chest tightness 5 (16.7), fevers 3 (10.0%), fatigue 3 (10%), skin rash 2 (6.7%) and stomach ulcer 2 (6.7%).", [["chest", "ANATOMY", 74, 79], ["chest", "ANATOMY", 96, 101], ["skin", "ANATOMY", 157, 161], ["stomach ulcer", "ANATOMY", 180, 193], ["night sweats", "DISEASE", 30, 42], ["dyspnoea", "DISEASE", 54, 62], ["chest pain", "DISEASE", 74, 84], ["chest tightness", "DISEASE", 96, 111], ["fevers", "DISEASE", 122, 128], ["fatigue", "DISEASE", 140, 147], ["skin rash", "DISEASE", 157, 166], ["stomach ulcer", "DISEASE", 180, 193], ["skin", "ORGAN", 157, 161], ["stomach", "ORGAN", 180, 187], ["The most common symptoms", "PROBLEM", 0, 24], ["night sweats", "PROBLEM", 30, 42], ["dyspnoea", "TEST", 54, 62], ["chest pain", "PROBLEM", 74, 84], ["chest tightness", "TEST", 96, 111], ["fevers", "PROBLEM", 122, 128], ["fatigue", "PROBLEM", 140, 147], ["skin rash", "PROBLEM", 157, 166], ["stomach ulcer", "PROBLEM", 180, 193], ["chest", "ANATOMY", 74, 79], ["chest", "ANATOMY", 96, 101], ["skin", "ANATOMY", 157, 161], ["rash", "OBSERVATION", 162, 166], ["stomach", "ANATOMY", 180, 187], ["ulcer", "OBSERVATION", 188, 193]]], ["Other symptoms present in at least one patient include dyspepsia, dysphagia, diarrhoea, constipation, kidney stones, joint and muscle pains, orthopnoea, nose and mouth skin lesions, intermittent bronchospasm, malaise and weight loss.Clinical presentation ::: ResultsComorbidities include asthma 2 (6.7%), coronary artery disease 2 (6.7%), diabetes mellitus 4 (13.3%) and hypertension 5 (16.6), and one each of gout, hypothyroidism, eczema, fibromyalgia and Crohn's disease.", [["kidney stones", "ANATOMY", 102, 115], ["joint", "ANATOMY", 117, 122], ["muscle", "ANATOMY", 127, 133], ["orthopnoea", "ANATOMY", 141, 151], ["nose", "ANATOMY", 153, 157], ["mouth skin lesions", "ANATOMY", 162, 180], ["coronary artery", "ANATOMY", 305, 320], ["dyspepsia", "DISEASE", 55, 64], ["dysphagia", "DISEASE", 66, 75], ["diarrhoea", "DISEASE", 77, 86], ["constipation", "DISEASE", 88, 100], ["kidney stones", "DISEASE", 102, 115], ["muscle pains", "DISEASE", 127, 139], ["orthopnoea", "DISEASE", 141, 151], ["mouth skin lesions", "DISEASE", 162, 180], ["intermittent bronchospasm", "DISEASE", 182, 207], ["weight loss", "DISEASE", 221, 232], ["asthma", "DISEASE", 288, 294], ["coronary artery disease", "DISEASE", 305, 328], ["diabetes mellitus", "DISEASE", 339, 356], ["hypertension", "DISEASE", 371, 383], ["gout", "DISEASE", 410, 414], ["hypothyroidism", "DISEASE", 416, 430], ["eczema", "DISEASE", 432, 438], ["fibromyalgia", "DISEASE", 440, 452], ["Crohn's disease", "DISEASE", 457, 472], ["patient", "ORGANISM", 39, 46], ["kidney", "ORGAN", 102, 108], ["joint", "MULTI-TISSUE_STRUCTURE", 117, 122], ["muscle", "ORGAN", 127, 133], ["nose", "ORGANISM_SUBDIVISION", 153, 157], ["skin", "ORGAN", 168, 172], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 305, 320], ["patient", "SPECIES", 39, 46], ["Other symptoms", "PROBLEM", 0, 14], ["dyspepsia", "PROBLEM", 55, 64], ["dysphagia", "PROBLEM", 66, 75], ["diarrhoea", "PROBLEM", 77, 86], ["constipation", "PROBLEM", 88, 100], ["kidney stones", "PROBLEM", 102, 115], ["joint and muscle pains", "PROBLEM", 117, 139], ["orthopnoea", "PROBLEM", 141, 151], ["nose and mouth skin lesions", "PROBLEM", 153, 180], ["intermittent bronchospasm", "PROBLEM", 182, 207], ["malaise", "PROBLEM", 209, 216], ["weight loss", "PROBLEM", 221, 232], ["ResultsComorbidities", "TEST", 259, 279], ["asthma", "PROBLEM", 288, 294], ["coronary artery disease", "PROBLEM", 305, 328], ["diabetes mellitus", "PROBLEM", 339, 356], ["hypertension", "PROBLEM", 371, 383], ["gout", "PROBLEM", 410, 414], ["hypothyroidism", "PROBLEM", 416, 430], ["eczema", "PROBLEM", 432, 438], ["fibromyalgia", "PROBLEM", 440, 452], ["Crohn's disease", "PROBLEM", 457, 472], ["dyspepsia", "OBSERVATION", 55, 64], ["dysphagia", "OBSERVATION", 66, 75], ["diarrhoea", "OBSERVATION", 77, 86], ["constipation", "OBSERVATION", 88, 100], ["kidney", "ANATOMY", 102, 108], ["stones", "OBSERVATION", 109, 115], ["joint", "ANATOMY", 117, 122], ["muscle", "ANATOMY", 127, 133], ["pains", "OBSERVATION", 134, 139], ["nose", "ANATOMY", 153, 157], ["mouth", "ANATOMY", 162, 167], ["skin", "ANATOMY", 168, 172], ["lesions", "OBSERVATION", 173, 180], ["intermittent", "OBSERVATION_MODIFIER", 182, 194], ["bronchospasm", "OBSERVATION", 195, 207], ["malaise", "OBSERVATION", 209, 216], ["weight loss", "OBSERVATION", 221, 232], ["asthma", "OBSERVATION", 288, 294], ["coronary artery", "ANATOMY", 305, 320], ["hypertension", "OBSERVATION", 371, 383], ["gout", "OBSERVATION", 410, 414], ["hypothyroidism", "OBSERVATION", 416, 430], ["eczema", "OBSERVATION", 432, 438], ["fibromyalgia", "OBSERVATION", 440, 452], ["Crohn", "OBSERVATION", 457, 462]]], ["Malignancies were extremely common with over half (53.3%) having a current or prior tumour, a finding noted previously by others.12 The malignancies prior to or at the time of presentation are breast 3, melanoma 3, uterine 2, sarcomas 3, tonsil 1, ovary 1, adrenal 1, colon 1 and Hodgkin's lymphoma 1.Radiographic studies ::: ResultsChest CT was performed on all 30 patients and all had symmetrical mediastinal and hilar adenopathy.", [["tumour", "ANATOMY", 84, 90], ["malignancies", "ANATOMY", 136, 148], ["breast 3", "ANATOMY", 193, 201], ["melanoma 3", "ANATOMY", 203, 213], ["uterine 2", "ANATOMY", 215, 224], ["sarcomas", "ANATOMY", 226, 234], ["tonsil 1", "ANATOMY", 238, 246], ["ovary 1", "ANATOMY", 248, 255], ["adrenal 1", "ANATOMY", 257, 266], ["colon 1", "ANATOMY", 268, 275], ["Hodgkin's lymphoma", "ANATOMY", 280, 298], ["mediastinal", "ANATOMY", 399, 410], ["hilar adenopathy", "ANATOMY", 415, 431], ["tumour", "DISEASE", 84, 90], ["malignancies", "DISEASE", 136, 148], ["melanoma", "DISEASE", 203, 211], ["sarcomas", "DISEASE", 226, 234], ["Hodgkin's lymphoma", "DISEASE", 280, 298], ["adenopathy", "DISEASE", 421, 431], ["Malignancies", "CANCER", 0, 12], ["tumour", "CANCER", 84, 90], ["malignancies", "CANCER", 136, 148], ["breast 3", "CANCER", 193, 201], ["melanoma 3", "CANCER", 203, 213], ["uterine 2", "CANCER", 215, 224], ["sarcomas 3", "CANCER", 226, 236], ["tonsil 1", "CANCER", 238, 246], ["ovary 1", "CANCER", 248, 255], ["adrenal 1", "CANCER", 257, 266], ["colon 1", "CANCER", 268, 275], ["Hodgkin's lymphoma", "CANCER", 280, 298], ["patients", "ORGANISM", 366, 374], ["hilar adenopathy", "CANCER", 415, 431], ["patients", "SPECIES", 366, 374], ["Malignancies", "PROBLEM", 0, 12], ["prior tumour", "PROBLEM", 78, 90], ["The malignancies", "PROBLEM", 132, 148], ["melanoma", "PROBLEM", 203, 211], ["sarcomas", "PROBLEM", 226, 234], ["colon 1 and Hodgkin's lymphoma", "PROBLEM", 268, 298], ["Radiographic studies", "TEST", 301, 321], ["ResultsChest CT", "TEST", 326, 341], ["symmetrical mediastinal and hilar adenopathy", "PROBLEM", 387, 431], ["tumour", "OBSERVATION", 84, 90], ["malignancies", "OBSERVATION", 136, 148], ["breast", "ANATOMY", 193, 199], ["melanoma", "OBSERVATION", 203, 211], ["uterine", "ANATOMY", 215, 222], ["sarcomas", "OBSERVATION", 226, 234], ["tonsil", "ANATOMY", 238, 244], ["ovary", "ANATOMY", 248, 253], ["adrenal", "ANATOMY", 257, 264], ["colon", "ANATOMY", 268, 273], ["Hodgkin's lymphoma", "OBSERVATION", 280, 298], ["symmetrical", "OBSERVATION_MODIFIER", 387, 398], ["mediastinal", "ANATOMY", 399, 410], ["hilar", "ANATOMY", 415, 420], ["adenopathy", "OBSERVATION", 421, 431]]], ["Four of 30 patients (13.3%) had obvious abdominal adenopathy.", [["abdominal", "ANATOMY", 40, 49], ["abdominal adenopathy", "DISEASE", 40, 60], ["patients", "ORGANISM", 11, 19], ["abdominal adenopathy", "PATHOLOGICAL_FORMATION", 40, 60], ["patients", "SPECIES", 11, 19], ["obvious abdominal adenopathy", "PROBLEM", 32, 60], ["abdominal", "ANATOMY", 40, 49], ["adenopathy", "OBSERVATION", 50, 60]]], ["Lung nodules were present in 12 patients (40%) and were radiographic stage II sarcoidosis.", [["Lung nodules", "ANATOMY", 0, 12], ["sarcoidosis", "DISEASE", 78, 89], ["Lung nodules", "CANCER", 0, 12], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Lung nodules", "PROBLEM", 0, 12], ["radiographic stage II sarcoidosis", "PROBLEM", 56, 89], ["nodules", "OBSERVATION", 5, 12], ["stage II", "OBSERVATION_MODIFIER", 69, 77], ["sarcoidosis", "OBSERVATION", 78, 89]]], ["The other 18 patients (60%) had stage I disease.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["stage I disease", "PROBLEM", 32, 47], ["stage I", "OBSERVATION_MODIFIER", 32, 39], ["disease", "OBSERVATION", 40, 47]]], ["All 12 stage II patients were symptomatic.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["symptomatic", "PROBLEM", 30, 41], ["stage II", "OBSERVATION_MODIFIER", 7, 15], ["symptomatic", "OBSERVATION_MODIFIER", 30, 41]]], ["PET/CT scans were performed in 25 of 30 patients with sarcoidosis.", [["sarcoidosis", "DISEASE", 54, 65], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["PET/CT scans", "TEST", 0, 12], ["sarcoidosis", "PROBLEM", 54, 65], ["sarcoidosis", "OBSERVATION", 54, 65]]], ["All patients demonstrated glucose avidity in the enlarged mediastinal and hilar nodes (see figure 2 for typical example), and glucose avidity was seen in the abnormal abdominal nodes in the four patients with radiographic adenopathy below the diaphragm.Laboratory results ::: ResultsTwelve of 30 patients had lymph node tissue sent at the time of mediastinoscopy for aerobic, fungal and mycobacterial cultures.", [["mediastinal", "ANATOMY", 58, 69], ["hilar nodes", "ANATOMY", 74, 85], ["abdominal nodes", "ANATOMY", 167, 182], ["diaphragm", "ANATOMY", 243, 252], ["lymph node tissue", "ANATOMY", 309, 326], ["glucose", "CHEMICAL", 26, 33], ["glucose", "CHEMICAL", 126, 133], ["adenopathy", "DISEASE", 222, 232], ["glucose", "CHEMICAL", 26, 33], ["glucose", "CHEMICAL", 126, 133], ["patients", "ORGANISM", 4, 12], ["glucose", "SIMPLE_CHEMICAL", 26, 33], ["mediastinal", "ORGAN", 58, 69], ["hilar nodes", "MULTI-TISSUE_STRUCTURE", 74, 85], ["glucose", "SIMPLE_CHEMICAL", 126, 133], ["abdominal nodes", "MULTI-TISSUE_STRUCTURE", 167, 182], ["patients", "ORGANISM", 195, 203], ["diaphragm", "ORGAN", 243, 252], ["patients", "ORGANISM", 296, 304], ["lymph node tissue", "TISSUE", 309, 326], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 296, 304], ["glucose avidity", "TEST", 26, 41], ["the enlarged mediastinal and hilar nodes", "PROBLEM", 45, 85], ["glucose avidity", "TEST", 126, 141], ["the abnormal abdominal nodes", "PROBLEM", 154, 182], ["radiographic adenopathy", "PROBLEM", 209, 232], ["lymph node tissue", "PROBLEM", 309, 326], ["mediastinoscopy", "TEST", 347, 362], ["aerobic, fungal and mycobacterial cultures", "TEST", 367, 409], ["glucose avidity", "OBSERVATION", 26, 41], ["enlarged", "OBSERVATION_MODIFIER", 49, 57], ["mediastinal", "ANATOMY", 58, 69], ["hilar", "ANATOMY", 74, 79], ["nodes", "OBSERVATION", 80, 85], ["abnormal", "OBSERVATION_MODIFIER", 158, 166], ["abdominal", "ANATOMY", 167, 176], ["nodes", "OBSERVATION", 177, 182], ["adenopathy", "OBSERVATION", 222, 232], ["diaphragm", "ANATOMY", 243, 252], ["lymph node tissue", "OBSERVATION", 309, 326]]], ["All cultures showed no growth after 6 weeks of incubation.Bacterial DNA detected by PCR ::: ResultsEleven of 30 lymph nodes (36.7%) in patients with sarcoidosis had bacterial DNA present by PCR.", [["cultures", "ANATOMY", 4, 12], ["lymph nodes", "ANATOMY", 112, 123], ["sarcoidosis", "DISEASE", 149, 160], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 112, 123], ["patients", "ORGANISM", 135, 143], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["patients", "SPECIES", 135, 143], ["All cultures", "TEST", 0, 12], ["incubation", "TREATMENT", 47, 57], ["Bacterial DNA", "PROBLEM", 58, 71], ["PCR", "TEST", 84, 87], ["lymph nodes", "TEST", 112, 123], ["sarcoidosis", "PROBLEM", 149, 160], ["bacterial DNA", "PROBLEM", 165, 178], ["PCR", "TEST", 190, 193], ["no", "UNCERTAINTY", 20, 22], ["growth", "OBSERVATION_MODIFIER", 23, 29], ["lymph nodes", "OBSERVATION", 112, 123], ["sarcoidosis", "OBSERVATION", 149, 160], ["bacterial DNA", "OBSERVATION", 165, 178]]], ["Only 2 of 30 (6.7%) control patients were found to have bacterial DNA in their lymph nodes.", [["lymph nodes", "ANATOMY", 79, 90], ["patients", "ORGANISM", 28, 36], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 79, 90], ["patients", "SPECIES", 28, 36], ["bacterial DNA in their lymph nodes", "PROBLEM", 56, 90], ["bacterial DNA", "OBSERVATION", 56, 69], ["lymph nodes", "OBSERVATION", 79, 90]]], ["The microorganisms present in each group are shown in table 2.", [["microorganisms", "OBSERVATION", 4, 18]]], ["There are significantly more patient with sarcoidosis lymph nodes positive for microorganism DNA than control lymph nodes: 11/30 versus 2/30, p=0.00516 (2-tailed p value); OR is 8.1053 with 95% CIs 1.6115 to 40.7675, p=0.0111.Bacterial DNA detected by PCR ::: ResultsAll patients with sarcoidosis with detectable bacterial DNA in lymph nodes (36.7%) were symptomatic at presentation.", [["lymph nodes", "ANATOMY", 54, 65], ["lymph nodes", "ANATOMY", 110, 121], ["lymph nodes", "ANATOMY", 330, 341], ["sarcoidosis", "DISEASE", 42, 53], ["sarcoidosis", "DISEASE", 285, 296], ["patient", "ORGANISM", 29, 36], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 54, 65], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 110, 121], ["DNA", "CELLULAR_COMPONENT", 236, 239], ["patients", "ORGANISM", 271, 279], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 330, 341], ["patient", "SPECIES", 29, 36], ["patients", "SPECIES", 271, 279], ["sarcoidosis lymph nodes", "PROBLEM", 42, 65], ["microorganism DNA", "PROBLEM", 79, 96], ["p", "TEST", 142, 143], ["CIs", "TEST", 194, 197], ["p", "TEST", 217, 218], ["Bacterial DNA", "PROBLEM", 226, 239], ["sarcoidosis", "PROBLEM", 285, 296], ["detectable bacterial DNA in lymph nodes", "PROBLEM", 302, 341], ["symptomatic", "PROBLEM", 355, 366], ["significantly", "OBSERVATION_MODIFIER", 10, 23], ["sarcoidosis", "OBSERVATION", 42, 53], ["lymph nodes", "OBSERVATION", 54, 65], ["lymph nodes", "OBSERVATION", 110, 121], ["sarcoidosis", "OBSERVATION", 285, 296], ["detectable", "OBSERVATION_MODIFIER", 302, 312], ["bacterial DNA", "OBSERVATION", 313, 326], ["lymph nodes", "OBSERVATION", 330, 341]]], ["In addition, 73% (8/11) of bacterial DNA-positive patients with sarcoidosis were symptomatic at presentation and had radiographic stage II disease.Long-term follow-up ::: ResultsLong-term follow-up was complete in 25 of 30 (83.3%) patients with sarcoidosis, for a mean follow-up of 50.4\u00b128.2 months (median 48 months, range 4\u2013132 months).", [["sarcoidosis", "DISEASE", 64, 75], ["sarcoidosis", "DISEASE", 245, 256], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 231, 239], ["bacterial DNA", "TEST", 27, 40], ["sarcoidosis", "PROBLEM", 64, 75], ["symptomatic", "PROBLEM", 81, 92], ["radiographic stage II disease", "PROBLEM", 117, 146], ["sarcoidosis", "PROBLEM", 245, 256], ["sarcoidosis", "OBSERVATION", 64, 75], ["stage II", "OBSERVATION_MODIFIER", 130, 138], ["disease", "OBSERVATION", 139, 146], ["sarcoidosis", "OBSERVATION", 245, 256]]], ["Five of these patients are deceased: three from cancers, one from chronic obstructive pulmonary disease and one from unknown causes.", [["cancers", "ANATOMY", 48, 55], ["pulmonary", "ANATOMY", 86, 95], ["cancers", "DISEASE", 48, 55], ["chronic obstructive pulmonary disease", "DISEASE", 66, 103], ["patients", "ORGANISM", 14, 22], ["cancers", "CANCER", 48, 55], ["pulmonary", "ORGAN", 86, 95], ["patients", "SPECIES", 14, 22], ["cancers", "PROBLEM", 48, 55], ["chronic obstructive pulmonary disease", "PROBLEM", 66, 103], ["cancers", "OBSERVATION", 48, 55], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["obstructive", "OBSERVATION_MODIFIER", 74, 85], ["pulmonary", "ANATOMY", 86, 95], ["disease", "OBSERVATION", 96, 103]]], ["The other five patients lost to direct follow-up are still living based on information obtained from the Social Security Death Index.13Long-term follow-up ::: ResultsOf the 10 patients with sarcoidosis with bacterial DNA found in their lymph nodes in this series in whom long-term follow-up was available, all were symptomatic at a mean follow-up of 52.8\u00b132.4 months (median 47 months, range 12\u2013136 months).", [["lymph nodes", "ANATOMY", 236, 247], ["Death", "DISEASE", 121, 126], ["sarcoidosis", "DISEASE", 190, 201], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 176, 184], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 236, 247], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 176, 184], ["sarcoidosis", "PROBLEM", 190, 201], ["bacterial DNA", "PROBLEM", 207, 220], ["their lymph nodes", "PROBLEM", 230, 247], ["symptomatic", "PROBLEM", 315, 326], ["sarcoidosis", "OBSERVATION", 190, 201], ["bacterial DNA", "OBSERVATION", 207, 220], ["lymph nodes", "OBSERVATION", 236, 247]]], ["The one additional bacterial DNA-positive patient was lost to follow-up.Bacterial DNA ::: DiscussionAs expected, our molecular testing using PCR demonstrated that over one-third of patients with sarcoidosis (36.7%) had evidence of bacterial DNA in the nodes, indicating either the past or the current involvement with these microorganisms.", [["nodes", "ANATOMY", 252, 257], ["sarcoidosis", "DISEASE", 195, 206], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["patient", "ORGANISM", 42, 49], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["patients", "ORGANISM", 181, 189], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["nodes", "MULTI-TISSUE_STRUCTURE", 252, 257], ["bacterial DNA", "DNA", 19, 32], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 181, 189], ["bacterial DNA", "TEST", 19, 32], ["Bacterial DNA", "PROBLEM", 72, 85], ["our molecular testing", "TEST", 113, 134], ["PCR", "TEST", 141, 144], ["sarcoidosis", "PROBLEM", 195, 206], ["bacterial DNA in the nodes", "PROBLEM", 231, 257], ["these microorganisms", "PROBLEM", 318, 338], ["bacterial DNA", "OBSERVATION", 19, 32], ["sarcoidosis", "OBSERVATION", 195, 206], ["bacterial DNA", "OBSERVATION", 231, 244], ["nodes", "OBSERVATION", 252, 257]]], ["This percentage of bacterial DNA-positive specimens falls in the range found in numerous prior published studies from the past two decades (using various methodologies), which range from 26% to 80% positive (table 35714\u201317).", [["specimens", "ANATOMY", 42, 51], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["bacterial DNA", "PROBLEM", 19, 32], ["positive specimens falls", "PROBLEM", 33, 57], ["various methodologies", "TEST", 146, 167], ["bacterial DNA", "OBSERVATION", 19, 32], ["positive specimens", "OBSERVATION_MODIFIER", 33, 51], ["falls", "OBSERVATION_MODIFIER", 52, 57]]], ["Furthermore, atypical mycobacteria and P acnes represented almost all DNA identified, also consistent with the findings of the multiple prior studies (table 3).", [["DNA", "CELLULAR_COMPONENT", 70, 73], ["P acnes", "SPECIES", 39, 46], ["atypical mycobacteria", "PROBLEM", 13, 34], ["P acnes", "PROBLEM", 39, 46], ["the multiple prior studies", "TEST", 123, 149], ["atypical", "OBSERVATION_MODIFIER", 13, 21], ["mycobacteria", "OBSERVATION", 22, 34], ["acnes", "OBSERVATION", 41, 46], ["all DNA", "OBSERVATION_MODIFIER", 66, 73], ["consistent with", "UNCERTAINTY", 91, 106]]], ["Additionally identified were one skin and mucous membrane organism (Corynebacterium propinquum), and one aerobic Gram-negative bacillus (Duganella zoogloeoides) that is usually found in aqueous environments.", [["skin", "ANATOMY", 33, 37], ["mucous membrane", "ANATOMY", 42, 57], ["skin", "ORGAN", 33, 37], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 42, 57], ["Corynebacterium propinquum", "ORGANISM", 68, 94], ["Gram", "GENE_OR_GENE_PRODUCT", 113, 117], ["Duganella zoogloeoides", "ORGANISM", 137, 159], ["Corynebacterium propinquum", "SPECIES", 68, 94], ["Duganella zoogloeoides", "SPECIES", 137, 159], ["Corynebacterium propinquum", "SPECIES", 68, 94], ["Duganella zoogloeoides", "SPECIES", 137, 159], ["mucous membrane organism", "PROBLEM", 42, 66], ["Corynebacterium propinquum", "TEST", 68, 94], ["one aerobic Gram", "TEST", 101, 117], ["negative bacillus (Duganella zoogloeoides", "PROBLEM", 118, 159], ["skin", "ANATOMY", 33, 37], ["mucous membrane", "ANATOMY", 42, 57], ["negative bacillus", "OBSERVATION", 118, 135], ["aqueous environments", "OBSERVATION", 186, 206]]], ["Interestingly, the latter patient (no. 13) with D zoogloeoides was an asbestos technician originally from tropical Haiti.", [["patient", "ORGANISM", 26, 33], ["D zoogloeoides", "ORGANISM", 48, 62], ["patient", "SPECIES", 26, 33], ["D zoogloeoides", "SPECIES", 48, 62], ["D zoogloeoides", "TREATMENT", 48, 62], ["asbestos", "OBSERVATION", 70, 78]]], ["As a disclaimer, just the finding of DNA from a microorganism in lymph nodes does not tell us whether the viable organism is present or whether it caused the granulomatous reaction.Bacterial DNA ::: DiscussionSimilar to prior published studies summarised in table 3, significantly less (only 2 of 30 or 6.7%, p=0.00516) of control lymph nodes resected at the time of lung cancer surgery showed evidence of bacterial DNA (M avium and P acnes).", [["lymph nodes", "ANATOMY", 65, 76], ["granulomatous", "ANATOMY", 158, 171], ["lymph nodes", "ANATOMY", 331, 342], ["lung cancer", "ANATOMY", 367, 378], ["lung cancer", "DISEASE", 367, 378], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 65, 76], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 331, 342], ["lung cancer", "CANCER", 367, 378], ["DNA", "CELLULAR_COMPONENT", 416, 419], ["M avium", "GENE_OR_GENE_PRODUCT", 421, 428], ["M avium", "SPECIES", 421, 428], ["M avium", "SPECIES", 421, 428], ["DNA", "PROBLEM", 37, 40], ["a microorganism in lymph nodes", "PROBLEM", 46, 76], ["the viable organism", "PROBLEM", 102, 121], ["the granulomatous reaction", "PROBLEM", 154, 180], ["Bacterial DNA", "PROBLEM", 181, 194], ["prior published studies", "TEST", 220, 243], ["control lymph nodes", "PROBLEM", 323, 342], ["lung cancer surgery", "TREATMENT", 367, 386], ["bacterial DNA", "PROBLEM", 406, 419], ["DNA", "OBSERVATION", 37, 40], ["lymph nodes", "OBSERVATION", 65, 76], ["granulomatous", "OBSERVATION", 158, 171], ["lymph nodes", "OBSERVATION", 331, 342], ["lung", "ANATOMY", 367, 371], ["cancer", "OBSERVATION", 372, 378], ["evidence of", "UNCERTAINTY", 394, 405], ["bacterial DNA", "OBSERVATION", 406, 419]]], ["This difference strongly suggests that the demonstration of bacterial DNA in sarcoidosis lymph nodes is a real finding in our study (and in over 35 prior published studies) and they are not just processing contaminants, therefore pointing to microorganisms as potential contributors to the genesis of this disease.", [["sarcoidosis lymph nodes", "ANATOMY", 77, 100], ["sarcoidosis", "DISEASE", 77, 88], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 89, 100], ["bacterial DNA", "PROBLEM", 60, 73], ["sarcoidosis lymph nodes", "PROBLEM", 77, 100], ["our study", "TEST", 122, 131], ["microorganisms", "PROBLEM", 242, 256], ["this disease", "PROBLEM", 301, 313], ["bacterial DNA", "OBSERVATION", 60, 73], ["sarcoidosis", "OBSERVATION_MODIFIER", 77, 88], ["lymph nodes", "OBSERVATION", 89, 100]]], ["In addition, P acnes DNA was found in only 1 of 30 (3.3%) control lymph nodes in our study, in stark contrast to Ishige et al18 in Japan who reported this microorganism as an ubiquitous pulmonary lymph node commensal found in 8 of 11 (72.7%) non-sarcoid patients in their study.", [["lymph nodes", "ANATOMY", 66, 77], ["pulmonary lymph node", "ANATOMY", 186, 206], ["non-sarcoid", "DISEASE", 242, 253], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 66, 77], ["pulmonary lymph node", "MULTI-TISSUE_STRUCTURE", 186, 206], ["patients", "ORGANISM", 254, 262], ["P acnes DNA", "DNA", 13, 24], ["patients", "SPECIES", 254, 262], ["P acnes", "SPECIES", 13, 20], ["P acnes DNA", "TEST", 13, 24], ["lymph nodes", "TEST", 66, 77], ["our study", "TEST", 81, 90], ["this microorganism", "PROBLEM", 150, 168], ["an ubiquitous pulmonary lymph node commensal", "PROBLEM", 172, 216], ["their study", "TEST", 266, 277], ["lymph nodes", "OBSERVATION", 66, 77], ["pulmonary", "ANATOMY", 186, 195], ["lymph node", "OBSERVATION", 196, 206]]], ["Such a very high positive result in their study is likely due to either geographical/ethnic/racial differences or potential contamination in processing.Clinical characteristics ::: DiscussionPerhaps the most intriguing findings came from correlation of the PCR findings with the clinical information.", [["a very high positive result", "PROBLEM", 5, 32], ["their study", "TEST", 36, 47], ["geographical/ethnic/racial differences", "PROBLEM", 72, 110], ["potential contamination in processing", "PROBLEM", 114, 151], ["the PCR findings", "TEST", 253, 269], ["likely due to", "UNCERTAINTY", 51, 64], ["contamination", "OBSERVATION", 124, 137]]], ["All patients with lymph nodes containing bacterial DNA on presentation were also highly symptomatic and 75% of them had the poorer-prognosis radiographic stage II findings.", [["lymph nodes", "ANATOMY", 18, 29], ["patients", "ORGANISM", 4, 12], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 18, 29], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["patients", "SPECIES", 4, 12], ["lymph nodes", "PROBLEM", 18, 29], ["bacterial DNA", "PROBLEM", 41, 54], ["lymph nodes", "OBSERVATION", 18, 29], ["bacterial DNA", "OBSERVATION", 41, 54], ["highly", "OBSERVATION_MODIFIER", 81, 87], ["symptomatic", "OBSERVATION_MODIFIER", 88, 99]]], ["Moreover, after a median 4 years follow-up, all bacterial DNA-positive patients were still highly symptomatic.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["all bacterial DNA", "TEST", 44, 61]]], ["This striking correlation strongly suggests that demonstration of bacterial DNA by PCR in lymph nodes on initial presentation is an adverse prognostic factor and makes it unlikely that these patients will have a spontaneous remission.Clinical characteristics ::: DiscussionIndeed, if infection with one of these microorganisms triggers an exuberant granulomatous immune response, the 50\u201380% of patients who usually have a spontaneous remission1 likely clear the offending organism and the immune reaction subsides.", [["lymph nodes", "ANATOMY", 90, 101], ["infection", "DISEASE", 284, 293], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 90, 101], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 394, 402], ["bacterial DNA", "DNA", 66, 79], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 394, 402], ["bacterial DNA", "PROBLEM", 66, 79], ["PCR in lymph nodes", "PROBLEM", 83, 101], ["an adverse prognostic factor", "PROBLEM", 129, 157], ["a spontaneous remission", "PROBLEM", 210, 233], ["infection", "PROBLEM", 284, 293], ["these microorganisms", "PROBLEM", 306, 326], ["an exuberant granulomatous immune response", "PROBLEM", 336, 378], ["a spontaneous remission1", "PROBLEM", 420, 444], ["the offending organism", "PROBLEM", 458, 480], ["the immune reaction", "PROBLEM", 485, 504], ["bacterial DNA", "OBSERVATION", 66, 79], ["lymph nodes", "OBSERVATION", 90, 101], ["spontaneous", "OBSERVATION_MODIFIER", 212, 223], ["remission", "OBSERVATION", 224, 233], ["exuberant", "OBSERVATION_MODIFIER", 339, 348], ["granulomatous immune response", "OBSERVATION", 349, 378]]], ["We postulate that those patients who have persisting symptomatic disease likely continue to harbour the microorganism, which perpetuates the vigorous, destructive immune response as well as permit the microorganism to travel elsewhere to other organs to create distant granulomatous inflammation.Limitations of this study ::: DiscussionMany pathogenic microorganisms such as Mycobacterium leprae (leprosy) or coronaviruses (severe acute respiratory syndrome) cannot be grown directly in culture or they are very slow growing or difficult to culture such as Tropheryma whippelii (Whipple's disease).519 In these instances, detection and identification rely on molecular mechanisms such as PCR used in this study.", [["organs", "ANATOMY", 244, 250], ["granulomatous", "ANATOMY", 269, 282], ["inflammation", "DISEASE", 283, 295], ["Mycobacterium leprae (leprosy) or coronaviruses", "DISEASE", 375, 422], ["acute respiratory syndrome", "DISEASE", 431, 457], ["Tropheryma whippelii", "DISEASE", 557, 577], ["Whipple's disease", "DISEASE", 579, 596], ["patients", "ORGANISM", 24, 32], ["organs", "ORGAN", 244, 250], ["granulomatous inflammation", "PATHOLOGICAL_FORMATION", 269, 295], ["Mycobacterium leprae", "ORGANISM", 375, 395], ["Tropheryma whippelii", "ORGANISM", 557, 577], ["Whipple's disease", "CANCER", 579, 596], ["patients", "SPECIES", 24, 32], ["Mycobacterium leprae", "SPECIES", 375, 395], ["coronaviruses", "SPECIES", 409, 422], ["Tropheryma whippelii", "SPECIES", 557, 577], ["Mycobacterium leprae", "SPECIES", 375, 395], ["Tropheryma whippelii", "SPECIES", 557, 577], ["persisting symptomatic disease", "PROBLEM", 42, 72], ["the microorganism", "PROBLEM", 100, 117], ["the vigorous, destructive immune response", "PROBLEM", 137, 178], ["the microorganism", "PROBLEM", 197, 214], ["distant granulomatous inflammation", "PROBLEM", 261, 295], ["this study", "TEST", 311, 321], ["pathogenic microorganisms", "PROBLEM", 341, 366], ["Mycobacterium leprae (leprosy)", "PROBLEM", 375, 405], ["coronaviruses (severe acute respiratory syndrome", "PROBLEM", 409, 457], ["culture", "TEST", 487, 494], ["very slow growing", "PROBLEM", 507, 524], ["culture", "TEST", 541, 548], ["Tropheryma whippelii (Whipple's disease", "PROBLEM", 557, 596], ["molecular mechanisms", "PROBLEM", 659, 679], ["PCR", "TEST", 688, 691], ["this study", "TEST", 700, 710], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64], ["disease", "OBSERVATION", 65, 72], ["vigorous", "OBSERVATION_MODIFIER", 141, 149], ["destructive", "OBSERVATION_MODIFIER", 151, 162], ["distant", "OBSERVATION_MODIFIER", 261, 268], ["granulomatous", "OBSERVATION_MODIFIER", 269, 282], ["inflammation", "OBSERVATION", 283, 295], ["Mycobacterium leprae", "OBSERVATION", 375, 395], ["severe", "OBSERVATION_MODIFIER", 424, 430], ["acute", "OBSERVATION_MODIFIER", 431, 436], ["respiratory syndrome", "OBSERVATION", 437, 457]]], ["Nevertheless, the molecular approach has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin embedding process or postembedding handling and processing of the paraffin block.", [["paraffin", "CHEMICAL", 148, 156], ["paraffin", "CHEMICAL", 223, 231], ["false-positive results", "PROBLEM", 81, 103], ["contaminated PCR reagents", "TREATMENT", 117, 142], ["the paraffin embedding process", "TREATMENT", 144, 174], ["postembedding handling", "PROBLEM", 178, 200], ["the paraffin block", "TREATMENT", 219, 237], ["paraffin block", "OBSERVATION", 223, 237]]], ["However, in our study, 30 control lymph nodes were processed in an identical manner and bacterial DNA was detected in only 2/30 (6.6%), significantly less than the sarcoidosis nodes (36.7%, p=0.00516), suggesting that contamination is unlikely to account for the findings.Limitations of this study ::: DiscussionAnother obvious limitation in interpreting the results of this and other prior molecular studies relates to colonisation versus causation.", [["lymph nodes", "ANATOMY", 34, 45], ["sarcoidosis nodes", "ANATOMY", 164, 181], ["sarcoidosis", "DISEASE", 164, 175], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 34, 45], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["sarcoidosis nodes", "MULTI-TISSUE_STRUCTURE", 164, 181], ["bacterial DNA", "DNA", 88, 101], ["our study", "TEST", 12, 21], ["30 control lymph nodes", "PROBLEM", 23, 45], ["bacterial DNA", "TEST", 88, 101], ["the sarcoidosis nodes", "PROBLEM", 160, 181], ["contamination", "PROBLEM", 218, 231], ["this study", "TEST", 287, 297], ["other prior molecular studies", "TEST", 379, 408], ["lymph nodes", "OBSERVATION", 34, 45], ["bacterial DNA", "OBSERVATION", 88, 101], ["significantly", "OBSERVATION_MODIFIER", 136, 149], ["less", "OBSERVATION_MODIFIER", 150, 154], ["sarcoidosis nodes", "OBSERVATION", 164, 181], ["contamination", "OBSERVATION", 218, 231], ["unlikely to account for", "UNCERTAINTY", 235, 258]]], ["Just the finding of microbial DNA in the nodes does not prove that the organism is actively involved in the pathogenesis of the disease.", [["nodes", "ANATOMY", 41, 46], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["microbial DNA", "DNA", 20, 33], ["microbial DNA in the nodes", "PROBLEM", 20, 46], ["the organism", "PROBLEM", 67, 79], ["the disease", "PROBLEM", 124, 135], ["microbial DNA", "OBSERVATION", 20, 33], ["nodes", "OBSERVATION", 41, 46], ["does not prove", "UNCERTAINTY", 47, 61], ["disease", "OBSERVATION", 128, 135]]], ["The microorganism may just be a commensal or theoretically it might even be attracted to the area of granulomatous inflammation.", [["granulomatous", "ANATOMY", 101, 114], ["inflammation", "DISEASE", 115, 127], ["granulomatous inflammation", "PATHOLOGICAL_FORMATION", 101, 127], ["The microorganism", "PROBLEM", 0, 17], ["granulomatous inflammation", "PROBLEM", 101, 127], ["microorganism", "OBSERVATION", 4, 17], ["may just be", "UNCERTAINTY", 18, 29], ["area", "OBSERVATION_MODIFIER", 93, 97], ["granulomatous", "OBSERVATION_MODIFIER", 101, 114], ["inflammation", "OBSERVATION", 115, 127]]], ["Nevertheless, the marked difference in the percentage of microbial DNA-positive nodes in sarcoidosis versus control patients is certainly suggestive of disease causation by the microorganisms.Limitations of this study ::: DiscussionIn addition, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA.", [["nodes", "ANATOMY", 80, 85], ["lymph nodes", "ANATOMY", 259, 270], ["sarcoidosis", "DISEASE", 89, 100], ["formalin", "CHEMICAL", 365, 373], ["paraffin", "CHEMICAL", 387, 395], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["patients", "ORGANISM", 116, 124], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 259, 270], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["DNA", "CELLULAR_COMPONENT", 439, 442], ["prokaryotic DNA", "DNA", 427, 442], ["patients", "SPECIES", 116, 124], ["microbial DNA", "PROBLEM", 57, 70], ["positive nodes", "PROBLEM", 71, 85], ["sarcoidosis", "PROBLEM", 89, 100], ["disease causation", "PROBLEM", 152, 169], ["the microorganisms", "PROBLEM", 173, 191], ["this study", "TEST", 207, 217], ["lymph nodes", "PROBLEM", 259, 270], ["bacterial DNA", "PROBLEM", 284, 297], ["the formalin-fixation", "TREATMENT", 361, 382], ["paraffin embedding process", "TREATMENT", 387, 413], ["breakdown prokaryotic DNA", "PROBLEM", 417, 442], ["marked", "OBSERVATION_MODIFIER", 18, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["percentage", "OBSERVATION_MODIFIER", 43, 53], ["microbial DNA", "OBSERVATION", 57, 70], ["positive", "OBSERVATION_MODIFIER", 71, 79], ["nodes", "OBSERVATION", 80, 85], ["sarcoidosis", "OBSERVATION", 89, 100], ["certainly suggestive of", "UNCERTAINTY", 128, 151], ["disease", "OBSERVATION", 152, 159], ["lymph nodes", "OBSERVATION", 259, 270], ["bacterial DNA", "OBSERVATION", 284, 297], ["prokaryotic DNA", "OBSERVATION", 427, 442]]], ["Over time other investigators have found degradation of the prokaryotic bacterial DNA (especially mycobacteria) with ageing of the paraffin-embedded specimens.16 Of note, the only three sarcoidosis lymph nodes positive for mycobacteria in our study were less than 3 years old when evaluated by PCR.", [["specimens", "ANATOMY", 149, 158], ["lymph nodes", "ANATOMY", 198, 209], ["sarcoidosis", "DISEASE", 186, 197], ["paraffin", "CHEMICAL", 131, 139], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["specimens", "TISSUE", 149, 158], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 198, 209], ["prokaryotic bacterial DNA", "DNA", 60, 85], ["the prokaryotic bacterial DNA", "PROBLEM", 56, 85], ["mycobacteria", "PROBLEM", 98, 110], ["the paraffin", "TEST", 127, 139], ["three sarcoidosis lymph nodes", "PROBLEM", 180, 209], ["mycobacteria", "PROBLEM", 223, 235], ["our study", "TEST", 239, 248], ["bacterial DNA", "OBSERVATION", 72, 85], ["sarcoidosis", "OBSERVATION_MODIFIER", 186, 197], ["lymph nodes", "OBSERVATION", 198, 209], ["mycobacteria", "OBSERVATION", 223, 235]]], ["Had we used fresh lymph node tissue like Drake et al16 who found 60% PCR positive for mycobacteria spp, there may have been a much higher rate of positive bacterial DNA results (particularly mycobacteria) in our study.Implications of the study ::: DiscussionSarcoidosis is a granulomatous disease primarily involving the lungs, lymph nodes and other organs that appears to be the result of an exuberant T cell and macrophage immunological response to the continued presentation of a poorly degradable antigen.", [["lymph node tissue", "ANATOMY", 18, 35], ["granulomatous", "ANATOMY", 275, 288], ["lungs", "ANATOMY", 321, 326], ["lymph nodes", "ANATOMY", 328, 339], ["organs", "ANATOMY", 350, 356], ["T cell", "ANATOMY", 403, 409], ["macrophage", "ANATOMY", 414, 424], ["mycobacteria spp", "DISEASE", 86, 102], ["DiscussionSarcoidosis", "DISEASE", 248, 269], ["granulomatous disease", "DISEASE", 275, 296], ["lymph node", "MULTI-TISSUE_STRUCTURE", 18, 28], ["tissue", "TISSUE", 29, 35], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["lungs", "ORGAN", 321, 326], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 328, 339], ["organs", "ORGAN", 350, 356], ["T cell", "CELL", 403, 409], ["macrophage", "CELL", 414, 424], ["fresh lymph node tissue", "TREATMENT", 12, 35], ["60% PCR", "TEST", 65, 72], ["mycobacteria spp", "PROBLEM", 86, 102], ["positive bacterial DNA results", "PROBLEM", 146, 176], ["mycobacteria", "PROBLEM", 191, 203], ["our study", "TEST", 208, 217], ["the study", "TEST", 234, 243], ["a granulomatous disease", "PROBLEM", 273, 296], ["lymph nodes and other organs", "PROBLEM", 328, 356], ["an exuberant T cell", "PROBLEM", 390, 409], ["a poorly degradable antigen", "PROBLEM", 481, 508], ["lymph node tissue", "OBSERVATION", 18, 35], ["granulomatous", "OBSERVATION", 275, 288], ["lungs", "ANATOMY", 321, 326], ["lymph nodes", "OBSERVATION", 328, 339], ["organs", "ANATOMY", 350, 356], ["exuberant", "OBSERVATION_MODIFIER", 393, 402], ["T cell", "OBSERVATION", 403, 409], ["macrophage immunological response", "OBSERVATION", 414, 447], ["poorly degradable", "OBSERVATION_MODIFIER", 483, 500]]], ["Numerous non-infective agents have been implicated based on epidemiological studies but none have stood up to scrutiny.135 The focus over the past two decades has been on infective agents that might trigger sarcoidosis, with the strongest suspects found in the mycobacteria family and the common commensal P acnes.", [["sarcoidosis", "DISEASE", 207, 218], ["P acnes", "SPECIES", 306, 313], ["Numerous non-infective agents", "TREATMENT", 0, 29], ["epidemiological studies", "TEST", 60, 83], ["infective agents", "TREATMENT", 171, 187], ["sarcoidosis", "PROBLEM", 207, 218], ["non-infective", "OBSERVATION", 9, 22], ["focus", "OBSERVATION_MODIFIER", 127, 132], ["sarcoidosis", "OBSERVATION", 207, 218], ["mycobacteria", "OBSERVATION", 261, 273], ["acnes", "OBSERVATION", 308, 313]]], ["And like classical tuberculosis where up to 90% of people infected with M tuberculosis remain in remission without treatment,20 sarcoidosis also has a 65\u201380% spontaneous remission rate without treatment.1 One may speculate that similar to tuberculosis, the immune system, after its initial response to a triggering microorganism, is successful in eradicating the agent and the immune response subsides.", [["immune system", "ANATOMY", 257, 270], ["tuberculosis", "DISEASE", 19, 31], ["tuberculosis", "DISEASE", 74, 86], ["sarcoidosis", "DISEASE", 128, 139], ["tuberculosis", "DISEASE", 239, 251], ["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["M tuberculosis", "SPECIES", 72, 86], ["classical tuberculosis", "PROBLEM", 9, 31], ["M tuberculosis", "PROBLEM", 72, 86], ["treatment", "TREATMENT", 115, 124], ["20 sarcoidosis", "PROBLEM", 125, 139], ["treatment", "TREATMENT", 193, 202], ["tuberculosis", "PROBLEM", 239, 251], ["a triggering microorganism", "PROBLEM", 302, 328], ["the agent", "TREATMENT", 359, 368], ["tuberculosis", "OBSERVATION", 19, 31], ["tuberculosis", "OBSERVATION", 74, 86], ["sarcoidosis", "OBSERVATION", 128, 139], ["tuberculosis", "OBSERVATION", 239, 251]]], ["Then in the 20% or so with persistent and progressive sarcoidosis, the organism remains viable and perpetuates the destructive immune response.Implications of the study ::: DiscussionSymptomatic sarcoidosis is usually treated with various anti-inflammatory and immunosuppressive agents such as corticosteroids, methotrexate and TNF-inhibitors (biologics).21 The similarities in immunological abnormalities and treatment to another debilitating granulomatous disease, Crohn's disease, are striking.22 Granulomatous ileitis (Crohn's) has been suspected by many investigators to be the result of a chronic infection with the obligate intracellular microorganism M avium subspecies paratuberculosis (MAP) that is known to cause a granulomatous ileitis in cattle and other ruminants called Johne's disease.23 Although the classical treatment of Crohn's disease has been with immunosuppressive agents just like with sarcoidosis, many recent studies suggest a much more effective treatment with less side effects may be a triple antibiotic regimen geared towards the putative triggering agent MAP.24\u201326 In fact, many in the field suspect that this intracellular organism (MAP) that resides in the macrophage impairs the normal autophagy that would usually eradicate the organism.24 Agents that enhance autophagy such as 16\u03b1-bromoepiandersterone,2728 currently in human trials, may prove effective along with antibiotics in Crohn's disease.24Implications of the study ::: DiscussionCan some antibacterial/antimycobacterial regimen such as that used in Crohn's disease alter the natural history of sarcoidosis in chronically symptomatic patients?", [["granulomatous", "ANATOMY", 444, 457], ["Granulomatous", "ANATOMY", 500, 513], ["intracellular", "ANATOMY", 631, 644], ["intracellular", "ANATOMY", 1141, 1154], ["macrophage", "ANATOMY", 1190, 1200], ["sarcoidosis", "DISEASE", 54, 65], ["sarcoidosis", "DISEASE", 195, 206], ["methotrexate", "CHEMICAL", 311, 323], ["granulomatous disease", "DISEASE", 444, 465], ["Crohn's disease", "DISEASE", 467, 482], ["Granulomatous ileitis", "DISEASE", 500, 521], ["Crohn's)", "DISEASE", 523, 531], ["infection", "DISEASE", 603, 612], ["granulomatous ileitis", "DISEASE", 726, 747], ["Johne's disease", "DISEASE", 785, 800], ["Crohn's disease", "DISEASE", 840, 855], ["sarcoidosis", "DISEASE", 910, 921], ["16\u03b1-bromoepiandersterone", "CHEMICAL", 1313, 1337], ["Crohn's disease", "DISEASE", 1416, 1431], ["Crohn's disease", "DISEASE", 1544, 1559], ["sarcoidosis", "DISEASE", 1589, 1600], ["corticosteroids", "CHEMICAL", 294, 309], ["methotrexate", "CHEMICAL", 311, 323], ["16\u03b1-bromoepiandersterone", "CHEMICAL", 1313, 1337], ["corticosteroids", "SIMPLE_CHEMICAL", 294, 309], ["methotrexate", "SIMPLE_CHEMICAL", 311, 323], ["TNF-inhibitors", "SIMPLE_CHEMICAL", 328, 342], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 631, 644], ["avium subspecies paratuberculosis", "ORGANISM", 661, 694], ["MAP", "GENE_OR_GENE_PRODUCT", 696, 699], ["MAP", "GENE_OR_GENE_PRODUCT", 1086, 1089], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 1141, 1154], ["MAP", "GENE_OR_GENE_PRODUCT", 1165, 1168], ["macrophage", "CELL", 1190, 1200], ["16\u03b1-bromoepiandersterone", "SIMPLE_CHEMICAL", 1313, 1337], ["human", "ORGANISM", 1356, 1361], ["Crohn's disease", "CANCER", 1416, 1431], ["patients", "ORGANISM", 1628, 1636], ["TNF", "PROTEIN", 328, 331], ["macrophage", "CELL_TYPE", 1190, 1200], ["M avium", "SPECIES", 659, 666], ["subspecies paratuberculosis", "SPECIES", 667, 694], ["cattle", "SPECIES", 751, 757], ["human", "SPECIES", 1356, 1361], ["patients", "SPECIES", 1628, 1636], ["M avium subspecies paratuberculosis", "SPECIES", 659, 694], ["cattle", "SPECIES", 751, 757], ["Johne", "SPECIES", 785, 790], ["human", "SPECIES", 1356, 1361], ["persistent and progressive sarcoidosis", "PROBLEM", 27, 65], ["the organism", "PROBLEM", 67, 79], ["the destructive immune response", "PROBLEM", 111, 142], ["the study", "TEST", 159, 168], ["DiscussionSymptomatic sarcoidosis", "PROBLEM", 173, 206], ["various anti-inflammatory", "TREATMENT", 231, 256], ["immunosuppressive agents", "TREATMENT", 261, 285], ["corticosteroids", "TREATMENT", 294, 309], ["methotrexate", "TREATMENT", 311, 323], ["TNF-inhibitors", "TREATMENT", 328, 342], ["immunological abnormalities", "PROBLEM", 378, 405], ["treatment", "TREATMENT", 410, 419], ["another debilitating granulomatous disease", "PROBLEM", 423, 465], ["Crohn's disease", "PROBLEM", 467, 482], ["Granulomatous ileitis", "PROBLEM", 500, 521], ["Crohn's", "PROBLEM", 523, 530], ["a chronic infection", "PROBLEM", 593, 612], ["the obligate intracellular microorganism M avium subspecies paratuberculosis", "PROBLEM", 618, 694], ["a granulomatous ileitis", "PROBLEM", 724, 747], ["Johne's disease", "PROBLEM", 785, 800], ["Crohn's disease", "PROBLEM", 840, 855], ["immunosuppressive agents", "TREATMENT", 870, 894], ["sarcoidosis", "PROBLEM", 910, 921], ["a triple antibiotic regimen", "TREATMENT", 1013, 1040], ["this intracellular organism", "PROBLEM", 1136, 1163], ["antibiotics", "TREATMENT", 1401, 1412], ["Crohn's disease", "PROBLEM", 1416, 1431], ["the study", "TEST", 1450, 1459], ["some antibacterial/antimycobacterial regimen", "TREATMENT", 1478, 1522], ["Crohn's disease", "PROBLEM", 1544, 1559], ["sarcoidosis", "PROBLEM", 1589, 1600], ["persistent", "OBSERVATION_MODIFIER", 27, 37], ["progressive", "OBSERVATION_MODIFIER", 42, 53], ["sarcoidosis", "OBSERVATION", 54, 65], ["destructive", "OBSERVATION_MODIFIER", 115, 126], ["sarcoidosis", "OBSERVATION", 195, 206], ["immunological abnormalities", "OBSERVATION", 378, 405], ["debilitating", "OBSERVATION_MODIFIER", 431, 443], ["granulomatous", "OBSERVATION", 444, 457], ["Crohn", "OBSERVATION", 467, 472], ["Granulomatous", "OBSERVATION_MODIFIER", 500, 513], ["ileitis", "OBSERVATION", 514, 521], ["chronic", "OBSERVATION_MODIFIER", 595, 602], ["infection", "OBSERVATION", 603, 612], ["avium", "OBSERVATION_MODIFIER", 661, 666], ["subspecies", "OBSERVATION_MODIFIER", 667, 677], ["paratuberculosis", "OBSERVATION", 678, 694], ["known to cause", "UNCERTAINTY", 709, 723], ["granulomatous", "OBSERVATION_MODIFIER", 726, 739], ["ileitis", "OBSERVATION", 740, 747], ["Crohn", "OBSERVATION", 840, 845], ["sarcoidosis", "OBSERVATION", 910, 921], ["macrophage", "ANATOMY", 1190, 1200], ["normal autophagy", "OBSERVATION", 1213, 1229], ["sarcoidosis", "OBSERVATION", 1589, 1600], ["chronically", "OBSERVATION_MODIFIER", 1604, 1615], ["symptomatic", "OBSERVATION_MODIFIER", 1616, 1627]]], ["Sixty years ago a number of small trials using classical antituberculous drugs (isoniazid, streptomycin or cortisone) were published with discouraging results.29 However, atypical mycobacteria (rather than M tuberculosis) that are more likely to be one of the aetiological agents in sarcoidosis are almost all resistant to the standard antituberculosis agents such as isoniazid.30\u201335 And if other organisms such as P acnes or perhaps cell-wall deficient (L-forms) bacteria trigger and perpetuate sarcoidosis in some individuals, then the standard antituberculous drugs would also be ineffective.Implications of the study ::: DiscussionThe tetracycline derivatives (minocycline and doxycycline) as well as the antimalarial drug chloroquine have been shown to be quite effective in treating cutaneous sarcoidosis.36 Minocycline can produce complete responses in two-thirds of cases, although it is debated whether this is an antimicrobial effect or an immunomodulating effect.37Implications of the study ::: DiscussionAttention has recently turned to randomised sarcoidosis treatment trials with various antimicrobial agents.", [["cell-wall", "ANATOMY", 434, 443], ["cutaneous sarcoidosis", "ANATOMY", 789, 810], ["isoniazid", "CHEMICAL", 80, 89], ["streptomycin", "CHEMICAL", 91, 103], ["cortisone", "CHEMICAL", 107, 116], ["tuberculosis", "DISEASE", 208, 220], ["sarcoidosis", "DISEASE", 283, 294], ["isoniazid", "CHEMICAL", 368, 377], ["sarcoidosis", "DISEASE", 496, 507], ["tetracycline", "CHEMICAL", 639, 651], ["minocycline", "CHEMICAL", 665, 676], ["doxycycline", "CHEMICAL", 681, 692], ["chloroquine", "CHEMICAL", 727, 738], ["sarcoidosis", "DISEASE", 799, 810], ["Minocycline", "CHEMICAL", 814, 825], ["sarcoidosis", "DISEASE", 1060, 1071], ["isoniazid", "CHEMICAL", 80, 89], ["streptomycin", "CHEMICAL", 91, 103], ["cortisone", "CHEMICAL", 107, 116], ["isoniazid", "CHEMICAL", 368, 377], ["tetracycline", "CHEMICAL", 639, 651], ["minocycline", "CHEMICAL", 665, 676], ["doxycycline", "CHEMICAL", 681, 692], ["chloroquine", "CHEMICAL", 727, 738], ["Minocycline", "CHEMICAL", 814, 825], ["isoniazid", "SIMPLE_CHEMICAL", 80, 89], ["streptomycin", "SIMPLE_CHEMICAL", 91, 103], ["cortisone", "SIMPLE_CHEMICAL", 107, 116], ["isoniazid", "SIMPLE_CHEMICAL", 368, 377], ["cell", "CELL", 434, 438], ["tetracycline derivatives", "SIMPLE_CHEMICAL", 639, 663], ["minocycline", "SIMPLE_CHEMICAL", 665, 676], ["doxycycline", "SIMPLE_CHEMICAL", 681, 692], ["chloroquine", "SIMPLE_CHEMICAL", 727, 738], ["Minocycline", "SIMPLE_CHEMICAL", 814, 825], ["M tuberculosis", "SPECIES", 206, 220], ["M tuberculosis", "SPECIES", 206, 220], ["P acnes", "SPECIES", 415, 422], ["small trials", "TREATMENT", 28, 40], ["classical antituberculous drugs", "TREATMENT", 47, 78], ["isoniazid", "TREATMENT", 80, 89], ["streptomycin", "TREATMENT", 91, 103], ["cortisone", "TREATMENT", 107, 116], ["atypical mycobacteria", "PROBLEM", 171, 192], ["M tuberculosis", "PROBLEM", 206, 220], ["sarcoidosis", "PROBLEM", 283, 294], ["the standard antituberculosis agents", "TREATMENT", 323, 359], ["isoniazid", "TREATMENT", 368, 377], ["other organisms", "PROBLEM", 391, 406], ["P acnes", "PROBLEM", 415, 422], ["cell-wall deficient", "PROBLEM", 434, 453], ["bacteria trigger", "PROBLEM", 464, 480], ["sarcoidosis", "PROBLEM", 496, 507], ["some individuals", "PROBLEM", 511, 527], ["the standard antituberculous drugs", "TREATMENT", 534, 568], ["the study", "TEST", 611, 620], ["The tetracycline derivatives", "TREATMENT", 635, 663], ["minocycline", "TREATMENT", 665, 676], ["doxycycline", "TREATMENT", 681, 692], ["the antimalarial drug chloroquine", "TREATMENT", 705, 738], ["cutaneous sarcoidosis", "PROBLEM", 789, 810], ["Minocycline", "TREATMENT", 814, 825], ["an antimicrobial effect", "PROBLEM", 920, 943], ["an immunomodulating effect", "PROBLEM", 947, 973], ["the study", "TEST", 992, 1001], ["randomised sarcoidosis treatment trials", "TREATMENT", 1049, 1088], ["various antimicrobial agents", "TREATMENT", 1094, 1122], ["atypical", "OBSERVATION_MODIFIER", 171, 179], ["mycobacteria", "OBSERVATION", 180, 192], ["more likely to be", "UNCERTAINTY", 231, 248], ["sarcoidosis", "OBSERVATION", 283, 294], ["wall deficient", "OBSERVATION", 439, 453], ["sarcoidosis", "OBSERVATION", 496, 507], ["cutaneous", "ANATOMY", 789, 798], ["sarcoidosis", "OBSERVATION", 799, 810], ["antimicrobial effect", "OBSERVATION", 923, 943], ["immunomodulating effect", "OBSERVATION", 950, 973], ["sarcoidosis", "OBSERVATION", 1060, 1071]]], ["Drake et al38 just published positive results of the first randomised trial (NCT01074554) of an antimicrobial regimen (directed at atypical mycobacteria) in the USA using oral concomitant levofloxacin, ethambutol, azithromycin and rifampin (CLEAR) regimen to treat 30 patients with cutaneous sarcoidosis, with quite significant reductions in cutaneous lesion size.", [["oral", "ANATOMY", 171, 175], ["cutaneous lesion", "ANATOMY", 342, 358], ["levofloxacin", "CHEMICAL", 188, 200], ["ethambutol", "CHEMICAL", 202, 212], ["azithromycin", "CHEMICAL", 214, 226], ["rifampin", "CHEMICAL", 231, 239], ["CLEAR", "CHEMICAL", 241, 246], ["sarcoidosis", "DISEASE", 292, 303], ["levofloxacin", "CHEMICAL", 188, 200], ["ethambutol", "CHEMICAL", 202, 212], ["azithromycin", "CHEMICAL", 214, 226], ["rifampin", "CHEMICAL", 231, 239], ["CLEAR", "CHEMICAL", 241, 246], ["oral", "ORGANISM_SUBDIVISION", 171, 175], ["levofloxacin", "SIMPLE_CHEMICAL", 188, 200], ["ethambutol", "SIMPLE_CHEMICAL", 202, 212], ["azithromycin", "SIMPLE_CHEMICAL", 214, 226], ["rifampin", "SIMPLE_CHEMICAL", 231, 239], ["CLEAR", "SIMPLE_CHEMICAL", 241, 246], ["patients", "ORGANISM", 268, 276], ["cutaneous lesion", "PATHOLOGICAL_FORMATION", 342, 358], ["patients", "SPECIES", 268, 276], ["an antimicrobial regimen", "TREATMENT", 93, 117], ["atypical mycobacteria", "PROBLEM", 131, 152], ["oral concomitant levofloxacin", "TREATMENT", 171, 200], ["ethambutol", "TREATMENT", 202, 212], ["azithromycin", "TREATMENT", 214, 226], ["rifampin", "TREATMENT", 231, 239], ["CLEAR) regimen", "TREATMENT", 241, 255], ["cutaneous sarcoidosis", "PROBLEM", 282, 303], ["significant reductions in cutaneous lesion size", "PROBLEM", 316, 363], ["cutaneous", "ANATOMY", 282, 291], ["sarcoidosis", "OBSERVATION", 292, 303], ["significant", "OBSERVATION_MODIFIER", 316, 327], ["reductions", "OBSERVATION_MODIFIER", 328, 338], ["cutaneous", "ANATOMY", 342, 351], ["lesion", "OBSERVATION", 352, 358], ["size", "OBSERVATION_MODIFIER", 359, 363]]], ["Gupta et al39 in their comprehensive review of sarcoidosis and its similarities to tuberculosis present a convincing case for antituberculous treatment of sarcoidosis.", [["sarcoidosis", "DISEASE", 47, 58], ["tuberculosis", "DISEASE", 83, 95], ["sarcoidosis", "DISEASE", 155, 166], ["sarcoidosis", "PROBLEM", 47, 58], ["tuberculosis", "PROBLEM", 83, 95], ["antituberculous treatment", "TREATMENT", 126, 151], ["sarcoidosis", "PROBLEM", 155, 166], ["sarcoidosis", "OBSERVATION", 47, 58], ["tuberculosis", "OBSERVATION", 83, 95], ["sarcoidosis", "OBSERVATION", 155, 166]]], ["Gupta is also the principal investigator in an ongoing clinical trial in India using more standard antituberculous therapy \u201cRifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial\u201d (ClinicalTrials.gov Identifier: NCT01245036).40 The results of this trial in India with its high burden of tuberculosis will be available next year, though the drug regimen used may not be as effective in countries with a low tuberculosis burden.", [["Rifampicin", "CHEMICAL", 124, 134], ["Isoniazid", "CHEMICAL", 139, 148], ["Prednisolone", "CHEMICAL", 160, 172], ["Prednisolone Alone", "CHEMICAL", 185, 203], ["Sarcoidosis", "DISEASE", 220, 231], ["tuberculosis", "DISEASE", 377, 389], ["tuberculosis", "DISEASE", 496, 508], ["Rifampicin", "CHEMICAL", 124, 134], ["Isoniazid", "CHEMICAL", 139, 148], ["Prednisolone", "CHEMICAL", 160, 172], ["Prednisolone", "CHEMICAL", 185, 197], ["Rifampicin", "SIMPLE_CHEMICAL", 124, 134], ["Isoniazid", "SIMPLE_CHEMICAL", 139, 148], ["Prednisolone", "SIMPLE_CHEMICAL", 160, 172], ["Prednisolone", "SIMPLE_CHEMICAL", 185, 197], ["more standard antituberculous therapy", "TREATMENT", 85, 122], ["Rifampicin", "TREATMENT", 124, 134], ["Isoniazid", "TREATMENT", 139, 148], ["Prednisolone", "TREATMENT", 160, 172], ["Prednisolone", "TREATMENT", 185, 197], ["Sarcoidosis", "PROBLEM", 220, 231], ["a Pilot Randomized", "TREATMENT", 233, 251], ["tuberculosis", "PROBLEM", 377, 389], ["the drug regimen", "TREATMENT", 426, 442], ["a low tuberculosis burden", "PROBLEM", 490, 515], ["Sarcoidosis", "OBSERVATION", 220, 231], ["tuberculosis", "OBSERVATION", 377, 389], ["low", "OBSERVATION_MODIFIER", 492, 495], ["tuberculosis", "OBSERVATION", 496, 508]]], ["If indeed sarcoidosis arises from an abnormal immunological response to a microorganism(s), the patient's geographical location may dictate which microorganism is involved and what antimicrobial regimen will be most effective.ConclusionsOver the past three decades or more, numerous studies have examined every aspect of sarcoidosis including its dysfunctional immune response.", [["sarcoidosis", "DISEASE", 10, 21], ["sarcoidosis", "DISEASE", 321, 332], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["indeed sarcoidosis", "PROBLEM", 3, 21], ["an abnormal immunological response", "PROBLEM", 34, 68], ["a microorganism", "PROBLEM", 72, 87], ["antimicrobial regimen", "TREATMENT", 181, 202], ["numerous studies", "TEST", 274, 290], ["sarcoidosis", "PROBLEM", 321, 332], ["its dysfunctional immune response", "PROBLEM", 343, 376], ["sarcoidosis", "OBSERVATION", 10, 21], ["abnormal", "OBSERVATION_MODIFIER", 37, 45], ["immunological response", "OBSERVATION", 46, 68], ["sarcoidosis", "OBSERVATION", 321, 332], ["dysfunctional immune response", "OBSERVATION", 347, 376]]], ["The primary therapy is immune suppression in various forms but this treats only symptoms and does not seem to alter the natural history of the disease.421 Dozens of studies (table 3) have repeatedly demonstrated evidence of microorganisms in 30\u201380% of sarcoidosis tissues, mostly various mycobacteria and P acnes and more of these molecular studies are not likely warranted.ConclusionsPerhaps we should follow the lead of the Crohn's disease gastroenterologists2425 and proceed with a therapeutic clinical trial using a regimen of multiple antibiotics in patients with persistently symptomatic, advanced-stage sarcoidosis.", [["sarcoidosis tissues", "ANATOMY", 252, 271], ["sarcoidosis", "DISEASE", 252, 263], ["Crohn's disease", "DISEASE", 426, 441], ["sarcoidosis", "DISEASE", 610, 621], ["sarcoidosis tissues", "TISSUE", 252, 271], ["patients", "ORGANISM", 555, 563], ["patients", "SPECIES", 555, 563], ["P acnes", "SPECIES", 305, 312], ["The primary therapy", "TREATMENT", 0, 19], ["immune suppression", "PROBLEM", 23, 41], ["symptoms", "PROBLEM", 80, 88], ["the disease", "PROBLEM", 139, 150], ["studies", "TEST", 165, 172], ["microorganisms", "PROBLEM", 224, 238], ["sarcoidosis tissues", "PROBLEM", 252, 271], ["various mycobacteria and P acnes", "PROBLEM", 280, 312], ["these molecular studies", "TEST", 325, 348], ["a regimen", "TREATMENT", 518, 527], ["multiple antibiotics", "TREATMENT", 531, 551], ["advanced-stage sarcoidosis", "PROBLEM", 595, 621], ["immune suppression", "OBSERVATION", 23, 41], ["disease", "OBSERVATION", 143, 150], ["evidence of", "UNCERTAINTY", 212, 223], ["microorganisms", "OBSERVATION", 224, 238], ["sarcoidosis", "OBSERVATION", 252, 263], ["various", "OBSERVATION_MODIFIER", 280, 287], ["mycobacteria", "OBSERVATION", 288, 300], ["not likely", "UNCERTAINTY", 353, 363], ["symptomatic", "OBSERVATION_MODIFIER", 582, 593], ["advanced", "OBSERVATION_MODIFIER", 595, 603], ["-stage", "OBSERVATION_MODIFIER", 603, 609], ["sarcoidosis", "OBSERVATION", 610, 621]]], ["Indeed, if there is a persistent, viable microorganism infection causing the continuing or progressive debilitating symptoms and organ failure, antibiotics might favourably impact the course of this disease.", [["organ", "ANATOMY", 129, 134], ["infection", "DISEASE", 55, 64], ["organ failure", "DISEASE", 129, 142], ["organ", "ORGAN", 129, 134], ["a persistent, viable microorganism infection", "PROBLEM", 20, 64], ["progressive debilitating symptoms", "PROBLEM", 91, 124], ["organ failure", "PROBLEM", 129, 142], ["antibiotics", "TREATMENT", 144, 155], ["this disease", "PROBLEM", 194, 206], ["persistent", "OBSERVATION_MODIFIER", 22, 32], ["microorganism", "OBSERVATION_MODIFIER", 41, 54], ["infection", "OBSERVATION", 55, 64], ["progressive", "OBSERVATION_MODIFIER", 91, 102], ["debilitating", "OBSERVATION_MODIFIER", 103, 115], ["organ", "ANATOMY", 129, 134], ["failure", "OBSERVATION", 135, 142]]]], "PMC7402240": [["Doping and anti-doping ::: BackgroundAnti-doping is a prohibitive, legalistic system of athlete-centred surveillance, testing, and sanctioning (de Hon, 2016; Mazanov, 2013).", [["testing", "TEST", 118, 125], ["prohibitive", "OBSERVATION_MODIFIER", 54, 65]]], ["Indeed, the WADA Code identifies many illicit \u2018recreational drugs\u2019, such as cocaine, MDMA, heroin, and mephedrone, as substances prohibited in competition; the latter list includes controlled substances (namely cannabis, and opioid-substitution medications like buprenorphine) whose medical applications are increasingly recognized for purposes unrelated to performance enhancement (Abuhasira, Shbiro & Landschaft, 2018; Thomas et al., 2014).Doping and anti-doping ::: BackgroundBeyond health concerns, anti-doping is also supposed to ensure fair competition by preventing any athlete from gaining an unfair advantage.", [["cocaine", "CHEMICAL", 76, 83], ["MDMA", "CHEMICAL", 85, 89], ["heroin", "CHEMICAL", 91, 97], ["mephedrone", "CHEMICAL", 103, 113], ["cannabis", "CHEMICAL", 211, 219], ["buprenorphine", "CHEMICAL", 262, 275], ["cocaine", "CHEMICAL", 76, 83], ["MDMA", "CHEMICAL", 85, 89], ["heroin", "CHEMICAL", 91, 97], ["mephedrone", "CHEMICAL", 103, 113], ["buprenorphine", "CHEMICAL", 262, 275], ["cocaine", "SIMPLE_CHEMICAL", 76, 83], ["MDMA", "SIMPLE_CHEMICAL", 85, 89], ["heroin", "SIMPLE_CHEMICAL", 91, 97], ["mephedrone", "SIMPLE_CHEMICAL", 103, 113], ["buprenorphine", "SIMPLE_CHEMICAL", 262, 275], ["heroin", "TREATMENT", 91, 97], ["mephedrone", "TREATMENT", 103, 113], ["opioid-substitution medications", "TREATMENT", 225, 256], ["buprenorphine", "TREATMENT", 262, 275]]], ["This is primarily done through a system of testing biological samples from athletes collected both in and out of competition times and then banning athletes who test positive for doping.", [["testing biological samples", "TEST", 43, 69]]], ["WADA takes a zero-tolerance approach under the principle of strict liability, which holds individual athletes responsible for any substance detected in a urine or blood sample regardless of how it got there (WADA, 2019).", [["urine", "ANATOMY", 154, 159], ["blood sample", "ANATOMY", 163, 175], ["urine", "ORGANISM_SUBSTANCE", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["a zero-tolerance approach", "TREATMENT", 11, 36], ["a urine", "TEST", 152, 159], ["blood sample", "TEST", 163, 175]]], ["While this keeps athletes out of civil justice system, there is an automatic presumption of guilt if an athlete tests positive for a prohibited substance (Lenskyj, 2018).", [["an athlete tests", "TEST", 101, 117]]], ["First time Code violations are punishable by a competition ban lasting up to four years (WADA, 2019).Doping and anti-doping ::: BackgroundThe prevalence of doping is unclear, though there is a significant gap between prevalence estimated by researchers and the official testing results.", [["a significant gap", "PROBLEM", 191, 208], ["the official testing", "TEST", 257, 277], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["gap", "OBSERVATION", 205, 208]]], ["WADA consistently returns a positive test rate of 1\u20132% per year \u2013 with exceptions for years in which retesting has occurred \u2013 while researchers using more sophisticated survey and modelling methods have estimated much higher rates, varying between 14 and 57% (de Hon, Kuipers & van Bottenburg, 2015; Elbe & Pitsch, 2018; Ulrich et al., 2018).", [["modelling methods", "TEST", 180, 197]]], ["It is difficult to determine the effect anti-doping policies have had on doping prevalence, as there were no baseline prevalence studies before WADA's founding.", [["baseline prevalence studies", "PROBLEM", 109, 136]]], ["However, the discrepancy between the positive test rate and even the lowest prevalence estimates indicate that a large number of athletes who report engaging in doping are not being detected, potentially exacerbating PED-driven inequalities between athletes.", [["the positive test rate", "TEST", 33, 55], ["large", "OBSERVATION_MODIFIER", 113, 118]]], ["In this way, anti-doping policies may mirror the limited effectiveness of recreational drug prohibition in deterring consumption or punishing violations, lessons best illustrated in the case of the United States.", [["anti-doping policies", "TREATMENT", 13, 33]]], ["For example, the 2018 U.S. National Survey on Drug Use and Health estimated that roughly 53.2 million residents aged 12 and over had used illicit drugs in the past 12 months; that same year, the Federal Bureau of Investigation recorded less than 1.2 million arrests for possession of controlled substances, a capture rate just over 2% (likely inflated by the repeated arrest of certain individuals) (United States Department of Health & Human Services, 2018; United States Department of Justice, 2018).", [["Human", "SPECIES", 437, 442], ["a capture rate", "TEST", 307, 321]]], ["Overall, it is increasingly accepted that the introduction of highly punitive prison terms for drug offenses in countries worldwide has done little to reduce drug use, decrease drug purity, or increase drug prices, a failure starkly evidenced by successive and concurrent opioid epidemics in Eastern Europe and the CIS, Southwest Asia, North America, and Australia (Drug Policy Alliance, 2015; Pew Center, 2015; United States Sentencing Commission, 2017).", [["a failure", "PROBLEM", 215, 224]]], ["Even within a far more circumscribed arena of enforcement \u2013 certain types of substance use within specific sporting competitions \u2013 it is unlikely doping-free sport (WADA, 2020) will be achieved through a strategy of random or targeted testing and harsh sanctioning.", [["targeted testing", "TEST", 226, 242], ["harsh sanctioning", "TREATMENT", 247, 264], ["circumscribed", "OBSERVATION_MODIFIER", 23, 36]]], ["It is possible that elite individuals or teams might still see the advantages of doping as exceeding the risk of detection even if athlete testing was expanded.Doping and anti-doping ::: BackgroundThough there is a range of motivations for engaging in doping (Henning & Dimeo, 2014), a primary one at the elite level is winning.", [["athlete testing", "TEST", 131, 146]]], ["However, the physical and social risks of doping are multiplied when individuals must secure their own supply, determine their own doses, minimise side effects, and prevent being caught through in or out of competition testing.", [["competition testing", "TEST", 207, 226]]], ["While motivated by both shared and unique interests, systematic doping is similar to the phenomenon of Heroin Assisted Treatment (HAT), or the (tenuously) legal dispensing of pharmaceutical-grade heroin to individuals who have struggled with other modalities of opioid use treatment (Kilmer et al., 2018).", [["Heroin", "CHEMICAL", 103, 109], ["heroin", "CHEMICAL", 196, 202], ["heroin", "CHEMICAL", 196, 202], ["Heroin Assisted Treatment", "TREATMENT", 103, 128], ["opioid use treatment", "TREATMENT", 262, 282]]], ["Though systematic doping is often done for collective performance enhancement, related concerns include avoiding detection and ensuring athletes remain healthy enough to compete.", [["collective performance enhancement", "PROBLEM", 43, 77]]], ["As such, systematic doping may also be a way of managing risks (e.g. safe supply, dosing oversight, side effect management) that would be greater if each athlete were to undertake doping individually.", [["safe supply", "TREATMENT", 69, 80], ["side effect management", "TREATMENT", 100, 122]]], ["Of course, both HAT and systematic doping as it currently exists are still limited by international/national prohibition policies.Risk and enabling environments ::: BackgroundAs suggested by Rhodes (2009) drug harms are shaped by risk environments and a risk environment framework can therefore promote an improved understanding of harm, and harm reduction, as a matter of \u2018contingent causation\u2019 (p.", [["systematic doping", "TREATMENT", 24, 41]]], ["There has been quite a bit of research attention given to risk environments in which social or recreational drug use occurs (see Duff, 2009; 2010; McLean, 2016; Rhodes et al., 2003).", [["research attention", "TREATMENT", 30, 48]]]], "57e61a5675bbe59c337b8e3c8a40b3c2b458f06f": [["IntroductionChronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation and is a progressive disease that is not fully reversible (1) .", [["pulmonary", "ANATOMY", 32, 41], ["IntroductionChronic obstructive pulmonary disease", "DISEASE", 0, 49], ["COPD", "DISEASE", 51, 55], ["pulmonary", "ORGAN", 32, 41], ["IntroductionChronic obstructive pulmonary disease (COPD)", "PROBLEM", 0, 56], ["a disease", "PROBLEM", 60, 69], ["airflow limitation", "PROBLEM", 87, 105], ["a progressive disease", "PROBLEM", 113, 134], ["obstructive", "OBSERVATION_MODIFIER", 20, 31], ["pulmonary", "ANATOMY", 32, 41], ["disease", "OBSERVATION", 42, 49], ["COPD", "OBSERVATION", 51, 55], ["airflow limitation", "OBSERVATION", 87, 105], ["progressive", "OBSERVATION_MODIFIER", 115, 126], ["disease", "OBSERVATION", 127, 134], ["not", "UNCERTAINTY", 143, 146], ["fully reversible", "OBSERVATION_MODIFIER", 147, 163]]], ["The World Health Organization has predicted that COPD will be the third leading cause of death worldwide in 2030 (2, 3) .", [["COPD", "DISEASE", 49, 53], ["death", "DISEASE", 89, 94], ["COPD", "PROBLEM", 49, 53], ["death", "PROBLEM", 89, 94], ["COPD", "OBSERVATION", 49, 53]]], ["Tissues from patients with COPD are characterized by chronic inflammation, mucus metaplasia, alveolar destruction and structural cell apoptosis (4) .", [["Tissues", "ANATOMY", 0, 7], ["mucus metaplasia", "ANATOMY", 75, 91], ["alveolar", "ANATOMY", 93, 101], ["cell", "ANATOMY", 129, 133], ["COPD", "DISEASE", 27, 31], ["inflammation", "DISEASE", 61, 73], ["Tissues", "CANCER", 0, 7], ["patients", "ORGANISM", 13, 21], ["mucus metaplasia", "PATHOLOGICAL_FORMATION", 75, 91], ["alveolar", "TISSUE", 93, 101], ["cell", "CELL", 129, 133], ["patients", "SPECIES", 13, 21], ["COPD", "PROBLEM", 27, 31], ["chronic inflammation", "PROBLEM", 53, 73], ["mucus metaplasia", "PROBLEM", 75, 91], ["alveolar destruction", "PROBLEM", 93, 113], ["structural cell apoptosis", "PROBLEM", 118, 143], ["COPD", "OBSERVATION", 27, 31], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["inflammation", "OBSERVATION", 61, 73], ["mucus metaplasia", "OBSERVATION", 75, 91], ["alveolar", "ANATOMY_MODIFIER", 93, 101], ["destruction", "OBSERVATION", 102, 113], ["structural cell apoptosis", "OBSERVATION", 118, 143]]], ["Inflammation is an important factor in the development of COPD (5) .", [["Inflammation", "DISEASE", 0, 12], ["COPD", "DISEASE", 58, 62], ["Inflammation", "PROBLEM", 0, 12], ["COPD", "PROBLEM", 58, 62], ["COPD", "OBSERVATION", 58, 62]]], ["Inflammation in patients may be causally related to emphysema or other pathological alterations in the lungs and worsens with disease progression (6, 7) .", [["lungs", "ANATOMY", 103, 108], ["Inflammation", "DISEASE", 0, 12], ["emphysema", "DISEASE", 52, 61], ["patients", "ORGANISM", 16, 24], ["lungs", "ORGAN", 103, 108], ["patients", "SPECIES", 16, 24], ["Inflammation", "PROBLEM", 0, 12], ["emphysema", "PROBLEM", 52, 61], ["other pathological alterations in the lungs", "PROBLEM", 65, 108], ["disease progression", "PROBLEM", 126, 145], ["may be causally related to", "UNCERTAINTY", 25, 51], ["emphysema", "OBSERVATION", 52, 61], ["pathological", "OBSERVATION", 71, 83], ["lungs", "ANATOMY", 103, 108], ["worsens", "OBSERVATION_MODIFIER", 113, 120], ["disease", "OBSERVATION", 126, 133]]], ["Pulmonary inflammation might have an adverse impact on various extrapulmonary organs, such as blood vessels and the heart (8) (9) (10) .", [["Pulmonary", "ANATOMY", 0, 9], ["extrapulmonary organs", "ANATOMY", 63, 84], ["blood vessels", "ANATOMY", 94, 107], ["heart", "ANATOMY", 116, 121], ["Pulmonary inflammation", "DISEASE", 0, 22], ["Pulmonary", "ORGAN", 0, 9], ["organs", "ORGAN", 78, 84], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 94, 107], ["heart", "ORGAN", 116, 121], ["Pulmonary inflammation", "PROBLEM", 0, 22], ["an adverse impact on various extrapulmonary organs", "PROBLEM", 34, 84], ["inflammation", "OBSERVATION", 10, 22], ["adverse", "OBSERVATION_MODIFIER", 37, 44], ["extrapulmonary organs", "ANATOMY", 63, 84], ["blood vessels", "ANATOMY", 94, 107], ["heart", "ANATOMY", 116, 121]]], ["During the progression of pulmonary inflammation in COPD, both the innate immune and adaptive immune systems are involved.", [["pulmonary", "ANATOMY", 26, 35], ["pulmonary inflammation", "DISEASE", 26, 48], ["COPD", "DISEASE", 52, 56], ["pulmonary", "ORGAN", 26, 35], ["pulmonary inflammation", "PROBLEM", 26, 48], ["COPD", "PROBLEM", 52, 56], ["adaptive immune systems", "TREATMENT", 85, 108], ["progression", "OBSERVATION_MODIFIER", 11, 22], ["pulmonary", "ANATOMY", 26, 35], ["inflammation", "OBSERVATION", 36, 48], ["COPD", "OBSERVATION", 52, 56]]], ["This is particularly true for the innate immune system, whose role is unknown during the inflammation response in COPD.IntroductionInnate immunity is the first line of defense against foreign pathogens.", [["inflammation", "DISEASE", 89, 101], ["COPD", "DISEASE", 114, 118], ["the inflammation response", "PROBLEM", 85, 110], ["COPD", "PROBLEM", 114, 118], ["foreign pathogens", "PROBLEM", 184, 201], ["COPD", "OBSERVATION", 114, 118], ["foreign pathogens", "OBSERVATION", 184, 201]]], ["Its role in the airways involves the detection of pathogen-or damage-associated molecular patterns (PAMPs or DAMPs) by pattern recognition receptors (PRRs) including Toll-like receptors (TLRs) and retinoic acid inducible gene I (RIG-I)like receptors (RLRs) (11) .", [["airways", "ANATOMY", 16, 23], ["retinoic acid", "CHEMICAL", 197, 210], ["retinoic acid", "CHEMICAL", 197, 210], ["airways", "MULTI-TISSUE_STRUCTURE", 16, 23], ["DAMPs", "GENE_OR_GENE_PRODUCT", 109, 114], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 119, 148], ["PRRs", "GENE_OR_GENE_PRODUCT", 150, 154], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 166, 185], ["TLRs", "GENE_OR_GENE_PRODUCT", 187, 191], ["retinoic acid inducible gene I", "GENE_OR_GENE_PRODUCT", 197, 227], ["RIG-I)like receptors", "GENE_OR_GENE_PRODUCT", 229, 249], ["RLRs", "GENE_OR_GENE_PRODUCT", 251, 255], ["PAMPs", "PROTEIN", 100, 105], ["DAMPs", "PROTEIN", 109, 114], ["pattern recognition receptors", "PROTEIN", 119, 148], ["PRRs", "PROTEIN", 150, 154], ["Toll-like receptors", "PROTEIN", 166, 185], ["TLRs", "PROTEIN", 187, 191], ["retinoic acid inducible gene I (RIG-I)like receptors", "PROTEIN", 197, 249], ["RLRs", "DNA", 251, 255], ["pathogen", "PROBLEM", 50, 58], ["damage", "PROBLEM", 62, 68], ["DAMPs", "PROBLEM", 109, 114], ["Toll-like receptors", "TREATMENT", 166, 185], ["retinoic acid inducible gene I", "PROBLEM", 197, 227], ["airways", "ANATOMY", 16, 23]]], ["Latent infection of adenoviruses in childhood can promote chronic inflammation and thus gradually lead to COPD (12) .", [["infection", "DISEASE", 7, 16], ["inflammation", "DISEASE", 66, 78], ["COPD", "DISEASE", 106, 110], ["adenoviruses", "ORGANISM", 20, 32], ["Latent infection of adenoviruses", "PROBLEM", 0, 32], ["chronic inflammation", "PROBLEM", 58, 78], ["COPD", "PROBLEM", 106, 110], ["infection", "OBSERVATION", 7, 16], ["adenoviruses", "OBSERVATION", 20, 32], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["inflammation", "OBSERVATION", 66, 78], ["COPD", "OBSERVATION", 106, 110]]], ["Recent studies have demonstrated that a variety of viruses can cause exacerbation of the disease (13, 14) .", [["Recent studies", "TEST", 0, 14], ["a variety of viruses", "PROBLEM", 38, 58], ["exacerbation of the disease", "PROBLEM", 69, 96], ["viruses", "OBSERVATION", 51, 58], ["disease", "OBSERVATION", 89, 96]]], ["Compared with exacerbation due to other causes, viral-induced COPD exacerbation is more severe, lasts longer and is associated with airway and systemic inflammatory responses (15, 16) .", [["airway", "ANATOMY", 132, 138], ["COPD", "DISEASE", 62, 66], ["airway", "MULTI-TISSUE_STRUCTURE", 132, 138], ["exacerbation", "PROBLEM", 14, 26], ["viral-induced COPD exacerbation", "PROBLEM", 48, 79], ["airway and systemic inflammatory responses", "PROBLEM", 132, 174], ["viral", "OBSERVATION", 48, 53], ["COPD", "OBSERVATION", 62, 66], ["more severe", "OBSERVATION_MODIFIER", 83, 94], ["associated with", "UNCERTAINTY", 116, 131], ["airway", "ANATOMY", 132, 138], ["systemic", "OBSERVATION_MODIFIER", 143, 151], ["inflammatory", "OBSERVATION", 152, 164]]], ["RLRs are newly discovered pattern recognition receptors, which play a critical role in the elimination of viral infections (17) (18) (19) (20) (21) (22) .", [["viral infections", "DISEASE", 106, 122], ["RLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["RLRs", "PROTEIN", 0, 4], ["pattern recognition receptors", "PROTEIN", 26, 55], ["viral infections", "PROBLEM", 106, 122]]], ["RLRs include RIG-I, melanoma differentiation associated gene 5 (MDA-5) and laboratory of genetics and physiology 2 (LGP2) (23) (24) (25) .", [["melanoma", "ANATOMY", 20, 28], ["melanoma", "DISEASE", 20, 28], ["RIG-I", "GENE_OR_GENE_PRODUCT", 13, 18], ["melanoma differentiation associated gene 5", "GENE_OR_GENE_PRODUCT", 20, 62], ["MDA-5", "GENE_OR_GENE_PRODUCT", 64, 69], ["RLRs", "PROTEIN", 0, 4], ["RIG-I", "DNA", 13, 18], ["melanoma differentiation associated gene 5", "DNA", 20, 62], ["MDA", "DNA", 64, 67], ["melanoma differentiation", "PROBLEM", 20, 44], ["MDA", "TEST", 64, 67], ["physiology", "TEST", 102, 112], ["melanoma", "OBSERVATION", 20, 28]]], ["These RLRs localize within the cytoplasm.", [["cytoplasm", "ANATOMY", 31, 40], ["RLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 31, 40], ["RLRs", "PROTEIN", 6, 10], ["cytoplasm", "OBSERVATION_MODIFIER", 31, 40]]], ["When viral RNA binds to the C-terminal regulatory domain of RIG-I or MDA-5, it can initiate a signaling cascade leading to activation and nuclear translocation of the transcription factors NF-\u03baB and IRF-3, which are needed to turn on transcription of interferons (IFNs) (26) (27) (28) .", [["nuclear", "ANATOMY", 138, 145], ["C", "CHEMICAL", 28, 29], ["RIG-I", "GENE_OR_GENE_PRODUCT", 60, 65], ["MDA-5", "GENE_OR_GENE_PRODUCT", 69, 74], ["nuclear", "CELLULAR_COMPONENT", 138, 145], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 189, 194], ["IRF-3", "GENE_OR_GENE_PRODUCT", 199, 204], ["interferons", "GENE_OR_GENE_PRODUCT", 251, 262], ["viral RNA", "RNA", 5, 14], ["C-terminal regulatory domain", "PROTEIN", 28, 56], ["RIG-I", "PROTEIN", 60, 65], ["MDA-5", "PROTEIN", 69, 74], ["transcription factors", "PROTEIN", 167, 188], ["NF-\u03baB", "PROTEIN", 189, 194], ["IRF-3", "PROTEIN", 199, 204], ["interferons", "PROTEIN", 251, 262], ["IFNs", "PROTEIN", 264, 268], ["viral RNA binds", "PROBLEM", 5, 20], ["MDA", "TEST", 69, 72], ["a signaling cascade", "PROBLEM", 92, 111], ["NF", "TEST", 189, 191], ["IRF", "TEST", 199, 202], ["transcription of interferons", "TREATMENT", 234, 262]]], ["The LGP2 lacks a caspase activation and recruitment domain and incapable of interferon production (29) .IntroductionOnce triggered, RIG-I and MDA-5 activate intracellular signaling pathways that culminate in the induc-tion of antiviral cytokines and pro-inflammatory mediators.", [["intracellular", "ANATOMY", 157, 170], ["LGP2", "GENE_OR_GENE_PRODUCT", 4, 8], ["caspase", "GENE_OR_GENE_PRODUCT", 17, 24], ["interferon", "GENE_OR_GENE_PRODUCT", 76, 86], ["RIG-I", "GENE_OR_GENE_PRODUCT", 132, 137], ["MDA-5", "GENE_OR_GENE_PRODUCT", 142, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["LGP2", "PROTEIN", 4, 8], ["caspase activation and recruitment domain", "PROTEIN", 17, 58], ["interferon", "PROTEIN", 76, 86], ["MDA-5", "PROTEIN", 142, 147], ["antiviral cytokines", "PROTEIN", 226, 245], ["pro-inflammatory mediators", "PROTEIN", 250, 276], ["a caspase activation", "TREATMENT", 15, 35], ["recruitment domain", "TEST", 40, 58], ["interferon production", "TREATMENT", 76, 97], ["MDA", "TEST", 142, 145], ["intracellular signaling pathways", "PROBLEM", 157, 189], ["antiviral cytokines", "TREATMENT", 226, 245], ["pro-inflammatory mediators", "TREATMENT", 250, 276], ["caspase activation", "OBSERVATION", 17, 35], ["antiviral cytokines", "OBSERVATION", 226, 245]]], ["This raises the pivotal question of whether RIG-I and MDA-5 are involved in COPD pathogenesis.", [["COPD", "DISEASE", 76, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["MDA-5", "GENE_OR_GENE_PRODUCT", 54, 59], ["RIG-I", "PROTEIN", 44, 49], ["MDA-5", "PROTEIN", 54, 59], ["MDA", "TEST", 54, 57], ["COPD pathogenesis", "PROBLEM", 76, 93], ["COPD", "OBSERVATION", 76, 80]]], ["In this study, we assessed the expression of RIG-I and MDA-5 in peripheral blood mononuclear cells (PBMCs) and bronchial tissue of COPD patients.", [["peripheral blood mononuclear cells", "ANATOMY", 64, 98], ["PBMCs", "ANATOMY", 100, 105], ["bronchial tissue", "ANATOMY", 111, 127], ["COPD", "DISEASE", 131, 135], ["RIG-I", "GENE_OR_GENE_PRODUCT", 45, 50], ["MDA-5", "GENE_OR_GENE_PRODUCT", 55, 60], ["peripheral blood mononuclear cells", "CELL", 64, 98], ["PBMCs", "CELL", 100, 105], ["bronchial tissue", "TISSUE", 111, 127], ["patients", "ORGANISM", 136, 144], ["RIG-I", "PROTEIN", 45, 50], ["MDA-5", "PROTEIN", 55, 60], ["peripheral blood mononuclear cells", "CELL_TYPE", 64, 98], ["PBMCs", "CELL_TYPE", 100, 105], ["patients", "SPECIES", 136, 144], ["this study", "TEST", 3, 13], ["RIG", "TEST", 45, 48], ["MDA", "TEST", 55, 58], ["peripheral blood mononuclear cells", "TREATMENT", 64, 98], ["bronchial tissue of COPD patients", "PROBLEM", 111, 144], ["peripheral", "ANATOMY_MODIFIER", 64, 74], ["blood", "ANATOMY", 75, 80], ["mononuclear cells", "OBSERVATION", 81, 98], ["bronchial tissue", "ANATOMY", 111, 127], ["COPD", "OBSERVATION", 131, 135]]], ["We demonstrate that COPD patients have significantly different expression levels of RLRs and inflammatory cytokines, thus may define a critical role for RLRs in COPD airway inflammation.Study subjectsPeripheral blood of 29 COPD patients and 24 agematched health control subjects were respectively obtained from outpatients and a physical examination center of Ruijin Hospital, affiliated with Shanghai Jiaotong University, China.", [["airway", "ANATOMY", 166, 172], ["Peripheral blood", "ANATOMY", 200, 216], ["COPD", "DISEASE", 20, 24], ["COPD", "DISEASE", 161, 165], ["airway inflammation", "DISEASE", 166, 185], ["COPD", "DISEASE", 223, 227], ["patients", "ORGANISM", 25, 33], ["RLRs", "GENE_OR_GENE_PRODUCT", 84, 88], ["RLRs", "GENE_OR_GENE_PRODUCT", 153, 157], ["airway", "MULTI-TISSUE_STRUCTURE", 166, 172], ["Peripheral blood", "ORGANISM_SUBSTANCE", 200, 216], ["patients", "ORGANISM", 228, 236], ["subjects", "ORGANISM", 270, 278], ["RLRs", "PROTEIN", 84, 88], ["inflammatory cytokines", "PROTEIN", 93, 115], ["RLRs", "PROTEIN", 153, 157], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 228, 236], ["COPD", "PROBLEM", 20, 24], ["significantly different expression levels of RLRs", "PROBLEM", 39, 88], ["inflammatory cytokines", "PROBLEM", 93, 115], ["COPD airway inflammation", "PROBLEM", 161, 185], ["Study subjects", "TEST", 186, 200], ["Peripheral blood", "TEST", 200, 216], ["a physical examination", "TEST", 327, 349], ["COPD", "OBSERVATION", 20, 24], ["significantly different", "OBSERVATION_MODIFIER", 39, 62], ["expression", "OBSERVATION_MODIFIER", 63, 73], ["levels", "OBSERVATION_MODIFIER", 74, 80], ["inflammatory cytokines", "OBSERVATION", 93, 115], ["COPD", "OBSERVATION", 161, 165], ["airway", "ANATOMY", 166, 172], ["inflammation", "OBSERVATION", 173, 185], ["blood", "ANATOMY", 211, 216], ["COPD", "OBSERVATION", 223, 227]]], ["Endobronchial biopsies (8 COPD patients and 12 non-COPD control subjects) were recruited from the ward of respiratory medicine, Ruijin Hospital.", [["Endobronchial biopsies", "ANATOMY", 0, 22], ["COPD", "DISEASE", 26, 30], ["Endobronchial biopsies", "MULTI-TISSUE_STRUCTURE", 0, 22], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Endobronchial biopsies", "TEST", 0, 22], ["biopsies", "OBSERVATION", 14, 22]]], ["Bronchoalveolar lavage (BAL) in 25 COPD patients and 15 non-COPD control subjects was performed by infusing 50 mL of sterile sodium chloride in either the middle or lingula lobe.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["BAL", "ANATOMY", 24, 27], ["lingula lobe", "ANATOMY", 165, 177], ["COPD", "DISEASE", 35, 39], ["sodium chloride", "CHEMICAL", 125, 140], ["sodium chloride", "CHEMICAL", 125, 140], ["Bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 0, 22], ["BAL", "MULTI-TISSUE_STRUCTURE", 24, 27], ["patients", "ORGANISM", 40, 48], ["sodium chloride", "SIMPLE_CHEMICAL", 125, 140], ["lingula lobe", "MULTI-TISSUE_STRUCTURE", 165, 177], ["patients", "SPECIES", 40, 48], ["Bronchoalveolar lavage", "TEST", 0, 22], ["BAL)", "TEST", 24, 28], ["sterile sodium chloride", "TREATMENT", 117, 140], ["middle", "ANATOMY_MODIFIER", 155, 161], ["lingula lobe", "ANATOMY", 165, 177]]], ["The diagnosis of COPD was made according to the guidelines of the Global Initiative for Chronic Obstructive Lung Disease.", [["Lung", "ANATOMY", 108, 112], ["COPD", "DISEASE", 17, 21], ["Chronic Obstructive Lung Disease", "DISEASE", 88, 120], ["Lung", "ORGAN", 108, 112], ["COPD", "PROBLEM", 17, 21], ["Chronic Obstructive Lung Disease", "PROBLEM", 88, 120], ["COPD", "OBSERVATION", 17, 21], ["Chronic", "OBSERVATION_MODIFIER", 88, 95], ["Obstructive", "OBSERVATION_MODIFIER", 96, 107], ["Lung", "ANATOMY", 108, 112], ["Disease", "OBSERVATION", 113, 120]]], ["All subjects were in a stable condition at the time of the study, and all control subjects have normal lung function.", [["lung", "ANATOMY", 103, 107], ["lung", "ORGAN", 103, 107], ["the study", "TEST", 55, 64], ["normal", "OBSERVATION", 96, 102], ["lung", "ANATOMY", 103, 107]]], ["Exclusion criteria included a current or recent (past month) respiratory tract infection, exacerbation of respiratory disease or a course of oral steroids or antibiotics in the previous month.", [["respiratory tract", "ANATOMY", 61, 78], ["respiratory", "ANATOMY", 106, 117], ["oral", "ANATOMY", 141, 145], ["respiratory tract infection", "DISEASE", 61, 88], ["respiratory disease", "DISEASE", 106, 125], ["steroids", "CHEMICAL", 146, 154], ["steroids", "CHEMICAL", 146, 154], ["tract", "ORGANISM_SUBDIVISION", 73, 78], ["oral", "ORGANISM_SUBDIVISION", 141, 145], ["respiratory tract infection", "PROBLEM", 61, 88], ["respiratory disease", "PROBLEM", 106, 125], ["oral steroids", "TREATMENT", 141, 154], ["antibiotics", "TREATMENT", 158, 169], ["respiratory tract", "ANATOMY", 61, 78], ["infection", "OBSERVATION", 79, 88], ["respiratory disease", "OBSERVATION", 106, 125]]], ["This study was reviewed and approved by the Ethics Committees of Ruijin Hospital, and written informed consent was obtained from all subjects.Immunohistochemical analysisImmunohistochemistry was used to analyze the protein levels of RIG-I and MDA-5 in bronchial tissues of COPD and control patients.", [["bronchial tissues", "ANATOMY", 252, 269], ["COPD", "DISEASE", 273, 277], ["RIG-I", "GENE_OR_GENE_PRODUCT", 233, 238], ["MDA-5", "GENE_OR_GENE_PRODUCT", 243, 248], ["bronchial tissues", "TISSUE", 252, 269], ["patients", "ORGANISM", 290, 298], ["RIG-I", "PROTEIN", 233, 238], ["MDA-5", "PROTEIN", 243, 248], ["patients", "SPECIES", 290, 298], ["This study", "TEST", 0, 10], ["Immunohistochemical analysisImmunohistochemistry", "TEST", 142, 190], ["the protein levels", "TEST", 211, 229], ["RIG", "TEST", 233, 236], ["MDA", "TEST", 243, 246], ["COPD", "PROBLEM", 273, 277], ["bronchial tissues", "ANATOMY", 252, 269], ["COPD", "OBSERVATION", 273, 277]]], ["Forty biopsies were obtained from 20 subjects, and 40 specimens were used for immunohistochemistry analysis.", [["biopsies", "ANATOMY", 6, 14], ["specimens", "ANATOMY", 54, 63], ["biopsies", "CANCER", 6, 14], ["Forty biopsies", "TEST", 0, 14], ["40 specimens", "TEST", 51, 63], ["immunohistochemistry analysis", "TEST", 78, 107]]], ["Briefly, lung sections (endobronchial biopsies) were embedded in paraffin and sectioned to 5 \u03bcm, followed by dewaxing in xylene and rehydration.", [["lung sections", "ANATOMY", 9, 22], ["endobronchial biopsies", "ANATOMY", 24, 46], ["xylene", "CHEMICAL", 121, 127], ["paraffin", "CHEMICAL", 65, 73], ["xylene", "CHEMICAL", 121, 127], ["lung sections", "MULTI-TISSUE_STRUCTURE", 9, 22], ["endobronchial biopsies", "MULTI-TISSUE_STRUCTURE", 24, 46], ["xylene", "SIMPLE_CHEMICAL", 121, 127], ["lung sections", "TEST", 9, 22], ["endobronchial biopsies", "TEST", 24, 46], ["rehydration", "TREATMENT", 132, 143], ["lung", "ANATOMY", 9, 13], ["endobronchial", "ANATOMY", 24, 37]]], ["Endogenous peroxidases were inhibited with 0.5% hydrogen peroxide in methanol for 10 min, then slides were incubated overnight at 4\u00b0C with a rabbit polyclonal immunoglobulin G (IgG) antibody against RIG-I or MDA-5.", [["hydrogen peroxide", "CHEMICAL", 48, 65], ["hydrogen peroxide", "CHEMICAL", 48, 65], ["methanol", "CHEMICAL", 69, 77], ["peroxidases", "GENE_OR_GENE_PRODUCT", 11, 22], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 48, 65], ["methanol", "SIMPLE_CHEMICAL", 69, 77], ["rabbit", "ORGANISM", 141, 147], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 159, 175], ["IgG", "GENE_OR_GENE_PRODUCT", 177, 180], ["RIG-I", "GENE_OR_GENE_PRODUCT", 199, 204], ["MDA-5", "GENE_OR_GENE_PRODUCT", 208, 213], ["peroxidases", "PROTEIN", 11, 22], ["rabbit polyclonal immunoglobulin G (IgG) antibody", "PROTEIN", 141, 190], ["RIG-I", "PROTEIN", 199, 204], ["MDA-5", "PROTEIN", 208, 213], ["rabbit", "SPECIES", 141, 147], ["rabbit", "SPECIES", 141, 147], ["Endogenous peroxidases", "PROBLEM", 0, 22], ["0.5% hydrogen peroxide in methanol", "TREATMENT", 43, 77], ["a rabbit polyclonal immunoglobulin G", "TEST", 139, 175], ["IgG) antibody", "TEST", 177, 190], ["RIG", "TEST", 199, 202], ["MDA", "TEST", 208, 211], ["peroxidases", "OBSERVATION_MODIFIER", 11, 22]]], ["Immunodetection was performed with biotinylated goat anti-rabbit IgG reagent, horseradish peroxidase (HRP) reagent and diaminobenzidine.Isolation of PBMCsBlood samples were collected in heparinized, 10-mL evacuated test tube (BD Vacutainer system, Plymouth, UK) from all the subjects.", [["PBMCsBlood samples", "ANATOMY", 149, 167], ["diaminobenzidine", "CHEMICAL", 119, 135], ["diaminobenzidine", "CHEMICAL", 119, 135], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 78, 100], ["HRP", "SIMPLE_CHEMICAL", 102, 105], ["diaminobenzidine", "SIMPLE_CHEMICAL", 119, 135], ["PBMCsBlood samples", "CANCER", 149, 167], ["tube", "TISSUE", 220, 224], ["biotinylated goat anti-rabbit IgG reagent", "PROTEIN", 35, 76], ["horseradish peroxidase", "PROTEIN", 78, 100], ["HRP", "PROTEIN", 102, 105], ["goat", "SPECIES", 48, 52], ["anti-rabbit", "SPECIES", 53, 64], ["horseradish", "SPECIES", 78, 89], ["goat", "SPECIES", 48, 52], ["anti-rabbit", "SPECIES", 53, 64], ["Immunodetection", "TEST", 0, 15], ["biotinylated goat anti-rabbit IgG reagent", "TREATMENT", 35, 76], ["horseradish peroxidase (HRP) reagent", "TREATMENT", 78, 114], ["diaminobenzidine", "TREATMENT", 119, 135], ["PBMCsBlood samples", "TEST", 149, 167], ["BD Vacutainer system", "TREATMENT", 226, 246]]], ["PBMCs were separated from the peripheral blood using Ficoll-Paque Plus (Sigma, Shanghai, China) for 30 min at 1800 rpm.", [["PBMCs", "ANATOMY", 0, 5], ["peripheral blood", "ANATOMY", 30, 46], ["PBMCs", "CELL", 0, 5], ["peripheral blood", "ORGANISM_SUBSTANCE", 30, 46], ["PBMCs", "CELL_TYPE", 0, 5], ["PBMCs", "TEST", 0, 5], ["peripheral", "ANATOMY_MODIFIER", 30, 40], ["blood", "ANATOMY", 41, 46]]], ["The band containing PBMCs was collected and transferred to new tubes.", [["PBMCs", "ANATOMY", 20, 25], ["PBMCs", "CELL", 20, 25], ["PBMCs", "CELL_TYPE", 20, 25], ["The band containing PBMCs", "TREATMENT", 0, 25], ["new tubes", "TREATMENT", 59, 68], ["PBMCs", "OBSERVATION", 20, 25], ["new", "OBSERVATION_MODIFIER", 59, 62], ["tubes", "OBSERVATION", 63, 68]]], ["Phosphate buffered saline (PBS) was added to the PBMCs and the PBMCs were washed three times by centrifugation for 10 min at 1000 rpm.", [["PBMCs", "ANATOMY", 49, 54], ["PBMCs", "ANATOMY", 63, 68], ["Phosphate", "CHEMICAL", 0, 9], ["Phosphate", "CHEMICAL", 0, 9], ["Phosphate buffered saline", "SIMPLE_CHEMICAL", 0, 25], ["PBS", "SIMPLE_CHEMICAL", 27, 30], ["PBMCs", "CELL", 49, 54], ["PBMCs", "CELL", 63, 68], ["PBMCs", "CELL_TYPE", 49, 54], ["PBMCs", "CELL_TYPE", 63, 68], ["Phosphate buffered saline (PBS)", "TREATMENT", 0, 31], ["the PBMCs", "TREATMENT", 59, 68]]], ["In COPD patients, the cell count is higher but the percentage of monocytes, lymphocytes, neutrophils of PBMCs is the same as that of control group.RNA extraction and real-time PCRTotal RNA from PBMCs and bronchial tissue was extracted using an RNeasy kit (Qiagen, Hilden, Germany), and the quality and quantity of the obtained RNA was determined by spectrophotometry based on the absorbance A260/A280.", [["cell", "ANATOMY", 22, 26], ["monocytes", "ANATOMY", 65, 74], ["lymphocytes", "ANATOMY", 76, 87], ["neutrophils", "ANATOMY", 89, 100], ["PBMCs", "ANATOMY", 104, 109], ["PBMCs", "ANATOMY", 194, 199], ["bronchial tissue", "ANATOMY", 204, 220], ["COPD", "DISEASE", 3, 7], ["patients", "ORGANISM", 8, 16], ["cell", "CELL", 22, 26], ["monocytes", "CELL", 65, 74], ["lymphocytes", "CELL", 76, 87], ["neutrophils", "CELL", 89, 100], ["PBMCs", "CELL", 104, 109], ["PBMCs", "CELL", 194, 199], ["bronchial tissue", "TISSUE", 204, 220], ["monocytes", "CELL_TYPE", 65, 74], ["lymphocytes", "CELL_TYPE", 76, 87], ["neutrophils", "CELL_TYPE", 89, 100], ["PBMCs", "CELL_TYPE", 104, 109], ["PCRTotal RNA", "RNA", 176, 188], ["PBMCs", "CELL_TYPE", 194, 199], ["patients", "SPECIES", 8, 16], ["the cell count", "TEST", 18, 32], ["monocytes", "TEST", 65, 74], ["lymphocytes", "TEST", 76, 87], ["neutrophils", "TEST", 89, 100], ["PBMCs", "TEST", 104, 109], ["RNA extraction", "TREATMENT", 147, 161], ["bronchial tissue", "PROBLEM", 204, 220], ["an RNeasy kit", "TREATMENT", 241, 254], ["the absorbance", "TEST", 376, 390], ["COPD", "OBSERVATION", 3, 7], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["monocytes", "ANATOMY", 65, 74], ["PBMCs", "ANATOMY", 194, 199], ["bronchial tissue", "ANATOMY", 204, 220]]], ["One microgram of total RNA for each sample was used with oligo(dT) as primers for the synthesis of cDNA (RevertAid TM First Strand cDNA Synthesis Kit, Fermentas, Burlington, ON, Canada).", [["sample", "ANATOMY", 36, 42], ["total RNA", "RNA", 17, 26], ["cDNA", "DNA", 99, 103], ["total RNA", "TREATMENT", 17, 26], ["each sample", "TEST", 31, 42], ["oligo(dT)", "TREATMENT", 57, 66], ["the synthesis of cDNA", "TREATMENT", 82, 103], ["RevertAid TM", "TREATMENT", 105, 117], ["Strand cDNA Synthesis Kit", "TREATMENT", 124, 149]]], ["Real-time PCR was performed with a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with FastStart Universal SYBR Green (Roche, Basel, Switzerland) after cDNA synthesis.", [["Real-time PCR", "TEST", 0, 13], ["cDNA synthesis", "TREATMENT", 179, 193]]], ["PCR conditions were as follows: initial denaturation at 95\u00b0C (10 min), followed by 40 cycles of amplification 95\u00b0C (15 s), 60\u00b0C (60 s).", [["PCR conditions", "TEST", 0, 14], ["initial denaturation", "PROBLEM", 32, 52], ["amplification", "TEST", 96, 109]]], ["The standard curve for quantification was made using a modified procedure as previously described (30) .", [["a modified procedure", "TREATMENT", 53, 73]]], ["The sequences of all primers are shown in Table 2 .", [["all primers", "TEST", 17, 28]]], ["Fold change of the gene expression were calculated 2 -\u0394\u0394Ct relative to the internal reference gene [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] and the mean of all sample.Western blotsPBMCs isolated from peripheral blood were lysed in 100-\u03bcL lysis buffer (150 mM NaCl, 50 mM Tris-Cl pH 7.4, 1 mM ethylene diamine tetraacetic acid, 0.1% sodium dodecyl sulfate, 1.0% deoxycholatic, 1.0% Tritonx-100, 1 mM phenylmethanesulfonyl fluoride).", [["blotsPBMCs", "ANATOMY", 185, 195], ["peripheral blood", "ANATOMY", 210, 226], ["glyceraldehyde-3-phosphate", "CHEMICAL", 100, 126], ["NaCl", "CHEMICAL", 269, 273], ["Tris-Cl", "CHEMICAL", 281, 288], ["ethylene diamine tetraacetic acid", "CHEMICAL", 302, 335], ["sodium dodecyl sulfate", "CHEMICAL", 342, 364], ["deoxycholatic", "CHEMICAL", 371, 384], ["Tritonx-100", "CHEMICAL", 391, 402], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 409, 439], ["glyceraldehyde-3-phosphate", "CHEMICAL", 100, 126], ["NaCl", "CHEMICAL", 269, 273], ["Tris-Cl", "CHEMICAL", 281, 288], ["ethylene diamine tetraacetic acid", "CHEMICAL", 302, 335], ["sodium dodecyl sulfate", "CHEMICAL", 342, 364], ["Tritonx-100", "CHEMICAL", 391, 402], ["phenylmethanesulfonyl fluoride", "CHEMICAL", 409, 439], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 100, 140], ["GAPDH", "GENE_OR_GENE_PRODUCT", 142, 147], ["blotsPBMCs", "CELL", 185, 195], ["peripheral blood", "ORGANISM_SUBSTANCE", 210, 226], ["ethylene diamine tetraacetic acid", "SIMPLE_CHEMICAL", 302, 335], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 342, 364], ["deoxycholatic", "SIMPLE_CHEMICAL", 371, 384], ["Tritonx-100", "SIMPLE_CHEMICAL", 391, 402], ["phenylmethanesulfonyl fluoride", "SIMPLE_CHEMICAL", 409, 439], ["internal reference gene", "DNA", 75, 98], ["glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 100, 140], ["GAPDH", "PROTEIN", 142, 147], ["blotsPBMCs", "CELL_TYPE", 185, 195], ["glyceraldehyde-3-phosphate dehydrogenase (GAPDH)", "TREATMENT", 100, 148], ["peripheral blood", "TEST", 210, 226], ["NaCl", "TEST", 269, 273], ["Tris", "TEST", 281, 285], ["pH", "TEST", 289, 291], ["1 mM ethylene diamine tetraacetic acid", "TREATMENT", 297, 335], ["sodium dodecyl sulfate", "TREATMENT", 342, 364], ["deoxycholatic", "TEST", 371, 384], ["Tritonx", "TEST", 391, 398], ["1 mM phenylmethanesulfonyl fluoride", "TREATMENT", 404, 439], ["peripheral", "ANATOMY_MODIFIER", 210, 220], ["blood", "ANATOMY", 221, 226]]], ["Protein concentrations were quantified using the BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions.", [["Protein concentrations", "TEST", 0, 22]]], ["Equal amounts of proteins (30 \u03bcg) were resolved by sodium dodecyl sulfate-polyacrylamide gelelectrophoresis and transferred onto a poly(vinylidene fluoride) membrane.", [["sodium dodecyl sulfate-polyacrylamide", "CHEMICAL", 51, 88], ["poly(vinylidene fluoride", "CHEMICAL", 131, 155], ["sodium dodecyl sulfate", "CHEMICAL", 51, 73], ["polyacrylamide", "CHEMICAL", 74, 88], ["poly(vinylidene fluoride)", "CHEMICAL", 131, 156], ["sodium dodecyl sulfate-polyacrylamide gelelectrophoresis", "SIMPLE_CHEMICAL", 51, 107], ["poly(vinylidene fluoride", "SIMPLE_CHEMICAL", 131, 155], ["proteins", "TEST", 17, 25], ["sodium dodecyl sulfate", "TREATMENT", 51, 73], ["polyacrylamide gelelectrophoresis", "TREATMENT", 74, 107], ["a poly(vinylidene fluoride) membrane", "TREATMENT", 129, 165], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["The membrane was blocked with PBS containing 5% nonfat milk for 2 h at room temperature, then incubated overnight at 4\u00b0C with an After washing, 1-mL chemiluminescent substrate (Thermo Scientific) was added to the membrane.", [["membrane", "ANATOMY", 4, 12], ["nonfat milk", "ANATOMY", 48, 59], ["membrane", "ANATOMY", 213, 221], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 55, 59], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["PBS", "TREATMENT", 30, 33], ["1-mL chemiluminescent substrate", "TREATMENT", 144, 175]]], ["The signal was detected and quantified with an enhanced chemiluminescence system (ImageQuant LAS-4000 MINI, GE, Fairfield, CT, USA).", [["an enhanced chemiluminescence system", "TEST", 44, 80], ["ImageQuant LAS", "TEST", 82, 96], ["CT", "TEST", 123, 125]]], ["All samples were normalized to \u03b2-actin.", [["samples", "ANATOMY", 4, 11], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 31, 38], ["\u03b2-actin", "PROTEIN", 31, 38], ["All samples", "TEST", 0, 11], ["\u03b2-actin", "TREATMENT", 31, 38]]], ["Data were represented as mean \u00b1 standard error (SEM).Cytokine enzyme-linked immunosorbent assays (ELISAs)IL-8 and tumor necrosis factor (TNF)-\u03b1 concentrations in the bronchoalveolar lavage fluid (BALF) were determined using DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.Statistical analysisResults are presented as mean \u00b1 SEM.", [["bronchoalveolar lavage fluid", "ANATOMY", 166, 194], ["BALF", "ANATOMY", 196, 200], ["necrosis", "DISEASE", 120, 128], ["IL-8", "GENE_OR_GENE_PRODUCT", 105, 109], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 114, 143], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 166, 194], ["BALF", "ORGANISM_SUBSTANCE", 196, 200], ["Cytokine enzyme", "PROTEIN", 53, 68], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 114, 143], ["Cytokine enzyme", "TEST", 53, 68], ["immunosorbent assays", "TEST", 76, 96], ["ELISAs", "TEST", 98, 104], ["IL", "TEST", 105, 107], ["tumor necrosis factor", "PROBLEM", 114, 135], ["TNF", "TEST", 137, 140], ["\u03b1 concentrations", "PROBLEM", 142, 158], ["the bronchoalveolar lavage fluid (BALF", "TEST", 162, 200], ["Statistical analysisResults", "TEST", 324, 351], ["tumor", "OBSERVATION_MODIFIER", 114, 119], ["necrosis", "OBSERVATION", 120, 128], ["bronchoalveolar lavage", "OBSERVATION", 166, 188]]], ["A two-tailed t-test was performed with each group.", [["A two-tailed t-test", "TEST", 0, 19]]], ["Associations between variables were assessed using Spearman's rank correlation test.", [["Spearman's rank correlation test", "TEST", 51, 83]]], ["Statistical analyses were performed using SPSS 18.0 and P values \u22640.05 were considered statistically significant.Immunohistochemistry analysis of MDA-5 and RIG-I in bronchial mucosa of COPD patientsMDA-5 and RIG-I were mainly present in the airway epithelium cells (Fig. 1) .", [["bronchial mucosa", "ANATOMY", 165, 181], ["airway epithelium cells", "ANATOMY", 241, 264], ["COPD", "DISEASE", 185, 189], ["MDA-5", "GENE_OR_GENE_PRODUCT", 146, 151], ["RIG-I", "GENE_OR_GENE_PRODUCT", 156, 161], ["bronchial mucosa", "MULTI-TISSUE_STRUCTURE", 165, 181], ["patients", "ORGANISM", 190, 198], ["MDA-5", "GENE_OR_GENE_PRODUCT", 198, 203], ["RIG-I", "GENE_OR_GENE_PRODUCT", 208, 213], ["airway epithelium cells", "CELL", 241, 264], ["MDA", "PROTEIN", 146, 149], ["RIG-I", "PROTEIN", 156, 161], ["RIG-I", "PROTEIN", 208, 213], ["airway epithelium cells", "CELL_TYPE", 241, 264], ["patients", "SPECIES", 190, 198], ["Statistical analyses", "TEST", 0, 20], ["SPSS", "TEST", 42, 46], ["P values", "TEST", 56, 64], ["Immunohistochemistry analysis", "TEST", 113, 142], ["MDA", "TEST", 146, 149], ["RIG", "TEST", 156, 159], ["COPD", "PROBLEM", 185, 189], ["MDA", "TEST", 198, 201], ["bronchial mucosa", "ANATOMY", 165, 181], ["COPD", "OBSERVATION", 185, 189], ["airway", "ANATOMY", 241, 247], ["epithelium cells", "OBSERVATION", 248, 264]]], ["COPD patients had a higher expression level of MDA-5 in bronchial mucosa compared with control subjects (Fig. 1A and B) .", [["bronchial mucosa", "ANATOMY", 56, 72], ["COPD", "DISEASE", 0, 4], ["MDA-5", "CHEMICAL", 47, 52], ["patients", "ORGANISM", 5, 13], ["MDA-5", "GENE_OR_GENE_PRODUCT", 47, 52], ["bronchial mucosa", "MULTI-TISSUE_STRUCTURE", 56, 72], ["B", "CELL", 117, 118], ["MDA-5", "PROTEIN", 47, 52], ["patients", "SPECIES", 5, 13], ["COPD", "PROBLEM", 0, 4], ["a higher expression level of MDA", "PROBLEM", 18, 50], ["bronchial mucosa", "ANATOMY", 56, 72]]], ["No significant differences in RIG-I was observed between the two groups ( Fig. 1C and D) .MDA-5 and RIG-I mRNA expression in the bronchial mucosa of COPD patientsTotal RNA was isolated from bronchial biopsies samples of 12 non-COPD and 8 COPD subjects, and then were analyzed for MDA-5 and RIG-I mRNA expression by real-time PCR (Fig. 2) .", [["bronchial mucosa", "ANATOMY", 129, 145], ["bronchial biopsies samples", "ANATOMY", 190, 216], ["COPD", "DISEASE", 149, 153], ["COPD", "DISEASE", 227, 231], ["COPD", "DISEASE", 238, 242], ["RIG-I", "GENE_OR_GENE_PRODUCT", 30, 35], ["MDA-5", "GENE_OR_GENE_PRODUCT", 90, 95], ["RIG-I", "GENE_OR_GENE_PRODUCT", 100, 105], ["bronchial mucosa", "MULTI-TISSUE_STRUCTURE", 129, 145], ["patients", "ORGANISM", 154, 162], ["bronchial biopsies samples", "ORGANISM_SUBSTANCE", 190, 216], ["MDA-5", "GENE_OR_GENE_PRODUCT", 280, 285], ["RIG-I", "GENE_OR_GENE_PRODUCT", 290, 295], ["RIG-I", "DNA", 30, 35], ["patients", "SPECIES", 154, 162], ["MDA", "TEST", 90, 93], ["RIG-I mRNA expression", "TREATMENT", 100, 121], ["COPD", "PROBLEM", 149, 153], ["Total RNA", "TEST", 162, 171], ["bronchial biopsies samples", "TEST", 190, 216], ["non-COPD", "PROBLEM", 223, 231], ["8 COPD subjects", "PROBLEM", 236, 251], ["MDA", "TEST", 280, 283], ["RIG", "TEST", 290, 293], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["bronchial mucosa", "ANATOMY", 129, 145], ["COPD", "OBSERVATION", 149, 153], ["bronchial", "ANATOMY", 190, 199], ["biopsies", "OBSERVATION", 200, 208], ["COPD", "OBSERVATION", 227, 231]]], ["Fold change in RIG-I mRNA levels between COPD patients and control subjects was 0.767 (COPD/control), and showed no significant difference (P = 0.7871) (Fig. 2B) .", [["COPD", "DISEASE", 41, 45], ["RIG-I", "GENE_OR_GENE_PRODUCT", 15, 20], ["patients", "ORGANISM", 46, 54], ["RIG-I mRNA", "RNA", 15, 25], ["patients", "SPECIES", 46, 54], ["Fold change in RIG-I mRNA levels", "PROBLEM", 0, 32], ["COPD", "PROBLEM", 41, 45], ["COPD/control", "TREATMENT", 87, 99], ["significant difference", "PROBLEM", 116, 138], ["P", "TEST", 140, 141], ["change", "OBSERVATION", 5, 11], ["no", "UNCERTAINTY", 113, 115], ["significant", "OBSERVATION_MODIFIER", 116, 127]]], ["The ratio of MDA-5 expression to the housekeeping gene GAPDH was significantly higher in COPD subjects than in control subjects (COPD/control fold change = 2.427, P = 0.0023) (Fig. 2A) .", [["COPD", "DISEASE", 89, 93], ["MDA-5", "CHEMICAL", 13, 18], ["MDA-5", "GENE_OR_GENE_PRODUCT", 13, 18], ["GAPDH", "GENE_OR_GENE_PRODUCT", 55, 60], ["MDA", "PROTEIN", 13, 16], ["housekeeping gene", "DNA", 37, 54], ["The ratio", "TEST", 0, 9], ["MDA", "TEST", 13, 16], ["the housekeeping gene GAPDH", "PROBLEM", 33, 60], ["COPD subjects", "PROBLEM", 89, 102], ["COPD/control fold change", "PROBLEM", 129, 153], ["P", "TEST", 163, 164], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["higher", "OBSERVATION_MODIFIER", 79, 85], ["COPD", "OBSERVATION", 89, 93]]], ["These results were consistent with immunohistochemistry results illustrated in Fig. 1 .Expression of MDA-5 and RIG-I in PBMCsDetected by real-time PCR, MDA-5 mRNA levels were significantly higher in COPD subjects than in control subjects (COPD/control fold change = 3.690, P = 0.0051) (Fig. 3A) .", [["COPD", "DISEASE", 199, 203], ["MDA-5", "GENE_OR_GENE_PRODUCT", 101, 106], ["RIG-I", "GENE_OR_GENE_PRODUCT", 111, 116], ["PBMCsDetected", "CELL", 120, 133], ["MDA-5", "GENE_OR_GENE_PRODUCT", 152, 157], ["MDA", "PROTEIN", 101, 104], ["RIG-I", "PROTEIN", 111, 116], ["MDA-5 mRNA", "RNA", 152, 162], ["MDA", "TEST", 101, 104], ["PCR", "TEST", 147, 150], ["MDA", "TEST", 152, 155], ["mRNA levels", "TEST", 158, 169], ["COPD subjects", "PROBLEM", 199, 212], ["COPD/control fold change", "PROBLEM", 239, 263], ["P", "TEST", 273, 274], ["consistent with", "UNCERTAINTY", 19, 34], ["COPD", "OBSERVATION", 199, 203]]], ["Similar results were obtained with MDA-5 protein levels, assessed by Western blotting (Fig. 3C) .", [["MDA-5", "GENE_OR_GENE_PRODUCT", 35, 40], ["MDA", "PROTEIN", 35, 38], ["MDA-5 protein levels", "TEST", 35, 55]]], ["MDA-5 protein levels in PBMCs were threefold higher in COPD subjects than control subjects (Fig. 3E ).", [["PBMCs", "ANATOMY", 24, 29], ["COPD", "DISEASE", 55, 59], ["MDA-5", "GENE_OR_GENE_PRODUCT", 0, 5], ["PBMCs", "CELL", 24, 29], ["MDA", "PROTEIN", 0, 3], ["PBMCs", "CELL_TYPE", 24, 29], ["MDA-5 protein levels", "TEST", 0, 20], ["PBMCs", "TEST", 24, 29], ["COPD subjects", "PROBLEM", 55, 68], ["COPD", "OBSERVATION", 55, 59]]], ["Whereas the RIG-I mRNA level was almost identical in both groups (COPD/control fold change = 1.650, P = 0.0759) (Fig. 3B) .", [["RIG-I", "GENE_OR_GENE_PRODUCT", 12, 17], ["RIG-I mRNA", "RNA", 12, 22], ["the RIG-I mRNA level", "TEST", 8, 28], ["COPD/control fold change", "PROBLEM", 66, 90], ["P", "TEST", 100, 101], ["COPD", "OBSERVATION", 66, 70]]], ["Similar results were obtained with the RIG-I protein level in PBMCs (COPD/control fold change = 0.977, P = 0.4726) ( Fig. 3D and F).Cytokine expression in PBMCs and BALFCompared with control subjects, COPD patients showed significantly higher mRNA expression levels of IL-1\u03b2, IL-8 and IFN-\u03b1 in peripheral blood (Fig. 4 A-C).", [["PBMCs", "ANATOMY", 62, 67], ["PBMCs", "ANATOMY", 155, 160], ["peripheral blood", "ANATOMY", 294, 310], ["COPD", "DISEASE", 201, 205], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["PBMCs", "CELL", 62, 67], ["Cytokine", "GENE_OR_GENE_PRODUCT", 132, 140], ["PBMCs", "CELL", 155, 160], ["patients", "ORGANISM", 206, 214], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 269, 274], ["IL-8", "GENE_OR_GENE_PRODUCT", 276, 280], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 285, 290], ["peripheral blood", "ORGANISM_SUBSTANCE", 294, 310], ["Fig. 4 A-C", "CELL", 312, 322], ["RIG", "PROTEIN", 39, 42], ["PBMCs", "CELL_TYPE", 62, 67], ["Cytokine", "PROTEIN", 132, 140], ["PBMCs", "CELL_TYPE", 155, 160], ["IL-1\u03b2, IL-8", "PROTEIN", 269, 280], ["IFN-\u03b1", "PROTEIN", 285, 290], ["patients", "SPECIES", 206, 214], ["the RIG-I protein level", "TEST", 35, 58], ["PBMCs", "TEST", 62, 67], ["COPD/control fold change", "TREATMENT", 69, 93], ["P", "TEST", 103, 104], ["Cytokine expression in PBMCs", "PROBLEM", 132, 160], ["COPD", "PROBLEM", 201, 205], ["significantly higher mRNA expression levels", "PROBLEM", 222, 265], ["IL", "TEST", 269, 271], ["IL", "TEST", 276, 278], ["IFN", "TEST", 285, 288], ["peripheral blood", "TEST", 294, 310], ["peripheral", "ANATOMY_MODIFIER", 294, 304], ["blood", "ANATOMY", 305, 310]]], ["The levels of IL-8 and TNF-\u03b1, assessed by ELISA, were also higher in BALF of COPD patients than control subjects (Fig. 4D and E) .", [["BALF", "ANATOMY", 69, 73], ["COPD", "DISEASE", 77, 81], ["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["BALF", "ORGANISM_SUBSTANCE", 69, 73], ["patients", "ORGANISM", 82, 90], ["IL-8", "PROTEIN", 14, 18], ["TNF-\u03b1", "PROTEIN", 23, 28], ["patients", "SPECIES", 82, 90], ["The levels", "TEST", 0, 10], ["IL", "TEST", 14, 16], ["TNF", "TEST", 23, 26], ["ELISA", "TEST", 42, 47], ["COPD", "PROBLEM", 77, 81], ["COPD", "OBSERVATION", 77, 81]]], ["These results demonstrate a persistent inflammation in the system and airway of COPD patients, consistent with previous reports (31) .Relationships between RLRs mRNA expression level, cytokine expression level and clinical outcomesIn this study we found a negative correlation between MDA-5 mRNA level of PBMCs and forced expiratoryDiscussionViral infection is a significant cause of chronic obstructive pulmonary disease (COPD) and acute exacerbation of COPD (13, 32, 33) .", [["airway", "ANATOMY", 70, 76], ["PBMCs", "ANATOMY", 305, 310], ["pulmonary", "ANATOMY", 404, 413], ["inflammation", "DISEASE", 39, 51], ["COPD", "DISEASE", 80, 84], ["DiscussionViral infection", "DISEASE", 332, 357], ["chronic obstructive pulmonary disease", "DISEASE", 384, 421], ["COPD", "DISEASE", 423, 427], ["COPD", "DISEASE", 455, 459], ["airway", "MULTI-TISSUE_STRUCTURE", 70, 76], ["patients", "ORGANISM", 85, 93], ["RLRs", "GENE_OR_GENE_PRODUCT", 156, 160], ["MDA-5", "GENE_OR_GENE_PRODUCT", 285, 290], ["PBMCs", "CELL", 305, 310], ["pulmonary", "ORGAN", 404, 413], ["RLRs mRNA", "RNA", 156, 165], ["cytokine", "PROTEIN", 184, 192], ["MDA-5 mRNA", "RNA", 285, 295], ["PBMCs", "CELL_TYPE", 305, 310], ["patients", "SPECIES", 85, 93], ["a persistent inflammation in the system and airway of COPD patients", "PROBLEM", 26, 93], ["cytokine expression level", "PROBLEM", 184, 209], ["this study", "TEST", 234, 244], ["MDA", "TEST", 285, 288], ["PBMCs", "TEST", 305, 310], ["forced expiratory", "PROBLEM", 315, 332], ["DiscussionViral infection", "PROBLEM", 332, 357], ["chronic obstructive pulmonary disease", "PROBLEM", 384, 421], ["COPD)", "PROBLEM", 423, 428], ["acute exacerbation", "PROBLEM", 433, 451], ["COPD", "PROBLEM", 455, 459], ["persistent", "OBSERVATION_MODIFIER", 28, 38], ["inflammation", "OBSERVATION", 39, 51], ["system", "ANATOMY", 59, 65], ["airway", "ANATOMY", 70, 76], ["COPD", "OBSERVATION", 80, 84], ["consistent with", "UNCERTAINTY", 95, 110], ["expiratory", "OBSERVATION", 322, 332], ["infection", "OBSERVATION", 348, 357], ["significant cause of", "UNCERTAINTY", 363, 383], ["chronic", "OBSERVATION_MODIFIER", 384, 391], ["obstructive", "OBSERVATION_MODIFIER", 392, 403], ["pulmonary", "ANATOMY", 404, 413], ["disease", "OBSERVATION", 414, 421], ["COPD", "OBSERVATION", 423, 427], ["acute", "OBSERVATION_MODIFIER", 433, 438], ["exacerbation", "OBSERVATION_MODIFIER", 439, 451], ["COPD", "OBSERVATION", 455, 459]]], ["Compared with exacerbation due to other causes, viral-induced COPD exacerbation is more severe, lasts longer and is associated with airway and systemic inflammatory responses (15, 16) .", [["airway", "ANATOMY", 132, 138], ["COPD", "DISEASE", 62, 66], ["airway", "MULTI-TISSUE_STRUCTURE", 132, 138], ["exacerbation", "PROBLEM", 14, 26], ["viral-induced COPD exacerbation", "PROBLEM", 48, 79], ["airway and systemic inflammatory responses", "PROBLEM", 132, 174], ["viral", "OBSERVATION", 48, 53], ["COPD", "OBSERVATION", 62, 66], ["more severe", "OBSERVATION_MODIFIER", 83, 94], ["associated with", "UNCERTAINTY", 116, 131], ["airway", "ANATOMY", 132, 138], ["systemic", "OBSERVATION_MODIFIER", 143, 151], ["inflammatory", "OBSERVATION", 152, 164]]], ["Structural cells, especially epithelial cells, endothelium and fibroblasts, take part in the airway inflammation.", [["cells", "ANATOMY", 11, 16], ["epithelial cells", "ANATOMY", 29, 45], ["endothelium", "ANATOMY", 47, 58], ["fibroblasts", "ANATOMY", 63, 74], ["airway", "ANATOMY", 93, 99], ["airway inflammation", "DISEASE", 93, 112], ["cells", "CELL", 11, 16], ["epithelial cells", "CELL", 29, 45], ["endothelium", "TISSUE", 47, 58], ["fibroblasts", "CELL", 63, 74], ["airway", "MULTI-TISSUE_STRUCTURE", 93, 99], ["epithelial cells", "CELL_TYPE", 29, 45], ["fibroblasts", "CELL_TYPE", 63, 74], ["Structural cells", "PROBLEM", 0, 16], ["epithelial cells", "PROBLEM", 29, 45], ["endothelium and fibroblasts", "PROBLEM", 47, 74], ["the airway inflammation", "PROBLEM", 89, 112], ["epithelial cells", "OBSERVATION", 29, 45], ["endothelium", "OBSERVATION_MODIFIER", 47, 58], ["fibroblasts", "OBSERVATION", 63, 74], ["airway", "ANATOMY", 93, 99], ["inflammation", "OBSERVATION", 100, 112]]], ["Patients with COPD are more susceptible to viral infections, and up to one half of cases of COPD exacerbations are associated with viral infections (16, 34) .", [["COPD", "DISEASE", 14, 18], ["viral infections", "DISEASE", 43, 59], ["COPD", "DISEASE", 92, 96], ["viral infections", "DISEASE", 131, 147], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COPD", "PROBLEM", 14, 18], ["viral infections", "PROBLEM", 43, 59], ["COPD exacerbations", "PROBLEM", 92, 110], ["viral infections", "PROBLEM", 131, 147], ["COPD", "OBSERVATION", 14, 18], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infections", "OBSERVATION", 49, 59], ["COPD", "OBSERVATION", 92, 96], ["associated with", "UNCERTAINTY", 115, 130], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["infections", "OBSERVATION", 137, 147]]], ["An epidemiology survey illustrates that viral infection is the main cause of COPD exacerbation, and the top four causes are rhinovirus (RV), coronavirus, influenza virus and respiratory syncytial virus (13) .DiscussionRLRs are essential for virus recognition in the cytoplasm.", [["cytoplasm", "ANATOMY", 266, 275], ["viral infection", "DISEASE", 40, 55], ["COPD", "DISEASE", 77, 81], ["rhinovirus (RV), coronavirus, influenza virus", "DISEASE", 124, 169], ["respiratory syncytial virus", "DISEASE", 174, 201], ["rhinovirus", "ORGANISM", 124, 134], ["coronavirus", "ORGANISM", 141, 152], ["influenza virus", "ORGANISM", 154, 169], ["respiratory syncytial virus", "ORGANISM", 174, 201], ["cytoplasm", "ORGANISM_SUBSTANCE", 266, 275], ["coronavirus, influenza virus", "SPECIES", 141, 169], ["respiratory syncytial virus", "SPECIES", 174, 201], ["RV", "SPECIES", 136, 138], ["respiratory syncytial virus", "SPECIES", 174, 201], ["An epidemiology survey", "TEST", 0, 22], ["viral infection", "PROBLEM", 40, 55], ["COPD exacerbation", "PROBLEM", 77, 94], ["rhinovirus", "PROBLEM", 124, 134], ["coronavirus", "PROBLEM", 141, 152], ["influenza virus", "PROBLEM", 154, 169], ["respiratory syncytial virus", "PROBLEM", 174, 201], ["virus recognition in the cytoplasm", "PROBLEM", 241, 275], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55], ["COPD", "OBSERVATION", 77, 81], ["rhinovirus", "OBSERVATION", 124, 134], ["influenza virus", "OBSERVATION", 154, 169], ["syncytial virus", "OBSERVATION", 186, 201], ["essential for", "UNCERTAINTY", 227, 240]]], ["Both RIG-I and MDA-5 detect dsRNA in the cytoplasm, where they are linked to downstreamsignaling molecules via MAVS (35) .", [["cytoplasm", "ANATOMY", 41, 50], ["RIG-I", "GENE_OR_GENE_PRODUCT", 5, 10], ["MDA-5", "GENE_OR_GENE_PRODUCT", 15, 20], ["cytoplasm", "ORGANISM_SUBSTANCE", 41, 50], ["MAVS", "GENE_OR_GENE_PRODUCT", 111, 115], ["RIG", "PROTEIN", 5, 8], ["MDA", "PROTEIN", 15, 18], ["downstreamsignaling molecules", "PROTEIN", 77, 106], ["MAVS", "PROTEIN", 111, 115], ["MDA", "TEST", 15, 18], ["dsRNA", "PROBLEM", 28, 33], ["RIG", "OBSERVATION_MODIFIER", 5, 8], ["dsRNA", "OBSERVATION", 28, 33], ["cytoplasm", "ANATOMY_MODIFIER", 41, 50]]], ["Previous studies have shown that human RIG-I and MDA-5 are implicated in the recognition of different groups of RNA viruses, and subsequently activate the NF-\u03baB-and IRF3/7-signaling pathways, resulting in production of pro-inflammatory cytokines and type-I interferons (36) .", [["human", "ORGANISM", 33, 38], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["MDA-5", "GENE_OR_GENE_PRODUCT", 49, 54], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["IRF3", "GENE_OR_GENE_PRODUCT", 165, 169], ["7", "GENE_OR_GENE_PRODUCT", 170, 171], ["type-I interferons", "GENE_OR_GENE_PRODUCT", 250, 268], ["human RIG-I", "PROTEIN", 33, 44], ["MDA-5", "PROTEIN", 49, 54], ["NF-\u03baB", "PROTEIN", 155, 160], ["IRF3", "PROTEIN", 165, 169], ["pro-inflammatory cytokines", "PROTEIN", 219, 245], ["type-I interferons", "PROTEIN", 250, 268], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["Previous studies", "TEST", 0, 16], ["human RIG", "TEST", 33, 42], ["RNA viruses", "PROBLEM", 112, 123], ["the NF", "TEST", 151, 157], ["B", "TEST", 159, 160], ["IRF3", "TEST", 165, 169], ["signaling pathways", "PROBLEM", 172, 190], ["pro-inflammatory cytokines", "PROBLEM", 219, 245], ["type-I interferons", "TREATMENT", 250, 268], ["RNA viruses", "OBSERVATION", 112, 123], ["pro-inflammatory cytokines", "OBSERVATION", 219, 245]]], ["It has been shown that MDA5 and RIG-I recognize widely distinct groups of viruses.", [["MDA5", "GENE_OR_GENE_PRODUCT", 23, 27], ["RIG-I", "GENE_OR_GENE_PRODUCT", 32, 37], ["MDA5", "PROTEIN", 23, 27], ["RIG-I", "PROTEIN", 32, 37], ["viruses", "PROBLEM", 74, 81], ["MDA5", "OBSERVATION", 23, 27], ["widely", "OBSERVATION_MODIFIER", 48, 54], ["distinct", "OBSERVATION_MODIFIER", 55, 63], ["viruses", "OBSERVATION", 74, 81]]], ["RIG-I preferentially detects variety of positive-and negative-strand viruses through recognition of a 5\u2032 triphosphate group of genomic RNAs such as influenza, paramyxovirus and flavivirus (37) .", [["5\u2032 triphosphate", "CHEMICAL", 102, 117], ["influenza, paramyxovirus and flavivirus", "DISEASE", 148, 187], ["5\u2032 triphosphate", "CHEMICAL", 102, 117], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["5\u2032 triphosphate", "SIMPLE_CHEMICAL", 102, 117], ["paramyxovirus", "ORGANISM", 159, 172], ["RIG-I", "PROTEIN", 0, 5], ["genomic RNAs", "RNA", 127, 139], ["strand viruses", "PROBLEM", 62, 76], ["genomic RNAs", "PROBLEM", 127, 139], ["influenza", "PROBLEM", 148, 157], ["paramyxovirus", "PROBLEM", 159, 172], ["flavivirus", "PROBLEM", 177, 187], ["positive", "OBSERVATION", 40, 48], ["strand viruses", "OBSERVATION", 62, 76], ["genomic RNAs", "OBSERVATION", 127, 139]]], ["In contrast, MDA5 recognizes long dsRNAs through detection of dsRNA replication intermediates and genomic dsRNAs, and likely detects positive-strand and dsRNA viruses including RV and reoviruses (38) (39) (40) .", [["MDA5", "GENE_OR_GENE_PRODUCT", 13, 17], ["MDA5", "PROTEIN", 13, 17], ["long dsRNAs", "DNA", 29, 40], ["genomic dsRNAs", "DNA", 98, 112], ["dsRNA replication intermediates", "PROBLEM", 62, 93], ["genomic dsRNAs", "PROBLEM", 98, 112], ["positive-strand and dsRNA viruses", "PROBLEM", 133, 166], ["RV", "TEST", 177, 179], ["reoviruses", "TEST", 184, 194], ["dsRNA replication", "OBSERVATION", 62, 79], ["genomic dsRNAs", "OBSERVATION", 98, 112], ["dsRNA viruses", "OBSERVATION", 153, 166]]], ["An epidemiological survey has illustrated that RV, a positive and single-stranded RNA virus, is responsible for the majority of virus-induced COPD exacerbation (13, 34) .", [["COPD", "DISEASE", 142, 146], ["An epidemiological survey", "TEST", 0, 25], ["RV", "TEST", 47, 49], ["a positive and single-stranded RNA virus", "PROBLEM", 51, 91], ["virus", "PROBLEM", 128, 133], ["COPD exacerbation", "PROBLEM", 142, 159], ["RV", "ANATOMY", 47, 49], ["RNA virus", "OBSERVATION", 82, 91], ["virus", "OBSERVATION", 128, 133], ["COPD", "OBSERVATION", 142, 146]]], ["In COPD patients, RV infection causes a rapid decline in lung function.", [["RV", "ANATOMY", 18, 20], ["lung", "ANATOMY", 57, 61], ["COPD", "DISEASE", 3, 7], ["RV infection", "DISEASE", 18, 30], ["patients", "ORGANISM", 8, 16], ["lung", "ORGAN", 57, 61], ["patients", "SPECIES", 8, 16], ["RV", "SPECIES", 18, 20], ["RV infection", "PROBLEM", 18, 30], ["a rapid decline in lung function", "PROBLEM", 38, 70], ["COPD", "OBSERVATION", 3, 7], ["RV", "ANATOMY", 18, 20], ["infection", "OBSERVATION", 21, 30], ["rapid", "OBSERVATION_MODIFIER", 40, 45], ["decline", "OBSERVATION_MODIFIER", 46, 53], ["lung", "ANATOMY", 57, 61], ["function", "OBSERVATION", 62, 70]]], ["Recent studies by Wang and colleagues provide evidence that MDA-5, but not RIG-I, is responsible for recognizing RV, and subsequently activates the signaling pathways, causing an exaggerated inflammatory response in COPD patients, with increased levels of IL-8, IL-6, CXCL1, TNF-\u03b1, IL-1\u03b2 and monocyte chemotactic protein 1 (41) .", [["RV", "ANATOMY", 113, 115], ["COPD", "DISEASE", 216, 220], ["MDA-5", "CHEMICAL", 60, 65], ["MDA-5", "GENE_OR_GENE_PRODUCT", 60, 65], ["RIG-I", "GENE_OR_GENE_PRODUCT", 75, 80], ["RV", "MULTI-TISSUE_STRUCTURE", 113, 115], ["patients", "ORGANISM", 221, 229], ["IL-8", "GENE_OR_GENE_PRODUCT", 256, 260], ["IL-6", "GENE_OR_GENE_PRODUCT", 262, 266], ["CXCL1", "GENE_OR_GENE_PRODUCT", 268, 273], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 275, 280], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 282, 287], ["monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 292, 322], ["MDA", "PROTEIN", 60, 63], ["RIG-I", "PROTEIN", 75, 80], ["IL-8", "PROTEIN", 256, 260], ["IL-6", "PROTEIN", 262, 266], ["CXCL1", "PROTEIN", 268, 273], ["TNF", "PROTEIN", 275, 278], ["IL-1\u03b2", "PROTEIN", 282, 287], ["monocyte chemotactic protein 1", "PROTEIN", 292, 322], ["patients", "SPECIES", 221, 229], ["Recent studies", "TEST", 0, 14], ["MDA", "TEST", 60, 63], ["an exaggerated inflammatory response", "PROBLEM", 176, 212], ["COPD patients", "PROBLEM", 216, 229], ["IL", "TEST", 256, 258], ["IL", "TEST", 262, 264], ["CXCL1", "TEST", 268, 273], ["TNF", "TEST", 275, 278], ["IL", "TEST", 282, 284], ["monocyte chemotactic protein", "TEST", 292, 320], ["RV", "ANATOMY", 113, 115], ["exaggerated", "OBSERVATION_MODIFIER", 179, 190], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203], ["COPD", "OBSERVATION", 216, 220]]], ["Baines and colleagues found that compared with healthy primary bronchial epithelial (pBECs), pBECs from COPD patients express large amounts of antiviral and proinflammatory agents and were highly susceptible to apoptosis when responded to RV infection (22) .DiscussionIn this study, we found that compared with control subjects, the basal levels of TNF-\u03b1, IL-1\u03b2 and IL-8 in patients with COPD were elevated in the BALF or PBMCs.", [["primary bronchial epithelial", "ANATOMY", 55, 83], ["pBECs", "ANATOMY", 85, 90], ["pBECs", "ANATOMY", 93, 98], ["BALF", "ANATOMY", 414, 418], ["PBMCs", "ANATOMY", 422, 427], ["COPD", "DISEASE", 104, 108], ["RV infection", "DISEASE", 239, 251], ["COPD", "DISEASE", 388, 392], ["bronchial epithelial", "TISSUE", 63, 83], ["pBECs", "CELL", 85, 90], ["pBECs", "CELL", 93, 98], ["patients", "ORGANISM", 109, 117], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 349, 354], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 356, 361], ["IL-8", "GENE_OR_GENE_PRODUCT", 366, 370], ["patients", "ORGANISM", 374, 382], ["BALF", "CELL", 414, 418], ["PBMCs", "CELL", 422, 427], ["pBECs", "CELL_TYPE", 85, 90], ["pBECs", "CELL_TYPE", 93, 98], ["TNF", "PROTEIN", 349, 352], ["IL-1\u03b2", "PROTEIN", 356, 361], ["IL-8", "PROTEIN", 366, 370], ["BALF", "CELL_TYPE", 414, 418], ["PBMCs", "CELL_TYPE", 422, 427], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 374, 382], ["pBECs", "PROBLEM", 93, 98], ["COPD", "PROBLEM", 104, 108], ["antiviral and proinflammatory agents", "TREATMENT", 143, 179], ["apoptosis", "PROBLEM", 211, 220], ["RV infection", "PROBLEM", 239, 251], ["this study", "TEST", 271, 281], ["the basal levels", "TEST", 329, 345], ["TNF", "TEST", 349, 352], ["IL", "TEST", 356, 358], ["IL", "TEST", 366, 368], ["COPD", "PROBLEM", 388, 392], ["bronchial epithelial", "ANATOMY", 63, 83], ["COPD", "OBSERVATION", 104, 108], ["large", "OBSERVATION_MODIFIER", 126, 131], ["amounts", "OBSERVATION_MODIFIER", 132, 139], ["RV", "ANATOMY", 239, 241], ["infection", "OBSERVATION", 242, 251], ["COPD", "OBSERVATION", 388, 392]]], ["These results are consistent with previously reported increases in systemic and airway cytokine in COPD patients (42) .", [["airway", "ANATOMY", 80, 86], ["COPD", "DISEASE", 99, 103], ["airway", "MULTI-TISSUE_STRUCTURE", 80, 86], ["patients", "ORGANISM", 104, 112], ["airway cytokine", "PROTEIN", 80, 95], ["patients", "SPECIES", 104, 112], ["systemic and airway cytokine in COPD patients", "PROBLEM", 67, 112], ["consistent with", "UNCERTAINTY", 18, 33], ["increases", "OBSERVATION_MODIFIER", 54, 63], ["systemic", "OBSERVATION_MODIFIER", 67, 75], ["airway", "ANATOMY", 80, 86], ["cytokine", "OBSERVATION", 87, 95], ["COPD", "OBSERVATION", 99, 103]]], ["However, we show for the first time that the basal level of MDA-5 is elevated in the bronchial mucosa and PBMCs from patients with COPD.", [["bronchial mucosa", "ANATOMY", 85, 101], ["PBMCs", "ANATOMY", 106, 111], ["COPD", "DISEASE", 131, 135], ["MDA-5", "CHEMICAL", 60, 65], ["MDA-5", "GENE_OR_GENE_PRODUCT", 60, 65], ["bronchial mucosa", "MULTI-TISSUE_STRUCTURE", 85, 101], ["PBMCs", "CELL", 106, 111], ["patients", "ORGANISM", 117, 125], ["MDA", "PROTEIN", 60, 63], ["PBMCs", "CELL_TYPE", 106, 111], ["patients", "SPECIES", 117, 125], ["MDA", "TEST", 60, 63], ["elevated in the bronchial mucosa", "PROBLEM", 69, 101], ["COPD", "PROBLEM", 131, 135], ["basal", "ANATOMY_MODIFIER", 45, 50], ["MDA", "OBSERVATION", 60, 63], ["elevated", "OBSERVATION_MODIFIER", 69, 77], ["bronchial mucosa", "ANATOMY", 85, 101], ["COPD", "OBSERVATION", 131, 135]]], ["Our data implies that the exaggerated inflammatory response to RV infection in COPD patients may be associated with the high level of MDA-5 in airway epithelial cells.", [["RV", "ANATOMY", 63, 65], ["airway epithelial cells", "ANATOMY", 143, 166], ["RV infection", "DISEASE", 63, 75], ["COPD", "DISEASE", 79, 83], ["MDA-5", "CHEMICAL", 134, 139], ["MDA-5", "CHEMICAL", 134, 139], ["RV", "ORGAN", 63, 65], ["patients", "ORGANISM", 84, 92], ["MDA-5", "GENE_OR_GENE_PRODUCT", 134, 139], ["airway epithelial cells", "CELL", 143, 166], ["MDA-5", "PROTEIN", 134, 139], ["airway epithelial cells", "CELL_TYPE", 143, 166], ["patients", "SPECIES", 84, 92], ["Our data", "TEST", 0, 8], ["the exaggerated inflammatory response", "PROBLEM", 22, 59], ["RV infection", "PROBLEM", 63, 75], ["COPD", "PROBLEM", 79, 83], ["the high level of MDA", "PROBLEM", 116, 137], ["exaggerated", "OBSERVATION_MODIFIER", 26, 37], ["inflammatory", "OBSERVATION_MODIFIER", 38, 50], ["RV", "ANATOMY", 63, 65], ["infection", "OBSERVATION", 66, 75], ["COPD", "OBSERVATION", 79, 83], ["airway", "ANATOMY", 143, 149], ["epithelial cells", "OBSERVATION", 150, 166]]], ["Excess MDA-5 in COPD patients activated by RV could lead to induction of a 'cytokine flood' .", [["MDA-5", "CHEMICAL", 7, 12], ["COPD", "DISEASE", 16, 20], ["MDA-5", "CHEMICAL", 7, 12], ["MDA-5", "GENE_OR_GENE_PRODUCT", 7, 12], ["patients", "ORGANISM", 21, 29], ["RV", "MULTI-TISSUE_STRUCTURE", 43, 45], ["cytokine", "PROTEIN", 76, 84], ["patients", "SPECIES", 21, 29], ["Excess MDA", "PROBLEM", 0, 10], ["a 'cytokine flood'", "TREATMENT", 73, 91], ["RV", "ANATOMY", 43, 45]]], ["This 'cytokine flood' is not only effective in facilitating viral clearance, but also may further contribute to airway inflammation.DiscussionFurthermore, we found that in COPD patients, there were strong correlations among MDA-5 mRNA levels, pro-inflammatory cytokine mRNA levels and airflow obstruction severity in PBMCs.", [["airway", "ANATOMY", 112, 118], ["PBMCs", "ANATOMY", 317, 322], ["airway inflammation", "DISEASE", 112, 131], ["COPD", "DISEASE", 172, 176], ["airflow obstruction", "DISEASE", 285, 304], ["MDA-5", "CHEMICAL", 224, 229], ["airway", "MULTI-TISSUE_STRUCTURE", 112, 118], ["patients", "ORGANISM", 177, 185], ["MDA-5", "GENE_OR_GENE_PRODUCT", 224, 229], ["PBMCs", "CELL", 317, 322], ["cytokine", "PROTEIN", 6, 14], ["MDA-5 mRNA", "RNA", 224, 234], ["pro-inflammatory cytokine mRNA", "RNA", 243, 273], ["PBMCs", "CELL_TYPE", 317, 322], ["patients", "SPECIES", 177, 185], ["This 'cytokine flood", "TREATMENT", 0, 20], ["airway inflammation", "PROBLEM", 112, 131], ["MDA", "TEST", 224, 227], ["mRNA levels", "TEST", 230, 241], ["pro-inflammatory cytokine mRNA levels", "TEST", 243, 280], ["airflow obstruction severity in PBMCs", "PROBLEM", 285, 322], ["not only", "UNCERTAINTY", 25, 33], ["viral clearance", "OBSERVATION", 60, 75], ["airway", "ANATOMY", 112, 118], ["inflammation", "OBSERVATION", 119, 131], ["airflow obstruction", "OBSERVATION", 285, 304]]], ["These correlations indicate that MDA-5 may be an important receptor that influences disease outcome or are the result of permanent stimulation of high levels of proinflammatory cytokines.", [["MDA-5", "CHEMICAL", 33, 38], ["MDA-5", "CHEMICAL", 33, 38], ["MDA-5", "GENE_OR_GENE_PRODUCT", 33, 38], ["proinflammatory cytokines", "PROTEIN", 161, 186], ["MDA", "TEST", 33, 36], ["permanent stimulation", "TREATMENT", 121, 142], ["proinflammatory cytokines", "PROBLEM", 161, 186], ["proinflammatory cytokines", "OBSERVATION", 161, 186]]], ["There was no significant correlation between the mRNA levels of MDA-5 in bronchial biopsy and FEV 1 %pred, which may have been due to the small number of bronchial biopsies samples in this study or the particular cell types present.", [["bronchial biopsy", "ANATOMY", 73, 89], ["bronchial biopsies samples", "ANATOMY", 154, 180], ["cell", "ANATOMY", 213, 217], ["MDA-5", "CHEMICAL", 64, 69], ["MDA-5", "GENE_OR_GENE_PRODUCT", 64, 69], ["bronchial biopsy", "MULTI-TISSUE_STRUCTURE", 73, 89], ["bronchial biopsies samples", "CANCER", 154, 180], ["cell", "CELL", 213, 217], ["MDA", "PROTEIN", 64, 67], ["the mRNA levels", "TEST", 45, 60], ["MDA", "TEST", 64, 67], ["bronchial biopsy", "TEST", 73, 89], ["FEV", "TEST", 94, 97], ["bronchial biopsies samples", "TEST", 154, 180], ["this study", "TEST", 184, 194], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["bronchial", "ANATOMY", 73, 82], ["biopsy", "OBSERVATION", 83, 89], ["may have been due to", "UNCERTAINTY", 113, 133], ["small", "OBSERVATION_MODIFIER", 138, 143], ["number", "OBSERVATION_MODIFIER", 144, 150], ["bronchial", "ANATOMY", 154, 163], ["biopsies", "OBSERVATION", 164, 172], ["particular cell types", "OBSERVATION", 202, 223]]], ["As we all know, the major cell type in PBMCs are lymphocytes and monocytes, while the major cell type in bronchial biopsies samples is epithelial cells.", [["cell", "ANATOMY", 26, 30], ["PBMCs", "ANATOMY", 39, 44], ["lymphocytes", "ANATOMY", 49, 60], ["monocytes", "ANATOMY", 65, 74], ["cell", "ANATOMY", 92, 96], ["bronchial biopsies samples", "ANATOMY", 105, 131], ["epithelial cells", "ANATOMY", 135, 151], ["cell type", "CELL", 26, 35], ["PBMCs", "CELL", 39, 44], ["lymphocytes", "CELL", 49, 60], ["monocytes", "CELL", 65, 74], ["cell type", "CELL", 92, 101], ["bronchial biopsies samples", "TISSUE", 105, 131], ["epithelial cells", "CELL", 135, 151], ["PBMCs", "CELL_TYPE", 39, 44], ["lymphocytes", "CELL_TYPE", 49, 60], ["monocytes", "CELL_TYPE", 65, 74], ["epithelial cells", "CELL_TYPE", 135, 151], ["lymphocytes", "TEST", 49, 60], ["monocytes", "TEST", 65, 74], ["bronchial biopsies samples", "TEST", 105, 131], ["epithelial cells", "PROBLEM", 135, 151], ["cell type", "OBSERVATION", 26, 35], ["PBMCs", "ANATOMY", 39, 44], ["bronchial", "ANATOMY", 105, 114], ["biopsies", "OBSERVATION", 115, 123], ["epithelial cells", "OBSERVATION", 135, 151]]], ["As the lymphocytes and monocytes are a critical component in the immune system to fight infection and adapt to intruders, the MDA-5 produced in these cells can Figure 5 .", [["lymphocytes", "ANATOMY", 7, 18], ["monocytes", "ANATOMY", 23, 32], ["immune system", "ANATOMY", 65, 78], ["cells", "ANATOMY", 150, 155], ["infection", "DISEASE", 88, 97], ["MDA-5", "CHEMICAL", 126, 131], ["MDA-5", "CHEMICAL", 126, 131], ["lymphocytes", "CELL", 7, 18], ["monocytes", "CELL", 23, 32], ["MDA-5", "GENE_OR_GENE_PRODUCT", 126, 131], ["cells", "CELL", 150, 155], ["lymphocytes", "CELL_TYPE", 7, 18], ["monocytes", "CELL_TYPE", 23, 32], ["MDA-5", "PROTEIN", 126, 131], ["a critical component", "PROBLEM", 37, 57], ["fight infection", "PROBLEM", 82, 97], ["the MDA", "TEST", 122, 129], ["lymphocytes", "ANATOMY", 7, 18], ["monocytes", "ANATOMY", 23, 32]]], ["Correlations between retinoic acid inducible gene I-like receptors mRNA levels, cytokine expression level and forced expiratory volume in 1 s (FEV1) %pred.", [["retinoic acid", "CHEMICAL", 21, 34], ["retinoic acid", "CHEMICAL", 21, 34], ["retinoic acid inducible gene I-like receptors", "GENE_OR_GENE_PRODUCT", 21, 66], ["retinoic acid inducible gene I-like receptors", "PROTEIN", 21, 66], ["cytokine", "PROTEIN", 80, 88], ["retinoic acid inducible gene I-like receptors mRNA levels", "PROBLEM", 21, 78], ["cytokine expression level", "TEST", 80, 105], ["forced expiratory volume", "TEST", 110, 134], ["FEV1", "TEST", 143, 147], ["expiratory volume", "OBSERVATION", 117, 134]]], ["There were significant correlations between melanoma differentiation associated gene 5 (MDA-5) mRNA level of peripheral blood mononuclear cells (PBMCs) and FEV1 %pred in chronic obstructive pulmonary disease (COPD) patients (A).", [["melanoma", "ANATOMY", 44, 52], ["peripheral blood mononuclear cells", "ANATOMY", 109, 143], ["PBMCs", "ANATOMY", 145, 150], ["pulmonary", "ANATOMY", 190, 199], ["melanoma", "DISEASE", 44, 52], ["chronic obstructive pulmonary disease", "DISEASE", 170, 207], ["COPD", "DISEASE", 209, 213], ["melanoma differentiation associated gene 5", "GENE_OR_GENE_PRODUCT", 44, 86], ["MDA-5", "GENE_OR_GENE_PRODUCT", 88, 93], ["peripheral blood mononuclear cells", "CELL", 109, 143], ["PBMCs", "CELL", 145, 150], ["pulmonary", "ORGAN", 190, 199], ["patients", "ORGANISM", 215, 223], ["melanoma differentiation associated gene 5", "DNA", 44, 86], ["(MDA-5) mRNA", "RNA", 87, 99], ["peripheral blood mononuclear cells", "CELL_TYPE", 109, 143], ["PBMCs", "CELL_TYPE", 145, 150], ["patients", "SPECIES", 215, 223], ["significant correlations between melanoma differentiation", "PROBLEM", 11, 68], ["MDA", "TEST", 88, 91], ["mRNA level", "TEST", 95, 105], ["peripheral blood mononuclear cells", "TEST", 109, 143], ["PBMCs", "TEST", 145, 150], ["FEV1", "TEST", 156, 160], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 170, 214], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["melanoma", "OBSERVATION", 44, 52], ["peripheral", "ANATOMY_MODIFIER", 109, 119], ["blood", "ANATOMY", 120, 125], ["mononuclear cells", "OBSERVATION", 126, 143], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["obstructive", "OBSERVATION_MODIFIER", 178, 189], ["pulmonary", "ANATOMY", 190, 199], ["disease", "OBSERVATION", 200, 207], ["COPD", "OBSERVATION", 209, 213]]], ["However, there was no significant correlation between RIG-I mRNA level of PBMCs and FEV1 %pred (B).", [["PBMCs", "ANATOMY", 74, 79], ["RIG-I", "GENE_OR_GENE_PRODUCT", 54, 59], ["PBMCs", "CELL", 74, 79], ["RIG-I mRNA", "RNA", 54, 64], ["PBMCs", "CELL_TYPE", 74, 79], ["RIG", "TEST", 54, 57], ["PBMCs", "TEST", 74, 79], ["FEV1", "TEST", 84, 88], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33]]], ["Correlation between PBMCs IL-1\u03b2 mRNA levels and MDA-5 mRNA levels in PBMCs of COPD patients was significant (C), and correlation between PBMCs IL-8 mRNA levels and MDA-5 mRNA levels in PBMCs of COPD patients was also significant (D).Discussioninduce higher inflammatory response than in epithelial cells, which may lead to different correlation between bronchial biopsy and PBMCs.DiscussionOn the other hand, there were no changes in both mRNA and protein levels of RIG-I in COPD patients.", [["PBMCs", "ANATOMY", 20, 25], ["PBMCs", "ANATOMY", 69, 74], ["PBMCs", "ANATOMY", 137, 142], ["PBMCs", "ANATOMY", 185, 190], ["epithelial cells", "ANATOMY", 287, 303], ["bronchial biopsy", "ANATOMY", 353, 369], ["PBMCs", "ANATOMY", 374, 379], ["COPD", "DISEASE", 78, 82], ["COPD", "DISEASE", 194, 198], ["COPD", "DISEASE", 475, 479], ["PBMCs", "CELL", 20, 25], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["MDA-5", "GENE_OR_GENE_PRODUCT", 48, 53], ["PBMCs", "CELL", 69, 74], ["patients", "ORGANISM", 83, 91], ["PBMCs", "CELL", 137, 142], ["IL-8", "GENE_OR_GENE_PRODUCT", 143, 147], ["MDA-5", "GENE_OR_GENE_PRODUCT", 164, 169], ["PBMCs", "CELL", 185, 190], ["patients", "ORGANISM", 199, 207], ["epithelial cells", "CELL", 287, 303], ["bronchial biopsy", "MULTI-TISSUE_STRUCTURE", 353, 369], ["PBMCs", "CELL", 374, 379], ["RIG-I", "GENE_OR_GENE_PRODUCT", 466, 471], ["patients", "ORGANISM", 480, 488], ["PBMCs", "CELL_TYPE", 20, 25], ["IL-1\u03b2 mRNA", "RNA", 26, 36], ["MDA-5 mRNA", "RNA", 48, 58], ["PBMCs", "CELL_TYPE", 69, 74], ["PBMCs", "CELL_TYPE", 137, 142], ["IL-8 mRNA", "RNA", 143, 152], ["MDA-5 mRNA", "RNA", 164, 174], ["PBMCs", "CELL_TYPE", 185, 190], ["epithelial cells", "CELL_TYPE", 287, 303], ["PBMCs", "CELL_TYPE", 374, 379], ["RIG-I", "PROTEIN", 466, 471], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 480, 488], ["PBMCs IL", "TEST", 20, 28], ["mRNA levels", "TEST", 32, 43], ["MDA", "TEST", 48, 51], ["mRNA levels", "TEST", 54, 65], ["PBMCs", "TEST", 69, 74], ["COPD", "PROBLEM", 78, 82], ["PBMCs IL", "TEST", 137, 145], ["mRNA levels", "TEST", 148, 159], ["MDA", "TEST", 164, 167], ["mRNA levels", "TEST", 170, 181], ["COPD", "PROBLEM", 194, 198], ["higher inflammatory response", "PROBLEM", 250, 278], ["bronchial biopsy", "TEST", 353, 369], ["COPD", "OBSERVATION", 78, 82], ["COPD", "OBSERVATION", 194, 198], ["higher", "OBSERVATION_MODIFIER", 250, 256], ["inflammatory", "OBSERVATION_MODIFIER", 257, 269], ["epithelial cells", "OBSERVATION", 287, 303], ["bronchial", "ANATOMY", 353, 362], ["biopsy", "OBSERVATION", 363, 369], ["COPD", "OBSERVATION", 475, 479]]], ["The different outcome of the basal level of MDA-5 and RIG-I may due to the divergent reorganization mechanism and feedback regulation of these two receptors.DiscussionRecently, Schneider and colleagues reported that the mRNA levels of MDA-5 and RIG-I are enhanced in the airway epithelial cells of COPD patients, and it is RIG-I rather than MDA-5 that has statistical significant (43) .", [["airway epithelial cells", "ANATOMY", 271, 294], ["COPD", "DISEASE", 298, 302], ["MDA-5", "CHEMICAL", 44, 49], ["MDA-5", "GENE_OR_GENE_PRODUCT", 44, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 54, 59], ["MDA-5", "GENE_OR_GENE_PRODUCT", 235, 240], ["RIG-I", "GENE_OR_GENE_PRODUCT", 245, 250], ["airway epithelial cells", "CELL", 271, 294], ["patients", "ORGANISM", 303, 311], ["RIG-I", "GENE_OR_GENE_PRODUCT", 323, 328], ["MDA-5", "GENE_OR_GENE_PRODUCT", 341, 346], ["MDA", "PROTEIN", 44, 47], ["RIG-I", "PROTEIN", 54, 59], ["MDA", "PROTEIN", 235, 238], ["RIG-I", "PROTEIN", 245, 250], ["airway epithelial cells", "CELL_TYPE", 271, 294], ["patients", "SPECIES", 303, 311], ["MDA", "TEST", 44, 47], ["the divergent reorganization mechanism", "PROBLEM", 71, 109], ["the mRNA levels", "TEST", 216, 231], ["MDA", "TEST", 235, 238], ["RIG", "TEST", 245, 248], ["COPD patients", "PROBLEM", 298, 311], ["MDA", "TEST", 341, 344], ["different", "OBSERVATION_MODIFIER", 4, 13], ["may due to", "UNCERTAINTY", 60, 70], ["divergent", "OBSERVATION_MODIFIER", 75, 84], ["reorganization", "OBSERVATION", 85, 99], ["enhanced", "OBSERVATION", 255, 263], ["airway", "ANATOMY", 271, 277], ["epithelial cells", "OBSERVATION", 278, 294], ["COPD", "OBSERVATION", 298, 302], ["significant", "OBSERVATION_MODIFIER", 368, 379]]], ["The heterogeneity may be due to the differences in genetic background, different exposure to the viruses, cigarette smoke and other environmental agents.DiscussionIn summary, our findings indicate that MDA-5 is upregulated in bronchial tissues and PBMCs of COPD patients, and that this upregulation may participate in the high expression levels of inflammatory cytokines.", [["bronchial tissues", "ANATOMY", 226, 243], ["PBMCs", "ANATOMY", 248, 253], ["smoke", "CHEMICAL", 116, 121], ["MDA-5", "CHEMICAL", 202, 207], ["COPD", "DISEASE", 257, 261], ["MDA-5", "CHEMICAL", 202, 207], ["cigarette", "ORGANISM", 106, 115], ["MDA-5", "GENE_OR_GENE_PRODUCT", 202, 207], ["bronchial tissues", "TISSUE", 226, 243], ["PBMCs", "CELL", 248, 253], ["patients", "ORGANISM", 262, 270], ["MDA", "PROTEIN", 202, 205], ["PBMCs", "CELL_TYPE", 248, 253], ["inflammatory cytokines", "PROTEIN", 348, 370], ["patients", "SPECIES", 262, 270], ["the differences in genetic background", "PROBLEM", 32, 69], ["MDA", "TEST", 202, 205], ["COPD patients", "PROBLEM", 257, 270], ["inflammatory cytokines", "PROBLEM", 348, 370], ["heterogeneity", "OBSERVATION", 4, 17], ["may be due to", "UNCERTAINTY", 18, 31], ["viruses", "OBSERVATION", 97, 104], ["bronchial tissues", "ANATOMY", 226, 243], ["COPD", "OBSERVATION", 257, 261], ["high expression", "OBSERVATION_MODIFIER", 322, 337], ["inflammatory cytokines", "OBSERVATION", 348, 370]]], ["Importantly, MDA-5 expression levels negatively correlate with FEV 1 %pred, which indicated that MDA-5 may play a critical role in the disease progression.", [["MDA-5", "CHEMICAL", 97, 102], ["MDA-5", "CHEMICAL", 97, 102], ["MDA-5", "GENE_OR_GENE_PRODUCT", 13, 18], ["FEV 1", "GENE_OR_GENE_PRODUCT", 63, 68], ["MDA-5", "GENE_OR_GENE_PRODUCT", 97, 102], ["MDA", "PROTEIN", 13, 16], ["MDA-5 expression levels", "TEST", 13, 36], ["FEV", "TEST", 63, 66], ["MDA", "TEST", 97, 100], ["the disease progression", "PROBLEM", 131, 154], ["disease", "OBSERVATION", 135, 142]]], ["Thus, it also identifies a new target, against which therapies can be developed to modulate the severity of viral-induced responses in clinical settings.", [["viral-induced responses", "PROBLEM", 108, 131], ["new", "OBSERVATION_MODIFIER", 27, 30], ["viral", "OBSERVATION", 108, 113]]], ["Understanding the molecular mechanisms underlying these processes will open novel avenues for the treatment of COPD.", [["COPD", "DISEASE", 111, 115], ["COPD", "PROBLEM", 111, 115], ["COPD", "OBSERVATION", 111, 115]]]], "36e6b1542ba21852a409bfa5c4c698345e8e71cf": [["INTRODUCTIONOn December 31, 2019, some cases of pneumonia of unknown etiology have emerged in the Hubei region of China.", [["pneumonia", "DISEASE", 48, 57], ["pneumonia", "PROBLEM", 48, 57], ["pneumonia", "OBSERVATION", 48, 57], ["Hubei", "ANATOMY_MODIFIER", 98, 103], ["region", "ANATOMY_MODIFIER", 104, 110], ["China", "ANATOMY", 114, 119]]], ["Then, on January 07, 2020, the causative agent has been identified by means of oropharyngeal swabs, i.e., a virus belonging to the Coronaviridae family called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).", [["oropharyngeal swabs", "ANATOMY", 79, 98], ["SARS", "DISEASE", 159, 163], ["acute respiratory syndrome coronavirus", "DISEASE", 178, 216], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 79, 98], ["SARS-CoV-2", "ORGANISM", 159, 169], ["SARS-CoV", "SPECIES", 159, 167], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 159, 216], ["oropharyngeal swabs", "PROBLEM", 79, 98], ["a virus", "PROBLEM", 106, 113], ["CoV", "TEST", 164, 167], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 171, 216], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["respiratory syndrome", "OBSERVATION", 184, 204]]], ["This new coronavirus was responsible of the respiratory syndrome called , 2020).", [["coronavirus", "DISEASE", 9, 20], ["respiratory syndrome", "DISEASE", 44, 64], ["coronavirus", "ORGANISM", 9, 20], ["This new coronavirus", "PROBLEM", 0, 20], ["the respiratory syndrome", "PROBLEM", 40, 64], ["coronavirus", "OBSERVATION", 9, 20], ["respiratory syndrome", "OBSERVATION", 44, 64]]], ["Most patients with positive swab test developed only minor symptoms, such as fever, dry cough, and pharyngitis, with a benign evolution and spontaneous resolution of the clinical picture.", [["fever", "DISEASE", 77, 82], ["dry cough", "DISEASE", 84, 93], ["pharyngitis", "DISEASE", 99, 110], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["positive swab test", "TEST", 19, 37], ["minor symptoms", "PROBLEM", 53, 67], ["fever", "PROBLEM", 77, 82], ["dry cough", "PROBLEM", 84, 93], ["pharyngitis", "PROBLEM", 99, 110], ["a benign evolution", "PROBLEM", 117, 135], ["the clinical picture", "PROBLEM", 166, 186], ["cough", "OBSERVATION", 88, 93], ["pharyngitis", "OBSERVATION", 99, 110], ["benign", "OBSERVATION_MODIFIER", 119, 125], ["spontaneous", "OBSERVATION_MODIFIER", 140, 151], ["resolution", "OBSERVATION_MODIFIER", 152, 162]]], ["However, some patients developed severe complications, such as interstitial pneumoniae with acute respiratory distress syndrome, pulmonary edema, multiorgan failure, septic shock, and even death (Sohrabi et al., 2020) .", [["interstitial", "ANATOMY", 63, 75], ["respiratory", "ANATOMY", 98, 109], ["pulmonary", "ANATOMY", 129, 138], ["multiorgan", "ANATOMY", 146, 156], ["interstitial pneumoniae", "DISEASE", 63, 86], ["acute respiratory distress syndrome", "DISEASE", 92, 127], ["pulmonary edema", "DISEASE", 129, 144], ["multiorgan failure", "DISEASE", 146, 164], ["septic shock", "DISEASE", 166, 178], ["death", "DISEASE", 189, 194], ["patients", "ORGANISM", 14, 22], ["pulmonary", "ORGAN", 129, 138], ["patients", "SPECIES", 14, 22], ["severe complications", "PROBLEM", 33, 53], ["interstitial pneumoniae", "PROBLEM", 63, 86], ["acute respiratory distress syndrome", "PROBLEM", 92, 127], ["pulmonary edema", "PROBLEM", 129, 144], ["multiorgan failure", "PROBLEM", 146, 164], ["septic shock", "PROBLEM", 166, 178], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["complications", "OBSERVATION", 40, 53], ["interstitial", "ANATOMY_MODIFIER", 63, 75], ["pneumoniae", "OBSERVATION", 76, 86], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory distress syndrome", "OBSERVATION", 98, 127], ["pulmonary", "ANATOMY", 129, 138], ["edema", "OBSERVATION", 139, 144], ["multiorgan failure", "OBSERVATION", 146, 164], ["septic shock", "OBSERVATION", 166, 178]]], ["Patients at risk were especially males, aged older than 60 years, suffering from cardiovascular comorbidities (e.g., arterial hypertension, diabetes, and chronic coronary artery disease), and affected by chronic pneumopathies or cancer (World Health Organization [WHO] , 2020; Zhou et al., 2020) .INTRODUCTIONIn the following month, the disease spread to other countries outside China, including Italy, where the first positive cases were found on February 21, 2020 (Spina et al., 2020) .", [["cardiovascular", "ANATOMY", 81, 95], ["arterial", "ANATOMY", 117, 125], ["coronary artery", "ANATOMY", 162, 177], ["cancer", "ANATOMY", 229, 235], ["cardiovascular comorbidities", "DISEASE", 81, 109], ["arterial hypertension", "DISEASE", 117, 138], ["diabetes", "DISEASE", 140, 148], ["chronic coronary artery disease", "DISEASE", 154, 185], ["chronic pneumopathies", "DISEASE", 204, 225], ["cancer", "DISEASE", 229, 235], ["Patients", "ORGANISM", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 117, 125], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 162, 177], ["cancer", "CANCER", 229, 235], ["Patients", "SPECIES", 0, 8], ["cardiovascular comorbidities", "PROBLEM", 81, 109], ["arterial hypertension", "PROBLEM", 117, 138], ["diabetes", "PROBLEM", 140, 148], ["chronic coronary artery disease)", "PROBLEM", 154, 186], ["chronic pneumopathies", "PROBLEM", 204, 225], ["cancer", "PROBLEM", 229, 235], ["the disease spread", "PROBLEM", 333, 351], ["cardiovascular", "ANATOMY", 81, 95], ["comorbidities", "OBSERVATION", 96, 109], ["arterial", "ANATOMY", 117, 125], ["hypertension", "OBSERVATION", 126, 138], ["diabetes", "OBSERVATION", 140, 148], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["coronary artery", "ANATOMY", 162, 177], ["disease", "OBSERVATION", 178, 185], ["chronic", "OBSERVATION_MODIFIER", 204, 211], ["pneumopathies", "OBSERVATION", 212, 225], ["cancer", "OBSERVATION", 229, 235], ["disease", "OBSERVATION", 337, 344]]], ["Italy experienced a significant increase in new cases, mostly in the month of March, in particular in the North regions, and this caused in turn a growing alarm throughout the Italian medical-hospital sector due to the imbalance between the resources of the national health system (indicated as SSN, i.e., \"Sistema Sanitario Nazionale\") and the expected need for treatment required by forecasts on the virus spread.", [["a significant increase in new cases", "PROBLEM", 18, 53], ["a growing alarm", "PROBLEM", 145, 160], ["the imbalance", "PROBLEM", 215, 228], ["treatment", "TREATMENT", 363, 372], ["the virus spread", "PROBLEM", 398, 414], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["new", "OBSERVATION_MODIFIER", 44, 47], ["cases", "OBSERVATION", 48, 53], ["North", "ANATOMY_MODIFIER", 106, 111], ["regions", "ANATOMY_MODIFIER", 112, 119]]], ["This concern was publicly expressed in the guidelines published by the Italian Society of Anesthesia, Analgesia, and Intensive Care (named SIAARTI, i.e., \"Societ\u00e0 Italiana Anestesia, Analgesia, Rianimazione e Terapia Intensiva\") on March 06, 2020, which reported that in case of huge imbalance between the population clinical needs and the effective availability of intensive resources, medical doctors should have selected patients for intensive therapies based on their actual hopes of survival (SIAARTI, 2020) .", [["patients", "ORGANISM", 424, 432], ["patients", "SPECIES", 424, 432], ["Anesthesia", "TREATMENT", 90, 100], ["Analgesia", "TREATMENT", 102, 111], ["Analgesia", "TREATMENT", 183, 192], ["Rianimazione", "TREATMENT", 194, 206], ["huge imbalance", "PROBLEM", 279, 293], ["intensive therapies", "TREATMENT", 437, 456]]], ["In fact, in Italy, there were about 5,200 beds in total for intensive care units, and on March 11, 2020, 1,028 of these beds had already been destined to patients suffering from COVID-19.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["COVID", "TEST", 178, 183]]], ["According to the predicted number of new cases, the peak of contagions would have been reached by mid of April, when at least 4,000 beds in the intensive care units would have been needed in order to treat patients with COVID-19 (Remuzzi and Remuzzi, 2020) , with significant consequences also for patients not affected by COVID-19, who would have given less assistance in the aforementioned units.INTRODUCTIONHowever, on the one hand, doctors and other health workers multiplied their alarms relatively to this critical situation and to the related recommendations regarding behaviors to be followed and the hygienic conduct to be implemented; on the other hand, there were daily episodes of violation of such medical recommendations by the population, apparently only scarcely aware of the problem.", [["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 298, 306], ["COVID", "TEST", 220, 225], ["Remuzzi", "TREATMENT", 230, 237], ["Remuzzi", "TREATMENT", 242, 249]]], ["For this reason, i.e., the failure of the unanimous spontaneous compliance of the population to the proposed hygienic rules and health practices, since February 23 the Italian Government implemented increasingly restrictive dispositions to limit the spread of the disease throughout the country with various Prime Minister Decrees (named DPCM, i.e., Decreto del Presidente del Consiglio dei Ministri; see DPCM on February 23, March 01, March 04, March 08, March 09, and March 11, 2020) .", [["the disease", "PROBLEM", 260, 271]]], ["In fact, a significant portion of population continued to engage in risky behaviors, prompting increasingly stricter rules emanated by the authorities.", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["portion", "OBSERVATION_MODIFIER", 23, 30], ["population", "OBSERVATION", 34, 44]]], ["Therefore, a gap appeared to emerge between the indications and requests from the national health system staff and the reception of these same indications by the population, as well as a general difference in the perception and evaluation of the risks associated with the COVID-19 infection between the two groups.", [["infection", "DISEASE", 281, 290], ["evaluation", "TEST", 228, 238], ["the COVID-19 infection", "PROBLEM", 268, 290], ["infection", "OBSERVATION", 281, 290]]], ["Such a difference seemed more evident especially in the areas of central and southern Italy, where the COVID-19 spread was lower than those of northern Italy, as reported by the daily data provided by the national civil protection (see Cereda et al., 2020) .INTRODUCTIONThe spread of the SARS-CoV virus in 2002 has shown how this type of epidemic disease has important psychopathological consequences, in the short and long term, in particular on health workers (Sim and Chua, 2004; Lung et al., 2009; Maunder, 2009) .", [["SARS", "DISEASE", 288, 292], ["SARS-CoV virus", "ORGANISM", 288, 302], ["CoV virus", "SPECIES", 293, 302], ["SARS-CoV virus", "SPECIES", 288, 302], ["the COVID", "TEST", 99, 108], ["the SARS-CoV virus", "PROBLEM", 284, 302], ["epidemic disease", "PROBLEM", 338, 354], ["central", "ANATOMY_MODIFIER", 65, 72], ["spread", "OBSERVATION_MODIFIER", 274, 280], ["Lung", "ANATOMY", 483, 487]]], ["Thus, in the actual spread of the new SARS-CoV-2 virus attention to psychological health of doctors and others healthcare workers had already been expressed regarding the Chinese situation relating to COVID-19 (see for example Xiang et al., 2020) , with proposals for intervention and support from the hospital structures .", [["SARS", "DISEASE", 38, 42], ["SARS-CoV-2 virus", "ORGANISM", 38, 54], ["SARS-CoV-2 virus", "SPECIES", 38, 54], ["the new SARS", "PROBLEM", 30, 42], ["intervention", "TREATMENT", 268, 280], ["support", "TREATMENT", 285, 292]]], ["In fact, Chinese health workers in Wuhan faced a situation characterized by poor safety and protection, with excessive workloads, high infectious risk, absence of adequate personal protective equipment, and shortage of staff.", [["high infectious risk", "PROBLEM", 130, 150]]], ["In fact, these health workers showed a symptomatology characterized by tiredness, worry, fear, frustration, isolation, depression, anxiety, stress, insomnia, anger, and negation (Kang et al., 2020) .", [["tiredness", "DISEASE", 71, 80], ["depression", "DISEASE", 119, 129], ["anxiety", "DISEASE", 131, 138], ["insomnia", "DISEASE", 148, 156], ["anger", "DISEASE", 158, 163], ["a symptomatology", "PROBLEM", 37, 53], ["tiredness", "PROBLEM", 71, 80], ["frustration", "PROBLEM", 95, 106], ["depression", "PROBLEM", 119, 129], ["anxiety", "PROBLEM", 131, 138], ["stress", "PROBLEM", 140, 146], ["insomnia", "PROBLEM", 148, 156], ["anger", "PROBLEM", 158, 163]]], ["In particular, in this group of workers, women, workers with more than 10 years of service, and operators who had a history of psychological suffering showed higher risk of stress, anxiety, and depression (Zhu et al., 2020) .INTRODUCTIONA further risk factor for psychological distress has been also a reduced social network support, a protective factor in the stress resilience (Ozbay et al., 2007) .", [["psychological suffering", "DISEASE", 127, 150], ["anxiety", "DISEASE", 181, 188], ["depression", "DISEASE", 194, 204], ["psychological distress", "DISEASE", 263, 285], ["women", "ORGANISM", 41, 46], ["women", "SPECIES", 41, 46], ["psychological suffering", "PROBLEM", 127, 150], ["stress", "PROBLEM", 173, 179], ["anxiety", "PROBLEM", 181, 188], ["depression", "PROBLEM", 194, 204], ["psychological distress", "PROBLEM", 263, 285], ["a reduced social network support", "TREATMENT", 300, 332]]], ["In the emergency situation caused by SARS-CoV-2, healthcare workers are indeed at high risk of acute stress, and this risk could be even higher if they feel such a disjunction from the social community formed by the other citizens, as the situation in Italy seemed to lead.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV", "SPECIES", 37, 45], ["acute stress", "PROBLEM", 95, 107], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["stress", "OBSERVATION", 101, 107]]], ["In addition to the personal consequences on the psychophysical health of the health professionals, this could easily lead to a progressive decline in their health services, with a worsening of the quality of care provided.", [["a progressive decline", "PROBLEM", 125, 146], ["progressive", "OBSERVATION_MODIFIER", 127, 138], ["decline", "OBSERVATION_MODIFIER", 139, 146], ["worsening", "OBSERVATION_MODIFIER", 180, 189]]], ["The experience with the disease caused by H1N1 in Japan showed how policies that take care of healthcare and give physicians confidence positively affected the overall care they provide to the population (Maunder, 2009; Imai, 2020) .", [["H1N1", "DISEASE", 42, 46], ["the disease", "PROBLEM", 20, 31], ["H1N1", "PROBLEM", 42, 46], ["disease", "OBSERVATION", 24, 31]]], ["In this manner, it would be possible to evaluate the analogies and the differences with the Chinese model at both intracultural and intercultural levels (McCrae, 2001) , for considering which intervention strategies could be suited for Italian healthcare workers and thus importing the most adequate recently developed for the Chinese healthcare system in response to the spread of COVID-19.INTRODUCTIONIn such an emergency situation, characterized by contrasts between the opinions and the worries of medical doctors on one side and the behaviors and the attitudes of the general population on the other, we designed and conducted this study.", [["intercultural levels", "TEST", 132, 152], ["intervention strategies", "TREATMENT", 192, 215], ["this study", "TEST", 632, 642]]], ["According to the evidences reported above, our objectives were (i) to probe the opinions and the worries relative to COVID-19 spread in both the general population and healthcare workers; (ii) to study which demographic, geographic, and psychological variables were related to a higher perception of the health risks; and lastly (iii) to assess any difference in risk perception relatively to COVID-19 between the general population and healthcare workers.", [["COVID", "TEST", 393, 398]]], ["Thus, our aim was to understand the influence of psychological and training/working experience in shaping opinions, worries, and risk perception relatively to COVID-19.", [["COVID", "TEST", 159, 164]]], ["To this aim, we administered an online battery including a questionnaire about the direct experience, the opinions and the worries relative to the COVID-19, and some questionnaires evaluating the psychological distress state.", [["the COVID", "TEST", 143, 152], ["the psychological distress state", "PROBLEM", 192, 224]]], ["To evaluate the participants distress level, we administered questionnaires measuring perceived stress, anxiety, and death anxiety as they usually increased in the general population (Brooks et al., 2020) and in healthcare workers (Brady, 2015; Kang et al., 2020) during emergency situation.", [["anxiety", "DISEASE", 104, 111], ["death anxiety", "DISEASE", 117, 130], ["participants", "SPECIES", 16, 28], ["distress level", "PROBLEM", 29, 43], ["anxiety", "PROBLEM", 104, 111], ["death anxiety", "PROBLEM", 117, 130]]], ["As the social-health situation in Italy was evolving continuously in the beginning of March, we limited the data collection in the days 10-12 March 2020.INTRODUCTIONBased on the evidence reviewed so far, we hypothesized that healthcare workers would show higher levels of distress in terms of stress, anxiety, and death anxiety, particularly in North Italy, where the contagion was higher.", [["anxiety", "DISEASE", 301, 308], ["death", "DISEASE", 314, 319], ["anxiety", "DISEASE", 320, 327], ["distress", "PROBLEM", 272, 280], ["stress", "PROBLEM", 293, 299], ["anxiety", "PROBLEM", 301, 308], ["death anxiety", "PROBLEM", 314, 327]]], ["In fact, as reported by Lai et al. (2020) , direct exposition to virus outbreak affected the psychological health of healthcare workers, with those living in the region of Wuhan reporting higher distress than colleagues living elsewhere.", [["higher distress", "PROBLEM", 188, 203]]], ["Then, we hypothesized that healthcare workers would perceive higher levels of risk for themselves and for their relatives and that this effect would be true even when controlling for such psychological distress.", [["psychological distress", "DISEASE", 188, 210], ["such psychological distress", "PROBLEM", 183, 210]]], ["In fact, we expected that this higher risk perception was not linked only to a worse psychological state, but also to a greater knowledge of the COVID-19 disease and of its possible consequences.", [["the COVID-19 disease", "PROBLEM", 141, 161]]], ["Thus, we also expected that healthcare workers would report higher levels of knowledge of the new coronavirus.", [["coronavirus", "DISEASE", 98, 109], ["coronavirus", "ORGANISM", 98, 109], ["the new coronavirus", "PROBLEM", 90, 109]]], ["About containment and prevention measures, we expected that healthcare workers would report a higher engagement in preventing measures with respect to other people and request for more stringent containment measures, in order to prevent SSN collapse due to an increased number of accesses in hospital.", [["people", "ORGANISM", 157, 163], ["people", "SPECIES", 157, 163], ["prevention measures", "TREATMENT", 22, 41], ["stringent containment measures", "TREATMENT", 185, 215], ["SSN collapse", "PROBLEM", 237, 249], ["collapse", "OBSERVATION", 241, 249], ["increased", "OBSERVATION_MODIFIER", 260, 269]]], ["Following all the previous hypotheses, we expected that participants not in the healthcare workers group would provide more optimistic forecast about the progress of the spread of COVID-19.ParticipantsThree hundred fifty-three Italian adults participated in this study (mean age = 38.26 years, SD = 12.24 years; females = 265, males = 88).", [["COVID-19", "CHEMICAL", 180, 188], ["adults", "ORGANISM", 235, 241], ["participants", "SPECIES", 56, 68], ["Participants", "SPECIES", 189, 201], ["COVID", "TEST", 180, 185], ["this study", "TEST", 258, 268]]], ["We divided our sample by means of their job or training: in the first group, we included medical doctors, nurses, paramedics, and students in medicine/nursing/other medical disciplines (\"MED\" group; n = 167; mean age = 35.56 years, SD = 9.90 years; female = 133, males = 34), whereas in the second group, we included all the other participants (no-med or \"NOM\" group; n = 186; mean age = 40.69 years, SD = 13.58 years; females = 132, males = 54).ProcedureWe recruited our participants with a convenience sample method via email and social media.", [["participants", "SPECIES", 331, 343], ["participants", "SPECIES", 472, 484], ["MED", "ANATOMY", 187, 190], ["med", "ANATOMY", 348, 351]]], ["Participants received a brief description of the study together with an informed consent module.", [["Participants", "SPECIES", 0, 12], ["the study", "TEST", 45, 54]]], ["Data were collected in anonymous format, and participants were invited at the end of the battery to leave their email in order to be contacted for possible follow-up measures.", [["participants", "SPECIES", 45, 57]]], ["In this study, we collected data not reported here, as fully specified in the \"Materials and Methods\" section.MaterialsIn this study, we administered questionnaires to evaluate the psychological condition and personality traits of each participant.", [["participant", "SPECIES", 236, 247], ["this study", "TEST", 3, 13], ["this study", "TEST", 122, 132], ["the psychological condition", "PROBLEM", 177, 204]]], ["We included in our battery the following questionnaires:Materials\u2022 The four-item Perceived Stress Scale (PSS; Cohen et al., 2006) , a questionnaire evaluating the stress perceived by the participant in the last month, that is, the participant's perceived feeling to be in control over external events, relationships, and emotional life.", [["participant", "SPECIES", 187, 198], ["participant", "SPECIES", 231, 242]]], ["We used the short fouritem version.", [["the short fouritem version", "TREATMENT", 8, 34]]], ["Each item was evaluated on a five-point Likert scale ranging from 0 (never) to 4 (very often).", [["Likert scale", "TEST", 40, 52]]], ["In our sample, the four-item PSS showed a good reliability score, Cronbach's \u03b1 = 0.73, similar to what was reported in the original version, \u03b1 = 0.72. \u2022 The six-item version of State-Trait Anxiety Inventory (STAI; Marteau and Bekker, 1992) , which assessed the anxiety of the participants on six items including emotions or feelings.", [["anxiety", "DISEASE", 261, 268], ["participants", "SPECIES", 276, 288], ["Cronbach's \u03b1", "TEST", 66, 78], ["good", "OBSERVATION_MODIFIER", 42, 46]]], ["Each item was evaluated on a four-point Likert scale ranging from 1 (almost never) to 4 (almost always).", [["Likert scale", "TEST", 40, 52]]], ["In our sample, the six-item STAI showed a similar reliability score, Cronbach's \u03b1 = 0.85, to that reported in the original version, \u03b1 = 0.82. \u2022 The death anxiety scale of the Existential Concerns Questionnaire (ECQ; van Bruggen et al., 2017) , which evaluated the anxiety of the participant relatively to his/her sense of finitude, to the fear of diseases and death.", [["death anxiety", "DISEASE", 148, 161], ["anxiety", "DISEASE", 264, 271], ["death", "DISEASE", 360, 365], ["six-item STAI", "DNA", 19, 32], ["the six-item STAI", "TEST", 15, 32], ["Cronbach's \u03b1", "TEST", 69, 81], ["The death anxiety scale", "PROBLEM", 144, 167], ["diseases", "PROBLEM", 347, 355], ["death", "PROBLEM", 360, 365], ["diseases", "OBSERVATION", 347, 355]]], ["The total score was computed overall five items.", [["The total score", "TEST", 0, 15]]], ["Each item was evaluated on a five-point Likert scale ranging from 0 (never) to 4 (always).", [["Likert scale", "TEST", 40, 52]]], ["In our sample, the ECQ death anxiety scale showed a good reliability score, Cronbach's \u03b1 = 0.89 (in the original version, only the internal consistency for the global score was reported, \u03b1 = 0.92). \u2022 The Marlowe and Crowne social desirability scale (M&C;MaterialsManganelli Rattazzi et al., 2000) , which assessed the tendency of answering in a socially desirable manner.", [["death", "DISEASE", 23, 28], ["anxiety", "DISEASE", 29, 36], ["the ECQ death anxiety scale", "TEST", 15, 42], ["Cronbach's \u03b1", "TEST", 76, 88], ["the global score", "TEST", 156, 172], ["good", "OBSERVATION_MODIFIER", 52, 56]]], ["This version of the scale implied nine items evaluated over a six-point Likert scale ranging from 1 (absolutely false) to 6 (absolutely true).", [["the scale", "TREATMENT", 16, 25], ["Likert scale", "TEST", 72, 84]]], ["In our sample, the M&C scale showed an acceptable reliability score, Cronbach's \u03b1 = 0.62, slightly lower than that reported in the cited Italian validation, \u03b1 = 0.69.MaterialsWe also included in the battery other questionnaires, which results were not reported in the present work: the 10-item Big Five Questionnaire (Guido et al., 2015) , the Acceptance and Action Questionnaire II (Pennato et al., 2013) , and the Emotion Regulation Questionnaire (Balzarotti et al., 2010) .MaterialsWe further developed a questionnaire about SARS-CoV-2 and COVID-19-related experience and personal opinion.", [["SARS", "DISEASE", 528, 532], ["the M&C scale", "TEST", 15, 28], ["Cronbach's \u03b1", "TEST", 69, 81], ["SARS", "TEST", 528, 532], ["CoV", "TEST", 533, 536], ["COVID", "TEST", 543, 548], ["slightly", "OBSERVATION_MODIFIER", 90, 98], ["lower", "OBSERVATION_MODIFIER", 99, 104]]], ["A complete list of the items was reported in Appendix A.MaterialsTo keep the questionnaire simple and easy to understand, we preferred to include mostly yes/no questions.", [["Appendix", "ANATOMY", 45, 53]]], ["As first step, we assessed differences in our sample between the MED and NOM groups for the demographic variables in order to control for unbalanced factors in our sample.", [["the MED and NOM groups", "TREATMENT", 61, 83], ["the demographic variables", "TEST", 88, 113], ["unbalanced factors", "PROBLEM", 138, 156], ["MED", "ANATOMY", 65, 68]]], ["We conducted these comparisons by means of t-tests for numerical data and of \u03c7 2 tests for frequencies.Data AnalysisThen, we described the experiences about COVID-19 infection in our sample and compared MED and NOM groups again and areas (North vs. Center vs. South Italy).", [["infection", "DISEASE", 166, 175], ["COVID-19", "CELL", 157, 165], ["numerical data", "TEST", 55, 69], ["\u03c7 2 tests", "TEST", 77, 86], ["COVID-19 infection", "PROBLEM", 157, 175], ["MED and NOM groups", "TREATMENT", 203, 221], ["infection", "OBSERVATION", 166, 175], ["MED", "ANATOMY", 203, 206]]], ["We also compared the psychological state of our participants by group and area to assess difference in levels of anxiety, stress, and death anxiety.", [["anxiety", "DISEASE", 113, 120], ["death anxiety", "DISEASE", 134, 147], ["participants", "SPECIES", 48, 60], ["anxiety", "PROBLEM", 113, 120], ["stress", "PROBLEM", 122, 128], ["death anxiety", "PROBLEM", 134, 147]]], ["For these comparisons, we implied mixed-effects analyses of variance (ANOVAs) with one between factor (group, two levels: MED vs. NOM) and one within factor (area, three levels: North, Center, South).", [["these comparisons", "TEST", 4, 21], ["MED", "ANATOMY", 122, 125]]], ["We further decomposed significant main or interaction effects by means of least significant difference-corrected post hoc pairwise comparisons.Data AnalysisAs main analysis, we computed hierarchical logistic regression on the dichotomic responses and reported overall our participants about preoccupations, opinions, and behaviors relatively to their experience with the new coronavirus.", [["coronavirus", "DISEASE", 375, 386], ["coronavirus", "ORGANISM", 375, 386], ["participants", "SPECIES", 272, 284], ["hoc pairwise comparisons", "TEST", 118, 142], ["Data AnalysisAs main analysis", "TEST", 143, 172], ["the new coronavirus", "PROBLEM", 367, 386], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["main", "OBSERVATION_MODIFIER", 34, 38], ["interaction effects", "OBSERVATION", 42, 61]]], ["This analysis allowed us to estimate the odds to obtain a positive response to a particular question given a set of parameters.", [["This analysis", "TEST", 0, 13]]], ["For non-dichotomous variables (e.g., contagious spread in the next days could either increase, decrease, or stay stable), we created N dichotomous dummy variables, where N was the number of possible alternative responses to \"equal\" response (e.g., for contagious spread in the next days, we created a dummy variable for increased forecast and a dummy variable for decreased forecast).", [["non-dichotomous variables", "PROBLEM", 4, 29], ["contagious spread", "PROBLEM", 37, 54], ["contagious spread", "PROBLEM", 252, 269], ["increased forecast", "PROBLEM", 320, 338]]], ["Moreover, we did not analyze the questions for which we obtained identical or almost identical responses by all our participants, i.e., question with >98% of equal responses.", [["participants", "SPECIES", 116, 128]]], ["In fact, for such questions, it was easy to find one of the outcome categories so underrepresented that it could lead to rare event outcome or be linearly separated by only one of the independent variables (IVs).Data AnalysisWe introduced the regressors in the model at different steps of computation.", [["the regressors", "TREATMENT", 239, 253]]], ["At the second step, we added to these variables the psychological state factors of perceived stress (PSS score), anxiety (STAI score), and death anxiety (ECQ score), in order to investigate the contribution of these regressors.", [["anxiety", "DISEASE", 113, 120], ["death anxiety", "DISEASE", 139, 152], ["perceived stress (PSS score)", "PROBLEM", 83, 111], ["anxiety", "PROBLEM", 113, 120], ["STAI score", "TEST", 122, 132], ["death anxiety", "PROBLEM", 139, 152], ["these regressors", "TREATMENT", 210, 226]]], ["As last step, we investigated the difference between MED and NOM groups in responding to the questionnaire.", [["MED and NOM groups", "TREATMENT", 53, 71], ["MED", "ANATOMY", 53, 56]]], ["For this aim, at the third step, we introduced the group variable as regressor.Data AnalysisWhen conducting logistic regression analysis, we should check for assumption violations.", [["logistic regression analysis", "TEST", 108, 136]]], ["First, we considered the sample size issue.", [["size", "OBSERVATION_MODIFIER", 32, 36]]], ["In the full model, i.e., model at Step 3, we had a total of eight IVs including all the regressors and the covariates.", [["eight IVs", "TREATMENT", 60, 69], ["all the regressors", "TREATMENT", 80, 98]]], ["Considering our sample size of 353 participants, this resulted in an event per variable (EPV) of approximately 50, computed as the ratio between number of participants and number of IVs.", [["participants", "SPECIES", 35, 47], ["participants", "SPECIES", 155, 167], ["IVs", "TREATMENT", 182, 185], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["This EPV could be considered as fairly sufficient to make the interpretation of our global model meaningful (Harrell, 2015; Ogundimu et al., 2016) , even if the more stringent Bujang et al.'s rule of thumb Bujang et al. (2018) would suggest to include at least 450 participants for such a number of variables.", [["participants", "SPECIES", 265, 277], ["thumb", "ANATOMY", 200, 205]]], ["Moreover, for each tested model, we checked for influential outliers and for multicollinearity.", [["each tested model", "TEST", 14, 31], ["multicollinearity", "PROBLEM", 77, 94]]], ["To test for influential outliers, we computed Cook's distance for each data point and check for values larger than 3 SD from the mean, as a large value of Cook's distance indicates an influential observation (Mart\u00edn and Pardo, 2009; Zhang, 2016) .", [["values", "TEST", 96, 102], ["large", "OBSERVATION_MODIFIER", 140, 145]]], ["To test multicollinearity, we computed the variance inflation factor (VIF) for each regressor and check for any value greater than 2.5, considered as more strict threshold with respect to the usual value of 5 or 10 (Midi et al., 2010) .", [["inflation factor", "PROTEIN", 52, 68], ["VIF", "PROTEIN", 70, 73], ["each regressor", "TEST", 79, 93]]], ["For all our logistic regression models, we found no influential outliers or any VIFs greater than the threshold value.", [["influential outliers", "PROBLEM", 52, 72], ["any VIFs", "PROBLEM", 76, 84], ["no", "UNCERTAINTY", 49, 51]]], ["The results of these tests, together with the reported EPV greater than 50, testified that our logistic regression analyses could be considered sufficiently reliable.Data AnalysisTo further support our logistic regression model results, we conducted semipartial correlation analysis by means of the ppcor package for R (Kim, 2015) .", [["these tests", "TEST", 15, 26], ["our logistic regression analyses", "TEST", 91, 123]]], ["We assessed the degree of relationship between group (coded as NOM = 0 and MED = 1) and each dependent variable of the COVID-19 questionnaire while controlling for sex, age, living area, anxiety, death anxiety, and stress.", [["anxiety", "DISEASE", 187, 194], ["death anxiety", "DISEASE", 196, 209], ["NOM", "TEST", 63, 66], ["the COVID", "TEST", 115, 124], ["anxiety", "PROBLEM", 187, 194], ["death anxiety", "PROBLEM", 196, 209], ["stress", "PROBLEM", 215, 221]]], ["Semipartial correlations were reported as Pearson r for each computed correlation, with values ranging from \u22121, very strong negative relationship, to 1, very strong positive relationship.Data AnalysisEven if we conducted a great number of statistical analyses on the same sample, we decided not to apply a general correction to significance level for multiple tests.", [["each computed correlation", "TEST", 56, 81], ["values", "TEST", 88, 94], ["a general correction", "TREATMENT", 304, 324], ["multiple tests", "TEST", 351, 365]]], ["Because of the exploratory nature of this study, we preferred not to strictly control over false-positive rate (Type I error) while avoiding to inflate falsenegative rate (Type II error); i.e., we decided to collect all the significant results emerging from our analysis so to guide further, confirmatory experiments and studies (see Fiedler et al., 2012 , for an overview of the problem on multiple testing correction).", [["this study", "TEST", 37, 47], ["Type II error", "PROBLEM", 172, 185], ["our analysis", "TEST", 258, 270], ["confirmatory experiments", "TEST", 292, 316], ["studies", "TEST", 321, 328]]], ["Table 1 reports the descriptive statistics for the two groups and the relative tests for samples' comparison.", [["the relative tests", "TEST", 66, 84], ["samples' comparison", "TEST", 89, 108]]], ["As shown, participants in the MED group were younger (mean = 35.56 vs. 40.69), studied more years (mean = 23.02 vs. 21.34), had less children (mean = 0.40 vs. 0.58), reported to sleep in average less time per night (mean = 6.84 vs. 7.06), and were more frequently vaccinated for annual flu in 2019 (40% vs. 13%).Experience With the COVID-19In this first results section, we reported the analysis of the data relatively to the experience with the COVID-19.", [["children", "ORGANISM", 133, 141], ["COVID-19", "DNA", 446, 454], ["participants", "SPECIES", 10, 22], ["children", "SPECIES", 133, 141], ["mean", "TEST", 99, 103], ["mean", "TEST", 143, 147], ["annual flu", "TEST", 279, 289], ["the COVID", "TEST", 442, 451], ["MED", "ANATOMY", 30, 33]]], ["We thus referred to the data in the first part of the questionnaire, in which we asked if participants had personal experiences or contacts with COVID-19 infection.", [["COVID-19", "CHEMICAL", 145, 153], ["infection", "DISEASE", 154, 163], ["participants", "SPECIES", 90, 102], ["COVID-19 infection", "PROBLEM", 145, 163], ["infection", "OBSERVATION", 154, 163]]], ["We reported data overall participants and divided by groups in Table 2 .", [["participants", "SPECIES", 25, 37]]], ["Frequencies were compared by means of \u03c7 2 test.Experience With the COVID-19For the overall sample, we found an effect of the living area on question 3, about the presence of symptoms related to COVID-19, \u03c7 2 (2) = 44.48, p < 0.01; question 4, about thinking that the symptoms relate to a COVID-19 infection, \u03c7 2 (2) = 11.64, p < 0.01; question 6, about the quarantine status, \u03c7 2 (2) = 30.67, p < 0.01; question 7, about contact with people at risk of infection, \u03c7 2 (2) = 21.87, p < 0.01; and question 9, about the presence of positive case in the living area or city, \u03c7 2 (2) = 132.71, p < 0.01.", [["infection", "DISEASE", 297, 306], ["infection", "DISEASE", 452, 461], ["people", "ORGANISM", 434, 440], ["people", "SPECIES", 434, 440], ["the COVID", "TEST", 63, 72], ["symptoms", "PROBLEM", 174, 182], ["COVID", "TEST", 194, 199], ["the symptoms", "PROBLEM", 263, 275], ["a COVID", "TEST", 286, 293], ["infection", "PROBLEM", 297, 306], ["p", "TEST", 325, 326], ["the quarantine status", "TEST", 353, 374], ["p", "TEST", 393, 394], ["infection", "PROBLEM", 452, 461], ["p", "TEST", 588, 589], ["infection", "OBSERVATION", 452, 461], ["positive", "OBSERVATION", 528, 536]]], ["In answering to all these questions, participants from North Italy reported a greater direct experience with COVID-19 than participants from Center or South Italy, whereas participants from Center Italy reported more personal experiences than participants from the South.Experience With the COVID-19Then, we compared the frequencies between the two groups, MED versus NOM.", [["NOM", "DISEASE", 368, 371], ["participants", "SPECIES", 37, 49], ["participants", "SPECIES", 123, 135], ["participants", "SPECIES", 172, 184], ["participants", "SPECIES", 243, 255], ["MED", "ANATOMY", 357, 360]]], ["We found significant differences in question 7, about contact with people at risk of infection, \u03c7 2 (1) = 14.41, p < 0.01, and in question 8, about contact with people positive for COVID-19 test, \u03c7 2 (1) = 20.01, p < 0.01, with participants in the MED group reporting more frequent contacts with people at high risk of infection or already positive.Comparing Psychological Variables Between GroupsWe measured various indexes of psychological distress state, i.e., anxiety, death anxiety, and stress.", [["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 319, 328], ["anxiety", "DISEASE", 464, 471], ["death anxiety", "DISEASE", 473, 486], ["people", "ORGANISM", 67, 73], ["people", "ORGANISM", 161, 167], ["people", "ORGANISM", 296, 302], ["people", "SPECIES", 67, 73], ["people", "SPECIES", 161, 167], ["participants", "SPECIES", 228, 240], ["people", "SPECIES", 296, 302], ["infection", "PROBLEM", 85, 94], ["COVID", "TEST", 181, 186], ["infection", "PROBLEM", 319, 328], ["psychological distress state", "PROBLEM", 428, 456], ["anxiety", "PROBLEM", 464, 471], ["death anxiety", "PROBLEM", 473, 486], ["stress", "PROBLEM", 492, 498], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["differences", "OBSERVATION_MODIFIER", 21, 32], ["infection", "OBSERVATION", 85, 94], ["MED", "ANATOMY", 248, 251], ["infection", "OBSERVATION", 319, 328]]], ["To this aim, we conducted mixed-effects (ANOVAs) with a between-variable of group (MED vs. NOM) and a within-variable of living area (North vs. Center vs. South Italy).", [["MED", "ANATOMY", 83, 86]]], ["We probed significant effects by means of post hoc corrected tests.", [["post hoc corrected tests", "TEST", 42, 66]]], ["For the death anxiety score (ECQ; see Figure 1 , left panel), we found no significant main effects or significant interaction, all p's > 0.19.", [["death anxiety", "DISEASE", 8, 21], ["the death anxiety score", "PROBLEM", 4, 27], ["ECQ", "TEST", 29, 32], ["left panel", "TEST", 49, 59], ["significant interaction", "PROBLEM", 102, 125], ["no significant", "UNCERTAINTY", 71, 85], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["interaction", "OBSERVATION", 114, 125]]], ["For the Perceived Stress Score (PSS; see Figure 1 , middle panel), we found a significant main effect of the living area, F(2,348) = 6.52, p < 0.01, with participants from North Italy reporting higher stress levels than participants from both Center, p < 0.01, and South Italy, p < 0.01.", [["participants", "SPECIES", 154, 166], ["participants", "SPECIES", 220, 232], ["the Perceived Stress Score", "TEST", 4, 30], ["PSS", "TEST", 32, 35], ["higher stress levels", "PROBLEM", 194, 214], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["main", "OBSERVATION_MODIFIER", 90, 94]]], ["The analysis also revealed a significant group \u00d7 living area interaction, F(5,345) = 3.16, p < 0.05, with MED participants from North reporting higher stress score than other MED participants from both Center, p < 0.01, and South Italy, p < 0.01, as well as higher stress score than the NOM group participants from all living areas, all p's < 0.05.", [["participants", "SPECIES", 110, 122], ["participants", "SPECIES", 179, 191], ["participants", "SPECIES", 297, 309], ["The analysis", "TEST", 0, 12], ["a significant group \u00d7 living area interaction", "PROBLEM", 27, 72], ["higher stress score", "PROBLEM", 144, 163], ["higher stress score", "PROBLEM", 258, 277], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["MED", "ANATOMY", 106, 109], ["MED", "ANATOMY", 175, 178]]], ["For the anxiety score (STAI; Figure 1 , right panel), we found a significant main effect of living area, F(2,348) = 3.31, p < 0.05, with participants from North Italy reporting higher anxiety levels than participants from Center, and a significant group \u00d7 living area interaction, F(5,345) = 2.96, p < 0.05.", [["anxiety", "DISEASE", 8, 15], ["anxiety", "DISEASE", 184, 191], ["participants", "SPECIES", 137, 149], ["participants", "SPECIES", 204, 216], ["the anxiety score", "TEST", 4, 21], ["STAI", "TEST", 23, 27], ["right panel", "TEST", 40, 51], ["higher anxiety levels", "PROBLEM", 177, 198], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["main", "OBSERVATION_MODIFIER", 77, 81], ["significant", "OBSERVATION_MODIFIER", 236, 247]]], ["The interaction was due to a significant difference in anxiety between MED participants from North with respect to the MED participants from Center and South Italy, p's < 0.01, and with respect to NOM participants from Center Italy, p < 0.01.", [["anxiety", "DISEASE", 55, 62], ["participants", "SPECIES", 75, 87], ["participants", "SPECIES", 123, 135], ["participants", "SPECIES", 201, 213], ["a significant difference in anxiety", "PROBLEM", 27, 62], ["MED", "ANATOMY", 119, 122]]], ["This analysis thus revealed that the MED group participants from North Italy reported higher levels of anxiety and stress than the general population and the medical and paramedical staff from other living areas.Descriptive Statistics of the Questionnaire About COVID-19Before conducting the regression analysis on the questionnaire data, we reported some descriptive information and statistics about the response frequency of participants.", [["anxiety", "DISEASE", 103, 110], ["participants", "SPECIES", 47, 59], ["participants", "SPECIES", 427, 439], ["This analysis", "TEST", 0, 13], ["anxiety", "PROBLEM", 103, 110], ["stress", "PROBLEM", 115, 121], ["MED", "ANATOMY", 37, 40]]], ["Response frequencies for each item overall sample as well as divided by group are reported in Table 3 , left group of columns.", [["left", "ANATOMY_MODIFIER", 104, 108], ["columns", "ANATOMY_MODIFIER", 118, 125]]], ["Here we reported also a \u03c7 2 test comparing the frequency of \"yes\" responses for the two groups.Descriptive Statistics of the Questionnaire About COVID-19Of note, 57% of participants were thought to be at risk of contagion, but only 18% were thought to be at risk when the first cases appeared in Italy.", [["participants", "ORGANISM", 169, 181], ["participants", "SPECIES", 169, 181], ["a \u03c7 2 test", "TEST", 22, 32]]], ["The MED group reported higher frequency of thinking to be at risk (71%).", [["MED", "ANATOMY", 4, 7]]], ["Many participants in this group (57%) were scared about health consequences or death if infected, but almost all (93%) were more worried for family or loved ones' consequences of infection.", [["death", "DISEASE", 79, 84], ["infection", "DISEASE", 179, 188], ["participants", "SPECIES", 5, 17], ["infected", "PROBLEM", 88, 96], ["infection", "PROBLEM", 179, 188], ["infection", "OBSERVATION", 179, 188]]], ["Similarly, the 73% of them reported worries about the global sociopolitical implication of virus spread, and the 83% about the possible collapsing of the national health system.", [["virus spread", "PROBLEM", 91, 103], ["collapsing of the national health system", "PROBLEM", 136, 176], ["virus", "OBSERVATION", 91, 96], ["possible", "UNCERTAINTY", 127, 135], ["collapsing", "OBSERVATION", 136, 146]]], ["Moreover, 83% of them thought that people's behavior could be ever scaring of the infection and 73% were worried by the increased aggression risk for health workers in the near future.Descriptive Statistics of the Questionnaire About COVID-19Most of our sample (97%) reported to adhere to hygiene measures and to avoid public events or places (94%), and only a few participants reported to have risky behaviors for themselves (18%) or their family (17%).", [["infection", "DISEASE", 82, 91], ["aggression", "DISEASE", 130, 140], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["participants", "SPECIES", 365, 377], ["the infection", "PROBLEM", 78, 91], ["COVID", "TEST", 234, 239], ["our sample", "TEST", 250, 260], ["hygiene measures", "TREATMENT", 289, 305], ["infection", "OBSERVATION", 82, 91]]], ["However, only 16% of NOM and 6% of MED believed that people's behavior was adequate to the situation.", [["NOM", "DISEASE", 21, 24], ["NOM", "CANCER", 21, 24], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["MED", "ANATOMY", 35, 38]]], ["About violation of the public health dispositions, most of participants thought that violation should be punished more severely (90%) or that the national army should be implied (91%), as they reported to be preoccupied or angry toward such violations (89%).", [["participants", "SPECIES", 59, 71]]], ["Few reported to have bought more canned food (23%), and very few participants reported that they would try to escape if the infection would spread in their living area (2%), even if a great part of them (71%) believed that the infection fear could be considered a valid reason to break the containment rules.Descriptive Statistics of the Questionnaire About COVID-19About the possible problem of accessing healthcare services, most of participants (71%) believed in the national health system, whereas few thought that it was right to give priority to people with greater hope of survival in case of shortage of hospital beds (25%) and even less (5%) that they would accept an exclusion for them or their loved ones at all kindly.Descriptive Statistics of the Questionnaire About COVID-19About their opinions on the containment measures disposed, 98% of the participants thought that these measures were necessary, but only 56% thought that these same measures were adequate (the MED group was more skeptical than the NOM group), and 80% proposed to strengthen them.", [["infection", "DISEASE", 124, 133], ["infection", "DISEASE", 227, 236], ["participants", "ORGANISM", 65, 77], ["people", "ORGANISM", 552, 558], ["participants", "SPECIES", 65, 77], ["participants", "SPECIES", 435, 447], ["people", "SPECIES", 552, 558], ["participants", "SPECIES", 858, 870], ["the infection", "PROBLEM", 120, 133], ["the infection fear", "PROBLEM", 223, 241], ["infection", "OBSERVATION", 124, 133], ["infection", "OBSERVATION", 227, 236]]], ["In line with this, most participants thought that it was right to limit people's freedom for controlling the virus (93%), as well as one's own freedom (99%), as they already limited their behaviors (99%).Descriptive Statistics of the Questionnaire About COVID-19About the information, they reported to be properly informed about the virus (84%) and the social situation related to it (70%), but also requested more information from experts (68%).", [["participants", "ORGANISM", 24, 36], ["people", "ORGANISM", 72, 78], ["participants", "SPECIES", 24, 36], ["people", "SPECIES", 72, 78], ["the virus", "PROBLEM", 105, 114], ["the virus", "PROBLEM", 329, 338]]], ["About perception of risk in public opinion, 64% of participants reported to think that it was lesser than it should be and 30% that it was greater.", [["participants", "ORGANISM", 51, 63], ["participants", "SPECIES", 51, 63]]], ["Interestingly, 40% reported to think that there was some hidden information about the virus, and 68% of these that such hidden information was related to a greater danger related to the infection.", [["infection", "DISEASE", 186, 195], ["the virus", "PROBLEM", 82, 91], ["the infection", "PROBLEM", 182, 195], ["infection", "OBSERVATION", 186, 195]]], ["The MED group, instead, reported to be less convinced of the existence of hidden information (34% vs. 46% of the NOM group).Descriptive Statistics of the Questionnaire About COVID-19Lastly, about the spread of the virus, the MED group was more pessimistic than the NOM group.", [["the virus", "PROBLEM", 210, 219], ["MED", "ANATOMY", 4, 7], ["MED", "ANATOMY", 225, 228]]], ["In fact, they reported less likely that the spread would slow down in some days (19% vs. 45%) or in some weeks (71% vs. 78%).Logistic Regression Overall Sample: Effect of DemographicsIn this subsection, we present logistic regression results on the COVID-19 questionnaire.", [["the COVID", "TEST", 245, 254], ["less likely", "UNCERTAINTY", 23, 34]]], ["We used each question as a dependent variable in a three-step hierarchical logistic regression.", [["a dependent variable", "PROBLEM", 25, 45]]], ["AtLogistic Regression Overall Sample: Effect of DemographicsStep 1, we used as regressors the demographic variables (see \"Data Analysis\" section) and the living area, considering North Italy as the reference (the coefficients reported should be interpreted as the odds that a participant from Center or South Italy would answer \"yes\" to a question compared to a participant from North Italy).", [["DemographicsStep 1", "TREATMENT", 48, 66]]], ["AtLogistic Regression Overall Sample: Effect of DemographicsStep 2, we added as regressors the psychological factors of perceived stress, anxiety, and death anxiety.", [["anxiety", "DISEASE", 138, 145], ["death anxiety", "DISEASE", 151, 164], ["DemographicsStep 2", "TREATMENT", 48, 66], ["perceived stress", "PROBLEM", 120, 136], ["anxiety", "PROBLEM", 138, 145], ["death anxiety", "PROBLEM", 151, 164]]], ["For the sake of brevity, we reported only the questions for which we obtained significant regressors.Logistic Regression Overall Sample: Effect of DemographicsAtLogistic Regression Overall Sample: Effect of DemographicsStep 1 (see Table 3 ,Logistic Regression Overall Sample: Effect of DemographicsStep 1 block of columns), we included in the model only demographic variables.", [["DemographicsStep 1 block of columns", "TREATMENT", 286, 321]]], ["With respect to male sex, female sex was linked to higher odds to be concerned by the following risks: being infected (1.68), loved ones being infected (1.71), developing serious complication or dying (2.99), global crisis (1.88), people's behavior in response of virus outbreak (1.89), infecting family members or love ones (2.38), and people's violating the containment provisions (2.65).", [["people", "ORGANISM", 231, 237], ["people", "ORGANISM", 337, 343], ["people", "SPECIES", 231, 237], ["people", "SPECIES", 337, 343], ["serious complication", "PROBLEM", 171, 191], ["global crisis", "PROBLEM", 209, 222], ["people's behavior", "PROBLEM", 231, 248], ["virus outbreak", "PROBLEM", 264, 278], ["serious", "OBSERVATION_MODIFIER", 171, 178], ["complication", "OBSERVATION", 179, 191]]], ["In fact, females had higher odds to report that the public opinion had less riskrelated perception about COVID-19 than it should be (1.80), that risky behavior should be punished more severely (3.37), that containment provisions should be improved (1.90), and that it would be right to limit people's freedom in this situation (4.71).", [["people", "ORGANISM", 292, 298], ["people", "SPECIES", 292, 298], ["COVID", "TEST", 105, 110]]], ["In line with these results, they reported more likely to have not continued to attend public places and events (0.32).Logistic Regression Overall Sample: Effect of DemographicsAbout age factor, older age was related to lower odds of reporting worries about the risk of infection for the loved ones (0.98), or about people's behavior as more dangerous that virus infection (0.95), or about the perception of risk in public opinion as lower that is should be (0.95).", [["infection", "DISEASE", 269, 278], ["infection", "DISEASE", 362, 371], ["people", "ORGANISM", 315, 321], ["people", "SPECIES", 315, 321], ["infection", "PROBLEM", 269, 278], ["virus infection", "PROBLEM", 356, 371], ["infection", "OBSERVATION", 269, 278]]], ["Older age people also reported TABLE 3 | Hierarchical logistic regression odds for demographics (Step 1), psychological (Step 2), and group (Step 3) factors for the COVID-19 questionnaire.QuestionFrequency of \"yes\" responsesQuestionStep 1QuestionStep 2QuestionStep 3 Questions in italics showed imbalanced responses (almost all \"yes\" or \"no\").", [["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["the COVID", "TEST", 161, 170]]], ["Group was coded as 0 = NOM and 1 = MED.", [["MED", "ANATOMY", 35, 38]]], ["ECQ = Existential Concerns Questionnaire (death anxiety scale); PSS = Perceived Stress Scale; STAI = State-Trait Anxiety Inventory.", [["death anxiety", "DISEASE", 42, 55], ["Questionnaire (death anxiety scale)", "PROBLEM", 27, 62], ["PSS", "TEST", 64, 67], ["Anxiety Inventory", "PROBLEM", 113, 130]]], ["Rightmost column (Sp. cor.) reports Pearson r for semipartial correlations between group and questionnaire responses (coded as 0 = \"no\" and 1 = \"yes\") controlling for all the other variables, i.e., sex, age, living area, anxiety, death anxiety, and stress.", [["anxiety", "DISEASE", 221, 228], ["death anxiety", "DISEASE", 230, 243], ["anxiety", "PROBLEM", 221, 228], ["death anxiety", "PROBLEM", 230, 243], ["stress", "PROBLEM", 249, 255]]], ["Significance level marked as follows: + p < 0.10, *p < 0.05, **p < 0.01.QuestionFrontiers in Psychology | www.frontiersin.org lower odds to be concerned about their behavior as risky for themselves (0.97) or loved ones (0.96), but higher odds to be concerned about their health status in case of COVID-19 infection (1.03) and by people reaction to virus spreading (1.03).", [["COVID-19", "CHEMICAL", 296, 304], ["infection", "DISEASE", 305, 314], ["people", "ORGANISM", 329, 335], ["people", "SPECIES", 329, 335], ["COVID-19", "SPECIES", 296, 304], ["Significance level", "TEST", 0, 18], ["p", "TEST", 40, 41], ["COVID-19 infection", "PROBLEM", 296, 314], ["virus spreading", "PROBLEM", 348, 363], ["marked", "OBSERVATION_MODIFIER", 19, 25]]], ["With respect to participants from North Italy, those from both Center and South Italy showed greater odds to judge the actual containment measures as adequate (Center = 2.41, South = 2.74) and to think that some information about COVID-19 was hidden from them (Center = 1.69, South = 2.23), whereas they reported less likely to be at infectious risk (Center = 0.46, South = 0.64 not significant) or to consider themselves at risk when the first cases were discovered in Italy (Center = 0.38, South = 0.41).", [["participants", "SPECIES", 16, 28], ["COVID", "TEST", 230, 235], ["infectious", "OBSERVATION", 334, 344]]], ["Of note, participants in South area reported lower odds with respect to participants in North area to consider fear of infection as a valid reason to violate the containment measures (0.47).Logistic Regression Overall Sample: Effect of Psychological FactorsAt Step 2 (see Table 3 , Step 2 block of columns) of hierarchical model, we added psychological factors of perceived stress (PSS), anxiety (STAI), and death anxiety (ECQ).", [["infection", "DISEASE", 119, 128], ["anxiety", "DISEASE", 388, 395], ["death anxiety", "DISEASE", 408, 421], ["ECQ", "DISEASE", 423, 426], ["participants", "SPECIES", 9, 21], ["participants", "SPECIES", 72, 84], ["infection", "PROBLEM", 119, 128], ["Psychological FactorsAt Step", "TEST", 236, 264], ["perceived stress (PSS)", "TREATMENT", 364, 386], ["anxiety", "PROBLEM", 388, 395], ["death anxiety", "PROBLEM", 408, 421], ["infection", "OBSERVATION", 119, 128], ["containment", "OBSERVATION_MODIFIER", 162, 173]]], ["In particular, the PSS score was related to a higher worry to be currently at infection risk (1.11) and a major need of information by experts (1.14), while their opinion on the virus spread was that it would show equal speed in the weeks following the compilation (0.84 for both accelerated or slowed-down spread).", [["infection", "DISEASE", 78, 87], ["the PSS score", "TEST", 15, 28], ["a higher worry", "PROBLEM", 44, 58], ["infection risk", "PROBLEM", 78, 92], ["the virus spread", "PROBLEM", 174, 190], ["infection", "OBSERVATION", 78, 87]]], ["Instead, the STAI score was related to higher concerns of accelerated spread of virus in the weeks following the compilation of the questionnaire (1.14).", [["the STAI score", "TEST", 9, 23], ["accelerated spread of virus", "PROBLEM", 58, 85]]], ["Lastly, the ECQ score was related to a higher level of worrying about the COVID-19 situation, in particular about possible severe outcome of the disease for themselves (1.16) or loved ones (1.11) and marginally related to higher level of worrying about possible catastrophic social global outcomes (1.05) or violation of containment measures (1.07).Effect of Group on Logistic Regression ModelAt Step 3, we added to the logistic regression model the group factor to check for the predictive effect of being in the MED or NOM group while controlling for both demographic and psychological variables.", [["ECQ", "PROTEIN", 12, 15], ["the ECQ score", "TEST", 8, 21], ["the COVID", "TEST", 70, 79], ["the disease", "PROBLEM", 141, 152], ["catastrophic social global outcomes", "PROBLEM", 262, 297], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 145, 152], ["catastrophic", "OBSERVATION_MODIFIER", 262, 274], ["containment", "OBSERVATION_MODIFIER", 321, 332], ["MED", "ANATOMY", 514, 517]]], ["Participants in the MED group reported higher odds of thinking to be at actual risk of infection (2.71) and also to be at risk from the beginning of the COVID-19 spread in Italy (1.94).", [["infection", "DISEASE", 87, 96], ["Participants", "SPECIES", 0, 12], ["infection", "PROBLEM", 87, 96], ["the COVID", "TEST", 149, 158], ["MED", "ANATOMY", 20, 23], ["infection", "OBSERVATION", 87, 96]]], ["They also reported more likely to think that their family or loved ones were at risk of infection (1.70).", [["infection", "DISEASE", 88, 97], ["infection", "PROBLEM", 88, 97], ["infection", "OBSERVATION", 88, 97]]], ["The MED group showed higher odds to report that the fear of contagion would be a valid reason to violate the containment measures (1.65) and that the SSN would adequately cure them in case of infection (3.78) and to report a sufficient level of information about the characteristics of the disease (4.53) and about the social situation relative to .", [["infection", "DISEASE", 192, 201], ["infection", "PROBLEM", 192, 201], ["the disease", "PROBLEM", 286, 297], ["MED", "ANATOMY", 4, 7], ["infection", "OBSERVATION", 192, 201], ["disease", "OBSERVATION", 290, 297]]], ["They also reported less likely that some information about the virus was hidden (0.60), but the ones who answered affirmatively to this question had more than two times the odds with respect to the NOM group thinking that such hidden information was related to a greater virus-related danger (2.70).", [["the virus", "PROBLEM", 59, 68], ["a greater virus", "PROBLEM", 261, 276], ["less likely", "UNCERTAINTY", 19, 30]]], ["About the spreading of the virus, participants in the MED group were less probably convinced that the virus spread would slow down in the following days after the compilation of the questionnaire (0.28).", [["participants", "SPECIES", 34, 46], ["the virus", "PROBLEM", 23, 32], ["the virus spread", "PROBLEM", 98, 114], ["virus", "OBSERVATION", 27, 32], ["MED", "ANATOMY", 54, 57], ["virus", "OBSERVATION", 102, 107]]], ["Lastly, the MED group participants more likely reported that perception of risk in public opinion was lower than it should be (1.83).Effect of Group on Logistic Regression ModelSemipartial correlations mostly confirmed this pattern of results.", [["participants", "SPECIES", 22, 34], ["Logistic Regression ModelSemipartial correlations", "TEST", 152, 201], ["MED", "ANATOMY", 12, 15]]], ["However, differently from the logistic regression, this analysis revealed that the MED group was related to the opinion that people's behavior was not adequate to the situation, r = \u22120.12, and to agree to give care priority to people with greater hope of survival, r = 0.27.", [["people", "ORGANISM", 125, 131], ["people", "ORGANISM", 227, 233], ["people", "SPECIES", 125, 131], ["people", "SPECIES", 227, 233], ["this analysis", "TEST", 51, 64], ["MED", "ANATOMY", 83, 86]]], ["Also, semipartial correlations did not confirm the regression results for the questions about the fear of contagion as a valid reason to violate the containment measures, r = \u22120.05, and the adequacy of the SSN to take care of people in case of infection, r = 0.09.DISCUSSIONIn this article, we investigated the worries and the perception of risk toward the health and social situation in Italy related to the outbreak of COVID-19.", [["infection", "DISEASE", 244, 253], ["COVID-19", "CHEMICAL", 421, 429], ["people", "ORGANISM", 226, 232], ["people", "SPECIES", 226, 232], ["infection", "PROBLEM", 244, 253], ["COVID", "TEST", 421, 426], ["containment", "OBSERVATION_MODIFIER", 149, 160], ["infection", "OBSERVATION", 244, 253]]], ["To this aim, we conducted a crosssectional study by means of online questionnaires administered to a convenience sample of volunteer participants including both health workers and the general population.", [["participants", "SPECIES", 133, 145], ["a crosssectional study", "TEST", 26, 48]]], ["We asked participants to report their worries and opinions about COVID-19 in about 50 different questions combined with psychological variables measuring stress, anxiety, and death anxiety.", [["anxiety", "DISEASE", 162, 169], ["death anxiety", "DISEASE", 175, 188], ["participants", "SPECIES", 9, 21], ["psychological variables measuring stress", "PROBLEM", 120, 160], ["anxiety", "PROBLEM", 162, 169], ["death anxiety", "PROBLEM", 175, 188]]], ["We obtained and analyzed data from 353 Italian adult, divided in 167 participants in the MED group (medical doctors, paramedics, health workers, and students) and 186 participants in the NOM group.", [["participants", "SPECIES", 69, 81], ["participants", "SPECIES", 167, 179], ["MED", "ANATOMY", 89, 92]]], ["We also investigated the effect of the living area in Italy, as the northern regions were more involved than the central and southern ones (Cereda et al., 2020) .Anxiety and Stress as Related to Living Area and JobFirst, we assessed risky situations in which people were involved relatively to COVID-19.", [["Anxiety", "DISEASE", 162, 169], ["people", "ORGANISM", 259, 265], ["people", "SPECIES", 259, 265], ["Anxiety", "PROBLEM", 162, 169], ["Stress", "PROBLEM", 174, 180], ["COVID", "TEST", 294, 299]]], ["As expected, people from North Italy reported more direct experiences with COVID-19, including more symptoms related to the infection, more prolonged quarantine status, more contacts with people at risk, and higher numbers of positive cases in their zone.", [["infection", "DISEASE", 124, 133], ["people", "ORGANISM", 13, 19], ["people", "ORGANISM", 188, 194], ["people", "SPECIES", 13, 19], ["people", "SPECIES", 188, 194], ["COVID", "TEST", 75, 80], ["more symptoms", "PROBLEM", 95, 108], ["the infection", "PROBLEM", 120, 133], ["positive cases in their zone", "PROBLEM", 226, 254], ["infection", "OBSERVATION", 124, 133], ["positive cases", "OBSERVATION", 226, 240]]], ["The MED group, instead, reported a higher number of contacts with people currently infected or at risk.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["MED", "ANATOMY", 4, 7]]], ["Following this, we found that participants from North Italy reported higher levels of stress and anxiety and in particular that health workers in North area showed a higher level of both health workers from other areas and the general population from the same area.", [["anxiety", "DISEASE", 97, 104], ["participants", "SPECIES", 30, 42], ["stress", "PROBLEM", 86, 92], ["anxiety", "PROBLEM", 97, 104]]], ["Thus, both living area and job combined with the higher exposition to infection risk in order to increase the level of stress and anxiety in health workers from North Italy.Anxiety and Stress as Related to Living Area and JobWe would caution about the relatively small number of participants in each area divided by group: our results about living area should be considered strictly as preliminary.", [["infection", "DISEASE", 70, 79], ["anxiety", "DISEASE", 130, 137], ["Anxiety", "DISEASE", 173, 180], ["Stress", "DISEASE", 185, 191], ["participants", "SPECIES", 279, 291], ["infection risk", "PROBLEM", 70, 84], ["anxiety", "PROBLEM", 130, 137], ["Anxiety", "PROBLEM", 173, 180], ["Stress", "PROBLEM", 185, 191], ["infection", "OBSERVATION", 70, 79]]], ["Further studies are welcome in order to confirm or refute the results that we presented on this topic.", [["Further studies", "TEST", 0, 15]]], ["However, we should note that our result was in line with the psychological response of health workers in China, where Lai et al. (2020) found that psychological distress increased for workers closer to the outbreak of epidemic (i.e., who lived and worked in Wuhan region) or assigned to patients affected by COVID-19.", [["psychological distress", "DISEASE", 147, 169], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["psychological distress", "PROBLEM", 147, 169]]], ["Thus, the same rule applies here: the closer to the risk of infection, the higher the risk of acute psychological distress.Anxiety and Stress as Related to Living Area and JobSimilar results were found in previous researches on new disease outbreaks.", [["infection", "DISEASE", 60, 69], ["acute psychological distress", "DISEASE", 94, 122], ["Anxiety", "DISEASE", 123, 130], ["Stress", "DISEASE", 135, 141], ["infection", "PROBLEM", 60, 69], ["acute psychological distress", "PROBLEM", 94, 122], ["Anxiety", "PROBLEM", 123, 130], ["Stress", "PROBLEM", 135, 141], ["new disease outbreaks", "PROBLEM", 228, 249], ["infection", "OBSERVATION", 60, 69], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["new", "OBSERVATION_MODIFIER", 228, 231], ["disease", "OBSERVATION", 232, 239]]], ["For example, Wong et al. (2007) reported higher levels of anxiety in university students during the SARS epidemic, in particular among medicine students and students living in the area in which the infection spread more.", [["anxiety", "DISEASE", 58, 65], ["SARS", "DISEASE", 100, 104], ["infection", "DISEASE", 198, 207], ["anxiety", "PROBLEM", 58, 65], ["the infection spread", "PROBLEM", 194, 214], ["infection", "OBSERVATION", 198, 207]]], ["Also Wheaton et al. (2012) reported higher levels of anxiety in students in response to pandemic spread of H1N1.", [["anxiety", "DISEASE", 53, 60], ["H1N1", "DISEASE", 107, 111], ["anxiety", "PROBLEM", 53, 60], ["H1N1", "PROBLEM", 107, 111]]], ["More generally, anxiety emerged in response to various viral diseases, from the annual influenza virus to the H1N1 pandemic (Coughlin, 2012) .", [["anxiety", "DISEASE", 16, 23], ["viral diseases", "DISEASE", 55, 69], ["influenza virus", "DISEASE", 87, 102], ["H1N1", "DISEASE", 110, 114], ["influenza virus", "SPECIES", 87, 102], ["anxiety", "PROBLEM", 16, 23], ["various viral diseases", "PROBLEM", 47, 69], ["the annual influenza virus", "PROBLEM", 76, 102], ["viral diseases", "OBSERVATION", 55, 69]]], ["In the period of viruses spread, anxiety seems to increase in population along with mood disorders, and this increase was related to exposition and infection risk.", [["anxiety", "DISEASE", 33, 40], ["mood disorders", "DISEASE", 84, 98], ["infection", "DISEASE", 148, 157], ["viruses spread", "PROBLEM", 17, 31], ["anxiety", "PROBLEM", 33, 40], ["mood disorders", "PROBLEM", 84, 98], ["infection risk", "PROBLEM", 148, 162], ["viruses", "OBSERVATION", 17, 24], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["infection", "OBSERVATION", 148, 157]]], ["In line with these results, participants of our study reported higher levels of perceived stress and of anxiety proportional to their risk of infection, i.e., health workers from North were more stressed and anxious than both their colleagues in Center and South Italy and the general population.Anxiety and Stress as Related to Living Area and JobWhile our result supports an acute increase of stress and anxiety, we should carefully monitor the psychological state evolution in order to assess also the effect of COVID-19 over time.", [["anxiety", "DISEASE", 104, 111], ["infection", "DISEASE", 142, 151], ["Anxiety", "DISEASE", 296, 303], ["Stress", "DISEASE", 308, 314], ["anxiety", "DISEASE", 406, 413], ["participants", "SPECIES", 28, 40], ["our study", "TEST", 44, 53], ["perceived stress", "PROBLEM", 80, 96], ["anxiety", "PROBLEM", 104, 111], ["infection", "PROBLEM", 142, 151], ["Anxiety", "PROBLEM", 296, 303], ["Stress", "PROBLEM", 308, 314], ["stress", "PROBLEM", 395, 401], ["anxiety", "PROBLEM", 406, 413], ["COVID", "TREATMENT", 515, 520], ["infection", "OBSERVATION", 142, 151], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["increase", "OBSERVATION_MODIFIER", 383, 391]]], ["In fact, we expected that the virus spread and the quarantine state endurance in Italy could have also mid-and long-term consequences.", [["the virus spread", "PROBLEM", 26, 42], ["long-term consequences", "PROBLEM", 111, 133], ["long-term consequences", "OBSERVATION_MODIFIER", 111, 133]]], ["Survivors from SARS reported posttraumatic stress, anxiety, and depression symptoms 1 month after discharge, suggesting that lifethreating condition could have important psychic sequelae (Wu et al., 2005) .", [["SARS", "DISEASE", 15, 19], ["posttraumatic stress, anxiety", "DISEASE", 29, 58], ["depression", "DISEASE", 64, 74], ["posttraumatic stress", "PROBLEM", 29, 49], ["anxiety", "PROBLEM", 51, 58], ["depression symptoms", "PROBLEM", 64, 83], ["lifethreating condition", "PROBLEM", 125, 148]]], ["Such sequelae could be even more significant in health workers, showing higher levels of psychological distress both during and after a quarantine period (Brooks et al., 2020) .", [["psychological distress", "DISEASE", 89, 111], ["Such sequelae", "PROBLEM", 0, 13], ["psychological distress", "PROBLEM", 89, 111]]], ["For this reason, supporting psychological intervention for healthcare workers could be crucial in the first phase of an outbreak (Xiang et al., 2020) , in particular considering that a timely and effective intervention could greatly reduce the later onset of posttraumatic stress disorder symptoms following a catastrophic event (Watson et al., 2002) .Risk Perception and Worries About COVID-19We analyzed the answers to our questionnaire on COVID-19 by means of logistic regression.", [["posttraumatic stress disorder", "DISEASE", 259, 288], ["psychological intervention", "TREATMENT", 28, 54], ["effective intervention", "TREATMENT", 196, 218], ["posttraumatic stress disorder symptoms", "PROBLEM", 259, 297], ["a catastrophic event", "PROBLEM", 308, 328], ["COVID", "TEST", 442, 447]]], ["For each item, we computed the response odds related to each regressor in three successive steps, by adding sequentially demographic factors, psychological factors, and the group factor.", [["psychological factors", "PROTEIN", 142, 163], ["group factor", "PROTEIN", 173, 185]]], ["In this section, we discuss the variable that we found for the items relatively to risk perception and worries related to the COVID-19 outbreak in Italy.Risk Perception and Worries About COVID-19Group was strongly related to risk perception: healthcare workers showed about 2.5 times the odds of other participants to perceive themselves at risk of infection, as well as about two times the odds to think they were at risk even at the very start of virus outbreak in Italy.", [["infection", "DISEASE", 349, 358], ["participants", "SPECIES", 302, 314], ["the COVID", "TEST", 122, 131], ["infection", "PROBLEM", 349, 358], ["infection", "OBSERVATION", 349, 358]]], ["Moreover, they worried about their family situation and about virus spread as they reported that it would not slow down.", [["virus spread", "PROBLEM", 62, 74]]], ["This supported the idea that medical doctors, nurses, and paramedics had greater risk perception about the COVID-19 infection, probably due to also a greater exposition to danger and to suspect positive cases.", [["infection", "DISEASE", 116, 125], ["the COVID-19 infection", "PROBLEM", 103, 125], ["positive cases", "PROBLEM", 194, 208], ["infection", "OBSERVATION", 116, 125]]], ["Also, living area predicted the perception of risk, as both participants from Center and South Italy reported 0.5 times less preoccupation about risk of infection with respect to participants from North Italy.", [["infection", "DISEASE", 153, 162], ["participants", "SPECIES", 60, 72], ["participants", "SPECIES", 179, 191], ["infection", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 153, 162]]], ["Again, combination of work, i.e., health workers, and area, i.e., North Italy, combined for the greater perception risk.Risk Perception and Worries About COVID-19About the demographics, the stronger regressor of such worries was female sex, which was related to higher perception of risk, both at personal and family levels, and of a number of worries about social situation and people's behaviors.", [["people", "ORGANISM", 379, 385], ["people", "SPECIES", 379, 385]]], ["In particular, female healthcare workers were reported to be at higher risks of stress, anxiety, and depression during the COVID-19 outbreak in China (Lai et al., 2020; Zhu et al., 2020) .", [["anxiety", "DISEASE", 88, 95], ["depression", "DISEASE", 101, 111], ["stress", "PROBLEM", 80, 86], ["anxiety", "PROBLEM", 88, 95], ["depression", "PROBLEM", 101, 111]]], ["This increased distress level in female health workers could be related to an increased perception of risk for themselves and for their relatives as we found in our study, as also reported usually in researches about risk perception in female participants (Gustafsod, 1998) .", [["participants", "SPECIES", 243, 255], ["This increased distress level", "PROBLEM", 0, 29], ["our study", "TEST", 161, 170], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["distress", "OBSERVATION", 15, 23]]], ["Another important demographic variable was age, as we found that aged people were more worried than younger people about severe consequences of COVID-19, as they already knew that the disease was more dangerous for older people, in particular when older than 60 years (Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020).Risk Perception and Worries About COVID-19Lastly, also psychological factors influenced the odds of perceived risk of infection.", [["Pneumonia", "DISEASE", 287, 296], ["infection", "DISEASE", 459, 468], ["people", "ORGANISM", 70, 76], ["people", "ORGANISM", 108, 114], ["people", "ORGANISM", 221, 227], ["people", "SPECIES", 70, 76], ["people", "SPECIES", 108, 114], ["people", "SPECIES", 221, 227], ["the disease", "PROBLEM", 180, 191], ["Novel Coronavirus Pneumonia", "PROBLEM", 269, 296], ["COVID", "TEST", 375, 380], ["infection", "PROBLEM", 459, 468], ["disease", "OBSERVATION", 184, 191], ["infection", "OBSERVATION", 459, 468]]], ["In fact, stress was related to increase in perceived risk, while death anxiety was related to the concern about fatal or severe consequences of COVID-19.", [["death", "DISEASE", 65, 70], ["anxiety", "DISEASE", 71, 78], ["COVID-19", "CHEMICAL", 144, 152], ["stress", "PROBLEM", 9, 15], ["death anxiety", "PROBLEM", 65, 78], ["COVID", "TEST", 144, 149], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["While the effect of both stress (Traczyk et al., 2015; Sobkow et al., 2016) and death anxiety (Langford, 2002) on risk perception and risk taking was already reported in literature, it should be noted that higher levels of stress could also be due to actual exposure to contagion risk in the case of COVID-19, as shown by our results about comparisons on levels of perceived stress between healthcare workers from North, Center, and South Italy.Risk Perception and Worries About COVID-19Taken together, all these results suggested a higher risk perception relative to COVID-19 in healthcare workers living in outbreak areas, especially if females and with high levels of stress.", [["death anxiety", "DISEASE", 80, 93], ["contagion", "DISEASE", 270, 279], ["COVID-19", "CHEMICAL", 568, 576], ["death anxiety", "PROBLEM", 80, 93], ["stress", "PROBLEM", 223, 229], ["COVID", "TEST", 300, 305], ["COVID", "TEST", 479, 484]]], ["For COVID-19, knowledge on medicine and on virus could thus increase risk perception, whereas in other fields such as nuclear radiation usually knowledge was associated to lower risk perception (e.g., Sj\u00f6berg and Drottz-Sj\u00f6berg, 1991) .", [["nuclear", "ANATOMY", 118, 125], ["nuclear", "CELLULAR_COMPONENT", 118, 125], ["COVID", "TEST", 4, 9], ["medicine", "TREATMENT", 27, 35], ["virus", "TREATMENT", 43, 48], ["lower risk perception", "PROBLEM", 172, 193]]], ["It should be noted that, in case of nuclear radiation, knowledge could be associated to an increase capacity of avoiding risky behavior or situations, whereas in case of COVID-19 spread knowing, the health risks related to disease, but feeling powerless against its containment could exacerbate the danger perception.", [["nuclear", "ANATOMY", 36, 43], ["nuclear", "CELLULAR_COMPONENT", 36, 43], ["nuclear radiation", "TREATMENT", 36, 53], ["an increase capacity", "PROBLEM", 88, 108], ["COVID", "TEST", 170, 175], ["disease", "PROBLEM", 223, 230]]], ["A reducing stress intervention by means of psychological support to medical workers could reduce the worries due to the perceived risk, so that they could avoid both risky behaviors and overwhelming, stressful concerns.COVID-19-Related Behaviors and Containment ActionsWe proceed here by discussing the variables related to risky behaviors, judgments about behaviors, and confinement actions.", [["A reducing stress intervention", "TREATMENT", 0, 30], ["psychological support", "TREATMENT", 43, 64], ["COVID", "TEST", 219, 224]]], ["In this respect, female participants reported higher levels of worries about their own behavior, as well as other people's behaviors as risky.", [["participants", "ORGANISM", 24, 36], ["people", "ORGANISM", 114, 120], ["participants", "SPECIES", 24, 36], ["people", "SPECIES", 114, 120]]], ["Related to this, they also were four times more likely than men to report the thought that it would be right to limit people's freedom in order to block the virus spread and three times more likely than men to request more severe punishment for risky behaviors.", [["risky behaviors", "DISEASE", 245, 260], ["men", "ORGANISM", 60, 63], ["people", "ORGANISM", 118, 124], ["men", "ORGANISM", 203, 206], ["men", "SPECIES", 60, 63], ["people", "SPECIES", 118, 124], ["men", "SPECIES", 203, 206], ["the virus spread", "PROBLEM", 153, 169], ["virus", "OBSERVATION", 157, 162]]], ["Capraro and Sippel (2017) showed that females adopted stricter moral judgments than men in personal dilemmas, such as behaving appropriately in the actual COVID-19 outbreak scenario.", [["men", "ORGANISM", 84, 87], ["men", "SPECIES", 84, 87]]], ["Females seemed more prone to strict adherence to rules and even to imply stricter rules, probably also in relationship to their increased perception of risk (see section \"Risk Perception and Worries About COVID-19\").COVID-19-Related Behaviors and Containment ActionsAlso, the living area showed a strong relationship with these dependent variables.", [["COVID", "TEST", 216, 221]]], ["Participants from Center and South Italy were more likely to judge the containment measures as adequate compared to participants from North Italy.", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 116, 128], ["containment", "OBSERVATION", 71, 82]]], ["On note, participants from South also reported less likely than North ones that concerns about COVID-19 were a valid reason to violate the containment measures.", [["participants", "SPECIES", 9, 21], ["COVID", "TEST", 95, 100], ["containment", "OBSERVATION", 139, 150]]], ["This result could be related to the recent great \"escape\" of people from the North Italy (when virus spread initially) toward the South, increasing worries in South population, politicians, and medical staff.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["great", "OBSERVATION_MODIFIER", 43, 48]]], ["Again, please consider results on living area no more than preliminary because of the limited number of participants per area in our sample.COVID-19-Related Behaviors and Containment ActionsLastly, we should mention that both the group variable and the psychological factors had none or little impact on these variables Thus, our data suggest that opinions and judgments about behaviors and containment actions rely more on demographic variables than on psychological or work-related ones.COVID-19-Related Behaviors and Containment Actionsconflict of interests or searching media visibility.", [["participants", "SPECIES", 104, 116], ["COVID", "TEST", 140, 145], ["COVID", "TEST", 489, 494]]], ["The same criticisms, however, are often not applied, for the antiscientific community, to the studies supporting their theories (Kata, 2010) .", [["the studies", "TEST", 90, 101], ["criticisms", "OBSERVATION", 9, 19]]], ["All these factors could have an effect also on the underestimation of medical advices and warning on COVID-19 infection by the general population, resulting in the unappropriated behaviors expressed.", [["COVID-19", "CHEMICAL", 101, 109], ["infection", "DISEASE", 110, 119], ["medical advices", "TREATMENT", 70, 85], ["COVID-19 infection", "PROBLEM", 101, 119]]], ["Thus, providing more information to population could be ineffective, if not supported by psychological evaluation of social dynamics underlying the antiscientific phenomenon, for example, the questioning of the legitimacy of traditional authorities (see Kata, 2010) .", [["psychological evaluation", "TEST", 89, 113], ["the antiscientific phenomenon", "PROBLEM", 144, 173]]], ["Understanding how to contrast such a phenomenon could be even more important in case a vaccine for COVID-19 is provided, as already happened for the H1N1 flu in 2009, when many people refused to vaccinate despite the availability of a vaccine (see Offit, 2009 ).", [["H1N1 flu", "ORGANISM", 149, 157], ["people", "ORGANISM", 177, 183], ["people", "SPECIES", 177, 183], ["H1N1 flu", "SPECIES", 149, 157], ["a phenomenon", "PROBLEM", 35, 47], ["a vaccine", "TREATMENT", 85, 94], ["COVID", "TEST", 99, 104], ["a vaccine", "TREATMENT", 233, 242]]], ["Further studies are needed in order to investigate these contrasting hypotheses for planning effective interventions relative to public health problems.Limitations and Future DirectionsThis study is not free from limitations.", [["Further studies", "TEST", 0, 15], ["planning effective interventions", "TREATMENT", 84, 116], ["public health problems", "PROBLEM", 129, 151], ["This study", "TEST", 185, 195]]], ["Second, we implied a convenience sample method to recruit our volunteer participants, with a possibility for introducing biases that could undermine the possibility to generalize our results to the entire population.", [["participants", "SPECIES", 72, 84]]], ["We also collected a small sample with respect to the optimal one, i.e., about 450 participants (as suggested by Bujang et al., 2018) , thus calling for caution while interpreting our results.", [["participants", "SPECIES", 82, 94], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["For all these reasons, we should underline that our results could not be considered as conclusive and they should be confirmed with further experiments or studies.", [["studies", "TEST", 155, 162]]], ["However, we should note that we conducted this study with two major difficulties.", [["this study", "TEST", 42, 52]]], ["The first was a time-related issue: we had a very short time to collect data as the containment rules and the virus spread vary at a day-by-day rate.", [["the virus spread", "PROBLEM", 106, 122]]], ["The second issue was a logistic one: most people in Italy, including the authors of this article, were quarantined at the time we collected and analyzed the data, so we were forced to opt for an online methodology of data collection.Limitations and Future DirectionsWhile methodologically limited, our results could open a number of possible future studies.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["future studies", "TEST", 342, 356]]], ["First, this study could be considered as a time-zero data collection for a longitudinal study.", [["this study", "TEST", 7, 17], ["a longitudinal study", "TEST", 73, 93]]], ["In this regard, we would contact our previous participants in order to ask if they will participate to further data collection.", [["participants", "SPECIES", 46, 58]]], ["Thus, we could follow the change in risk perception and psychological situation in the general population and healthcare workers during the evolution of COVID-19 infection spread.", [["infection", "DISEASE", 162, 171], ["COVID", "TEST", 153, 158], ["infection spread", "PROBLEM", 162, 178], ["infection", "OBSERVATION", 162, 171]]], ["More experimental and cross-sectional studies are requested in order to better understand the relationship between healthcare workers' and the general population's information gap and risk perception in a pandemic disease scenario.", [["cross-sectional studies", "TEST", 22, 45], ["a pandemic disease scenario", "PROBLEM", 203, 230]]], ["Reducing such information gap could also help in reducing the sense of separation between the healthcare workers and the rest of population and thus the sense of isolation with its negative psychological consequences on both groups.CONCLUSIONOur study supports that a difference in risk perception between health workers and the general population exists and suggests a number of explanations for its causes as well as possible solutions to reduce it, with benefits in the psychological conditions of both groups of participants.", [["participants", "SPECIES", 516, 528], ["CONCLUSIONOur study", "TEST", 232, 251]]], ["More efforts need to be done in this direction, also because reducing psychological distress could advantage physical health state (Prince et al., 2007) , in particular for medical staff facing such a difficult time, improving the quality of care they could provide (Maunder, 2009; Imai, 2020) .DATA AVAILABILITY STATEMENTThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.ETHICS STATEMENTEthical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements.", [["human", "ORGANISM", 550, 555], ["human", "SPECIES", 550, 555], ["participants", "SPECIES", 556, 568], ["human", "SPECIES", 550, 555], ["reducing psychological distress", "PROBLEM", 61, 92], ["the study", "TEST", 537, 546]]], ["The patients/participants provided their written informed consent to participate in this study.AUTHOR CONTRIBUTIONSLS and CG designed the study and administered the questionnaire.", [["patients", "ORGANISM", 4, 12], ["participants", "ORGANISM", 13, 25], ["patients", "SPECIES", 4, 12], ["participants", "SPECIES", 13, 25], ["this study", "TEST", 84, 94], ["the study", "TEST", 134, 143]]], ["LS conducted the data analysis.", [["the data analysis", "TEST", 13, 30]]]], "PMC7165661": [["IntroductionThe role of bats in the maintenance and transmission of rabies and other lyssaviruses has long been known, and they are now increasingly recognized as reservoirs for other viruses (e.g. members of the families Paramyxoviridae, Togaviridae, Flaviviridae, Bunyaviridae, Reoviridae, Herpesviridae, Coronaviridae) that \u2018spill over\u2019 or cross species barriers to infect humans, domestic animals and other wildlife (Calisher et al., 2006).", [["rabies", "DISEASE", 68, 74], ["lyssaviruses", "DISEASE", 85, 97], ["Flaviviridae, Bunyaviridae", "DISEASE", 252, 278], ["bats", "ORGANISM", 24, 28], ["rabies", "ORGANISM", 68, 74], ["Togaviridae", "GENE_OR_GENE_PRODUCT", 239, 250], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 280, 290], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 292, 305], ["humans", "ORGANISM", 376, 382], ["humans", "SPECIES", 376, 382], ["rabies", "SPECIES", 68, 74], ["humans", "SPECIES", 376, 382], ["the maintenance", "TREATMENT", 32, 47], ["rabies", "PROBLEM", 68, 74], ["other viruses", "PROBLEM", 178, 191], ["Paramyxoviridae", "TREATMENT", 222, 237], ["Togaviridae", "TREATMENT", 239, 250], ["Flaviviridae", "TREATMENT", 252, 264], ["Bunyaviridae", "TREATMENT", 266, 278], ["Reoviridae", "TREATMENT", 280, 290], ["Herpesviridae", "TREATMENT", 292, 305], ["Coronaviridae", "TREATMENT", 307, 320]]], ["Given their abundance, wide distribution, high mobility and apparent ability to harbour highly pathogenic viruses with little or no effect, bats may present a greater risk of zoonotic transmission than do other animals (Calisher et al., 2006).", [["high mobility", "PROBLEM", 42, 55], ["pathogenic viruses", "PROBLEM", 95, 113], ["wide", "OBSERVATION_MODIFIER", 23, 27], ["distribution", "OBSERVATION_MODIFIER", 28, 40], ["high mobility", "OBSERVATION_MODIFIER", 42, 55]]], ["There is therefore considerable interest in characterizing viral diversity in these animals.", [["considerable", "OBSERVATION_MODIFIER", 19, 31], ["viral diversity", "OBSERVATION", 59, 74]]], ["Recent efforts applying metagenomic sequencing and/or consensus\u2010degenerate PCR primers and conventional sequencing techniques to bat faecal/oral swabs and other bat tissues have resulted in the detection of a wide range of viruses including bat influenza A viruses (Tong et al., 2012), several paramyxoviruses (Drexler et al., 2012), hepaciviruses and pegiviruses (Quan et al., 2013), and close relatives of the Middle East respiratory syndrome (MERS) coronavirus (Ithete et al., 2013; Memish et al., 2013).IntroductionEarlier serological studies suggest an even wider range including members of the Alphavirus and Flavivirus genera to which some of the most important human pathogens belong.", [["oral swabs", "ANATOMY", 140, 150], ["bat tissues", "ANATOMY", 161, 172], ["influenza A viruses", "DISEASE", 245, 264], ["hepaciviruses and pegiviruses", "DISEASE", 334, 363], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 412, 463], ["bat", "ORGANISM", 129, 132], ["faecal", "ORGANISM_SUBDIVISION", 133, 139], ["oral swabs", "MULTI-TISSUE_STRUCTURE", 140, 150], ["bat tissues", "TISSUE", 161, 172], ["bat influenza A viruses", "ORGANISM", 241, 264], ["Middle East respiratory", "ORGANISM", 412, 435], ["human", "ORGANISM", 669, 674], ["consensus\u2010degenerate PCR primers", "DNA", 54, 86], ["bat influenza A", "SPECIES", 241, 256], ["human", "SPECIES", 669, 674], ["bat influenza A viruses", "SPECIES", 241, 264], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 412, 463], ["human", "SPECIES", 669, 674], ["metagenomic sequencing", "TREATMENT", 24, 46], ["PCR primers", "TEST", 75, 86], ["conventional sequencing techniques", "TEST", 91, 125], ["bat faecal/oral swabs", "TEST", 129, 150], ["the detection", "TEST", 190, 203], ["a wide range of viruses", "PROBLEM", 207, 230], ["bat influenza A viruses", "PROBLEM", 241, 264], ["the Middle East respiratory syndrome", "PROBLEM", 408, 444], ["coronavirus", "PROBLEM", 452, 463], ["Earlier serological studies", "TEST", 519, 546], ["the Alphavirus", "TREATMENT", 596, 610], ["Flavivirus genera", "TREATMENT", 615, 632], ["Middle", "ANATOMY_MODIFIER", 412, 418], ["respiratory syndrome", "OBSERVATION", 424, 444]]], ["Alphavirus antibodies previously detected in bats include eastern (EEEV), Venezuelan (VEEV) and western (WEEV) equine encephalitis viruses (Price, 1978a; McLean et al., 1979; Ubico and McLean, 1995).", [["Venezuelan (VEEV) and western (WEEV) equine encephalitis", "DISEASE", 74, 130], ["WEEV) equine encephalitis viruses", "ORGANISM", 105, 138], ["Alphavirus antibodies", "PROTEIN", 0, 21], ["equine encephalitis viruses", "SPECIES", 111, 138], ["EEEV", "SPECIES", 67, 71], ["VEEV", "SPECIES", 86, 90], ["WEEV", "SPECIES", 105, 109], ["equine encephalitis viruses", "SPECIES", 111, 138], ["Alphavirus antibodies", "TEST", 0, 21], ["Venezuelan (VEEV", "TREATMENT", 74, 90], ["equine encephalitis viruses", "PROBLEM", 111, 138]]], ["All but the latter are associated with deadly epidemics in humans and/or horses.", [["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["deadly", "OBSERVATION_MODIFIER", 39, 45], ["epidemics", "OBSERVATION", 46, 55]]], ["Included among the flaviviruses for which antibodies have been detected are important pathogenic arboviruses such as WNV, SLEV, Japanese encephalitis virus (JEV), and dengue viruses (DENV) (Price, 1978a; Herbold et al., 1983; Ubico and McLean, 1995; Bunde et al., 2006; Aguilar\u2010Setien et al., 2008; Cui et al., 2008; Machain\u2010Williams et al., 2013).", [["Japanese encephalitis virus (JEV), and dengue viruses", "DISEASE", 128, 181], ["WNV", "ORGANISM", 117, 120], ["SLEV,", "ORGANISM", 122, 127], ["Japanese encephalitis virus", "ORGANISM", 128, 155], ["JEV", "ORGANISM", 157, 160], ["dengue viruses", "ORGANISM", 167, 181], ["DENV", "ORGANISM", 183, 187], ["antibodies", "PROTEIN", 42, 52], ["Japanese encephalitis virus", "SPECIES", 128, 155], ["WNV", "SPECIES", 117, 120], ["SLEV", "SPECIES", 122, 126], ["Japanese encephalitis virus", "SPECIES", 128, 155], ["JEV", "SPECIES", 157, 160], ["dengue viruses", "SPECIES", 167, 181], ["DENV", "SPECIES", 183, 187], ["the flaviviruses", "PROBLEM", 15, 31], ["pathogenic arboviruses", "PROBLEM", 86, 108], ["WNV", "PROBLEM", 117, 120], ["SLEV", "PROBLEM", 122, 126], ["Japanese encephalitis virus (JEV)", "PROBLEM", 128, 161], ["flaviviruses", "OBSERVATION", 19, 31]]], ["However, it is still unclear whether bats serve as important amplification/reservoir hosts for any of these viruses.IntroductionThere are also several flaviviruses that are considered bat viruses, such as Rio Bravo (RBV) and Tamana bat virus (TABV), which belong to the \u2018no known vector\u2019 group.", [["RBV", "CHEMICAL", 216, 219], ["bats", "ORGANISM", 37, 41], ["bat viruses", "ORGANISM", 184, 195], ["Rio Bravo (RBV", "ORGANISM", 205, 219], ["Tamana bat virus", "ORGANISM", 225, 241], ["TABV", "ORGANISM", 243, 247], ["Tamana bat virus", "SPECIES", 225, 241], ["Tamana bat virus", "SPECIES", 225, 241], ["TABV", "SPECIES", 243, 247], ["important amplification/reservoir hosts", "TREATMENT", 51, 90], ["these viruses", "PROBLEM", 102, 115], ["several flaviviruses", "PROBLEM", 143, 163], ["bat viruses", "PROBLEM", 184, 195], ["Rio Bravo (RBV)", "PROBLEM", 205, 220], ["Tamana bat virus", "PROBLEM", 225, 241], ["several", "OBSERVATION_MODIFIER", 143, 150], ["flaviviruses", "OBSERVATION", 151, 163], ["viruses", "OBSERVATION", 188, 195]]], ["Although not arthropod\u2010borne and phylogenetically distinct from SLEV (Grard et al., 2009), RBV is closely related antigenically to SLEV (Hendricks et al., 1983).", [["RBV", "CHEMICAL", 91, 94], ["SLEV", "SPECIES", 64, 68], ["SLEV", "SPECIES", 131, 135], ["RBV", "TEST", 91, 94]]], ["TABV has only ever been isolated once, from Pteronotus parnellii in Trinidad (Price, 1978b; de Lamballerie et al., 2002).", [["TABV", "CHEMICAL", 0, 4], ["TABV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pteronotus parnellii", "ORGANISM", 44, 64], ["TABV", "PROTEIN", 0, 4], ["Pteronotus parnellii", "SPECIES", 44, 64], ["Pteronotus parnellii", "SPECIES", 44, 64]]], ["Trinidad is also the only country to have reported the presence of RBV antibodies in bats and in humans (Price, 1978b).IntroductionThe last survey to detect arboviral antibodies in bats in Trinidad was performed almost 40 years ago (Price, 1978a,b), when sera from bats of 39 species were screened by either hemagglutination inhibition assays (HIA) or neutralization tests.", [["sera", "ANATOMY", 255, 259], ["RBV", "CHEMICAL", 67, 70], ["RBV", "CHEMICAL", 67, 70], ["humans", "ORGANISM", 97, 103], ["bats", "ORGANISM", 181, 185], ["sera", "ORGANISM_SUBSTANCE", 255, 259], ["RBV antibodies", "PROTEIN", 67, 81], ["arboviral antibodies", "PROTEIN", 157, 177], ["humans", "SPECIES", 97, 103], ["humans", "SPECIES", 97, 103], ["RBV antibodies", "PROBLEM", 67, 81], ["arboviral antibodies", "PROBLEM", 157, 177], ["sera", "TEST", 255, 259], ["hemagglutination inhibition assays", "TEST", 308, 342], ["neutralization tests", "TEST", 352, 372], ["RBV", "OBSERVATION", 67, 70]]], ["Of almost 1000 bat sera tested by HIA, 0.6% of bats of four species were EEEV\u2010seropositive and 15.3% (representing 11 species) were SLEV\u2010seropositive (Price, 1978a).", [["sera", "ANATOMY", 19, 23], ["bat", "ORGANISM", 15, 18], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["bats", "ORGANISM", 47, 51], ["EEEV", "SPECIES", 73, 77], ["SLEV", "SPECIES", 132, 136], ["bat sera", "TEST", 15, 23], ["four species", "TEST", 55, 67], ["EEEV\u2010seropositive", "TEST", 73, 90]]], ["Additionally, antibodies against RBV and TABV were detected at rates of 14.1% (125 of 887) and 8.5% (72 of 850), respectively (Price, 1978b).IntroductionIn the present study, 384 bats (14 species) sampled from 24 locations in Trinidad were screened for antibodies to VEEV, EEEV, WEEV, SLEV, WNV, RBV and TABV using HIA and also using epitope\u2010blocking ELISA in the cases of VEEV, EEEV and WNV.", [["RBV", "CHEMICAL", 33, 36], ["RBV", "CHEMICAL", 296, 299], ["RBV", "SIMPLE_CHEMICAL", 33, 36], ["TABV", "GENE_OR_GENE_PRODUCT", 41, 45], ["VEEV", "ORGANISM", 267, 271], ["EEEV", "GENE_OR_GENE_PRODUCT", 273, 277], ["WEEV", "GENE_OR_GENE_PRODUCT", 279, 283], ["SLEV", "GENE_OR_GENE_PRODUCT", 285, 289], ["WNV", "ORGANISM", 291, 294], ["RBV", "ORGANISM", 296, 299], ["TABV", "SIMPLE_CHEMICAL", 304, 308], ["VEEV", "ORGANISM", 373, 377], ["WNV", "ORGANISM", 388, 391], ["antibodies", "PROTEIN", 14, 24], ["RBV", "PROTEIN", 33, 36], ["TABV", "PROTEIN", 41, 45], ["antibodies", "PROTEIN", 253, 263], ["EEEV", "PROTEIN", 273, 277], ["WEEV", "PROTEIN", 279, 283], ["SLEV", "PROTEIN", 285, 289], ["RBV", "PROTEIN", 296, 299], ["TABV", "PROTEIN", 304, 308], ["RBV", "SPECIES", 33, 36], ["TABV", "SPECIES", 41, 45], ["VEEV", "SPECIES", 267, 271], ["EEEV", "SPECIES", 273, 277], ["WEEV", "SPECIES", 279, 283], ["SLEV", "SPECIES", 285, 289], ["WNV", "SPECIES", 291, 294], ["RBV", "SPECIES", 296, 299], ["TABV", "SPECIES", 304, 308], ["VEEV", "SPECIES", 373, 377], ["EEEV", "SPECIES", 379, 383], ["WNV", "SPECIES", 388, 391], ["antibodies", "TEST", 14, 24], ["RBV", "TEST", 33, 36], ["TABV", "TEST", 41, 45], ["rates", "TEST", 63, 68], ["the present study", "TEST", 156, 173], ["antibodies", "PROBLEM", 253, 263], ["WNV", "TREATMENT", 291, 294], ["RBV", "TREATMENT", 296, 299], ["TABV", "TREATMENT", 304, 308], ["HIA", "TREATMENT", 315, 318], ["epitope\u2010blocking ELISA", "TEST", 334, 356], ["VEEV", "PROBLEM", 373, 377], ["WNV", "PROBLEM", 388, 391]]], ["Additionally, associations between seropositivity and bat species, gender, age class (juvenile or adult), location, roost type and feed type were determined.Determination of sample size ::: Materials and MethodsAn estimated sample size (no) of 296 was determined using no =t2 (p) (1\u2010p)/d2 (Thrusfield, 2007), where distribution (t) = 1.96 (at 95% confidence level), prevalence (p) = 26% from a similar study performed in the region on different bat populations (Guatemala) where 87 of 332 samples tested were seropositive for one or more of 10 viruses assayed for (Ubico and McLean, 1995), and precision at a type 1 error (d) = 5%.Sampling locations ::: Materials and MethodsGlobal positioning system (GPS) coordinates at roost locations were recorded with a Garmin C76CSX unit (Garmin, Olathe, KS, USA) along with the names of the towns and mapped with Arcmap 9.2, ArcGIS 9 (ESRI, Redlands, CA, USA).", [["sample", "ANATOMY", 174, 180], ["samples", "ANATOMY", 489, 496], ["samples", "CANCER", 489, 496], ["MethodsAn estimated sample size", "TEST", 204, 235], ["prevalence", "TEST", 366, 376], ["a similar study", "TEST", 392, 407], ["332 samples", "TEST", 485, 496], ["MethodsGlobal positioning system", "TREATMENT", 668, 700], ["Arcmap", "TEST", 854, 860], ["ArcGIS", "TEST", 866, 872], ["ESRI", "TEST", 876, 880], ["CA", "TEST", 892, 894], ["size", "OBSERVATION_MODIFIER", 181, 185], ["size", "OBSERVATION_MODIFIER", 231, 235]]], ["Locations were defined as urban (200 or more persons per sq km) or rural (fewer than 200 persons per sq km) (CSO, 2001).Bat sampling strategy ::: Materials and MethodsThree hundred and eighty\u2010four (384) bats of 14 species were captured between 13 November, 2006 and 2 May, 2008 from 27 locations in 24 towns by systematic random sampling such that after randomly selecting a starting location, every third location was selected from a list obtained from the Anti\u2010Rabies Unit (ARU) of the Ministry of Agriculture, Land and Marine Resources (MALMR) in Trinidad.", [["bats", "ORGANISM", 203, 207], ["persons", "SPECIES", 45, 52], ["systematic random sampling", "TEST", 311, 337]]], ["This was followed by non\u2010random opportunistic sampling from known roosts of varying types (categorized as trees, tunnels, caves, bridges, houses and other buildings) at the selected location.Bat sampling strategy ::: Materials and MethodsTo limit ecological impact, fieldwork was performed under close direction and with the assistance of ARU staff that monitor bat populations and movement within Trinidad.", [["varying", "OBSERVATION_MODIFIER", 76, 83]]], ["Permission was given to trap up to 30 bats per roosts based on their prior knowledge of the population sizes at roosts/locations visited and adjustments were made in the field based on the observed population sizes.Bat sampling strategy ::: Materials and MethodsTrapping was carried out by ARU staff using mist\u2010nets (36 mm mesh) or hand\u2010held nets (Kunz and Kurta, 1988) between 5 pm and 11 pm when the bats emerged from their roosts for feeding.", [["MethodsTrapping", "TREATMENT", 255, 270], ["mist\u2010nets (36 mm mesh", "TREATMENT", 306, 327], ["sizes", "OBSERVATION_MODIFIER", 209, 214]]], ["Vampire bats were collected at periodic roost exterminations associated with the MALMR's rabies eradication exercises.", [["Vampire bats", "TREATMENT", 0, 12], ["the MALMR's rabies eradication exercises", "TREATMENT", 77, 117]]], ["Bats were transported live in covered metal cages to the School of Veterinary Medicine at the University of the West Indies where they were taxonomically classified based on morphology.", [["Bats", "CELL", 0, 4]]], ["Bat specimens were identified to species firstly by experienced ARU and MALMR personnel and then confirmed by our laboratory by descriptions made in Goodwin, 1961.", [["specimens", "ANATOMY", 4, 13], ["Bat specimens", "CANCER", 0, 13], ["Bat specimens", "TEST", 0, 13]]], ["Apart from mild dehydration, all bats studied were apparently healthy.", [["dehydration", "DISEASE", 16, 27], ["mild dehydration", "PROBLEM", 11, 27], ["mild", "OBSERVATION_MODIFIER", 11, 15], ["dehydration", "OBSERVATION", 16, 27]]], ["A repository of voucher specimens collected in this study is housed at the Zoology museum, UWI, St Augustine campus, for future reference.Serum collection ::: Materials and MethodsBats were anesthetized with 2% Bomazine (Bomac Laboratory Limited, Manukaau, Auckland, New Zealand) and 10% ketamine (Dutch Farm Veterinary Pharmaceuticals, Loosdrecht, the Netherlands) administered intraperitoneally (Heard et al., 1996; Fowler and Cubas, 2001).", [["specimens", "ANATOMY", 24, 33], ["Serum", "ANATOMY", 138, 143], ["Bomazine", "CHEMICAL", 211, 219], ["ketamine", "CHEMICAL", 288, 296], ["Bomazine", "CHEMICAL", 211, 219], ["ketamine", "CHEMICAL", 288, 296], ["specimens", "CANCER", 24, 33], ["Serum", "ORGANISM_SUBSTANCE", 138, 143], ["Bats", "CELL", 180, 184], ["Bomazine", "SIMPLE_CHEMICAL", 211, 219], ["ketamine", "SIMPLE_CHEMICAL", 288, 296], ["voucher specimens", "TEST", 16, 33], ["this study", "TEST", 47, 57], ["Serum collection", "TEST", 138, 154], ["MethodsBats", "TREATMENT", 173, 184], ["New Zealand)", "TREATMENT", 267, 279], ["10% ketamine", "TREATMENT", 284, 296]]], ["Cardiac exsanguination was then performed with 1 ml syringes and 25\u201327 gauge needles.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["Cardiac exsanguination", "TEST", 0, 22], ["1 ml syringes", "TREATMENT", 47, 60], ["25\u201327 gauge needles", "TREATMENT", 65, 84], ["exsanguination", "OBSERVATION", 8, 22]]], ["Sera were harvested and stored at \u221270\u00b0C until further processing.Hemagglutination inhibition assay ::: Materials and MethodsHemagglutination inhibition assay (HIA) was performed as previously described (Shope, 1963; Beaty et al., 1989).", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4], ["Hemagglutination inhibition assay", "TEST", 65, 98], ["MethodsHemagglutination inhibition assay", "TEST", 117, 157]]], ["Sucrose\u2010acetone antigens (hemagglutinins; HA) were prepared and stored at \u221270\u00b0C. They were Tr 126865 strain for RBV, Tr 127154 strain for TABV, BeAr 23379 strain for SLEV, NY\u2010385\u201099 for WNV, the TC\u201083 (Subtype IAB) vaccine strain for VEEV, McMillan 1963 strain for WEEV and North American strain NJ/60 for EEEV.", [["Sucrose\u2010acetone", "CHEMICAL", 0, 15], ["Tr 126865", "CHEMICAL", 91, 100], ["RBV", "CHEMICAL", 112, 115], ["Sucrose\u2010acetone", "CHEMICAL", 0, 15], ["Sucrose\u2010acetone", "SIMPLE_CHEMICAL", 0, 15], ["Tr 127154 strain", "ORGANISM", 117, 133], ["TABV", "CELL", 138, 142], ["BeAr 23379 strain", "ORGANISM", 144, 161], ["NY\u2010385\u201099", "ORGANISM", 172, 181], ["WNV", "ORGANISM", 186, 189], ["TC\u201083 (Subtype IAB", "ORGANISM", 195, 213], ["VEEV", "ORGANISM", 234, 238], ["EEEV", "CANCER", 306, 310], ["Sucrose\u2010acetone antigens", "PROTEIN", 0, 24], ["hemagglutinins", "PROTEIN", 26, 40], ["HA", "PROTEIN", 42, 44], ["Tr 126865 strain", "SPECIES", 91, 107], ["Tr 127154 strain", "SPECIES", 117, 133], ["TABV", "SPECIES", 138, 142], ["SLEV", "SPECIES", 166, 170], ["NY\u2010385\u201099", "SPECIES", 172, 181], ["WNV", "SPECIES", 186, 189], ["TC\u201083", "SPECIES", 195, 200], ["VEEV", "SPECIES", 234, 238], ["McMillan 1963 strain", "SPECIES", 240, 260], ["WEEV", "SPECIES", 265, 269], ["North American strain NJ/60", "SPECIES", 274, 301], ["EEEV", "SPECIES", 306, 310], ["Sucrose\u2010acetone antigens", "TREATMENT", 0, 24], ["HA", "PROBLEM", 42, 44], ["RBV", "TEST", 112, 115], ["Tr", "TEST", 117, 119], ["TABV", "TEST", 138, 142], ["WNV", "PROBLEM", 186, 189], ["the TC", "TEST", 191, 197], ["Subtype IAB) vaccine strain", "TREATMENT", 202, 229], ["VEEV", "PROBLEM", 234, 238], ["EEEV", "PROBLEM", 306, 310]]], ["Testing began at serum dilutions of 1 : 20 with titrations through to the HI endpoint.", [["serum", "ANATOMY", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["Testing", "TEST", 0, 7], ["serum dilutions", "TEST", 17, 32]]], ["A positive control serum titrated through to its endpoint was included for each antigen.", [["serum", "ANATOMY", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["A positive control serum", "PROBLEM", 0, 24]]], ["Sera were deemed positive for antibodies to a given virus if there was a fourfold or greater difference in antibody titres over other virus antigens.Epitope\u2010blocking ELISA for detection of flavivirus antibodies ::: Materials and MethodsEpitope\u2010blocking enzyme\u2010linked immunosorbent assays (ELISAs) were performed following the procedure of Blitvich et al. (2003) with minor modifications.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["flavivirus", "ORGANISM", 189, 199], ["antibodies", "PROTEIN", 30, 40], ["virus antigens", "PROTEIN", 134, 148], ["flavivirus antibodies", "PROTEIN", 189, 210], ["flavivirus", "SPECIES", 189, 199], ["Sera", "TEST", 0, 4], ["antibodies", "PROBLEM", 30, 40], ["virus", "PROBLEM", 52, 57], ["a fourfold or greater difference in antibody titres over other virus antigens", "PROBLEM", 71, 148], ["flavivirus antibodies", "PROBLEM", 189, 210], ["MethodsEpitope\u2010blocking enzyme\u2010linked", "TEST", 229, 266], ["immunosorbent assays", "TEST", 267, 287], ["ELISAs", "TEST", 289, 295], ["the procedure", "TREATMENT", 322, 335], ["minor modifications", "TREATMENT", 367, 386], ["antibody titres", "OBSERVATION", 107, 122], ["flavivirus", "OBSERVATION", 189, 199]]], ["A serum dilution of 1 : 10 was used along with monoclonal antibody (MAb) 3.1112G (Chemicon, Temecula, CA, USA), which reacts specifically with WNV (Scherret et al., 2001) and 6B5A\u20102 MAb (Chemicon), which reacts more specifically with (SLEV) (Scherret et al., 2001) but also with viruses closely related to SLEV (SLE\u2010like viruses).", [["serum", "ANATOMY", 2, 7], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["WNV", "ORGANISM", 143, 146], ["Chemicon", "GENE_OR_GENE_PRODUCT", 187, 195], ["SLEV", "GENE_OR_GENE_PRODUCT", 306, 310], ["SLE\u2010like viruses", "ORGANISM", 312, 328], ["monoclonal antibody (MAb) 3.1112G", "PROTEIN", 47, 80], ["6B5A", "PROTEIN", 175, 179], ["Chemicon", "PROTEIN", 187, 195], ["WNV", "SPECIES", 143, 146], ["SLEV", "SPECIES", 306, 310], ["A serum dilution", "TEST", 0, 16], ["monoclonal antibody", "TEST", 47, 66], ["MAb", "TEST", 68, 71], ["Chemicon", "TEST", 82, 90], ["6B5A", "TEST", 175, 179], ["viruses", "PROBLEM", 279, 286], ["SLEV (SLE\u2010like viruses", "PROBLEM", 306, 328], ["viruses", "OBSERVATION", 279, 286]]], ["The antigens used were WNV NY\u2010385\u201099 strain and SLEV strain TBH\u201028.Epitope\u2010blocking ELISA for detection of alphavirus antibodies ::: Materials and MethodsAn identification algorithm of murine monoclonal antibodies (MAbs) for subtyping VEEV was employed as described by Roehrig and Bolin (1997) except that MAb 5B4D\u20106 was used for detecting VEEV (TC\u201083 vaccine strain) and MAb 1B1C\u20104 for detecting EEEV, (Roehrig et al., 1990).", [["WNV NY\u2010385\u201099 strain", "ORGANISM", 23, 43], ["alphavirus", "ORGANISM", 107, 117], ["murine", "ORGANISM", 185, 191], ["VEEV", "ORGANISM", 235, 239], ["VEEV", "ORGANISM", 340, 344], ["alphavirus antibodies", "PROTEIN", 107, 128], ["murine monoclonal antibodies", "PROTEIN", 185, 213], ["MAbs", "PROTEIN", 215, 219], ["murine", "SPECIES", 185, 191], ["WNV NY\u2010385\u201099", "SPECIES", 23, 36], ["SLEV", "SPECIES", 48, 52], ["alphavirus", "SPECIES", 107, 117], ["VEEV", "SPECIES", 235, 239], ["VEEV", "SPECIES", 340, 344], ["EEEV", "SPECIES", 397, 401], ["alphavirus antibodies", "PROBLEM", 107, 128], ["murine monoclonal antibodies", "TEST", 185, 213], ["subtyping VEEV", "PROBLEM", 225, 239], ["VEEV", "TEST", 340, 344], ["TC", "TEST", 346, 348], ["MAb", "TEST", 372, 375]]], ["MAb 1B1C is cross\u2010reactive for both North American (NJ/60) and South American (BeAn 5122) EEEV.", [["MAb", "GENE_OR_GENE_PRODUCT", 0, 3], ["BeAn 5122) EEEV", "CANCER", 79, 94], ["MAb 1B1C", "PROTEIN", 0, 8]]], ["All MAbs were from Chemicon.", [["MAbs", "PROTEIN", 4, 8], ["All MAbs", "TREATMENT", 0, 8], ["Chemicon", "TEST", 19, 27]]], ["ELISAs were performed according to Wang et al. (2005) with minor modifications to detect alphaviral antibodies.", [["alphaviral antibodies", "GENE_OR_GENE_PRODUCT", 89, 110], ["alphaviral antibodies", "PROTEIN", 89, 110], ["ELISAs", "TEST", 0, 6], ["alphaviral antibodies", "PROBLEM", 89, 110]]], ["Optimal concentrations of viral antigens were first estimated by titration with each MAb.", [["viral antigens", "PROTEIN", 26, 40], ["viral antigens", "PROBLEM", 26, 40], ["each MAb", "TREATMENT", 80, 88], ["viral antigens", "OBSERVATION", 26, 40]]], ["The antigens used were VEE\u2010TC83 (subtype 1) strain for VEEV and North American Strain (NJ/60) for EEEV.Seropositivity (% inhibition) calculation ::: Materials and MethodsThe seropositivity for both flaviviruses and alphaviruses was calculated using the formula: % inhibition = 100 \u2013 {(TS \u2013 B)/(CS \u2013 B)} \u00d7 100, where TS = optical density (OD) of test sera, CS = OD of control sera and B = background OD (Hall et al., 1995).", [["sera", "ANATOMY", 350, 354], ["sera", "ANATOMY", 375, 379], ["VEE\u2010TC83 (subtype 1", "ORGANISM", 23, 42], ["VEEV", "ORGANISM", 55, 59], ["alphaviruses", "ORGANISM", 215, 227], ["sera", "ORGANISM_SUBSTANCE", 350, 354], ["sera", "ORGANISM_SUBSTANCE", 375, 379], ["VEE\u2010TC83", "SPECIES", 23, 31], ["VEEV", "SPECIES", 55, 59], ["North American Strain (NJ/60", "SPECIES", 64, 92], ["EEEV", "SPECIES", 98, 102], ["The antigens", "TEST", 0, 12], ["VEE", "TEST", 23, 26], ["VEEV", "PROBLEM", 55, 59], ["EEEV", "PROBLEM", 98, 102], ["Seropositivity", "TEST", 103, 117], ["Methods", "TREATMENT", 163, 170], ["both flaviviruses", "PROBLEM", 193, 210], ["alphaviruses", "PROBLEM", 215, 227], ["the formula", "TEST", 249, 260], ["TS", "TEST", 316, 318], ["test sera", "TEST", 345, 354], ["CS", "TEST", 356, 358], ["sera", "TEST", 375, 379]]], ["For TS, CS and B, the mean optical densities from duplicate tests were used.", [["TS", "TEST", 4, 6], ["CS", "TEST", 8, 10], ["duplicate tests", "TEST", 50, 65]]], ["An inhibition value of 30% or greater was considered to indicate the presence of viral antibodies (Blitvich et al., 2003).", [["viral antibodies", "PROTEIN", 81, 97], ["An inhibition value", "TEST", 0, 19], ["viral antibodies", "PROBLEM", 81, 97], ["viral", "OBSERVATION", 81, 86]]], ["Due to the small volumes available, some sera were tested only by ELISAs.Statistical analyses ::: Materials and MethodsThe seropositivity results of the HIA and epitope\u2010blocking ELISA were compared and the factors such as species, gender, age class (juvenile or adult), location (urban or rural town), roost type and types of food eaten were subjected to the chi\u2010squared test (\u03c72) with the level of significance determined at an alpha level of 0.05.", [["sera", "ANATOMY", 41, 45], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["the small volumes", "PROBLEM", 7, 24], ["some sera", "TEST", 36, 45], ["Methods", "TREATMENT", 112, 119], ["the HIA and epitope\u2010blocking ELISA", "PROBLEM", 149, 183], ["the chi\u2010squared test", "TEST", 355, 375], ["an alpha level", "TEST", 426, 440], ["small", "OBSERVATION_MODIFIER", 11, 16], ["volumes", "OBSERVATION", 17, 24]]], ["Statistical Package for the Social Sciences (spss) version 15.0 (SPSS Inc., Chicago, Il, USA) was used for analysis of the data.Ethical approval and permits ::: Materials and MethodsThe study was approved by the Ethics Committee of the Faculty of Medical Sciences, and the permit for capture of the bats was received from the Wildlife Section of the Ministry of Agriculture, Land and Marine Resources.Distribution and characteristics of sampled bats ::: ResultsFig.", [["analysis of the data", "TEST", 107, 127], ["Methods", "TREATMENT", 175, 182], ["The study", "TEST", 182, 191], ["sampled bats", "OBSERVATION", 437, 449]]], ["1 shows the 24 sampled locations and the number of bats captured at each.", [["24 sampled", "OBSERVATION_MODIFIER", 12, 22]]], ["In total, 384 microchiropteran bats (174 males, 210 females) representing 10 genera and 14 species were sampled from six roost types.", [["bats", "ORGANISM", 31, 35]]], ["Additional details (i.e. species, roost type, gender and feeding preference) are summarized in Table 1.Seropositive rates by epitope\u2010blocking ELISA and HIA ::: ResultsThe details of the HIA and ELISA seropositive bat species are shown in Table 1.", [["Seropositive rates", "TEST", 103, 121], ["the HIA", "TEST", 182, 189], ["ELISA seropositive bat species", "PROBLEM", 194, 224]]], ["Of the 384 sera tested by epitope\u2010blocking ELISA for antibodies against WNV, VEEV and EEEV, 11 (2.9%) representing five species were positive for VEEV\u2010specific antibodies and none had antibodies to EEEV or WNV (See Table 1).", [["sera", "ANATOMY", 11, 15], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["WNV", "ORGANISM", 72, 75], ["VEEV", "ORGANISM", 77, 81], ["EEEV", "CANCER", 86, 90], ["VEEV", "ORGANISM", 146, 150], ["WNV", "ORGANISM", 206, 209], ["antibodies", "PROTEIN", 53, 63], ["VEEV\u2010specific antibodies", "PROTEIN", 146, 170], ["antibodies", "PROTEIN", 184, 194], ["EEEV", "PROTEIN", 198, 202], ["VEEV", "SPECIES", 77, 81], ["WNV", "SPECIES", 72, 75], ["VEEV", "SPECIES", 77, 81], ["EEEV", "SPECIES", 86, 90], ["VEEV", "SPECIES", 146, 150], ["EEEV", "SPECIES", 198, 202], ["WNV", "SPECIES", 206, 209], ["epitope\u2010blocking ELISA", "TEST", 26, 48], ["antibodies", "TEST", 53, 63], ["WNV", "PROBLEM", 72, 75], ["VEEV", "TEST", 77, 81], ["EEEV", "TEST", 86, 90], ["five species", "TEST", 115, 127], ["VEEV\u2010specific antibodies", "PROBLEM", 146, 170], ["antibodies", "PROBLEM", 184, 194]]], ["Seven sera (from four bat species) contained antibodies that specifically block the binding of 6B5A\u20102 MAb to SLEV antigen (Table 1).", [["sera", "ANATOMY", 6, 10], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["SLEV antigen", "GENE_OR_GENE_PRODUCT", 109, 121], ["antibodies", "PROTEIN", 45, 55], ["6B5A\u20102 MAb", "PROTEIN", 95, 105], ["SLEV antigen", "PROTEIN", 109, 121], ["Table 1", "PROTEIN", 123, 130], ["Seven sera", "TEST", 0, 10], ["four bat species", "TEST", 17, 33], ["antibodies", "PROBLEM", 45, 55]]], ["As this antibody also binds to other related viruses, the conclusion was that these bats had antibodies to SLEV and/or a SLEV\u2010like viruses.", [["bats", "ORGANISM", 84, 88], ["SLEV", "GENE_OR_GENE_PRODUCT", 107, 111], ["SLEV\u2010like viruses", "ORGANISM", 121, 138], ["antibodies", "PROTEIN", 93, 103], ["SLEV", "PROTEIN", 107, 111], ["SLEV", "SPECIES", 107, 111], ["SLEV", "SPECIES", 121, 125], ["this antibody", "PROBLEM", 3, 16], ["other related viruses", "PROBLEM", 31, 52], ["antibodies", "PROBLEM", 93, 103], ["a SLEV\u2010like viruses", "PROBLEM", 119, 138], ["viruses", "OBSERVATION", 45, 52], ["viruses", "OBSERVATION", 131, 138]]], ["Of the 308 sera that were also tested by HIA for antibodies against SLEV, WNV, VEEV, EEEV, WEEV, TBV and RBV, 47 (15.3%) representing eight species were TABV\u2013seropositive, and three (1.0%) representing two species were seropositive for RBV.", [["sera", "ANATOMY", 11, 15], ["RBV", "CHEMICAL", 105, 108], ["RBV", "CHEMICAL", 236, 239], ["RBV", "CHEMICAL", 236, 239], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["SLEV", "GENE_OR_GENE_PRODUCT", 68, 72], ["WNV", "ORGANISM", 74, 77], ["VEEV", "ORGANISM", 79, 83], ["EEEV", "GENE_OR_GENE_PRODUCT", 85, 89], ["WEEV", "GENE_OR_GENE_PRODUCT", 91, 95], ["antibodies", "PROTEIN", 49, 59], ["SLEV", "SPECIES", 68, 72], ["WNV", "SPECIES", 74, 77], ["VEEV", "SPECIES", 79, 83], ["EEEV", "SPECIES", 85, 89], ["WEEV", "SPECIES", 91, 95], ["TBV", "SPECIES", 97, 100], ["RBV", "SPECIES", 105, 108], ["TABV", "SPECIES", 153, 157], ["RBV", "SPECIES", 236, 239], ["the 308 sera", "TEST", 3, 15], ["antibodies", "TEST", 49, 59], ["SLEV", "PROBLEM", 68, 72], ["WNV", "PROBLEM", 74, 77], ["VEEV", "PROBLEM", 79, 83], ["EEEV", "TEST", 85, 89], ["WEEV", "TEST", 91, 95], ["TBV", "TEST", 97, 100], ["RBV", "TEST", 105, 108], ["eight species", "TEST", 134, 147], ["TABV", "TEST", 153, 157], ["two species", "PROBLEM", 202, 213], ["RBV", "TREATMENT", 236, 239]]], ["For the eight TABV\u2010seropositive species (of the 13 species tested), rates ranged between 2.6% and 45.7%.", [["the eight TABV", "TEST", 4, 18], ["seropositive species", "TEST", 19, 39], ["the 13 species", "TEST", 44, 58], ["rates", "TEST", 68, 73]]], ["The latter was for the hematophagous vampire bat species Desmodus rotundus, which was also the most common species (35.0%) among the TABV\u2010positive bats (Table 1).Seropositive rates by epitope\u2010blocking ELISA and HIA ::: ResultsIn addition, there were six sera for which HIA detected antibodies that were cross\u2010reactive against SLEV and RBV (i.e. less than fourfold difference in titres), and two that were cross\u2010reactive against SLEV, RBV and TABV, suggesting the presence of antibodies against an undetermined flavivirus(es) at a rate of 2.6%.", [["sera", "ANATOMY", 254, 258], ["RBV", "CHEMICAL", 335, 338], ["RBV", "CHEMICAL", 434, 437], ["Desmodus rotundus", "ORGANISM", 57, 74], ["sera", "ORGANISM_SUBSTANCE", 254, 258], ["SLEV", "GENE_OR_GENE_PRODUCT", 326, 330], ["SLEV", "GENE_OR_GENE_PRODUCT", 428, 432], ["RBV", "SIMPLE_CHEMICAL", 434, 437], ["antibodies", "PROTEIN", 282, 292], ["SLEV", "PROTEIN", 326, 330], ["SLEV", "PROTEIN", 428, 432], ["antibodies", "PROTEIN", 475, 485], ["Desmodus rotundus", "SPECIES", 57, 74], ["Desmodus rotundus", "SPECIES", 57, 74], ["SLEV", "SPECIES", 326, 330], ["SLEV", "SPECIES", 428, 432], ["RBV", "SPECIES", 434, 437], ["TABV", "SPECIES", 442, 446], ["the hematophagous vampire bat species Desmodus rotundus", "PROBLEM", 19, 74], ["Seropositive rates", "TEST", 162, 180], ["six sera", "TEST", 250, 258], ["which HIA detected antibodies", "PROBLEM", 263, 292], ["SLEV", "PROBLEM", 326, 330], ["RBV", "TEST", 335, 338], ["RBV", "TEST", 434, 437], ["TABV", "TEST", 442, 446], ["antibodies", "PROBLEM", 475, 485], ["an undetermined flavivirus", "PROBLEM", 494, 520], ["a rate", "TEST", 528, 534], ["positive bats", "OBSERVATION", 138, 151], ["RBV", "OBSERVATION", 335, 338], ["flavivirus", "OBSERVATION", 510, 520]]], ["No antibodies to EEEV, WEEV and WNV were detected among the sera sampled by either HIA or ELISA.Seropositive rates by epitope\u2010blocking ELISA and HIA ::: ResultsThere is no evidence of flavivirus\u2013alphavirus co\u2010infections (i.e. no VEEV\u2010positive bat was seropositive for any other virus), but there was evidence of flaviviral co\u2010infection where two Molossus major bats were SLEV\u2010seropositive by epitope\u2010blocking ELISA and TABV\u2010seropositive by HIA.Factors associated with seropositivity ::: ResultsChi\u2010square analysis was used to test for associations between seropositivity and age (adult/juvenile; data not shown), species (Table 1), gender (Table 1), feed preference (Table 1), location (data not shown), location type (i.e. urban/rural; data not shown) and roost type (data not shown).Factors associated with seropositivity ::: ResultsNo statistically significant associations were found with age or gender.", [["sera", "ANATOMY", 60, 64], ["EEEV", "GENE_OR_GENE_PRODUCT", 17, 21], ["WEEV", "GENE_OR_GENE_PRODUCT", 23, 27], ["WNV", "ORGANISM", 32, 35], ["sera", "ORGANISM_SUBSTANCE", 60, 64], ["flavivirus\u2013alphavirus", "ORGANISM", 184, 205], ["bats", "ORGANISM", 361, 365], ["antibodies", "PROTEIN", 3, 13], ["EEEV", "PROTEIN", 17, 21], ["WEEV", "PROTEIN", 23, 27], ["EEEV", "SPECIES", 17, 21], ["WEEV", "SPECIES", 23, 27], ["WNV", "SPECIES", 32, 35], ["VEEV", "SPECIES", 229, 233], ["SLEV", "SPECIES", 371, 375], ["TABV", "SPECIES", 419, 423], ["antibodies", "PROBLEM", 3, 13], ["EEEV", "PROBLEM", 17, 21], ["WNV", "PROBLEM", 32, 35], ["the sera", "TEST", 56, 64], ["Seropositive rates", "TEST", 96, 114], ["flavivirus\u2013alphavirus co\u2010infections", "PROBLEM", 184, 219], ["VEEV", "PROBLEM", 229, 233], ["positive bat", "PROBLEM", 234, 246], ["seropositive", "PROBLEM", 251, 263], ["any other virus", "PROBLEM", 268, 283], ["flaviviral co\u2010infection", "PROBLEM", 312, 335], ["epitope\u2010blocking ELISA", "TEST", 392, 414], ["Chi\u2010square analysis", "TEST", 494, 513], ["antibodies", "OBSERVATION", 3, 13], ["no evidence of", "UNCERTAINTY", 169, 183], ["flavivirus\u2013alphavirus", "OBSERVATION", 184, 205], ["evidence of", "UNCERTAINTY", 300, 311], ["flaviviral co\u2010infection", "OBSERVATION", 312, 335]]], ["For VEEV, seropositive rates were associated with roost types (P = 0.001; \u03c72 = 20.70) and location (P < 0.001; \u03c72 = 85.32) (Table 2).", [["VEEV", "ORGANISM", 4, 8], ["VEEV", "SPECIES", 4, 8], ["VEEV", "PROBLEM", 4, 8], ["seropositive rates", "TEST", 10, 28], ["P", "TEST", 63, 64]]], ["For TABV, rates were significantly associated (P < 0.05; \u03c72) with bat species (P < 0.001; \u03c72 = 64.17), feeding preference (P < 0.001; \u03c72 = 40.81), location (P < 0.001; \u03c72 = 106.78) and location type (P < 0.001; \u03c72 = 20.54) (Table 2).", [["TABV", "TEST", 4, 8], ["rates", "TEST", 10, 15], ["bat species", "TEST", 66, 77], ["location type", "TEST", 185, 198]]], ["In the case of RBV, none of the factors tested was significantly associated with seropositivity rates.DiscussionUsing epitope\u2010blocking ELISAs, VEEV\u2010specific antibodies were detected in 2.9% of the 384 sera tested.", [["sera", "ANATOMY", 201, 205], ["RBV", "CHEMICAL", 15, 18], ["RBV", "CHEMICAL", 15, 18], ["RBV", "SIMPLE_CHEMICAL", 15, 18], ["VEEV", "ORGANISM", 143, 147], ["sera", "ORGANISM_SUBSTANCE", 201, 205], ["VEEV\u2010specific antibodies", "PROTEIN", 143, 167], ["VEEV", "SPECIES", 143, 147], ["RBV", "TREATMENT", 15, 18], ["seropositivity rates", "PROBLEM", 81, 101], ["epitope\u2010blocking ELISAs", "TEST", 118, 141], ["VEEV\u2010specific antibodies", "TEST", 143, 167], ["RBV", "OBSERVATION", 15, 18]]], ["No EEEV or WNV specific antibodies were detected by ELISA, and of the seven viruses screened for by HIA, only RBV (1.0%)\u2010 and TABV (15.3%)\u2010specific antibodies were detected in the 308 serum samples tested.", [["serum samples", "ANATOMY", 184, 197], ["RBV", "CHEMICAL", 110, 113], ["RBV", "CHEMICAL", 110, 113], ["EEEV", "GENE_OR_GENE_PRODUCT", 3, 7], ["WNV", "ORGANISM", 11, 14], ["serum samples", "ORGANISM_SUBSTANCE", 184, 197], ["EEEV", "PROTEIN", 3, 7], ["WNV specific antibodies", "PROTEIN", 11, 34], ["\u2010specific antibodies", "PROTEIN", 138, 158], ["EEEV", "SPECIES", 3, 7], ["WNV", "SPECIES", 11, 14], ["TABV", "SPECIES", 126, 130], ["EEEV", "PROBLEM", 3, 7], ["WNV specific antibodies", "TEST", 11, 34], ["ELISA", "TEST", 52, 57], ["HIA", "TEST", 100, 103], ["RBV", "TEST", 110, 113], ["TABV", "TEST", 126, 130], ["\u2010specific antibodies", "TEST", 138, 158], ["serum samples", "TEST", 184, 197], ["EEEV", "OBSERVATION", 3, 7]]], ["As HIA generally has a lower sensitivity than ELISA (Beaty et al., 1989), the detection of VEEV by ELISA in samples that were VEEV negative by HIA is unsurprising.DiscussionThe absence of antibodies to WEEV is consistent with the results of a 1978 serosurvey of almost 1000 Trinidad bats (Price, 1978a).", [["samples", "ANATOMY", 108, 115], ["VEEV", "ORGANISM", 91, 95], ["samples", "CANCER", 108, 115], ["antibodies", "PROTEIN", 188, 198], ["VEEV", "SPECIES", 91, 95], ["VEEV", "SPECIES", 126, 130], ["a lower sensitivity", "PROBLEM", 21, 40], ["the detection", "TEST", 74, 87], ["VEEV", "PROBLEM", 91, 95], ["ELISA in samples", "TEST", 99, 115], ["VEEV", "TEST", 126, 130]]], ["However, in contrast to our study, the latter detected antibodies to EEEV, albeit at a low rate (0.6%) (Price, 1978a).", [["EEEV", "GENE_OR_GENE_PRODUCT", 69, 73], ["antibodies", "PROTEIN", 55, 65], ["our study", "TEST", 24, 33]]], ["In the case of WNV, a recent study demonstrated the presence of WNV reactive antibodies among horses in Trinidad, but all livestock and wildlife (including birds) tested were seronegative (Thompson et al., 2012).DiscussionThe VEEV seropositivity rate of 2.9% (n = 11) obtained by ELISA was higher than the rate of 0.4% determined by Price (1978b) using the HIA.", [["WNV", "DISEASE", 15, 18], ["WNV", "ORGANISM", 15, 18], ["WNV", "ORGANISM", 64, 67], ["birds", "ORGANISM", 156, 161], ["VEEV", "ORGANISM", 226, 230], ["WNV reactive antibodies", "PROTEIN", 64, 87], ["WNV", "SPECIES", 15, 18], ["WNV", "SPECIES", 64, 67], ["horses", "SPECIES", 94, 100], ["VEEV", "SPECIES", 226, 230], ["WNV", "PROBLEM", 15, 18], ["a recent study", "TEST", 20, 34], ["WNV reactive antibodies", "PROBLEM", 64, 87], ["The VEEV seropositivity rate", "TEST", 222, 250], ["ELISA", "TEST", 280, 285], ["the rate", "TEST", 302, 310], ["WNV", "OBSERVATION", 15, 18], ["WNV", "OBSERVATION_MODIFIER", 64, 67], ["reactive", "OBSERVATION_MODIFIER", 68, 76], ["antibodies", "OBSERVATION", 77, 87]]], ["This difference may be a consequence of the higher sensitivity of ELISA, or it may reflect the fact that Price (1978b) screened for antibodies specific for subtype IIIA VEEV (i.e. Mucambo virus) while the VEEV serotype or strain responsible for the seropositivity in our study was not determined.", [["subtype IIIA VEEV", "ORGANISM", 156, 173], ["Mucambo virus", "ORGANISM", 180, 193], ["VEEV serotype", "ORGANISM", 205, 218], ["antibodies", "PROTEIN", 132, 142], ["Mucambo virus", "SPECIES", 180, 193], ["subtype IIIA VEEV", "SPECIES", 156, 173], ["Mucambo virus", "SPECIES", 180, 193], ["VEEV", "SPECIES", 205, 209], ["ELISA", "TEST", 66, 71], ["antibodies", "TEST", 132, 142], ["subtype IIIA VEEV", "PROBLEM", 156, 173], ["Mucambo virus", "PROBLEM", 180, 193], ["the VEEV serotype", "PROBLEM", 201, 218], ["strain", "PROBLEM", 222, 228], ["the seropositivity", "PROBLEM", 245, 263], ["our study", "TEST", 267, 276]]], ["During the period when our serosurvey was conducted, Mucambo virus was repeatedly isolated from mosquitoes collected from forested regions of Trinidad (Auguste et al., 2009, 2010) including one of the seropositive locations.", [["Mucambo virus", "ORGANISM", 53, 66], ["Mucambo virus", "SPECIES", 53, 66], ["our serosurvey", "TEST", 23, 37], ["Mucambo virus", "PROBLEM", 53, 66]]], ["It is therefore possible that this strain is the one circulating in bats in Trinidad.DiscussionThe five VEEV\u2010seropositive species were all first reports for Trinidad, but similar findings have been previously reported in Brazil, Guatemala and Mexico (Scherer et al., 1971; Correa\u2010Giron et al., 1972; Calisher et al., 1982; Ubico and McLean, 1995).", [["VEEV", "ORGANISM", 104, 108], ["this strain", "PROBLEM", 30, 41], ["seropositive species", "PROBLEM", 109, 129], ["therefore possible", "UNCERTAINTY", 6, 24]]], ["A significantly higher percentage of VEEV\u2010seropositive bats roosted in close association with people (e.g. houses, bridges and other buildings), compared to in caves and tunnels further from human habitations (Table 2), raising the issue of risk of infection for humans and their livestock.DiscussionNo SLEV\u2010specific antibodies were detected by HIA; however, antibodies to SLEV or a related \u2018SLEV\u2010like\u2019 virus were detected in 1.8% of the bats tested by epitope\u2010blocking ELISA.", [["infection", "DISEASE", 249, 258], ["VEEV", "ORGANISM", 37, 41], ["people", "ORGANISM", 94, 100], ["human", "ORGANISM", 191, 196], ["humans", "ORGANISM", 263, 269], ["SLEV", "GENE_OR_GENE_PRODUCT", 303, 307], ["SLEV", "GENE_OR_GENE_PRODUCT", 373, 377], ["\u2018", "ORGANISM", 391, 392], ["SLEV\u2010like\u2019 virus", "ORGANISM", 392, 408], ["SLEV\u2010specific antibodies", "PROTEIN", 303, 327], ["antibodies", "PROTEIN", 359, 369], ["SLEV", "PROTEIN", 373, 377], ["people", "SPECIES", 94, 100], ["human", "SPECIES", 191, 196], ["humans", "SPECIES", 263, 269], ["VEEV", "SPECIES", 37, 41], ["human", "SPECIES", 191, 196], ["humans", "SPECIES", 263, 269], ["SLEV", "SPECIES", 303, 307], ["SLEV", "SPECIES", 373, 377], ["SLEV\u2010like\u2019 virus", "SPECIES", 392, 408], ["human habitations", "TREATMENT", 191, 208], ["infection", "PROBLEM", 249, 258], ["specific antibodies", "TEST", 308, 327], ["antibodies to SLEV", "PROBLEM", 359, 377], ["a related \u2018SLEV\u2010like\u2019 virus", "PROBLEM", 381, 408], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["percentage", "OBSERVATION_MODIFIER", 23, 33], ["tunnels", "OBSERVATION", 170, 177], ["infection", "OBSERVATION", 249, 258]]], ["In contrast, Price (1978a) detected SLEV\u2010reactive antibodies at a much higher rate of 15.3% using HIA, but these positive sera were negative by neutralization tests, suggesting that the SLEV\u2010reactive antibodies were specific to another virus (e.g. Rio Bravo virus).", [["sera", "ANATOMY", 122, 126], ["sera", "ORGANISM_SUBSTANCE", 122, 126], ["SLEV", "GENE_OR_GENE_PRODUCT", 186, 190], ["Rio Bravo virus", "ORGANISM", 248, 263], ["SLEV\u2010reactive antibodies", "PROTEIN", 36, 60], ["SLEV\u2010reactive antibodies", "PROTEIN", 186, 210], ["SLEV", "SPECIES", 36, 40], ["SLEV", "SPECIES", 186, 190], ["Rio Bravo virus", "SPECIES", 248, 263], ["reactive antibodies", "TEST", 41, 60], ["HIA", "TEST", 98, 101], ["these positive sera", "TEST", 107, 126], ["neutralization tests", "TEST", 144, 164], ["the SLEV\u2010reactive antibodies", "PROBLEM", 182, 210], ["another virus", "PROBLEM", 228, 241], ["reactive antibodies", "OBSERVATION", 41, 60], ["reactive antibodies", "OBSERVATION", 191, 210]]], ["In fact the lower seropositivity rate (1.8%) of SLEV/SLE\u2010like virus in our study is closer to the 4.5% SLEV seropositivity reported from Guatemala by Ubico and McLean (1995).DiscussionThe flaviviruses for which antibodies were detected (i.e. RBV and TABV) have been previously reported in bats in Trinidad (Price, 1978a,b).", [["SLE", "DISEASE", 53, 56], ["RBV", "CHEMICAL", 242, 245], ["SLEV/SLE\u2010like virus", "ORGANISM", 48, 67], ["SLEV", "CANCER", 103, 107], ["flaviviruses", "ORGANISM", 188, 200], ["TABV", "GENE_OR_GENE_PRODUCT", 250, 254], ["antibodies", "PROTEIN", 211, 221], ["TABV", "PROTEIN", 250, 254], ["SLEV", "SPECIES", 48, 52], ["TABV", "SPECIES", 250, 254], ["the lower seropositivity rate", "TEST", 8, 37], ["SLEV/SLE\u2010like virus", "PROBLEM", 48, 67], ["our study", "TEST", 71, 80], ["The flaviviruses", "PROBLEM", 184, 200], ["lower", "OBSERVATION_MODIFIER", 12, 17], ["virus", "OBSERVATION", 62, 67]]], ["The overall RBV seropositivity rate was 1.0% compared to 14.1% previously reported in Trinidad (Price, 1978b) and 19.0% in Guatemala (Ubico and McLean, 1995).", [["RBV", "CHEMICAL", 12, 15], ["RBV", "CHEMICAL", 12, 15], ["The overall RBV seropositivity rate", "TEST", 0, 35], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["RBV", "OBSERVATION", 12, 15]]], ["The two RBV\u2010seropositive species in our study were Pteronotus parnellii (an insectivore) and Noctilio leporinus (a fish\u2010eating bat).", [["RBV", "CHEMICAL", 8, 11], ["RBV", "CHEMICAL", 8, 11], ["Pteronotus parnellii", "ORGANISM", 51, 71], ["Noctilio leporinus", "ORGANISM", 93, 111], ["Pteronotus parnellii", "SPECIES", 51, 71], ["Noctilio leporinus", "SPECIES", 93, 111], ["Pteronotus parnellii", "SPECIES", 51, 71], ["Noctilio leporinus", "SPECIES", 93, 111], ["The two RBV\u2010seropositive species", "PROBLEM", 0, 32], ["our study", "TEST", 36, 45], ["Pteronotus parnellii", "PROBLEM", 51, 71], ["Noctilio leporinus", "TREATMENT", 93, 111], ["two", "OBSERVATION_MODIFIER", 4, 7], ["RBV", "OBSERVATION", 8, 11], ["seropositive species", "OBSERVATION", 12, 32]]], ["Both were also included among the species screened in the earlier Trinidad study (Price, 1978b) and only the Pteronotus parnellii bats were RBV\u2010seropositive.", [["RBV", "CHEMICAL", 140, 143], ["Pteronotus parnellii bats", "ORGANISM", 109, 134], ["Pteronotus parnellii", "SPECIES", 109, 129], ["Pteronotus parnellii bats", "SPECIES", 109, 134], ["the Pteronotus parnellii bats", "TEST", 105, 134], ["RBV", "TEST", 140, 143]]], ["However, the number of Noctilio leporinus tested (n = 4) was small.DiscussionOur results indicate a seropositivity rate of 15.9% for TABV, which is higher than the 8.5% previously recorded in Trinidad, but there was no difference in the species of bats found to be seropositive compared to the earlier study (Price, 1978b).", [["Noctilio leporinus", "ORGANISM", 23, 41], ["Noctilio leporinus", "SPECIES", 23, 41], ["Noctilio leporinus", "SPECIES", 23, 41], ["TABV", "SPECIES", 133, 137], ["a seropositivity rate", "TEST", 98, 119], ["TABV", "TEST", 133, 137], ["the species of bats", "PROBLEM", 233, 252], ["the earlier study", "TEST", 290, 307], ["number", "OBSERVATION_MODIFIER", 13, 19], ["small", "OBSERVATION_MODIFIER", 61, 66], ["higher", "OBSERVATION_MODIFIER", 148, 154], ["no", "UNCERTAINTY", 216, 218]]], ["There are no other published serological reports of TABV for comparison, and with only one record of isolation (Price, 1978b), there is a dearth of information on the biology of this virus.", [["TABV", "CANCER", 52, 56], ["this virus", "PROBLEM", 178, 188], ["no", "UNCERTAINTY", 10, 12]]], ["This single isolation was from the saliva of a bat.", [["saliva", "ORGANISM_SUBSTANCE", 35, 41], ["This single isolation", "TREATMENT", 0, 21]]], ["Transmission via oral secretions could explain the observed associations with bat species (P < 0.001; \u03c72 = 64.17) and feeding preference (P < 0.001; \u03c72 = 40.81) for this \u2018no\u2010known vector\u2019 virus.", [["oral", "ANATOMY", 17, 21], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["oral secretions", "PROBLEM", 17, 32], ["bat species", "PROBLEM", 78, 89], ["this \u2018no\u2010known vector\u2019 virus", "PROBLEM", 165, 193]]], ["For example, in the case of frugivorous and nectar\u2010feeding bats, transmission could be facilitated when a large number of bats are feeding on the same fruits and flowers.DiscussionIn the case of Desmodus rotundus, it is conceivable that the successful spread of TABV is facilitated by its aggressive nature and habit of regurgitating its blood meal to roost mates (Wilkinson, 1990), large roosts sizes and the social habits of mutual grooming and biting during courtship and mating (Wong et al., 2007).", [["fruits", "ANATOMY", 151, 157], ["flowers", "ANATOMY", 162, 169], ["blood", "ANATOMY", 338, 343], ["TABV", "DISEASE", 262, 266], ["bats", "ORGANISM", 122, 126], ["fruits", "ORGANISM_SUBDIVISION", 151, 157], ["flowers", "ORGANISM_SUBDIVISION", 162, 169], ["Desmodus rotundus", "ORGANISM", 195, 212], ["TABV", "CANCER", 262, 266], ["blood", "ORGANISM_SUBSTANCE", 338, 343], ["Desmodus rotundus", "SPECIES", 195, 212], ["Desmodus rotundus", "SPECIES", 195, 212], ["TABV", "SPECIES", 262, 266], ["frugivorous and nectar\u2010feeding bats", "TREATMENT", 28, 63], ["large roosts sizes", "PROBLEM", 383, 401], ["frugivorous", "OBSERVATION", 28, 39], ["large", "OBSERVATION_MODIFIER", 106, 111], ["large", "OBSERVATION_MODIFIER", 383, 388], ["sizes", "OBSERVATION_MODIFIER", 396, 401]]], ["Given the hematophagous feeding nature of this bat species, there is also presumably a risk of infection of humans and livestock, particularly in rural areas where seroprevalence rates were significantly higher (P < 0.05; \u03c72) and where bat bites in livestock are not uncommon.DiscussionOf the sera tested by HIA, 6% were cross\u2010reactive, suggesting the presence of antibodies to unknown or undetermined flaviviruses.", [["sera", "ANATOMY", 293, 297], ["infection of humans and livestock", "DISEASE", 95, 128], ["bat", "ORGANISM", 47, 50], ["humans", "ORGANISM", 108, 114], ["sera", "ORGANISM_SUBSTANCE", 293, 297], ["antibodies", "PROTEIN", 364, 374], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114], ["this bat species", "PROBLEM", 42, 58], ["infection of humans", "PROBLEM", 95, 114], ["seroprevalence rates", "TEST", 164, 184], ["the sera", "TEST", 289, 297], ["antibodies", "PROBLEM", 364, 374], ["undetermined flaviviruses", "PROBLEM", 389, 414], ["presumably a risk of", "UNCERTAINTY", 74, 94], ["infection", "OBSERVATION", 95, 104], ["flaviviruses", "OBSERVATION", 402, 414]]], ["However, cross\u2010reactivity among flaviviruses (such as RBV, TABV, SLEV) in different complexes is frequently observed with HIA test especially in sequential flaviviral infections (Casals, 1957).", [["flaviviruses", "DISEASE", 32, 44], ["RBV", "CHEMICAL", 54, 57], ["flaviviral infections", "DISEASE", 156, 177], ["TABV", "GENE_OR_GENE_PRODUCT", 59, 63], ["SLEV", "GENE_OR_GENE_PRODUCT", 65, 69], ["RBV", "PROTEIN", 54, 57], ["TABV", "PROTEIN", 59, 63], ["SLEV", "PROTEIN", 65, 69], ["TABV", "SPECIES", 59, 63], ["SLEV", "SPECIES", 65, 69], ["flaviviruses", "PROBLEM", 32, 44], ["RBV", "TEST", 54, 57], ["HIA test", "TEST", 122, 130], ["sequential flaviviral infections", "PROBLEM", 145, 177], ["infections", "OBSERVATION", 167, 177]]], ["To positively identify the causative virus(es), a wider panel of HIA antigens including other flavi\u2010 and alphaviruses previously detected in this region (i.e. Dengue, Rocio, Cacipacore, Iguape, VEEV IIIA (Mucambo), Una and Mayaro viruses) or plaque reduction neutralization tests would be necessary.", [["plaque", "ANATOMY", 242, 248], ["Dengue", "DISEASE", 159, 165], ["plaque reduction", "DISEASE", 242, 258], ["flavi\u2010", "GENE_OR_GENE_PRODUCT", 94, 100], ["VEEV IIIA", "ORGANISM", 194, 203], ["Mayaro viruses", "ORGANISM", 223, 237], ["plaque", "PATHOLOGICAL_FORMATION", 242, 248], ["HIA antigens", "PROTEIN", 65, 77], ["the causative virus", "PROBLEM", 23, 42], ["a wider panel", "TEST", 48, 61], ["HIA antigens", "TEST", 65, 77], ["other flavi\u2010", "PROBLEM", 88, 100], ["alphaviruses", "PROBLEM", 105, 117], ["Dengue", "PROBLEM", 159, 165], ["Rocio", "TEST", 167, 172], ["Una and Mayaro viruses", "TREATMENT", 215, 237], ["plaque reduction neutralization tests", "TREATMENT", 242, 279], ["alphaviruses", "OBSERVATION", 105, 117]]], ["Unfortunately, the small volumes of sera available did not allow for this.", [["sera", "ANATOMY", 36, 40], ["sera", "ORGANISM_SUBSTANCE", 36, 40], ["small", "OBSERVATION_MODIFIER", 19, 24]]], ["PCR might also be used to detect viral RNA but as arboviral infections are generally transient, the chance of the sera collected being viremic is extremely low.", [["sera", "ANATOMY", 114, 118], ["arboviral infections", "DISEASE", 50, 70], ["sera", "ORGANISM_SUBSTANCE", 114, 118], ["viral RNA", "RNA", 33, 42], ["PCR", "TEST", 0, 3], ["viral RNA", "PROBLEM", 33, 42], ["arboviral infections", "PROBLEM", 50, 70], ["the sera", "TEST", 110, 118], ["viremic", "PROBLEM", 135, 142], ["low", "OBSERVATION_MODIFIER", 156, 159]]], ["Enzyme\u2010linked immunoassays and hemagglutination inhibition (HIA) test, among others, are classical tests that lack specificity and have inherent problems in interpretation, in areas that are hyperendemic for flaviviruses.", [["flaviviruses", "DISEASE", 208, 220], ["Enzyme\u2010linked immunoassays", "TEST", 0, 26], ["hemagglutination inhibition", "TEST", 31, 58], ["HIA) test", "TEST", 60, 69], ["classical tests", "TEST", 89, 104], ["inherent problems", "PROBLEM", 136, 153], ["hyperendemic", "PROBLEM", 191, 203], ["flaviviruses", "PROBLEM", 208, 220], ["hyperendemic", "OBSERVATION", 191, 203]]], ["Testing by these methods may result in broad cross\u2010reactions and therefore difficulty in determining the etiologic virus (Beaty et al., 1989).", [["these methods", "TEST", 11, 24], ["broad cross\u2010reactions", "PROBLEM", 39, 60], ["the etiologic virus", "PROBLEM", 101, 120]]], ["Hemagglutintion inhibition requires a wide panel of viral antigens usually along with acute and convalescent sera to adequately determine specific etiologic agents by identifying fourfold rise or fall in titre values.", [["sera", "ANATOMY", 109, 113], ["sera", "ORGANISM_SUBSTANCE", 109, 113], ["viral antigens", "PROTEIN", 52, 66], ["Hemagglutintion inhibition", "PROBLEM", 0, 26], ["viral antigens", "PROBLEM", 52, 66], ["acute and convalescent sera", "PROBLEM", 86, 113], ["fall in titre values", "PROBLEM", 196, 216]]], ["ELISA inhibition methods increase specificity and sensitivity and this has been demonstrated when compared with HIA for dengue diagnosis and surveillance (Beaty et al., 1989; Fern\u00e1ndez, 1990).", [["dengue", "DISEASE", 120, 126], ["dengue", "SPECIES", 120, 126], ["ELISA inhibition methods", "TEST", 0, 24], ["sensitivity", "TEST", 50, 61], ["dengue diagnosis", "TEST", 120, 136], ["surveillance", "TEST", 141, 153]]], ["Epitope\u2010blocking ELISAs have been developed with diagnostic efficacy similar to PRNT for detection of arboviral antibodies including WNV and VEEV (Blitvich et al., 2003; Wang et al., 2005).DiscussionIn conclusion, our study suggests that TABV, RBV and VEEV are currently in circulation in bats within Trinidad, including species not previously reported.", [["TABV", "CHEMICAL", 238, 242], ["RBV", "CHEMICAL", 244, 247], ["WNV", "ORGANISM", 133, 136], ["VEEV", "ORGANISM", 141, 145], ["TABV", "GENE_OR_GENE_PRODUCT", 238, 242], ["RBV", "SIMPLE_CHEMICAL", 244, 247], ["VEEV", "ORGANISM", 252, 256], ["PRNT", "PROTEIN", 80, 84], ["arboviral antibodies", "PROTEIN", 102, 122], ["TABV", "PROTEIN", 238, 242], ["arboviral", "SPECIES", 102, 111], ["WNV", "SPECIES", 133, 136], ["VEEV", "SPECIES", 141, 145], ["TABV", "SPECIES", 238, 242], ["VEEV", "SPECIES", 252, 256], ["Epitope\u2010blocking ELISAs", "TEST", 0, 23], ["PRNT", "TEST", 80, 84], ["arboviral antibodies", "PROBLEM", 102, 122], ["WNV", "PROBLEM", 133, 136], ["VEEV", "PROBLEM", 141, 145], ["our study", "TEST", 214, 223], ["TABV", "TEST", 238, 242], ["RBV", "TREATMENT", 244, 247], ["VEEV", "PROBLEM", 252, 256]]], ["Of the nine species (67 bats) found to be seropositive for at least one of these viruses, five are new records for VEEV antibodies and one for RBV.", [["RBV", "CHEMICAL", 143, 146], ["RBV", "CHEMICAL", 143, 146], ["VEEV", "ORGANISM", 115, 119], ["VEEV antibodies", "PROTEIN", 115, 130], ["VEEV", "SPECIES", 115, 119], ["the nine species", "PROBLEM", 3, 19], ["seropositive", "PROBLEM", 42, 54], ["these viruses", "PROBLEM", 75, 88], ["VEEV antibodies", "TEST", 115, 130], ["RBV", "TREATMENT", 143, 146], ["seropositive", "OBSERVATION", 42, 54], ["viruses", "OBSERVATION", 81, 88]]], ["We also found statistically significant associations among VEEV\u2010seropositive bats and roosts in close proximity to humans and their livestock, as well as for TABV\u2010seropositive bats (especially vampires) and their feeding and roosting habits in rural communities.", [["VEEV", "ORGANISM", 59, 63], ["humans", "ORGANISM", 115, 121], ["humans", "SPECIES", 115, 121], ["VEEV", "SPECIES", 59, 63], ["humans", "SPECIES", 115, 121], ["TABV", "SPECIES", 158, 162]]], ["Our data suggest that bat flaviviruses may be more easily transmitted among bats than the alphaviruses or that there is a difference in the viruses in circulation at the time of this study.", [["bat flaviviruses", "ORGANISM", 22, 38], ["Our data", "TEST", 0, 8], ["bat flaviviruses", "PROBLEM", 22, 38], ["the viruses in circulation", "PROBLEM", 136, 162], ["this study", "TEST", 178, 188], ["flaviviruses", "OBSERVATION", 26, 38], ["viruses", "OBSERVATION", 140, 147]]], ["Bat species tested and other factors may also influence the different rates observed.", [["Bat species", "TEST", 0, 11]]], ["However, there is not enough data here to suggest that bats are less infected by one of these genera.", [["bats", "ORGANISM", 55, 59], ["less", "OBSERVATION_MODIFIER", 64, 68], ["infected", "OBSERVATION", 69, 77]]], ["Further work would be required to determine the specific role of bats in the enzootic maintenance and spread of these viruses, how the risk factors identified relate to their biology and whether they pose a risk to human and livestock populations.Conflict of InterestAuthors declare that there are no conflicts of interest.", [["human", "ORGANISM", 215, 220], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["the enzootic maintenance", "TREATMENT", 73, 97], ["these viruses", "PROBLEM", 112, 125], ["viruses", "OBSERVATION", 118, 125], ["no", "UNCERTAINTY", 298, 300]]]], "PMC7476891": [["A Contextual Behavioral Science PerspectiveThe first conceptual framework guiding the current study is drawn from Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999, 2011).", [["the current study", "TEST", 82, 99]]], ["ACT is a third-wave therapy that deviates from traditional cognitive approaches in that it does not use techniques that challenge negative thoughts (e.g., cognitive restructuring).", [["a third-wave therapy", "TREATMENT", 7, 27], ["traditional cognitive approaches", "TREATMENT", 47, 79]]], ["Instead, ACT conceptualizes difficult thoughts and feelings as a natural part of the human experience to be flexibly embraced rather than excised or changed.", [["human", "ORGANISM", 85, 90], ["ACT", "PROTEIN", 9, 12], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90]]], ["ACT therefore focuses on responses to the difficult thoughts/feelings, targeting a set of six rigid responses collectively identified as \u201cpsychological inflexibility:\u201d (1) experiential avoidance (attempting to suppress unpleasant experiences), (2) self-as-content (overidentifying with negative thoughts), (3) cognitive fusion (getting caught up in difficult thoughts), (4) lack of present moment awareness (being inattentive or \u201con autopilot\u201d throughout daily life), (5) lack of contact with values (allowing difficult experiences to distract from deeper goals and priorities), and (6) inaction (getting stuck in setbacks and difficult experiences).", [["inattentive", "DISEASE", 414, 425], ["cognitive fusion", "PROBLEM", 310, 326]]], ["ACT has been shown to be effective at promoting wellbeing and reducing distress across a wide array of presenting problems, disorders, and contexts (see A-Tjak et al., 2015 for meta-analysis).", [["reducing distress", "PROBLEM", 62, 79], ["presenting problems", "PROBLEM", 103, 122], ["disorders", "PROBLEM", 124, 133], ["meta-analysis", "TEST", 177, 190]]], ["A meta-analysis focused on ACT-informed parenting interventions found they similarly can address a range of child problems and furthermore reduce parents\u2019 own depressive symptoms and parenting stress (Byrne, Ghrada, O\u2019Mahoney, & Brennan, 2020).", [["depressive symptoms", "DISEASE", 159, 178], ["A meta-analysis", "TEST", 0, 15], ["parenting interventions", "TREATMENT", 40, 63], ["own depressive symptoms", "PROBLEM", 155, 178]]], ["A growing body of work supports the idea that individual dimensions of psychological flexibility and inflexibility serve as key mechanisms explaining ACT treatment gains (e.g., Arch et al., 2012; Fledderus, Bohlmeijer, Smit, & Westerhof, 2010).A Contextual Behavioral Science Perspective", [["psychological flexibility", "PROBLEM", 71, 96], ["Arch", "ANATOMY", 177, 181]]]], "a7a13d5a94181521f7b81a7a344e272aa5e42dca": [["BackgroundFamily, loved ones, and formal caregivers provide care for nearly 1 million older adults that die each year from a serious chronic illness.", [["chronic illness", "DISEASE", 133, 148], ["a serious chronic illness", "PROBLEM", 123, 148], ["serious", "OBSERVATION_MODIFIER", 125, 132], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["illness", "OBSERVATION", 141, 148]]], ["1 These older patients experience significant physical and psychological symptom burden and progressive dependence on their network of care, 2 referred to as a social convoy.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["significant physical and psychological symptom burden", "PROBLEM", 34, 87], ["progressive dependence", "PROBLEM", 92, 114], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["progressive", "OBSERVATION_MODIFIER", 92, 103], ["dependence", "OBSERVATION_MODIFIER", 104, 114]]], ["Social Convoy Theory is a well-established framework [3] [4] [5] for understanding the relationships of individuals in a group of people with whom they give and receive social support over the life-cycle.", [["people", "ORGANISM", 130, 136], ["people", "SPECIES", 130, 136], ["social support", "TREATMENT", 169, 183]]], ["The convoy can include informal supports such as family members, friends, and neighbors, and formal supports such as professional caregivers that are trained and paid to provide care.BackgroundPalliative care provides an interdisciplinary and patient-family centered approach to address the physical, psychological, emotional, and spiritual suffering for patients and their convoy.", [["physical, psychological, emotional, and spiritual suffering", "DISEASE", 291, 350], ["patient", "ORGANISM", 243, 250], ["patients", "ORGANISM", 355, 363], ["patient", "SPECIES", 243, 250], ["patients", "SPECIES", 355, 363]]], ["6 Digital health, 7 including tele-heath, wearable devices, and mobile applications (mHealth), provides modern opportunities for patients and their convoy to engage in palliative care.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["tele-heath", "TREATMENT", 30, 40], ["wearable devices", "TREATMENT", 42, 58], ["palliative care", "TREATMENT", 168, 183]]], ["[8] [9] [10] An estimated 53% of convoy members have used a technology to help with caregiving and 12% are interested in learning how to use new technologies to support the health of their loved ones.", [["new technologies", "TREATMENT", 141, 157]]], ["11, 12 However, digital systems are typically designed for individual users, rather than integrating the patient's convoy to maximize benefit.", [["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112]]], ["As older adults with serious illness increasingly rely on the support of others, there is a need to foster effective integration of the convoy in digitally supported palliative care.BackgroundRecently the pandemic of the Novel Coronavirus Disease 2019 (COVID-19) shifted society's use of digital health, specifically synchronous telehealth, to provide palliative care and support convoys' care for older adults while maintaining social distancing.", [["Coronavirus Disease", "DISEASE", 227, 246], ["COVID-19", "CHEMICAL", 253, 261], ["serious illness", "PROBLEM", 21, 36], ["palliative care", "TREATMENT", 166, 181], ["the Novel Coronavirus Disease", "PROBLEM", 217, 246], ["COVID", "TEST", 253, 258], ["palliative care", "TREATMENT", 352, 367], ["Coronavirus Disease", "OBSERVATION", 227, 246]]], ["13, 14 While reserving synchronous telehealth for specific consultations, other digital health tools such as symptom monitoring and assessment apps, wearables, and digital education may offer clinical and psychosocial supports for older adults with serious illness and those caring for them.BackgroundThe aim of this study seeks to use heart failure (HF) specific palliative care as a model to investigate the design of digitally supported palliative care by older users and their convoy.", [["heart", "ANATOMY", 336, 341], ["heart failure", "DISEASE", 336, 349], ["HF", "DISEASE", 351, 353], ["heart", "ORGAN", 336, 341], ["symptom monitoring", "TEST", 109, 127], ["assessment apps", "TEST", 132, 147], ["this study", "TEST", 312, 322], ["heart failure", "PROBLEM", 336, 349], ["specific palliative care", "TREATMENT", 355, 379], ["palliative care", "TREATMENT", 440, 455], ["heart", "ANATOMY", 336, 341], ["failure", "OBSERVATION", 342, 349]]], ["HF is an excellent model, as it disproportionately affects older adults resulting in frequent hospitalizations and poor quality of life.", [["HF", "DISEASE", 0, 2], ["HF", "PROBLEM", 0, 2], ["excellent model", "OBSERVATION_MODIFIER", 9, 24]]], ["15, 16 Older adults with HF are at increased risk of COVID-19 complications and mortality, 17 and there is a need for HF specific digital health to monitor symptoms and assess palliative care needs.", [["HF", "DISEASE", 25, 27], ["COVID", "DISEASE", 53, 58], ["adults", "ORGANISM", 13, 19], ["HF", "PROBLEM", 25, 27], ["COVID-19 complications", "PROBLEM", 53, 75], ["symptoms", "PROBLEM", 156, 164], ["palliative care needs", "TREATMENT", 176, 197]]], ["18 This qualitative work will inform the design of the Social Convoy Palliative Care (Convoy-Pal) digital health intervention, currently in development, by summarizing patient, convoy, and health care provider feedback.", [["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["digital health intervention", "TREATMENT", 98, 125]]], ["Such work also seeks to produce a human-centered designed framework useful for researchers, clinicians, and industry partners to design digitally supported palliative care solutions for both older adults and their convoy during times of COVID-19 social distancing and beyond.MethodsA grounded theory 19 methodological orientation was used to inductively describe patient, social convoy, and provider perspectives regarding digital health interventions to support palliative care needs in the setting of HF.", [["HF", "DISEASE", 503, 505], ["human", "ORGANISM", 34, 39], ["patient", "ORGANISM", 363, 370], ["human", "SPECIES", 34, 39], ["patient", "SPECIES", 363, 370], ["human", "SPECIES", 34, 39], ["palliative care solutions", "TREATMENT", 156, 181], ["digital health interventions", "TREATMENT", 423, 451], ["palliative care needs", "TREATMENT", 463, 484], ["HF", "PROBLEM", 503, 505], ["HF", "OBSERVATION", 503, 505]]], ["The purpose of using a grounded approach was to develop a theoretical framework for integrating the social convoy in the design and context of digital health for older adults with serious illness.", [["a grounded approach", "TREATMENT", 21, 40], ["serious illness", "PROBLEM", 180, 195]]], ["Our work was informed by the Consolidated Criteria for Reporting Qualitative Research (COREQ) (Appendix A), 20 and methods were approved by the Colorado Multiple Institutional Review Board (COMIRB).Participants and RecruitmentStudy participants were identified using both purposeful and snowball methods of recruitment.", [["Participants", "SPECIES", 198, 210], ["participants", "SPECIES", 232, 244]]], ["19 The inclusion of patients, the patient convoy, and health care providers ensured 21 incorporation of diverse perspectives into the design process.Participants and RecruitmentPatients.", [["patients", "ORGANISM", 20, 28], ["patient", "ORGANISM", 34, 41], ["patients", "SPECIES", 20, 28], ["patient", "SPECIES", 34, 41], ["Participants", "SPECIES", 149, 161]]], ["Patients were identified from the health system's electronic medical record, Epic.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Epic", "TREATMENT", 77, 81]]], ["Inclusion criteria included being a patient with HF, \u226565 years of age, with \u22652 discharges for primary diagnosis of HF within the last 12 months.", [["HF", "DISEASE", 49, 51], ["HF", "DISEASE", 115, 117], ["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["HF", "PROBLEM", 49, 51], ["HF", "PROBLEM", 115, 117]]], ["Patients with a diagnosis of dementia, preparing for transplant or left ventricular assist device (LVAD), and/or those unable to provide informed consent were excluded.", [["left ventricular", "ANATOMY", 67, 83], ["dementia", "DISEASE", 29, 37], ["Patients", "ORGANISM", 0, 8], ["ventricular", "MULTI-TISSUE_STRUCTURE", 72, 83], ["Patients", "SPECIES", 0, 8], ["dementia", "PROBLEM", 29, 37], ["transplant", "TREATMENT", 53, 63], ["left ventricular assist device (LVAD", "TREATMENT", 67, 103], ["dementia", "OBSERVATION", 29, 37], ["left ventricular", "ANATOMY", 67, 83]]], ["We mailed eligible patients a letter introducing the study and requesting that patients \"opt-out\" by phone if they did not want to be contacted.", [["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 79, 87], ["the study", "TEST", 49, 58]]], ["Patients were contacted by phone, screened for eligibility, and invited to participate.Participants and RecruitmentConvoys.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Participants", "SPECIES", 87, 99]]], ["Patient convoys were identified during patient interviews by asking patients \"Could you please tell us all the people who help you with your heart condition or your daily life?\".", [["heart", "ANATOMY", 141, 146], ["patient", "ORGANISM", 39, 46], ["patients", "ORGANISM", 68, 76], ["people", "ORGANISM", 111, 117], ["heart", "ORGAN", 141, 146], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 39, 46], ["patients", "SPECIES", 68, 76], ["people", "SPECIES", 111, 117], ["your heart condition", "PROBLEM", 136, 156]]], ["Follow up probes were used as needed.", [["Follow up probes", "TEST", 0, 16]]], ["With the patient's permission, potential convoy participants were contacted for an interview via phone, email, and text message.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["participants", "SPECIES", 48, 60]]], ["Since the average social convoy size of older adults in the United States is approximately 3 people, 22 the research team aimed to interview at least 2 convoy members but no more than 6 per patient.Participants and RecruitmentConvoy members under the age of 15 or who were unable to provide informed consent were excluded.Participants and RecruitmentHealth Care Providers.", [["patient", "ORGANISM", 190, 197], ["people", "SPECIES", 93, 99], ["patient", "SPECIES", 190, 197], ["Participants", "SPECIES", 198, 210], ["Participants", "SPECIES", 322, 334], ["size", "OBSERVATION_MODIFIER", 32, 36]]], ["Health care provider participants were identified via the palliative care consult and advanced heart failure care teams.", [["heart", "ANATOMY", 95, 100], ["heart failure", "DISEASE", 95, 108], ["heart", "ORGAN", 95, 100], ["participants", "SPECIES", 21, 33], ["advanced heart failure care", "TREATMENT", 86, 113], ["heart", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108]]], ["Specific recruitment efforts are documented elsewhere.", [["recruitment efforts", "OBSERVATION", 9, 28]]], ["23Data CollectionWe developed three semi-structured interview guides targeting each sample group: patients, convoy, and health care providers (Appendix B).", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106]]], ["The guide was first drafted by the principle investigator (J.D.P) based on our previous qualitative work with older adults regarding digital health 24 and refined by geriatric, palliative care, and digital health experts (R.B., DB, S.C., and S.B.).", [["palliative care", "TREATMENT", 177, 192]]], ["During the interviews, we asked participants to first reflect on their experience managing HF or treating patients with HF.", [["HF", "DISEASE", 91, 93], ["HF", "DISEASE", 120, 122], ["patients", "ORGANISM", 106, 114], ["participants", "SPECIES", 32, 44], ["patients", "SPECIES", 106, 114], ["HF", "PROBLEM", 120, 122]]], ["We then asked participants to consider potential digital health solutions that might be helpful in a palliative care setting.", [["participants", "SPECIES", 14, 26], ["potential digital health solutions", "TREATMENT", 39, 73], ["a palliative care setting", "TREATMENT", 99, 124]]], ["We also asked participants to \"think aloud\" while navigating wireframes, i.e. images of potential digital features and functions, and to express opinions about palliative care content.Data CollectionWe invited participants for 60-minute interviews to accommodate health care provider and convoy members schedules.", [["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 210, 222], ["palliative care content", "TREATMENT", 160, 183]]], ["The shortest interview was due to the patient's health and fatigue, while the longer interviews allowed for further exploration of participants' experience and ideas.", [["fatigue", "DISEASE", 59, 66], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["participants", "SPECIES", 131, 143], ["fatigue", "PROBLEM", 59, 66]]], ["Interviews were held at a location convenient to the participant including: 1) in person at the patient/family home, 2) in person at the health clinic, 3) the provider's office, or 4) using university-supported Zoom conferencing depending.", [["patient", "ORGANISM", 96, 103], ["participant", "SPECIES", 53, 64], ["person", "SPECIES", 82, 88], ["patient", "SPECIES", 96, 103], ["person", "SPECIES", 123, 129]]], ["Field notes and researcher memos were maintained throughout data collection to assist in data interpretation.AnalysisAll audio files were professionally transcribed verbatim prior to analysis.", [["data interpretation", "TEST", 89, 108], ["Analysis", "TEST", 109, 117], ["analysis", "TEST", 183, 191]]], ["The unit of analysis (word, sentence, paragraph) was determined by the analytic team using an iterative 25 and inductive approach.", [["analysis", "TEST", 12, 20], ["an iterative 25 and inductive approach", "TREATMENT", 91, 129]]], ["19 We managed our data with DeDoose software (SocioCultural Research Consultants, LLC, 2018).", [["LLC", "ANATOMY", 82, 85]]], ["The grounded theory approach involved a constant comparison method of analyzing data.", [["analyzing data", "TEST", 70, 84]]], ["A second cycle of focused coding, known as axial coding, collapsed initial codes into umbrella categories.", [["collapsed", "OBSERVATION_MODIFIER", 57, 66], ["umbrella categories", "OBSERVATION", 86, 105]]], ["26 These categories were based on patterns in the data and to form themes that identify prototype design to incorporate preferred palliative care content.", [["palliative care content", "TREATMENT", 130, 153]]], ["The research team established a coding tree, deriving themes until reaching thematic saturation.", [["thematic saturation", "TEST", 76, 95]]], ["19 Our confidence in establishing saturation is based on several factors including: a sample size consistent with qualitative inquiries regarding older adults and digital health, [27] [28] [29] initial coding during data collection, and inclusion of multiple analytic perspectives, e.g. having a coder unaffiliated with the interview process and triangulation of transcript data with field notes and memos from three interviewers, to identify \"new\" concepts.", [["establishing saturation", "TEST", 21, 44], ["data collection", "TEST", 216, 231], ["transcript data", "TEST", 363, 378], ["multiple", "OBSERVATION_MODIFIER", 250, 258]]], ["21 Additionally, the principle investigator established monthly meetings with palliative care and HF experts as a form of member checking.", [["palliative care", "TREATMENT", 78, 93]]], ["21ParticipantsWe contacted 231 potential patient participants; 13.9% agreed to participate, 31.6% declined participation, and 54.5% were unable to contact.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["participants", "SPECIES", 49, 61]]], ["We identified 49 potential convoy participants from patients; 63.2% agreed to participate, we were unable to contact 36.7%, and only 1 convoy member declined participation.", [["patients", "ORGANISM", 52, 60], ["participants", "SPECIES", 34, 46], ["patients", "SPECIES", 52, 60]]], ["A total of 81 interviews were transcribed for analysis.", [["analysis", "TEST", 46, 54]]], ["Table 1 describes the demographics for patients (n=30) and their convoy (n=31).", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["The age range varied for patients (66-91 years old) and convoys (31-80 years old).", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["Social convoy participants were primarily adult children (28.8%) but also included spouses, siblings, grandchildren, and friends.", [["children", "ORGANISM", 48, 56], ["participants", "SPECIES", 14, 26], ["children", "SPECIES", 48, 56]]], ["We contacted 25 potential health care provider participants based on the health system's palliative care and advance heart failure care teams; 21 agreed to participate, 1 later declined, and 4 were unable to contact.", [["heart", "ANATOMY", 117, 122], ["heart failure", "DISEASE", 117, 130], ["heart", "ORGAN", 117, 122], ["participants", "SPECIES", 47, 59], ["palliative care", "TREATMENT", 89, 104], ["heart", "ANATOMY", 117, 122]]], ["The majority of providers identified as female, white, and had on average 9.78 (\u00b13.75) years of experience working with seriously ill older adults.ThemesWe initially used a grounded theory approach to develop new framework to inform social convoy digitally supported palliative care solutions.", [["a grounded theory approach", "TREATMENT", 171, 197], ["palliative care solutions", "TREATMENT", 267, 292]]], ["However, through the interview and analysis process, findings substantially aligned with design thinking, 30,31 particularly human-centered design framework (Figure 1 ).", [["human", "ORGANISM", 125, 130], ["human", "SPECIES", 125, 130], ["analysis process", "TEST", 35, 51]]], ["Human-centered design is a participatory approach to the design process that incorporates multiple user stakeholders to develop health solutions.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5]]], ["The model outlines a process to create digital solutions easy to use, useful, and meaningful to users by capturing the perspective of people experiencing the problem in which a solution is intended to solve.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["a solution", "TREATMENT", 175, 185]]], ["These background phases allow for productive brainstorming around features and functions for possible tools (Ideation).", [["productive brainstorming", "PROBLEM", 34, 58]]], ["Through this participatory approach, a human-centered prototype can then be developed and tested.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["a human-centered prototype", "TREATMENT", 37, 63]]], ["While we did not consider human centered design apriori, themes generated from this qualitative study highlight the first threeEmpathy: Patient, Caregiver, and Provider ExperienceThis theme captures participants' experience with managing serious illness.", [["human", "ORGANISM", 26, 31], ["human", "SPECIES", 26, 31], ["Patient", "SPECIES", 136, 143], ["participants", "SPECIES", 199, 211], ["human", "SPECIES", 26, 31], ["this qualitative study", "TEST", 79, 101], ["managing serious illness", "PROBLEM", 229, 253]]], ["Participants reported experiences about their health, social support, and technology use.", [["Participants", "SPECIES", 0, 12]]], ["Table 2 illustrates exemplar quotes.Empathy: Patient, Caregiver, and Provider ExperienceHealth Experience.", [["Patient", "SPECIES", 45, 52]]], ["Patients, convoys, and providers discussed the difficulty of living with major medical conditions, function limitations, and reduced well-being and engagement in pleasurable activities.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Although we targeted patients with HF, our patient participants indicated that \"heart failure is the least of [their] worries\".", [["heart", "ANATOMY", 80, 85], ["HF", "DISEASE", 35, 37], ["heart failure", "DISEASE", 80, 93], ["patients", "ORGANISM", 21, 29], ["patient", "ORGANISM", 43, 50], ["heart", "ORGAN", 80, 85], ["patients", "SPECIES", 21, 29], ["patient", "SPECIES", 43, 50], ["participants", "SPECIES", 51, 63], ["HF", "PROBLEM", 35, 37], ["heart failure", "PROBLEM", 80, 93], ["heart", "ANATOMY", 80, 85], ["failure", "OBSERVATION", 86, 93]]], ["Patient participants articulated that they managed multiple chronic conditions (MCC), including diabetes, cancer, neuropathy, among others.", [["cancer", "ANATOMY", 106, 112], ["MCC", "DISEASE", 80, 83], ["diabetes", "DISEASE", 96, 104], ["cancer", "DISEASE", 106, 112], ["neuropathy", "DISEASE", 114, 124], ["MCC", "CANCER", 80, 83], ["cancer", "CANCER", 106, 112], ["Patient", "SPECIES", 0, 7], ["participants", "SPECIES", 8, 20], ["multiple chronic conditions", "PROBLEM", 51, 78], ["diabetes", "PROBLEM", 96, 104], ["cancer", "PROBLEM", 106, 112], ["neuropathy", "PROBLEM", 114, 124], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["cancer", "OBSERVATION", 106, 112], ["neuropathy", "OBSERVATION", 114, 124]]], ["Patients were often more concerned about other health conditions, the decline of their health generally, and were largely content or neutral with their HF specific care.Empathy: Patient, Caregiver, and Provider ExperienceSocial Support.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["Patient", "SPECIES", 178, 185]]], ["Patients reported that they rely on social support and family caregivers in diverse ways.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Many reported their convoy members manage the logistics of health care, daily living activities (depending on patient's function), and monitor daily HF and MCC management.Empathy: Patient, Caregiver, and Provider ExperienceMost patients and caregivers reported different and conflicting perspectives.", [["HF", "DISEASE", 149, 151], ["patient", "ORGANISM", 110, 117], ["MCC", "CANCER", 156, 159], ["patients", "ORGANISM", 228, 236], ["patient", "SPECIES", 110, 117], ["Patient", "SPECIES", 180, 187], ["patients", "SPECIES", 228, 236], ["health care", "TREATMENT", 59, 70], ["MCC management", "TREATMENT", 156, 170]]], ["For example, patients commonly indicated that they did not want to bother their family while the social convoy often craved more information about the patient's status.", [["patients", "ORGANISM", 13, 21], ["patient", "ORGANISM", 151, 158], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 151, 158]]], ["Both patients and social convoys described the complex balance between receiving care from the convoy and the need for patients to feel self-sufficient and maintain independence.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 119, 127]]], ["Health care providers reported the importance of convoy involvement highlighting their contribution to the patient's overall health and adherence to HF care plan.", [["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["HF care plan", "TREATMENT", 149, 161]]], ["However, although patients and their convoys reported focusing their caregiving on daily needs such as transportation, coordinating medical appointments, and managing medications, leveraging social support to address important daily logistics was not reported as a barrier.Empathy: Patient, Caregiver, and Provider ExperienceTechnology Use.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["Patient", "SPECIES", 282, 289], ["managing medications", "TREATMENT", 158, 178], ["leveraging social support", "TREATMENT", 180, 205]]], ["Some patients indicated a reluctance to use newer-technology, such as text or sensor-based applications, with preference for face-to-face options or more wellknown technologies, such as phone calling.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["newer-technology", "TREATMENT", 44, 60]]], ["Most patients reported less interest in technology use, unlike convoy members and provider participants.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["participants", "SPECIES", 91, 103]]], ["Additionally, incongruence was observed across participants when probed for data sharing access, finding providers and convoys reported in support of data sharing whereas patients were less enthusiastic.", [["patients", "ORGANISM", 171, 179], ["participants", "SPECIES", 47, 59], ["patients", "SPECIES", 171, 179]]], ["After probing, patients and convoys describe the value in sharing reports and app activities with each other, however this was not universal.Empathy: Patient, Caregiver, and Provider ExperiencePatients, convoy, and provider participants all acknowledged that technology use and technology-literacy varies among patients and convoys, reflecting a generational gap in the culture of technology use and communication differences between participants.Define: Reactions to Evidence-Based Care Concepts and Barriers to UseDomains of palliative care generally include quality of life assessment, symptom management, family support including bereavement or grief, spiritual care, psychosocial support, decision support, value-based goal setting, and patient/family education.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 311, 319], ["patient", "ORGANISM", 742, 749], ["patients", "SPECIES", 15, 23], ["Patient", "SPECIES", 150, 157], ["participants", "SPECIES", 224, 236], ["patients", "SPECIES", 311, 319], ["participants", "SPECIES", 434, 446], ["patient", "SPECIES", 742, 749], ["palliative care", "TREATMENT", 527, 542], ["life assessment", "TEST", 572, 587], ["symptom management", "TREATMENT", 589, 607], ["spiritual care", "TREATMENT", 656, 670], ["psychosocial support", "TREATMENT", 672, 692]]], ["Participants provided feedback related to receiving and delivering these components of care via digital health.", [["Participants", "SPECIES", 0, 12]]], ["Overall, participants indicated that patients relied on their convoy for all of these palliative care domains and emphasized the need to increase patient-convoy communication.", [["patients", "ORGANISM", 37, 45], ["patient", "ORGANISM", 146, 153], ["participants", "SPECIES", 9, 21], ["patients", "SPECIES", 37, 45], ["patient", "SPECIES", 146, 153], ["these palliative care domains", "TREATMENT", 80, 109]]], ["The concept of using digital tools to connect the full convoy and communicate about palliative care needs in a new way was of most interest to participants.Define: Reactions to Evidence-Based Care Concepts and Barriers to UseSymptom Monitoring.", [["participants", "SPECIES", 143, 155], ["palliative care needs", "TREATMENT", 84, 105], ["UseSymptom Monitoring", "TEST", 222, 243]]], ["Overall, providers, patients, and convoys report the importance of having a way to self-monitor HF care.", [["HF", "DISEASE", 96, 98], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["HF care", "TREATMENT", 96, 103]]], ["However, patients tended to be divided on their willingness to use digital tools to manage their care.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["digital tools", "TEST", 67, 80]]], ["Other patients mentioned they would be willing to use technology for symptom monitoring if they had additional technical support.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["symptom monitoring", "TEST", 69, 87]]], ["Other patients already use or are interested in using a variety of technology to track their HF, ranging from activity trackers, patient portals, to sophisticated monitoring equipment.", [["HF", "DISEASE", 93, 95], ["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 129, 136], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 129, 136], ["their HF", "PROBLEM", 87, 95]]], ["Providers reported interest in ways to encourage patient reported outcomes and remote patient monitoring, however still questioned their clinical significance with vast amounts of real-time data.Define: Reactions to Evidence-Based Care Concepts and Barriers to UsePsychosocial Support.", [["patient", "ORGANISM", 49, 56], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 49, 56], ["patient", "SPECIES", 86, 93], ["remote patient monitoring", "TEST", 79, 104], ["UsePsychosocial Support", "TREATMENT", 261, 284]]], ["Many patients and convoys reported being positive and optimistic about their psychosocial wellbeing.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["However, some disclosed challenges around mental illness, social isolation, anxiety and depression.", [["illness", "DISEASE", 49, 56], ["anxiety", "DISEASE", 76, 83], ["depression", "DISEASE", 88, 98], ["mental illness", "PROBLEM", 42, 56], ["social isolation", "TREATMENT", 58, 74], ["anxiety", "PROBLEM", 76, 83], ["depression", "PROBLEM", 88, 98], ["mental illness", "OBSERVATION", 42, 56]]], ["There were mixed reviews on how to incorporate psychosocial support using technology.", [["psychosocial support", "TREATMENT", 47, 67]]], ["Some participants reported negative reactions to virtual assessments while others reported it as a useful way to check-in on patients or caregivers.", [["patients", "ORGANISM", 125, 133], ["participants", "SPECIES", 5, 17], ["patients", "SPECIES", 125, 133], ["virtual assessments", "TEST", 49, 68]]], ["Many patients expressed this support 'wasn't for me' but might be useful for patients or caregivers 'like me'.Ideation: Recommendations and Desired FeaturesParticipants were asked to brainstorm ideas on the palliative care domains and offer recommendations for future technology with older adults, caregivers, and palliative care.Ideation: Recommendations and Desired FeaturesSuggestions are outlined in Table 4 .Ideation: Recommendations and Desired FeaturesBoth patients and convoys recommended similar desired features related to content and technology interface, stressing the importance of tailoring and personalization.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 464, 472], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 464, 472], ["palliative care", "TREATMENT", 314, 329], ["tailoring and personalization", "TREATMENT", 595, 624]]], ["They reported interest in syncing palliative care tools to patient portals, and the importance of an easy-to-use interface with large fonts and accessibility.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["syncing palliative care", "TREATMENT", 26, 49], ["large", "OBSERVATION_MODIFIER", 128, 133], ["fonts", "OBSERVATION", 134, 139]]], ["For example, many participants recommended the technology be available for individuals using voice-to-text features for hearing or visual impairments.", [["hearing or visual impairments", "DISEASE", 120, 149], ["participants", "SPECIES", 18, 30], ["voice", "TEST", 93, 98], ["hearing", "PROBLEM", 120, 127], ["visual impairments", "PROBLEM", 131, 149]]], ["Balancing privacy and confidentiality was a preference for all participants, highlighting the varying levels of access to data when sharing reports.", [["participants", "SPECIES", 63, 75]]], ["Most patients and caregivers agreed with recommendations to not overburden end-users with assessments, and reminders (text messages or push notifications) should be often, however not too many.DiscussionThe aim of this study was to investigate patients, convoys, and health care providers' perspectives regarding palliative care digital health to inform the design of future digital interventions.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 244, 252], ["assessments", "TEST", 90, 101], ["this study", "TEST", 214, 224], ["palliative care", "TREATMENT", 313, 328], ["future digital interventions", "TREATMENT", 368, 396]]], ["While we initially intended to generate a grounded theory framework specific to geriatric palliative care, our results aligned with human centered design approaches.", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["geriatric palliative care", "TREATMENT", 80, 105]]], ["These participatory approaches allow for the generation of meaningful, valued, and evidence-based design of digital health solutions.", [["digital health solutions", "TREATMENT", 108, 132]]], ["30, 31 The documentation of participants experiences, opinions about palliative care domains, and desired features can be used to design digitally supported palliative care interventions for both older adults and their convoy.", [["participants", "SPECIES", 28, 40], ["palliative care domains", "TREATMENT", 69, 92], ["palliative care interventions", "TREATMENT", 157, 186]]], ["Digital health strategies are needed more than ever during COVID-19 pandemic to provide palliative care interventions, monitor patients, support convoys, and promote caregiving across the social convoy.DiscussionParticipants highlight the challenge of developing digital health tools in the setting of serious illness and also the need for tools incorporating MCC.", [["patients", "ORGANISM", 127, 135], ["MCC", "CANCER", 360, 363], ["patients", "SPECIES", 127, 135], ["Digital health strategies", "TREATMENT", 0, 25], ["palliative care interventions", "TREATMENT", 88, 117], ["serious illness", "PROBLEM", 302, 317]]], ["Many digital palliative care interventions address specific diseases.", [["Many digital palliative care interventions", "TREATMENT", 0, 42], ["specific diseases", "PROBLEM", 51, 68]]], ["However, this specificity may not be as meaningful to older adults and convoys that are managing MCC.", [["MCC", "DISEASE", 97, 100], ["MCC", "CANCER", 97, 100]]], ["Developing tools for conditions that commonly co-occur, providing tool settings to personalize targeted illnesses, or syncing interventions across multiple conditions may be helpful for this population.", [["targeted illnesses", "PROBLEM", 95, 113], ["syncing interventions", "TREATMENT", 118, 139]]], ["33 Results suggest that patients and convoys have conflicting perspectives about using and adopting specific technologies, the amount of information and tools needed, and personal health information sharing.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Differences in patient and caregiver needs and expectations is welldocumented, and incongruence in health management is associated with poorer health outcomes among patients and caregivers.", [["patient", "ORGANISM", 15, 22], ["patients", "ORGANISM", 165, 173], ["patient", "SPECIES", 15, 22], ["patients", "SPECIES", 165, 173]]], ["[34] [35] [36] [37] [38] Patients often wanted less tools and information, suggesting that too many tools would burden their convoy.", [["[34] [35] [36] [37] [38", "SIMPLE_CHEMICAL", 0, 23], ["Patients", "ORGANISM", 25, 33], ["Patients", "SPECIES", 25, 33]]], ["Introduction materials for digital interventions that include clear rationales for how each tool is useful to convoys, rather than burdensome, may be helpful for concerned patients.DiscussionPatients, convoy, and health care providers a like were excited about the opportunity to communicate about palliative care needs in a new, digitally supported way.", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["Introduction materials", "TREATMENT", 0, 22], ["digital interventions", "TREATMENT", 27, 48], ["palliative care needs", "TREATMENT", 298, 319]]], ["While several digital palliative care interventions currently target symptom monitoring and assessment 32, 39 and participants recognized the importance of these domains, they were less enthusiastic about these specific tools.", [["participants", "SPECIES", 114, 126], ["several digital palliative care interventions", "TREATMENT", 6, 51], ["symptom monitoring", "TEST", 69, 87], ["assessment", "TEST", 92, 102]]], ["Rather, participants were eager to use tools regarding decision support, convoy support, goal setting, and educational resources.", [["participants", "SPECIES", 8, 20]]], ["There is increased interest in developing digital decision aids, caregiver interventions, and mobile goal monitoring for older adults.", [["caregiver interventions", "TREATMENT", 65, 88], ["mobile goal monitoring", "TEST", 94, 116], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["interest", "OBSERVATION_MODIFIER", 19, 27]]], ["Integrating these tools in combination with symptom monitoring and assessment features to tailor educational resources may provide a more comprehensive digital palliative care experience for patients and their convoy.", [["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["symptom monitoring", "TEST", 44, 62], ["assessment", "TEST", 67, 77]]], ["Comprehensive digital solutions may allow patients and convoys to better self-manage and identify individualized palliative care needs, reserving synchronous palliative-telehealth for more complicated and intensive cases, particularly during the COVID-19 pandemic.DiscussionThe COVID-19 pandemic highlights the need for digital solutions to address spirituality, anticipatory grief, and bereavement needs.", [["anticipatory grief", "DISEASE", 363, 381], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Comprehensive digital solutions", "TREATMENT", 0, 31], ["individualized palliative care needs", "TREATMENT", 98, 134], ["the COVID", "TEST", 242, 251], ["pandemic", "PROBLEM", 255, 263], ["digital solutions", "TREATMENT", 320, 337]]], ["40 While our participants had some difficulty connecting spiritual needs with their HF care, due to social distancing measures, many people are staying connected with their spiritual and religious communities via discussion boards, social medical, and streaming services.", [["HF", "DISEASE", 84, 86], ["people", "ORGANISM", 133, 139], ["participants", "SPECIES", 13, 25], ["people", "SPECIES", 133, 139], ["their HF care", "TREATMENT", 78, 91]]], ["Best practices for integrating these supports post-social distancing will likely benefit older adults who are unable to participate in-person in the future.DiscussionDue to the high hospitalization and fatality rates of COVID-19 particularly among older adults with MCC, 17 anticipatory grief and bereavement tools may be most needed at this time.", [["COVID-19", "CHEMICAL", 220, 228], ["MCC", "DISEASE", 266, 269], ["grief", "DISEASE", 287, 292], ["MCC", "CANCER", 266, 269], ["person", "SPECIES", 135, 141], ["COVID", "TEST", 220, 225], ["bereavement tools", "TEST", 297, 314]]], ["While there are few non-synchronous bereavement options, less is available for anticipatory grief.", [["anticipatory grief", "DISEASE", 79, 97], ["anticipatory grief", "PROBLEM", 79, 97], ["few", "OBSERVATION_MODIFIER", 16, 19], ["non-synchronous", "OBSERVATION_MODIFIER", 20, 35]]], ["32 Based on these findings, we are currently developing the Convoy-Pal digital health intervention.", [["the Convoy-Pal digital health intervention", "TREATMENT", 56, 98]]], ["The human-centered design model was a useful method to merge both scientific evidence and user feedback.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9]]], ["Some key considerations we are incorporating in our design include: using a mobile platform for multiple users that includes patients and several caregivers; incorporating assessments on patients and convoy to tailor resources; increasing interoperability with technologies currently used by participants (wearables, calendars, videoconferencing); comprehensive tools that range from symptom monitoring to psycho-socialspiritual supports; and facilitating shared patient-convoy health decision making.", [["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 187, 195], ["patient", "ORGANISM", 463, 470], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 187, 195], ["participants", "SPECIES", 292, 304], ["patient", "SPECIES", 463, 470], ["symptom monitoring", "TEST", 384, 402]]], ["Our next steps include iterative usability testing and a feasibility trial.DiscussionWhile this study documents perspectives from a large, multi-stakeholder qualitative sample, there are limitations to our work.", [["iterative usability testing", "TEST", 23, 50], ["this study", "TEST", 91, 101], ["large", "OBSERVATION_MODIFIER", 132, 137]]], ["First, our sample lacked the desired diversity in race and ethnicity but included a broad age-range among patients and convoys.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["desired", "OBSERVATION_MODIFIER", 29, 36], ["diversity", "OBSERVATION_MODIFIER", 37, 46]]], ["Many of our sickest patients had a difficult time participating and providing detailed feedback.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Some patients were unable to identify convoy members, while for others we were able to recruit multiple convoy participants.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["participants", "SPECIES", 111, 123]]], ["Convoy participants were also primarily adult children.", [["children", "ORGANISM", 46, 54], ["participants", "SPECIES", 7, 19], ["children", "SPECIES", 46, 54]]], ["Although we member checked our results with clinical experts, we did not review findings with patient and convoy participants.DiscussionIn conclusion, digital health provides an opportunity to expand the reach of geriatric palliative care interventions.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["participants", "SPECIES", 113, 125], ["geriatric palliative care interventions", "TREATMENT", 213, 252]]], ["This paper documents human-centered preferences of geriatric palliative care digital health to ensure technologies are relevant and meaningful to all engaged stakeholders.Disclosure/Conflict of InterestThe authors have no conflicts to report.", [["human", "ORGANISM", 21, 26], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["geriatric palliative care", "TREATMENT", 51, 76]]], ["The more I know, the more it is easier for me to keep an eye on her entire health because she has many comorbidities.", [["eye", "ANATOMY", 57, 60], ["eye", "ORGAN", 57, 60], ["many comorbidities", "PROBLEM", 98, 116], ["eye", "ANATOMY", 57, 60]]], ["If I can keep track of those two heart issues and the basics -the things like the weight, the breathing issues, the oxygen levels, things like that, I can kind of -that gives me a little picture, too, of where she's at in general.", [["heart", "ANATOMY", 33, 38], ["oxygen", "CHEMICAL", 116, 122], ["oxygen", "CHEMICAL", 116, 122], ["heart", "ORGAN", 33, 38], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["those two heart issues", "PROBLEM", 23, 45], ["the breathing issues", "PROBLEM", 90, 110], ["the oxygen levels", "TEST", 112, 129], ["heart", "ANATOMY", 33, 38]]], ["One day you may feel fine, the next day you may feel like somebody smacked you a good one in the chest and you just can't function.", [["chest", "ANATOMY", 97, 102], ["chest", "ORGAN", 97, 102], ["chest", "ANATOMY", 97, 102]]], ["I mean, I don't -like in -mom's doing so well on her own, but I know there are people who were -it's a very big burden to take care of their love ones with heart failure.", [["heart", "ANATOMY", 156, 161], ["heart failure", "DISEASE", 156, 169], ["people", "ORGANISM", 79, 85], ["heart", "ORGAN", 156, 161], ["people", "SPECIES", 79, 85], ["heart failure", "PROBLEM", 156, 169], ["heart", "ANATOMY", 156, 161], ["failure", "OBSERVATION", 162, 169]]]], "abb20089fe55f2cb3c95114cbe9cd6c6cc9e087f": [["IntroductionMacro domain is an evolutionarily conserved protein domain, so named because it is found at the Cterminus of large variant core histones, macroH2A.", [["macroH2A", "GENE_OR_GENE_PRODUCT", 150, 158], ["Macro domain", "PROTEIN", 12, 24], ["evolutionarily conserved protein domain", "PROTEIN", 31, 70], ["Cterminus of large variant core histones", "PROTEIN", 108, 148], ["macroH2A", "PROTEIN", 150, 158], ["large variant core histones", "PROBLEM", 121, 148], ["protein domain", "OBSERVATION", 56, 70], ["large", "OBSERVATION_MODIFIER", 121, 126], ["variant", "OBSERVATION", 127, 134], ["core histones", "OBSERVATION", 135, 148]]], ["1 MacroH2A is found only in vertebrates and sea urchins, but the macro domain itself is of ancient origin, encoded by the genomes of many, but not all, bacteria and archaea.", [["MacroH2A", "GENE_OR_GENE_PRODUCT", 2, 10], ["sea urchins", "ORGANISM", 44, 55], ["MacroH2A", "PROTEIN", 2, 10], ["bacteria", "PROBLEM", 152, 160], ["archaea", "PROBLEM", 165, 172], ["sea urchins", "OBSERVATION", 44, 55], ["ancient origin", "OBSERVATION_MODIFIER", 91, 105], ["bacteria", "OBSERVATION", 152, 160], ["archaea", "OBSERVATION", 165, 172]]], ["2 The macro domain of approximately 170 aa folds into a globular mixed \u03b1/\u03b2-fold containing a deep groove, a potential ligand-binding pocket.", [["macro domain", "PROTEIN", 6, 18], ["\u03b1", "PROTEIN", 71, 72], ["\u03b2", "PROTEIN", 73, 74], ["The macro domain", "TEST", 2, 18], ["a globular mixed \u03b1/\u03b2-fold", "PROBLEM", 54, 79], ["a deep groove", "PROBLEM", 91, 104], ["a potential ligand-binding pocket", "PROBLEM", 106, 139], ["macro domain", "OBSERVATION", 6, 18], ["globular", "OBSERVATION_MODIFIER", 56, 64], ["mixed", "OBSERVATION_MODIFIER", 65, 70], ["fold", "OBSERVATION_MODIFIER", 75, 79], ["deep", "ANATOMY_MODIFIER", 93, 97], ["groove", "ANATOMY_MODIFIER", 98, 104], ["binding pocket", "OBSERVATION", 125, 139]]], ["3 Recent structural, enzymatic, and binding studies indicate that several macro domains can bind ADP-ribose or its derivates, including poly (ADP-ribose), and that some of them can hydrolyze ADP-ribose-1\u2033 phosphate (ADPR-1\u2033P) to yield ADP-ribose.", [["ADP-ribose", "CHEMICAL", 97, 107], ["poly (ADP-ribose", "CHEMICAL", 136, 152], ["ADP-ribose-1\u2033 phosphate", "CHEMICAL", 191, 214], ["ADPR-1\u2033P", "CHEMICAL", 216, 224], ["ADP-ribose", "CHEMICAL", 235, 245], ["ADP", "CHEMICAL", 97, 100], ["ribose", "CHEMICAL", 101, 107], ["poly (ADP-ribose)", "CHEMICAL", 136, 153], ["ADP-ribose-1\u2033 phosphate", "CHEMICAL", 191, 214], ["ADPR-1\u2033P", "CHEMICAL", 216, 224], ["ADP", "CHEMICAL", 235, 238], ["ribose", "CHEMICAL", 239, 245], ["ADP-ribose", "SIMPLE_CHEMICAL", 97, 107], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 136, 152], ["ADP-ribose-1\u2033 phosphate", "SIMPLE_CHEMICAL", 191, 214], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 216, 224], ["ADP-ribose", "SIMPLE_CHEMICAL", 235, 245], ["binding studies", "TEST", 36, 51], ["several macro domains", "PROBLEM", 66, 87], ["ribose", "TREATMENT", 101, 107], ["poly (ADP-ribose)", "TREATMENT", 136, 153], ["ADP", "TEST", 191, 194], ["ribose", "TEST", 195, 201], ["phosphate (ADPR", "TREATMENT", 205, 220], ["ADP-ribose", "TREATMENT", 235, 245]]], ["[4] [5] [6] Therefore, macro domain functions may relate to different ADP-ribose metabolites, although many aspects of their physiological roles remain uncertain.", [["ADP", "CHEMICAL", 70, 73], ["ribose", "CHEMICAL", 74, 80], ["ADP", "CHEMICAL", 70, 73], ["ribose", "CHEMICAL", 74, 80], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 0, 11], ["ADP-ribose", "SIMPLE_CHEMICAL", 70, 80], ["macro domain functions", "TEST", 23, 45], ["different ADP-ribose metabolites", "PROBLEM", 60, 92], ["may relate to", "UNCERTAINTY", 46, 59], ["ribose metabolites", "OBSERVATION", 74, 92]]], ["The macro domain protein Poa1p of Saccharomyces cerevisiae is quite divergent compared to human homologs, and the main function of the yeast protein has been proposed to be the hydrolysis of ADPR-1\u2033P, which is a by-product of tRNA splicing.", [["Poa1p", "GENE_OR_GENE_PRODUCT", 25, 30], ["Saccharomyces cerevisiae", "ORGANISM", 34, 58], ["human", "ORGANISM", 90, 95], ["ADPR-1\u2033P", "GENE_OR_GENE_PRODUCT", 191, 199], ["macro domain protein", "PROTEIN", 4, 24], ["Poa1p", "PROTEIN", 25, 30], ["human homologs", "PROTEIN", 90, 104], ["yeast protein", "PROTEIN", 135, 148], ["ADPR", "PROTEIN", 191, 195], ["P", "DNA", 198, 199], ["Saccharomyces cerevisiae", "SPECIES", 34, 58], ["human", "SPECIES", 90, 95], ["yeast", "SPECIES", 135, 140], ["Saccharomyces cerevisiae", "SPECIES", 34, 58], ["human", "SPECIES", 90, 95], ["yeast", "SPECIES", 135, 140], ["The macro domain protein", "TEST", 0, 24], ["Saccharomyces cerevisiae", "TREATMENT", 34, 58], ["the yeast protein", "PROBLEM", 131, 148], ["the hydrolysis of ADPR", "TREATMENT", 173, 195], ["a by-product of tRNA splicing", "TREATMENT", 210, 239], ["main", "OBSERVATION_MODIFIER", 114, 118], ["yeast protein", "OBSERVATION", 135, 148], ["tRNA splicing", "OBSERVATION", 226, 239]]], ["7 The human genome contains nine genes encoding macro domain proteins.", [["human", "ORGANISM", 6, 11], ["human genome", "DNA", 6, 18], ["macro domain proteins", "PROTEIN", 48, 69], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["The human genome", "PROBLEM", 2, 18], ["nine genes encoding macro domain proteins", "PROBLEM", 28, 69], ["human genome", "OBSERVATION", 6, 18]]], ["The two histones macroH2A1 and macroH2A2 have a role in genome silencing, are enriched in female inactive X-chromosomes and other heterochromatin areas, and can also be involved in the regulation of gene expression.", [["X-chromosomes", "ANATOMY", 106, 119], ["heterochromatin areas", "ANATOMY", 130, 151], ["macroH2A1", "GENE_OR_GENE_PRODUCT", 17, 26], ["macroH2A2", "GENE_OR_GENE_PRODUCT", 31, 40], ["chromosomes", "CELLULAR_COMPONENT", 108, 119], ["heterochromatin", "CELLULAR_COMPONENT", 130, 145], ["histones", "PROTEIN", 8, 16], ["macroH2A1", "PROTEIN", 17, 26], ["macroH2A2", "PROTEIN", 31, 40], ["female inactive X-chromosomes", "DNA", 90, 119], ["other heterochromatin areas", "PROBLEM", 124, 151], ["histones macroH2A1", "OBSERVATION", 8, 26], ["genome silencing", "OBSERVATION", 56, 72], ["inactive", "OBSERVATION_MODIFIER", 97, 105], ["heterochromatin areas", "OBSERVATION", 130, 151]]], ["[8] [9] [10] [11] The gene for an Snf2-like helicase (ALC1), related to the catalytic subunits of ATPdependent chromatin remodeling complexes, also encodes for a macro domain.", [["chromatin", "ANATOMY", 111, 120], ["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 17], ["Snf2", "GENE_OR_GENE_PRODUCT", 34, 38], ["ALC1", "GENE_OR_GENE_PRODUCT", 54, 58], ["chromatin", "CELLULAR_COMPONENT", 111, 120], ["Snf2-like helicase", "PROTEIN", 34, 52], ["ALC1", "PROTEIN", 54, 58], ["catalytic subunits", "PROTEIN", 76, 94], ["ATPdependent chromatin remodeling complexes", "PROTEIN", 98, 141], ["macro domain", "PROTEIN", 162, 174], ["an Snf2", "TREATMENT", 31, 38], ["ATPdependent chromatin remodeling complexes", "PROBLEM", 98, 141], ["ATPdependent chromatin", "OBSERVATION", 98, 120], ["remodeling complexes", "OBSERVATION", 121, 141]]], ["12 Three human genes encode the B-aggressive lymphoma (BAL) family of transcription factors.", [["aggressive lymphoma", "DISEASE", 34, 53], ["human", "ORGANISM", 9, 14], ["B-aggressive lymphoma", "CANCER", 32, 53], ["BAL", "CANCER", 55, 58], ["human genes", "DNA", 9, 20], ["B-aggressive lymphoma (BAL) family", "PROTEIN", 32, 66], ["transcription factors", "PROTEIN", 70, 91], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["aggressive lymphoma", "PROBLEM", 34, 53], ["transcription factors", "PROBLEM", 70, 91], ["aggressive", "OBSERVATION_MODIFIER", 34, 44], ["lymphoma", "OBSERVATION", 45, 53]]], ["[13] [14] [15] BAL proteins include two or three tandem macro domains followed by a poly (ADP-ribose) polymerase (PARP) domain, reinforcing the link of the macro family with ADP-ribose derivatives.", [["poly (ADP-ribose", "CHEMICAL", 84, 100], ["ADP-ribose", "CHEMICAL", 174, 184], ["poly (ADP-ribose)", "CHEMICAL", 84, 101], ["ADP", "CHEMICAL", 174, 177], ["ribose", "CHEMICAL", 178, 184], ["[13] [14] [15] BAL", "SIMPLE_CHEMICAL", 0, 18], ["poly (ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 84, 112], ["PARP", "GENE_OR_GENE_PRODUCT", 114, 118], ["ADP-ribose derivatives", "SIMPLE_CHEMICAL", 174, 196], ["[13] [14] [15] BAL proteins", "PROTEIN", 0, 27], ["tandem macro domains", "PROTEIN", 49, 69], ["poly (ADP-ribose) polymerase (PARP) domain", "PROTEIN", 84, 126], ["macro family", "PROTEIN", 156, 168], ["BAL proteins", "TEST", 15, 27], ["three tandem macro domains", "TREATMENT", 43, 69], ["a poly (ADP-ribose) polymerase (PARP) domain", "TREATMENT", 82, 126], ["ADP-ribose derivatives", "TREATMENT", 174, 196], ["ribose derivatives", "OBSERVATION", 178, 196]]], ["The final three human macro domain proteins are poorly understood.", [["human", "ORGANISM", 16, 21], ["human macro domain proteins", "PROTEIN", 16, 43], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21]]], ["LRP16 was originally named during the search for leukemia-relapserelated proteins, but was subsequently found by the authors not to have a connection with that process.", [["leukemia", "ANATOMY", 49, 57], ["leukemia", "DISEASE", 49, 57], ["LRP16", "GENE_OR_GENE_PRODUCT", 0, 5], ["leukemia", "CANCER", 49, 57], ["LRP16", "PROTEIN", 0, 5], ["leukemia-relapserelated proteins", "PROTEIN", 49, 81], ["LRP16", "TREATMENT", 0, 5], ["leukemia", "PROBLEM", 49, 57], ["relapserelated proteins", "PROBLEM", 58, 81], ["leukemia", "OBSERVATION", 49, 57]]], ["Therefore, it is here called macro domain protein 1 (MDO1).", [["macro domain protein 1", "GENE_OR_GENE_PRODUCT", 29, 51], ["MDO1", "GENE_OR_GENE_PRODUCT", 53, 57], ["macro domain protein 1", "PROTEIN", 29, 51], ["MDO1", "PROTEIN", 53, 57]]], ["The expression of the corresponding gene is activated by estradiol, and it may promote the growth of human breast cancer cells.", [["breast cancer cells", "ANATOMY", 107, 126], ["estradiol", "CHEMICAL", 57, 66], ["breast cancer", "DISEASE", 107, 120], ["estradiol", "CHEMICAL", 57, 66], ["estradiol", "SIMPLE_CHEMICAL", 57, 66], ["human", "ORGANISM", 101, 106], ["breast cancer cells", "CELL", 107, 126], ["human breast cancer cells", "CELL_TYPE", 101, 126], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["estradiol", "TREATMENT", 57, 66], ["human breast cancer cells", "PROBLEM", 101, 126], ["breast", "ANATOMY", 107, 113], ["cancer cells", "OBSERVATION", 114, 126]]], ["[16] [17] [18] Human locus 140733 encodes a protein [proposed name is macro domain protein 2 (MDO2)] whose macro domain is closely related to that of MDO1.", [["Human", "ORGANISM", 15, 20], ["macro domain protein 2", "GENE_OR_GENE_PRODUCT", 70, 92], ["MDO2", "GENE_OR_GENE_PRODUCT", 94, 98], ["MDO1", "GENE_OR_GENE_PRODUCT", 150, 154], ["macro domain protein 2", "PROTEIN", 70, 92], ["MDO2", "PROTEIN", 94, 98], ["macro domain", "PROTEIN", 107, 119], ["MDO1", "PROTEIN", 150, 154], ["Human", "SPECIES", 15, 20], ["a protein", "TEST", 42, 51], ["macro domain protein", "TREATMENT", 70, 90]]], ["This locus has been linked with a rare developmental disorder, Kabuki syndrome.", [["developmental disorder", "DISEASE", 39, 61], ["Kabuki syndrome", "DISEASE", 63, 78], ["locus", "CELLULAR_COMPONENT", 5, 10], ["a rare developmental disorder", "PROBLEM", 32, 61], ["Kabuki syndrome", "PROBLEM", 63, 78], ["rare", "OBSERVATION_MODIFIER", 34, 38], ["developmental disorder", "OBSERVATION", 39, 61], ["Kabuki syndrome", "OBSERVATION", 63, 78]]], ["19 The gene for gangliosideinduced differentiation-associated protein 2 (GDAP2), which could also be called macro domain protein 3 (MDO3), was described as one of the genes induced by ganglioside synthase expression in a mouse neuroblastoma cell line.", [["neuroblastoma cell line", "ANATOMY", 227, 250], ["neuroblastoma", "DISEASE", 227, 240], ["ganglioside", "CHEMICAL", 184, 195], ["gangliosideinduced differentiation-associated protein 2", "GENE_OR_GENE_PRODUCT", 16, 71], ["GDAP2", "GENE_OR_GENE_PRODUCT", 73, 78], ["macro domain protein 3", "GENE_OR_GENE_PRODUCT", 108, 130], ["MDO3", "GENE_OR_GENE_PRODUCT", 132, 136], ["ganglioside synthase", "GENE_OR_GENE_PRODUCT", 184, 204], ["mouse", "ORGANISM", 221, 226], ["neuroblastoma cell line", "CELL", 227, 250], ["gangliosideinduced differentiation-associated protein 2", "PROTEIN", 16, 71], ["GDAP2", "PROTEIN", 73, 78], ["macro domain protein 3", "PROTEIN", 108, 130], ["MDO3", "PROTEIN", 132, 136], ["ganglioside synthase", "PROTEIN", 184, 204], ["mouse neuroblastoma cell line", "CELL_LINE", 221, 250], ["mouse", "SPECIES", 221, 226], ["mouse", "SPECIES", 221, 226], ["gangliosideinduced differentiation", "PROBLEM", 16, 50], ["associated protein", "PROBLEM", 51, 69], ["macro domain protein", "TEST", 108, 128], ["ganglioside synthase expression", "TREATMENT", 184, 215], ["a mouse neuroblastoma cell line", "TREATMENT", 219, 250], ["ganglioside synthase expression", "OBSERVATION", 184, 215], ["mouse neuroblastoma cell line", "OBSERVATION", 221, 250]]], ["20 Macro domains are also encoded by several positive-strand RNA viruses: alphaviruses, rubella virus, hepatitis E virus (HEV), and coronaviruses [including the severe acute respiratory syndrome coronavirus (SARS-CoV)].", [["rubella virus", "DISEASE", 88, 101], ["hepatitis E", "DISEASE", 103, 114], ["acute respiratory syndrome coronavirus", "DISEASE", 168, 206], ["SARS-CoV)", "DISEASE", 208, 217], ["rubella virus", "ORGANISM", 88, 101], ["hepatitis E virus", "ORGANISM", 103, 120], ["HEV", "ORGANISM", 122, 125], ["coronaviruses", "ORGANISM", 132, 145], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 161, 206], ["SARS-CoV", "ORGANISM", 208, 216], ["rubella virus", "SPECIES", 88, 101], ["hepatitis E virus", "SPECIES", 103, 120], ["rubella virus", "SPECIES", 88, 101], ["hepatitis E virus", "SPECIES", 103, 120], ["HEV", "SPECIES", 122, 125], ["severe acute respiratory syndrome coronavirus", "SPECIES", 161, 206], ["SARS-CoV", "SPECIES", 208, 216], ["Macro domains", "TEST", 3, 16], ["several positive-strand RNA viruses", "PROBLEM", 37, 72], ["alphaviruses", "PROBLEM", 74, 86], ["rubella virus", "PROBLEM", 88, 101], ["hepatitis E virus", "PROBLEM", 103, 120], ["coronaviruses", "PROBLEM", 132, 145], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 157, 206], ["strand RNA viruses", "OBSERVATION", 54, 72], ["rubella virus", "OBSERVATION", 88, 101], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory syndrome", "OBSERVATION", 174, 194]]], ["1, 21 These viruses replicate their RNA in the cytoplasm of animal cells in membrane-associated replication complexes.", [["cytoplasm", "ANATOMY", 47, 56], ["cells", "ANATOMY", 67, 72], ["membrane", "ANATOMY", 76, 84], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["cells", "CELL", 67, 72], ["membrane", "CELLULAR_COMPONENT", 76, 84], ["animal cells", "CELL_TYPE", 60, 72], ["membrane-associated replication complexes", "PROTEIN", 76, 117], ["These viruses", "PROBLEM", 6, 19], ["viruses", "OBSERVATION", 12, 19], ["RNA", "OBSERVATION_MODIFIER", 36, 39], ["cytoplasm", "OBSERVATION_MODIFIER", 47, 56], ["animal cells", "OBSERVATION", 60, 72], ["replication complexes", "OBSERVATION", 96, 117]]], ["22 The viral macro domains are found in the viral replicase among the more typical replication protein domains, including an RNA-dependent RNA polymerase and RNA helicase.", [["viral macro domains", "DNA", 7, 26], ["viral replicase", "PROTEIN", 44, 59], ["replication protein domains", "PROTEIN", 83, 110], ["RNA-dependent RNA polymerase", "PROTEIN", 125, 153], ["RNA helicase", "PROTEIN", 158, 170], ["The viral macro domains", "PROBLEM", 3, 26], ["the viral replicase", "PROBLEM", 40, 59], ["an RNA", "TEST", 122, 128], ["dependent RNA polymerase", "PROBLEM", 129, 153], ["RNA helicase", "TREATMENT", 158, 170], ["viral", "OBSERVATION", 7, 12], ["macro domains", "OBSERVATION", 13, 26], ["viral replicase", "OBSERVATION", 44, 59], ["more typical", "OBSERVATION_MODIFIER", 70, 82], ["replication protein domains", "OBSERVATION", 83, 110]]], ["In alphaviruses, the macro domain is essential for virus viability in cell culture, and the macro-domain-containing nonstructural protein 3 (nsP3) is found at the sites of virus replication, on the outer surface of endosomal/lysosomal membranes.", [["cell culture", "ANATOMY", 70, 82], ["outer surface", "ANATOMY", 198, 211], ["endosomal", "ANATOMY", 215, 224], ["lysosomal membranes", "ANATOMY", 225, 244], ["cell culture", "CELL", 70, 82], ["macro-domain-containing nonstructural protein 3", "GENE_OR_GENE_PRODUCT", 92, 139], ["nsP3", "GENE_OR_GENE_PRODUCT", 141, 145], ["outer surface", "CELLULAR_COMPONENT", 198, 211], ["endosomal", "CELLULAR_COMPONENT", 215, 224], ["lysosomal membranes", "CELLULAR_COMPONENT", 225, 244], ["macro domain", "PROTEIN", 21, 33], ["macro-domain-containing nonstructural protein 3", "PROTEIN", 92, 139], ["nsP3", "PROTEIN", 141, 145], ["alphaviruses", "PROBLEM", 3, 15], ["the macro domain", "TEST", 17, 33], ["virus viability", "PROBLEM", 51, 66], ["cell culture", "TEST", 70, 82], ["the macro-domain", "TEST", 88, 104], ["nonstructural protein", "TEST", 116, 137], ["virus replication", "PROBLEM", 172, 189], ["endosomal/lysosomal membranes", "TREATMENT", 215, 244], ["alphaviruses", "OBSERVATION", 3, 15], ["essential for", "UNCERTAINTY", 37, 50], ["virus viability", "OBSERVATION", 51, 66], ["cell culture", "OBSERVATION", 70, 82], ["virus replication", "OBSERVATION", 172, 189], ["lysosomal membranes", "OBSERVATION", 225, 244]]], ["23, 24 The viral macro proteins are not known to enter the nucleus.", [["nucleus", "ANATOMY", 59, 66], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["viral macro proteins", "PROTEIN", 11, 31], ["The viral macro proteins", "TEST", 7, 31], ["viral", "OBSERVATION", 11, 16], ["macro proteins", "OBSERVATION", 17, 31], ["nucleus", "ANATOMY", 59, 66]]], ["The SARS-CoV macro domain has been shown to bind poly(ADP-ribose) and to hydrolyze ADPR-1\u2033P. 6, 25, 26 The viral macro domains have presumably originally been hijacked from the host genome, and certain amino acids in the ADP-ribose binding pocket are highly conserved between viruses and cellular organisms.", [["cellular organisms", "ANATOMY", 288, 306], ["SARS", "DISEASE", 4, 8], ["poly(ADP-ribose", "CHEMICAL", 49, 64], ["amino acids", "CHEMICAL", 202, 213], ["ADP", "CHEMICAL", 221, 224], ["ribose", "CHEMICAL", 225, 231], ["poly(ADP-ribose)", "CHEMICAL", 49, 65], ["ADPR-1\u2033P. 6, 25, 26", "CHEMICAL", 83, 102], ["amino acids", "CHEMICAL", 202, 213], ["ADP", "CHEMICAL", 221, 224], ["ribose", "CHEMICAL", 225, 231], ["ADP-ribose", "SIMPLE_CHEMICAL", 54, 64], ["amino acids", "AMINO_ACID", 202, 213], ["ADP", "SIMPLE_CHEMICAL", 221, 224], ["cellular organisms", "CELL", 288, 306], ["SARS-CoV macro domain", "PROTEIN", 4, 25], ["viral macro domains", "PROTEIN", 107, 126], ["ADP-ribose binding pocket", "PROTEIN", 221, 246], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV macro domain", "PROBLEM", 0, 25], ["ADP-ribose", "TREATMENT", 54, 64], ["hydrolyze ADPR", "TEST", 73, 87], ["The viral macro domains", "PROBLEM", 103, 126], ["certain amino acids", "PROBLEM", 194, 213], ["ribose binding pocket", "PROBLEM", 225, 246], ["viral macro", "OBSERVATION", 107, 118], ["host genome", "OBSERVATION", 177, 188], ["ribose binding pocket", "OBSERVATION", 225, 246], ["cellular organisms", "OBSERVATION", 288, 306]]], ["Thus, the function of viral macro proteins could be similar to the functions of some of the cellular macro domain proteins.", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100], ["viral macro proteins", "PROTEIN", 22, 42], ["cellular macro domain proteins", "PROTEIN", 92, 122], ["viral macro proteins", "PROBLEM", 22, 42], ["the cellular macro domain proteins", "PROBLEM", 88, 122], ["viral macro", "OBSERVATION", 22, 33], ["cellular macro", "OBSERVATION", 92, 106]]], ["Viral macro proteins could act to influence pathways normally regulated by cellular macro domains either to promote virus replication or to inhibit host responses directed against the virus.IntroductionWe have here studied three small putatively nonnuclear human macro domain proteins with respect to their ligand binding properties and subcellular localization, and compared them directly with the macro domains derived from RNA viruses.", [["cellular", "ANATOMY", 75, 83], ["subcellular", "ANATOMY", 337, 348], ["cellular", "CELL", 75, 83], ["human", "ORGANISM", 257, 262], ["Viral macro proteins", "PROTEIN", 0, 20], ["cellular macro domains", "PROTEIN", 75, 97], ["nonnuclear human macro domain proteins", "PROTEIN", 246, 284], ["macro domains", "PROTEIN", 399, 412], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["Viral macro proteins", "PROBLEM", 0, 20], ["virus replication", "TREATMENT", 116, 133], ["the virus", "PROBLEM", 180, 189], ["subcellular localization", "TEST", 337, 361], ["the macro domains", "TEST", 395, 412], ["RNA viruses", "PROBLEM", 426, 437], ["macro proteins", "OBSERVATION", 6, 20], ["RNA viruses", "OBSERVATION", 426, 437]]], ["We found that each of the three previously uncharacterized human macro proteins has a distinct profile of biochemical activity (also differing from the viral proteins), and that MDO1 is specifically localized in mitochondria.ResultsDomain structure, expression, and purification of macro domain proteins Figure 1a and b shows the domain structure and amino acid sequence alignment of human macro domain proteins MDO1, MDO2, and GDAP2 with the macro domains from Semliki Forest virus (SFV; an alphavirus), HEV (sole member of the Hepeviridae family), and SARS-CoV.", [["mitochondria", "ANATOMY", 212, 224], ["amino acid", "CHEMICAL", 351, 361], ["amino acid", "CHEMICAL", 351, 361], ["human", "ORGANISM", 59, 64], ["MDO1", "GENE_OR_GENE_PRODUCT", 178, 182], ["mitochondria", "CELLULAR_COMPONENT", 212, 224], ["macro domain proteins Figure 1a", "GENE_OR_GENE_PRODUCT", 282, 313], ["amino acid", "AMINO_ACID", 351, 361], ["human", "ORGANISM", 384, 389], ["MDO1", "GENE_OR_GENE_PRODUCT", 412, 416], ["MDO2", "GENE_OR_GENE_PRODUCT", 418, 422], ["GDAP2", "GENE_OR_GENE_PRODUCT", 428, 433], ["Semliki Forest virus", "ORGANISM", 462, 482], ["SFV", "ORGANISM", 484, 487], ["HEV", "ORGANISM", 505, 508], ["Hepeviridae", "GENE_OR_GENE_PRODUCT", 529, 540], ["SARS-CoV", "ORGANISM", 554, 562], ["human macro proteins", "PROTEIN", 59, 79], ["viral proteins", "PROTEIN", 152, 166], ["MDO1", "PROTEIN", 178, 182], ["macro domain proteins", "PROTEIN", 282, 303], ["Figure 1a and b", "PROTEIN", 304, 319], ["human macro domain proteins", "PROTEIN", 384, 411], ["MDO1", "PROTEIN", 412, 416], ["MDO2", "PROTEIN", 418, 422], ["GDAP2", "PROTEIN", 428, 433], ["macro domains", "PROTEIN", 443, 456], ["Hepeviridae family", "PROTEIN", 529, 547], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 384, 389], ["Semliki Forest virus", "SPECIES", 462, 482], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 384, 389], ["Semliki Forest virus", "SPECIES", 462, 482], ["SFV", "SPECIES", 484, 487], ["HEV", "SPECIES", 505, 508], ["SARS-CoV", "SPECIES", 554, 562], ["the viral proteins", "TEST", 148, 166], ["macro domain proteins", "TEST", 282, 303], ["the domain structure", "PROBLEM", 326, 346], ["amino acid sequence alignment", "TEST", 351, 380], ["MDO2", "TREATMENT", 418, 422], ["GDAP2", "TREATMENT", 428, 433], ["the macro domains", "TREATMENT", 439, 456], ["Semliki Forest virus (SFV", "TREATMENT", 462, 487], ["macro proteins", "OBSERVATION", 65, 79], ["distinct", "OBSERVATION_MODIFIER", 86, 94], ["profile", "OBSERVATION_MODIFIER", 95, 102], ["biochemical activity", "OBSERVATION", 106, 126], ["viral proteins", "OBSERVATION", 152, 166], ["Semliki Forest virus", "OBSERVATION", 462, 482]]], ["MDO1 and MDO2 do not contain any other predicted domains, although they have significant amino acid stretches attached, respectively, to the N-terminus or the C-terminus of the macro domain.", [["amino acid", "CHEMICAL", 89, 99], ["amino acid", "CHEMICAL", 89, 99], ["N", "CHEMICAL", 141, 142], ["C", "CHEMICAL", 159, 160], ["MDO1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MDO2", "GENE_OR_GENE_PRODUCT", 9, 13], ["amino acid", "AMINO_ACID", 89, 99], ["MDO1", "PROTEIN", 0, 4], ["MDO2", "PROTEIN", 9, 13], ["N-terminus", "PROTEIN", 141, 151], ["C-terminus", "PROTEIN", 159, 169], ["macro domain", "PROTEIN", 177, 189], ["MDO2", "TREATMENT", 9, 13], ["significant amino acid stretches", "PROBLEM", 77, 109], ["acid stretches", "OBSERVATION", 95, 109], ["terminus", "ANATOMY_MODIFIER", 161, 169], ["macro domain", "OBSERVATION", 177, 189]]], ["However, a high level of sequence homology between them extends for \u223c 230 aa, although the macro domain comprises only \u223c170 aa of these proteins.", [["macro domain", "PROTEIN", 91, 103], ["the macro domain", "TEST", 87, 103]]], ["GDAP2 includes in its C-terminus a predicted Sec14 domain, which is a putative lipidbinding domain.", [["GDAP2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Sec14", "GENE_OR_GENE_PRODUCT", 45, 50], ["GDAP2", "PROTEIN", 0, 5], ["C-terminus", "PROTEIN", 22, 32], ["Sec14 domain", "PROTEIN", 45, 57], ["putative lipidbinding domain", "PROTEIN", 70, 98]]], ["27 The viral macro proteins form parts of viral replicase polyproteins.", [["viral macro proteins", "PROTEIN", 7, 27], ["viral replicase polyproteins", "PROTEIN", 42, 70], ["The viral macro proteins", "TEST", 3, 27], ["viral replicase polyproteins", "PROBLEM", 42, 70], ["viral macro proteins", "OBSERVATION", 7, 27], ["viral replicase polyproteins", "OBSERVATION", 42, 70]]], ["SFV macro domain is located at the N-terminus of nsP3, followed by a unique alphavirus domain of unknown function and, after that, a hypervariable phosphorylated region.", [["N", "CHEMICAL", 35, 36], ["SFV", "ORGANISM", 0, 3], ["nsP3", "GENE_OR_GENE_PRODUCT", 49, 53], ["SFV macro domain", "PROTEIN", 0, 16], ["N-terminus", "PROTEIN", 35, 45], ["nsP3", "PROTEIN", 49, 53], ["alphavirus domain", "PROTEIN", 76, 93], ["hypervariable phosphorylated region", "PROTEIN", 133, 168], ["SFV", "SPECIES", 0, 3], ["a unique alphavirus domain", "PROBLEM", 67, 93], ["a hypervariable phosphorylated region", "PROBLEM", 131, 168], ["nsP3", "OBSERVATION", 49, 53], ["alphavirus", "OBSERVATION", 76, 86], ["hypervariable", "OBSERVATION_MODIFIER", 133, 146], ["phosphorylated region", "OBSERVATION", 147, 168]]], ["24 In HEV, the macro domain is immediately preceded by a proline-rich region and a putatively unstructured spacer in the replicase protein, and followed by the viral helicase coding region.", [["proline", "CHEMICAL", 57, 64], ["proline", "CHEMICAL", 57, 64], ["HEV", "ORGANISM", 6, 9], ["proline-rich region", "PROTEIN", 57, 76], ["replicase protein", "PROTEIN", 121, 138], ["viral helicase coding region", "DNA", 160, 188], ["HEV", "SPECIES", 6, 9], ["a proline-rich region", "TREATMENT", 55, 76], ["a putatively unstructured spacer in the replicase protein", "PROBLEM", 81, 138], ["the viral helicase coding region", "PROBLEM", 156, 188], ["spacer", "OBSERVATION_MODIFIER", 107, 113], ["replicase protein", "OBSERVATION", 121, 138], ["viral helicase", "OBSERVATION", 160, 174]]], ["28 In coronaviruses, the macro domain is flanked, depending on the virus, by papain-like protease domains or other domains of unknown function that remain in the same mature protein with the macro domain.", [["papain-like protease", "GENE_OR_GENE_PRODUCT", 77, 97], ["macro domain", "PROTEIN", 25, 37], ["papain-like protease domains", "PROTEIN", 77, 105], ["mature protein", "PROTEIN", 167, 181], ["macro domain", "PROTEIN", 191, 203], ["coronaviruses", "PROBLEM", 6, 19], ["the virus", "PROBLEM", 63, 72], ["papain", "TREATMENT", 77, 83], ["protease domains", "TREATMENT", 89, 105], ["coronaviruses", "OBSERVATION", 6, 19]]], ["29 To study their biochemical properties, we expressed the macro domains derived from MDO1, MDO2, GDAP2, SFV nsP3, and HEV in Escherichia coli as N-terminally hexahistidine-tagged proteins.", [["N", "CHEMICAL", 146, 147], ["MDO1", "GENE_OR_GENE_PRODUCT", 86, 90], ["MDO2", "GENE_OR_GENE_PRODUCT", 92, 96], ["GDAP2", "GENE_OR_GENE_PRODUCT", 98, 103], ["SFV", "ORGANISM", 105, 108], ["nsP3", "GENE_OR_GENE_PRODUCT", 109, 113], ["HEV", "ORGANISM", 119, 122], ["Escherichia coli", "ORGANISM", 126, 142], ["macro domains", "PROTEIN", 59, 72], ["MDO1", "PROTEIN", 86, 90], ["MDO2", "PROTEIN", 92, 96], ["GDAP2", "PROTEIN", 98, 103], ["SFV nsP3", "PROTEIN", 105, 113], ["N-terminally hexahistidine-tagged proteins", "PROTEIN", 146, 188], ["Escherichia coli", "SPECIES", 126, 142], ["SFV", "SPECIES", 105, 108], ["HEV", "SPECIES", 119, 122], ["Escherichia coli", "SPECIES", 126, 142], ["MDO1", "TEST", 86, 90], ["MDO2", "TEST", 92, 96], ["GDAP2", "TREATMENT", 98, 103], ["SFV nsP3", "TREATMENT", 105, 113], ["HEV in Escherichia coli", "TREATMENT", 119, 142], ["terminally hexahistidine", "TREATMENT", 148, 172], ["Escherichia coli", "OBSERVATION", 126, 142]]], ["The previously characterized yeast protein Poa1p 7 was produced as control, and the SARS-CoV macro domain was obtained as previously described.", [["yeast protein Poa1p 7", "GENE_OR_GENE_PRODUCT", 29, 50], ["yeast protein", "PROTEIN", 29, 42], ["Poa1p 7", "PROTEIN", 43, 50], ["SARS-CoV macro domain", "PROTEIN", 84, 105], ["yeast", "SPECIES", 29, 34], ["yeast", "SPECIES", 29, 34], ["SARS-CoV", "SPECIES", 84, 92], ["The previously characterized yeast protein Poa1p", "TEST", 0, 48], ["the SARS-CoV macro domain", "TEST", 80, 105], ["yeast protein", "OBSERVATION", 29, 42]]], ["30 The proteins were purified by metal chelate chromatography, in some cases followed by a second puri-fication step ( Fig. 1c ; see Materials and Methods).", [["metal chelate", "SIMPLE_CHEMICAL", 33, 46], ["metal chelate chromatography", "TEST", 33, 61], ["a second puri-fication step", "TREATMENT", 89, 116]]], ["The purified proteins were used in enzymatic and binding assays with ADP-ribose and its derivatives.ADPR-1\u2033P phosphatase activitySome macro domain proteins, including Poa1p, have been shown to hydrolyze ADPR-1\u2033P, 4,6 which arises as a by-product during tRNA splicing.", [["ADP-ribose", "CHEMICAL", 69, 79], ["ADP", "CHEMICAL", 69, 72], ["ribose", "CHEMICAL", 73, 79], ["ADP-ribose", "SIMPLE_CHEMICAL", 69, 79], ["ADPR-1\u2033P phosphatase", "GENE_OR_GENE_PRODUCT", 100, 120], ["Poa1p", "GENE_OR_GENE_PRODUCT", 167, 172], ["ADPR-1\u2033P", "GENE_OR_GENE_PRODUCT", 203, 211], ["purified proteins", "PROTEIN", 4, 21], ["ADPR-1\u2033P phosphatase", "PROTEIN", 100, 120], ["macro domain proteins", "PROTEIN", 134, 155], ["Poa1p", "PROTEIN", 167, 172], ["ADPR", "PROTEIN", 203, 207], ["The purified proteins", "TREATMENT", 0, 21], ["ADP-ribose", "TREATMENT", 69, 79], ["its derivatives", "TREATMENT", 84, 99], ["ADPR", "TEST", 100, 104], ["phosphatase activity", "TEST", 109, 129], ["Some macro domain proteins", "PROBLEM", 129, 155], ["ADPR", "TEST", 203, 207], ["tRNA splicing", "TREATMENT", 253, 266], ["tRNA splicing", "OBSERVATION", 253, 266]]], ["The enzymatic activity of the proteins with ADPR-1\u2033P was measured at room temperature, and the reaction products were detected on thin-layer chromatography (TLC).", [["ADPR-1\u2033", "CHEMICAL", 44, 51], ["ADPR-1\u2033P", "CHEMICAL", 44, 52], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 44, 52], ["ADPR", "PROTEIN", 44, 48], ["ADPR", "TEST", 44, 48], ["the reaction products", "PROBLEM", 91, 112], ["activity", "OBSERVATION_MODIFIER", 14, 22]]], ["It was observed that the closely related human proteins MDO1 and MDO2 both hydrolyzed ADPR-1\u2033P equally efficiently as yeast Poa1p (Fig. 2, lanes 3, 7, and 9 ).", [["ADPR-1\u2033", "CHEMICAL", 86, 93], ["ADPR-1\u2033", "CHEMICAL", 86, 93], ["human", "ORGANISM", 41, 46], ["MDO1", "GENE_OR_GENE_PRODUCT", 56, 60], ["MDO2", "SIMPLE_CHEMICAL", 65, 69], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 86, 92], ["human proteins", "PROTEIN", 41, 55], ["MDO1", "PROTEIN", 56, 60], ["MDO2", "PROTEIN", 65, 69], ["ADPR", "PROTEIN", 86, 90], ["P", "DNA", 93, 94], ["human", "SPECIES", 41, 46], ["yeast", "SPECIES", 118, 123], ["human", "SPECIES", 41, 46], ["yeast", "SPECIES", 118, 123], ["human proteins MDO1", "TREATMENT", 41, 60], ["MDO2 both hydrolyzed ADPR", "TREATMENT", 65, 90]]], ["HEV and SARS-CoV proteins also demonstrated similar activities (lanes 5 and 8).", [["HEV", "ORGANISM", 0, 3], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 8, 16], ["HEV and SARS-CoV proteins", "PROTEIN", 0, 25], ["HEV", "SPECIES", 0, 3], ["SARS-CoV", "SPECIES", 8, 16], ["HEV and SARS-CoV proteins", "TEST", 0, 25]]], ["6 However, SFV nsP3 had only a minor activity, whereas GDAP2 was inactive as an ADPR-1\u2033P phosphoesterase (lanes 6 and 4).", [["nsP3", "CHEMICAL", 15, 19], ["SFV", "ORGANISM", 11, 14], ["nsP3", "GENE_OR_GENE_PRODUCT", 15, 19], ["GDAP2", "SIMPLE_CHEMICAL", 55, 60], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 80, 86], ["SFV nsP3", "PROTEIN", 11, 19], ["GDAP2", "PROTEIN", 55, 60], ["P phosphoesterase", "PROTEIN", 87, 104], ["SFV", "SPECIES", 11, 14], ["SFV nsP3", "PROBLEM", 11, 19], ["P phosphoesterase (lanes", "TREATMENT", 87, 111], ["SFV nsP3", "OBSERVATION", 11, 19], ["minor activity", "OBSERVATION_MODIFIER", 31, 45]]], ["The level of activity for SFV nsP3 was independent of the specific construct used, as a protein containing the 167aa-long macro domain region only and an extended protein of 328 aa had similar activities (data not shown).", [["SFV", "ORGANISM", 26, 29], ["nsP3", "GENE_OR_GENE_PRODUCT", 30, 34], ["SFV nsP3", "PROTEIN", 26, 34], ["167aa-long macro domain region", "DNA", 111, 141], ["SFV", "SPECIES", 26, 29], ["SFV nsP3", "PROBLEM", 26, 34], ["a protein", "TEST", 86, 95], ["an extended protein", "TEST", 151, 170]]], ["In parallel with TLC, the reaction products from the hydrolysis of ADPR-1\u2033P by MDO1 were analyzed by HPLC and mass spectrometry.", [["ADPR", "CHEMICAL", 67, 71], ["ADPR-1\u2033P", "CHEMICAL", 67, 75], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 67, 75], ["MDO1", "SIMPLE_CHEMICAL", 79, 83], ["TLC", "TREATMENT", 17, 20], ["the reaction products", "TREATMENT", 22, 43], ["the hydrolysis of ADPR", "TREATMENT", 49, 71], ["mass spectrometry", "PROBLEM", 110, 127], ["TLC", "ANATOMY", 17, 20], ["mass spectrometry", "OBSERVATION", 110, 127]]], ["The mass of the reaction product was 558.1 m/z, confirming its identity as ADP-ribose (calculated monoisotopic mass of the protonated molecule, 559.1) and further demonstrating that the reaction involved the removal of the 1\u2033-phosphate and not another type of modification or degradation of the substrate.ADP-ribose bindingAs an alternative to enzymatic function, it has been suggested that cellular and viral macro do-mains might be ADP-ribose-binding modules.", [["cellular", "ANATOMY", 391, 399], ["ADP-ribose", "CHEMICAL", 75, 85], ["1\u2033-phosphate", "CHEMICAL", 223, 235], ["ADP-ribose", "CHEMICAL", 305, 315], ["ADP", "CHEMICAL", 434, 437], ["ribose", "CHEMICAL", 438, 444], ["ADP", "CHEMICAL", 75, 78], ["ribose", "CHEMICAL", 79, 85], ["1\u2033-phosphate", "CHEMICAL", 223, 235], ["ADP", "CHEMICAL", 305, 308], ["ribose", "CHEMICAL", 309, 315], ["ADP", "CHEMICAL", 434, 437], ["ribose", "CHEMICAL", 438, 444], ["ADP-ribose", "SIMPLE_CHEMICAL", 75, 85], ["1\u2033-phosphate", "SIMPLE_CHEMICAL", 223, 235], ["ADP-ribose", "SIMPLE_CHEMICAL", 305, 315], ["cellular", "CELL", 391, 399], ["ADP", "SIMPLE_CHEMICAL", 434, 437], ["ribose", "SIMPLE_CHEMICAL", 438, 444], ["ADP-ribose (calculated monoisotopic mass of the protonated molecule", "PROBLEM", 75, 142], ["the reaction", "PROBLEM", 182, 194], ["the removal", "TREATMENT", 204, 215], ["the 1\u2033-phosphate", "TREATMENT", 219, 235], ["ribose binding", "PROBLEM", 309, 323], ["enzymatic function", "TEST", 344, 362], ["cellular and viral macro", "PROBLEM", 391, 415], ["ADP", "PROBLEM", 434, 437], ["ribose-binding modules", "PROBLEM", 438, 460], ["mass", "OBSERVATION", 4, 8], ["modification", "OBSERVATION", 260, 272], ["ribose binding", "OBSERVATION", 309, 323], ["binding modules", "OBSERVATION", 445, 460]]], ["5, 6 We tested the affinity of human, yeast, and viral macro proteins for ADP-ribose by isothermal titration calorimetry (Fig. 3a) .", [["ADP-ribose", "CHEMICAL", 74, 84], ["ADP", "CHEMICAL", 74, 77], ["ribose", "CHEMICAL", 78, 84], ["human", "ORGANISM", 31, 36], ["yeast", "CELL", 38, 43], ["ADP-ribose", "SIMPLE_CHEMICAL", 74, 84], ["human, yeast, and viral macro proteins", "PROTEIN", 31, 69], ["human", "SPECIES", 31, 36], ["yeast", "SPECIES", 38, 43], ["human", "SPECIES", 31, 36], ["yeast", "SPECIES", 38, 43], ["yeast", "TEST", 38, 43], ["viral macro proteins", "TEST", 49, 69], ["ADP", "TEST", 74, 77], ["ribose", "TREATMENT", 78, 84], ["isothermal titration calorimetry", "TREATMENT", 88, 120]]], ["MDO1 and MDO2 showed the highest affinity for ADP-ribose, with K d values of 0.9 \u03bcM and 0.15 \u03bcM, respectively.", [["MDO1", "CHEMICAL", 0, 4], ["MDO2", "CHEMICAL", 9, 13], ["ADP-ribose", "CHEMICAL", 46, 56], ["K", "CHEMICAL", 63, 64], ["ADP", "CHEMICAL", 46, 49], ["ribose", "CHEMICAL", 50, 56], ["MDO1", "SIMPLE_CHEMICAL", 0, 4], ["MDO2", "SIMPLE_CHEMICAL", 9, 13], ["ADP-ribose", "SIMPLE_CHEMICAL", 46, 56], ["MDO1", "PROTEIN", 0, 4], ["MDO2", "PROTEIN", 9, 13], ["MDO1", "TEST", 0, 4], ["MDO2", "TEST", 9, 13], ["ADP", "TEST", 46, 49], ["ribose", "TEST", 50, 56], ["K d values", "TEST", 63, 73]]], ["The yeast protein Poa1p also had a reasonably high affinity (K d = 2.9 \u03bcM).", [["Poa1p", "GENE_OR_GENE_PRODUCT", 18, 23], ["yeast protein Poa1p", "PROTEIN", 4, 23], ["yeast", "SPECIES", 4, 9], ["yeast", "SPECIES", 4, 9], ["The yeast protein Poa1p", "TEST", 0, 23], ["K d", "TEST", 61, 64], ["yeast protein Poa1p", "OBSERVATION", 4, 23]]], ["Viral macro proteins from SARS-CoV and HEV were previously shown to bind ADPribose with a much weaker affinity of \u223c 24 \u03bcM or N 50 \u03bcM, respectively, 6 which was confirmed again in these experiments.", [["ADPribose", "CHEMICAL", 73, 82], ["ADPribose", "CHEMICAL", 73, 82], ["SARS-CoV", "ORGANISM", 26, 34], ["HEV", "ORGANISM", 39, 42], ["ADPribose", "SIMPLE_CHEMICAL", 73, 82], ["Viral macro proteins", "PROTEIN", 0, 20], ["SARS-CoV", "SPECIES", 26, 34], ["HEV", "SPECIES", 39, 42], ["Viral macro proteins", "TEST", 0, 20], ["SARS", "PROBLEM", 26, 30], ["CoV", "PROBLEM", 31, 34], ["HEV", "PROBLEM", 39, 42], ["a much weaker affinity", "PROBLEM", 88, 110], ["macro proteins", "OBSERVATION", 6, 20]]], ["We were unable to detect the binding of ADP-ribose to SFV macro.", [["ADP-ribose", "CHEMICAL", 40, 50], ["ADP", "CHEMICAL", 40, 43], ["ribose", "CHEMICAL", 44, 50], ["ADP-ribose", "SIMPLE_CHEMICAL", 40, 50], ["SFV", "ORGANISM", 54, 57], ["ADP", "TEST", 40, 43], ["ribose", "TREATMENT", 44, 50]]], ["SFV macro domain tended to precipitate in low-salt buffer when the protein concentration was high, as required in calorimetry experiments.", [["SFV", "ORGANISM", 0, 3], ["SFV macro domain", "PROTEIN", 0, 16], ["SFV", "SPECIES", 0, 3], ["low-salt buffer", "TREATMENT", 42, 57], ["the protein concentration", "TEST", 63, 88]]], ["Thus, the binding assays for SFV macro protein were repeated in the presence of 500 mM NaCl, where the protein remained soluble.", [["NaCl", "CHEMICAL", 87, 91], ["NaCl", "CHEMICAL", 87, 91], ["SFV", "ORGANISM", 29, 32], ["SFV macro protein", "PROTEIN", 29, 46], ["SFV", "SPECIES", 29, 32], ["the binding assays", "TEST", 6, 24], ["SFV macro protein", "TEST", 29, 46], ["500 mM NaCl", "TREATMENT", 80, 91], ["the protein", "TEST", 99, 110]]], ["Again, no ADP-ribose binding was detected for SFV macro (both the 167-aa and the 328-aa forms of the protein were tested), whereas MDO1 was able to bind ADP-ribose also in the highsalt buffer, although the dissociation constant measured was approximately twofold higher than that under standard conditions (data not shown).", [["ADP", "CHEMICAL", 10, 13], ["ribose", "CHEMICAL", 14, 20], ["ADP-ribose", "CHEMICAL", 153, 163], ["ADP", "CHEMICAL", 10, 13], ["ribose", "CHEMICAL", 14, 20], ["ADP", "CHEMICAL", 153, 156], ["ribose", "CHEMICAL", 157, 163], ["ADP-ribose", "SIMPLE_CHEMICAL", 10, 20], ["SFV", "ORGANISM", 46, 49], ["MDO1", "SIMPLE_CHEMICAL", 131, 135], ["ADP-ribose", "SIMPLE_CHEMICAL", 153, 163], ["MDO1", "PROTEIN", 131, 135], ["SFV", "SPECIES", 46, 49], ["ADP-ribose binding", "PROBLEM", 10, 28], ["SFV macro", "TEST", 46, 55], ["the protein", "TEST", 97, 108], ["ribose", "TREATMENT", 157, 163], ["the highsalt buffer", "TREATMENT", 172, 191], ["the dissociation constant", "PROBLEM", 202, 227], ["no", "UNCERTAINTY", 7, 9], ["ribose binding", "OBSERVATION", 14, 28]]], ["In several independent experiments, human GDAP2 was completely inactive in binding to ADP-ribose ( Fig. 3a) , although it remained soluble under the assay conditions.Binding of poly(ADP-ribose)Most of the ADP-ribose in the cells is in the form of poly(ADP-ribose), a polymer produced by PARPs.", [["cells", "ANATOMY", 223, 228], ["ADP-ribose", "CHEMICAL", 86, 96], ["poly(ADP-ribose", "CHEMICAL", 177, 192], ["ADP", "CHEMICAL", 205, 208], ["ribose", "CHEMICAL", 209, 215], ["poly(ADP-ribose", "CHEMICAL", 247, 262], ["ADP", "CHEMICAL", 86, 89], ["ribose", "CHEMICAL", 90, 96], ["poly(ADP-ribose)", "CHEMICAL", 177, 193], ["ADP", "CHEMICAL", 205, 208], ["ribose", "CHEMICAL", 209, 215], ["poly(ADP-ribose)", "CHEMICAL", 247, 263], ["human", "ORGANISM", 36, 41], ["GDAP2", "GENE_OR_GENE_PRODUCT", 42, 47], ["ADP-ribose", "SIMPLE_CHEMICAL", 86, 96], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 177, 192], ["ADP-ribose", "SIMPLE_CHEMICAL", 205, 215], ["cells", "CELL", 223, 228], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 247, 262], ["PARPs", "GENE_OR_GENE_PRODUCT", 287, 292], ["human GDAP2", "PROTEIN", 36, 47], ["PARPs", "PROTEIN", 287, 292], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["ADP-ribose ( Fig.", "TREATMENT", 86, 103], ["Binding of poly(ADP-ribose", "TREATMENT", 166, 192], ["the ADP-ribose in the cells", "TREATMENT", 201, 228], ["poly(ADP-ribose", "TREATMENT", 247, 262], ["PARPs", "PROBLEM", 287, 292]]], ["It has been shown that some macro domains bind poly (ADP-ribose).", [["poly (ADP-ribose", "CHEMICAL", 47, 63], ["poly (ADP-ribose)", "CHEMICAL", 47, 64], ["ADP-ribose", "SIMPLE_CHEMICAL", 53, 63], ["macro domains", "PROTEIN", 28, 41], ["some macro domains bind poly (ADP-ribose)", "TREATMENT", 23, 64]]], ["5,6 Thus, we wanted to examine if this represents a common property for all the macro domains.", [["5,6", "CHEMICAL", 0, 3]]], ["For this assay, poly(ADP-ribose) was produced from radioactively labeled NAD + by auto-ADP-ribosylation of PARP-1 (see Materials and Methods).", [["poly(ADP-ribose", "CHEMICAL", 16, 31], ["NAD", "CHEMICAL", 73, 76], ["poly(ADP-ribose)", "CHEMICAL", 16, 32], ["NAD +", "CHEMICAL", 73, 78], ["auto-ADP", "CHEMICAL", 82, 90], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 16, 31], ["radioactively", "SIMPLE_CHEMICAL", 51, 64], ["NAD +", "SIMPLE_CHEMICAL", 73, 78], ["auto-ADP", "SIMPLE_CHEMICAL", 82, 90], ["PARP-1", "GENE_OR_GENE_PRODUCT", 107, 113], ["auto-ADP", "PROTEIN", 82, 90], ["PARP", "PROTEIN", 107, 111], ["this assay", "TEST", 4, 14], ["poly(ADP-ribose", "TREATMENT", 16, 31], ["PARP", "TEST", 107, 111]]], ["Macro domain proteins immobilized on a nitrocellulose filter were incubated with a protein-free purified poly(ADP-ribose) preparation or with a preparation in which the labeled polymer was still bound to PARP-1.", [["poly(ADP-ribose", "CHEMICAL", 105, 120], ["nitrocellulose", "CHEMICAL", 39, 53], ["poly(ADP-ribose)", "CHEMICAL", 105, 121], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 105, 120], ["PARP-1", "GENE_OR_GENE_PRODUCT", 204, 210], ["Macro domain proteins", "PROTEIN", 0, 21], ["PARP-1", "PROTEIN", 204, 210], ["Macro domain proteins", "PROBLEM", 0, 21], ["a nitrocellulose filter", "TREATMENT", 37, 60], ["a protein", "TEST", 81, 90], ["free purified poly(ADP-ribose) preparation", "TREATMENT", 91, 133], ["a preparation", "TREATMENT", 142, 155], ["PARP", "TEST", 204, 208], ["immobilized", "OBSERVATION_MODIFIER", 22, 33]]], ["Overall, the experiments showed that the binding of poly(ADP-ribose) with PARP-1 in the preparation and the binding of poly (ADP-ribose) without PARP-1 in the preparation were practically identical.", [["poly(ADP-ribose", "CHEMICAL", 52, 67], ["poly (ADP-ribose", "CHEMICAL", 119, 135], ["poly(ADP-ribose)", "CHEMICAL", 52, 68], ["poly (ADP-ribose)", "CHEMICAL", 119, 136], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 52, 67], ["PARP-1", "GENE_OR_GENE_PRODUCT", 74, 80], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 119, 135], ["PARP-1", "GENE_OR_GENE_PRODUCT", 145, 151], ["PARP-1", "PROTEIN", 74, 80], ["PARP", "PROTEIN", 145, 149], ["poly(ADP-ribose", "TREATMENT", 52, 67], ["PARP", "TREATMENT", 74, 78], ["poly (ADP-ribose", "TREATMENT", 119, 135], ["PARP", "PROBLEM", 145, 149]]], ["Incubation of macro domains with radioactive NAD + alone produced no radioactive signal.Binding of poly(ADP-ribose)The viral macro domains from HEV and SFV bound poly(ADP-ribose) effectively (Fig. 3b) , 6 although they bound monomeric ADP-ribose with low affinity (HEV) or no affinity at all (SFV) in previous experiments.", [["NAD", "CHEMICAL", 45, 48], ["poly(ADP-ribose", "CHEMICAL", 99, 114], ["poly(ADP-ribose", "CHEMICAL", 162, 177], ["ADP-ribose", "CHEMICAL", 235, 245], ["NAD +", "CHEMICAL", 45, 50], ["poly(ADP-ribose)", "CHEMICAL", 99, 115], ["poly(ADP-ribose)", "CHEMICAL", 162, 178], ["ADP", "CHEMICAL", 235, 238], ["ribose", "CHEMICAL", 239, 245], ["NAD +", "SIMPLE_CHEMICAL", 45, 50], ["ADP", "SIMPLE_CHEMICAL", 104, 107], ["HEV", "ORGANISM", 144, 147], ["SFV", "ORGANISM", 152, 155], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 162, 177], ["ADP-ribose", "SIMPLE_CHEMICAL", 235, 245], ["macro domains", "PROTEIN", 14, 27], ["viral macro domains", "PROTEIN", 119, 138], ["HEV", "SPECIES", 144, 147], ["SFV", "SPECIES", 152, 155], ["SFV", "SPECIES", 293, 296], ["radioactive NAD", "TREATMENT", 33, 48], ["radioactive signal", "PROBLEM", 69, 87], ["Binding of poly(ADP-ribose", "TREATMENT", 88, 114], ["The viral macro domains", "PROBLEM", 115, 138], ["HEV and SFV bound poly(ADP-ribose)", "TREATMENT", 144, 178], ["low affinity", "PROBLEM", 251, 263], ["affinity", "PROBLEM", 276, 284], ["no", "UNCERTAINTY", 66, 68], ["radioactive signal", "OBSERVATION", 69, 87], ["SFV", "ANATOMY", 152, 155]]], ["In complete contrast, macro domains derived from MDO2 and Poa1p did not show effective binding to poly(ADP-ribose) (Fig. 3b ), although they bound monomeric ADP-ribose tightly.", [["poly(ADP-ribose", "CHEMICAL", 98, 113], ["ADP", "CHEMICAL", 157, 160], ["MDO2", "CHEMICAL", 49, 53], ["Poa1p", "CHEMICAL", 58, 63], ["poly(ADP-ribose)", "CHEMICAL", 98, 114], ["ADP", "CHEMICAL", 157, 160], ["ribose", "CHEMICAL", 161, 167], ["MDO2", "GENE_OR_GENE_PRODUCT", 49, 53], ["Poa1p", "GENE_OR_GENE_PRODUCT", 58, 63], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 98, 113], ["ADP-ribose", "SIMPLE_CHEMICAL", 157, 167], ["macro domains", "PROTEIN", 22, 35], ["MDO2", "PROTEIN", 49, 53], ["Poa1p", "PROTEIN", 58, 63], ["poly(ADP-ribose)", "TREATMENT", 98, 114], ["ribose tightly", "OBSERVATION", 161, 175]]], ["MDO1 bound poly(ADP-ribose) and also the monomer, and GDAP2 was inefficient in binding poly(ADP-ribose) and ADP-ribose (Table 1) .", [["MDO1", "CHEMICAL", 0, 4], ["poly(ADP-ribose", "CHEMICAL", 11, 26], ["poly(ADP-ribose", "CHEMICAL", 87, 102], ["ADP-ribose", "CHEMICAL", 108, 118], ["poly(ADP-ribose)", "CHEMICAL", 11, 27], ["poly(ADP-ribose)", "CHEMICAL", 87, 103], ["ADP", "CHEMICAL", 108, 111], ["ribose", "CHEMICAL", 112, 118], ["MDO1", "SIMPLE_CHEMICAL", 0, 4], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 11, 27], ["GDAP2", "GENE_OR_GENE_PRODUCT", 54, 59], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 87, 103], ["ADP-ribose", "SIMPLE_CHEMICAL", 108, 118], ["MDO1", "PROTEIN", 0, 4], ["GDAP2", "PROTEIN", 54, 59], ["MDO1 bound poly(ADP-ribose)", "TREATMENT", 0, 27], ["ADP-ribose)", "TREATMENT", 92, 103], ["ADP-ribose (Table", "TREATMENT", 108, 125]]], ["Thus, the binding of poly(ADP-ribose) showed striking differences between macro domains and was not directly related to monomer binding.Binding of poly(ADP-ribose)The binding of poly(ADP-ribose) appeared to be specific in the case of MDO1, SFV macro, and HEV macro.", [["poly(ADP-ribose", "CHEMICAL", 21, 36], ["poly(ADP-ribose", "CHEMICAL", 147, 162], ["poly(ADP-ribose", "CHEMICAL", 178, 193], ["poly(ADP-ribose)", "CHEMICAL", 21, 37], ["poly(ADP-ribose)", "CHEMICAL", 147, 163], ["poly(ADP-ribose)", "CHEMICAL", 178, 194], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 21, 36], ["ADP", "SIMPLE_CHEMICAL", 152, 155], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 178, 193], ["MDO1", "GENE_OR_GENE_PRODUCT", 234, 238], ["SFV", "ORGANISM", 240, 243], ["HEV", "ORGANISM", 255, 258], ["MDO1", "PROTEIN", 234, 238], ["SFV", "SPECIES", 240, 243], ["HEV", "SPECIES", 255, 258], ["poly(ADP-ribose)", "TEST", 21, 37], ["striking differences between macro domains", "PROBLEM", 45, 87], ["monomer binding", "PROBLEM", 120, 135], ["Binding of poly(ADP-ribose", "TREATMENT", 136, 162], ["poly(ADP-ribose", "TREATMENT", 178, 193], ["MDO1", "TREATMENT", 234, 238], ["SFV macro", "TREATMENT", 240, 249], ["monomer binding", "OBSERVATION", 120, 135], ["HEV macro", "OBSERVATION", 255, 264]]], ["When the filter-bound proteins were incubated with a large molar excess of poly(A) (\u223c 400fold) or monomeric ADP-ribose (1500-fold excess), together with poly(ADP-ribose), no competition for the binding of poly(ADP-ribose) was noted (data not shown).", [["poly(A", "CHEMICAL", 75, 81], ["ADP-ribose", "CHEMICAL", 108, 118], ["poly(ADP-ribose", "CHEMICAL", 153, 168], ["poly(ADP-ribose", "CHEMICAL", 205, 220], ["poly(A)", "CHEMICAL", 75, 82], ["ADP", "CHEMICAL", 108, 111], ["ribose", "CHEMICAL", 112, 118], ["poly(ADP-ribose)", "CHEMICAL", 153, 169], ["poly(ADP-ribose)", "CHEMICAL", 205, 221], ["poly(A)", "SIMPLE_CHEMICAL", 75, 82], ["ADP-ribose", "SIMPLE_CHEMICAL", 108, 118], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 153, 168], ["ADP-ribose", "SIMPLE_CHEMICAL", 210, 220], ["filter-bound proteins", "PROTEIN", 9, 30], ["the filter-bound proteins", "TEST", 5, 30], ["a large molar excess of poly", "PROBLEM", 51, 79], ["monomeric ADP-ribose", "TREATMENT", 98, 118], ["poly(ADP-ribose", "TREATMENT", 153, 168], ["poly(ADP-ribose", "TREATMENT", 205, 220], ["large", "OBSERVATION_MODIFIER", 53, 58], ["molar", "OBSERVATION", 59, 64]]], ["Competition of ADP-ribose with poly (ADP-ribose) was also tested in experiments in which the proteins were first preincubated with the monomer, followed by addition of the polymer, with similar results.", [["ADP-ribose", "CHEMICAL", 15, 25], ["poly (ADP-ribose", "CHEMICAL", 31, 47], ["ADP", "CHEMICAL", 15, 18], ["ribose", "CHEMICAL", 19, 25], ["poly (ADP-ribose)", "CHEMICAL", 31, 48], ["ADP-ribose", "SIMPLE_CHEMICAL", 15, 25], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 31, 47], ["ADP", "TEST", 15, 18], ["ribose with poly (ADP-ribose)", "TREATMENT", 19, 48], ["the polymer", "TREATMENT", 168, 179]]], ["When we tested the binding of labeled poly(A) alone, however, all the proteins that bound poly(ADP-ribose) were also able to bind poly (A) ( Fig. 3c ; Table 1 ).", [["poly(A", "CHEMICAL", 38, 44], ["poly(ADP-ribose", "CHEMICAL", 90, 105], ["poly(A)", "CHEMICAL", 38, 45], ["poly(ADP-ribose)", "CHEMICAL", 90, 106], ["poly (A)", "CHEMICAL", 130, 138], ["poly(A)", "SIMPLE_CHEMICAL", 38, 45], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 90, 105], ["bound poly(ADP-ribose)", "TREATMENT", 84, 106]]], ["MDO2 did not bind poly(A); however, surprisingly, GDAP2, which was inactive in all of the ADP-ribose-related assays, bound poly (A) in this assay, leading to a hypothesis that sequence alterations in the substrate-binding pocket of GDAP2, as compared to other macro domain proteins, might be related to different substrate specificities [nucleic acid binding versus poly(ADPribose) binding].Binding of poly(ADP-ribose)So far, only one enzyme, poly(ADP-ribose) glycohydrolase (PARG), has been known to hydrolyze poly(ADP-ribose) to monomeric ADP-ribose.", [["poly(A", "CHEMICAL", 18, 24], ["ADP", "CHEMICAL", 90, 93], ["ribose", "CHEMICAL", 94, 100], ["nucleic acid", "CHEMICAL", 338, 350], ["poly", "CHEMICAL", 366, 370], ["ADPribose", "CHEMICAL", 371, 380], ["poly(ADP-ribose", "CHEMICAL", 402, 417], ["poly(ADP-ribose", "CHEMICAL", 443, 458], ["poly(ADP-ribose", "CHEMICAL", 511, 526], ["ADP-ribose", "CHEMICAL", 541, 551], ["poly(A)", "CHEMICAL", 18, 25], ["ADP", "CHEMICAL", 90, 93], ["ribose", "CHEMICAL", 94, 100], ["poly (A)", "CHEMICAL", 123, 131], ["poly(ADPribose)", "CHEMICAL", 366, 381], ["poly(ADP-ribose)", "CHEMICAL", 402, 418], ["poly(ADP-ribose)", "CHEMICAL", 443, 459], ["poly(ADP-ribose)", "CHEMICAL", 511, 527], ["ADP", "CHEMICAL", 541, 544], ["ribose", "CHEMICAL", 545, 551], ["MDO2", "SIMPLE_CHEMICAL", 0, 4], ["poly(A", "SIMPLE_CHEMICAL", 18, 24], ["GDAP2", "GENE_OR_GENE_PRODUCT", 50, 55], ["ADP", "SIMPLE_CHEMICAL", 90, 93], ["poly (A", "SIMPLE_CHEMICAL", 123, 130], ["GDAP2", "GENE_OR_GENE_PRODUCT", 232, 237], ["poly(ADPribose)", "SIMPLE_CHEMICAL", 366, 381], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 402, 417], ["poly(ADP-ribose) glycohydrolase", "GENE_OR_GENE_PRODUCT", 443, 474], ["PARG", "GENE_OR_GENE_PRODUCT", 476, 480], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 511, 526], ["ADP-ribose", "SIMPLE_CHEMICAL", 541, 551], ["MDO2", "PROTEIN", 0, 4], ["poly(A)", "PROTEIN", 18, 25], ["GDAP2", "PROTEIN", 50, 55], ["poly (A)", "PROTEIN", 123, 131], ["substrate-binding pocket", "PROTEIN", 204, 228], ["GDAP2", "PROTEIN", 232, 237], ["macro domain proteins", "PROTEIN", 260, 281], ["poly(ADP-ribose) glycohydrolase", "PROTEIN", 443, 474], ["PARG", "PROTEIN", 476, 480], ["bound poly (A) in this assay", "PROBLEM", 117, 145], ["a hypothesis", "PROBLEM", 158, 170], ["sequence alterations in the substrate-binding pocket of GDAP2", "PROBLEM", 176, 237], ["other macro domain proteins", "PROBLEM", 254, 281], ["different substrate specificities", "PROBLEM", 303, 336], ["nucleic acid binding", "PROBLEM", 338, 358], ["poly(ADPribose) binding", "PROBLEM", 366, 389], ["Binding of poly(ADP-ribose)", "TREATMENT", 391, 418], ["one enzyme", "TEST", 431, 441], ["poly(ADP-ribose) glycohydrolase (PARG)", "TREATMENT", 443, 481], ["hydrolyze poly(ADP-ribose", "TREATMENT", 501, 526], ["monomeric ADP-ribose", "TREATMENT", 531, 551]]], ["We also tested the macro proteins' poly(ADP-ribose) hydrolysis activity.", [["poly(ADP-ribose", "CHEMICAL", 35, 50], ["poly(ADP-ribose)", "CHEMICAL", 35, 51], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 35, 50], ["macro proteins", "PROTEIN", 19, 33], ["ADP", "TEST", 40, 43]]], ["The proteins were incubated with poly(ADP-ribose) in hydrolysis buffer, and the reactions were analyzed by TLC for separation of the monomer from the polymer.", [["poly(ADP-ribose", "CHEMICAL", 33, 48], ["poly(ADP-ribose)", "CHEMICAL", 33, 49], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 33, 48], ["poly(ADP-ribose)", "TREATMENT", 33, 49], ["hydrolysis buffer", "TREATMENT", 53, 70], ["the reactions", "PROBLEM", 76, 89], ["TLC", "TEST", 107, 110]]], ["None of the macro proteins degraded poly(ADP-ribose) under these conditions, whereas cell lysates containing abundant PARG yielded clear evidence of ADP-ribose generation (data not shown).", [["cell lysates", "ANATOMY", 85, 97], ["poly(ADP-ribose", "CHEMICAL", 36, 51], ["ADP-ribose", "CHEMICAL", 149, 159], ["poly(ADP-ribose)", "CHEMICAL", 36, 52], ["ADP", "CHEMICAL", 149, 152], ["ribose", "CHEMICAL", 153, 159], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 36, 51], ["cell lysates", "ORGANISM_SUBSTANCE", 85, 97], ["PARG", "GENE_OR_GENE_PRODUCT", 118, 122], ["ADP-ribose", "SIMPLE_CHEMICAL", 149, 159], ["macro proteins", "PROTEIN", 12, 26], ["PARG", "PROTEIN", 118, 122], ["the macro proteins", "TEST", 8, 26], ["poly(ADP-ribose", "TREATMENT", 36, 51], ["cell lysates", "TEST", 85, 97], ["abundant PARG", "PROBLEM", 109, 122], ["ADP-ribose generation", "PROBLEM", 149, 170], ["ribose generation", "OBSERVATION", 153, 170]]], ["Thus, the macro domains derived from HEV, SFV, and human MDO1-rather than hydrolytic enzymes acting on poly(ADP-ribose)-are specific poly(ADP-ribose)binding modules.Mutagenesis of the active siteBased on the existing macro domain structures, 3, 5, 6 we constructed mutations to the suggested ligandbinding pockets of human MDO1 and SFV macro.", [["poly(ADP-ribose", "CHEMICAL", 103, 118], ["poly(ADP-ribose", "CHEMICAL", 133, 148], ["poly(ADP-ribose)", "CHEMICAL", 103, 119], ["poly(ADP-ribose)", "CHEMICAL", 133, 149], ["HEV", "ORGANISM", 37, 40], ["SFV", "ORGANISM", 42, 45], ["human", "ORGANISM", 51, 56], ["MDO1", "GENE_OR_GENE_PRODUCT", 57, 61], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 103, 118], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 133, 148], ["human", "ORGANISM", 317, 322], ["MDO1", "GENE_OR_GENE_PRODUCT", 323, 327], ["SFV", "ORGANISM", 332, 335], ["macro domains", "PROTEIN", 10, 23], ["human MDO1", "PROTEIN", 51, 61], ["hydrolytic enzymes", "PROTEIN", 74, 92], ["poly(ADP-ribose)binding modules", "PROTEIN", 133, 164], ["ligandbinding pockets", "PROTEIN", 292, 313], ["human MDO1", "PROTEIN", 317, 327], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 317, 322], ["HEV", "SPECIES", 37, 40], ["SFV", "SPECIES", 42, 45], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 317, 322], ["the macro domains", "TEST", 6, 23], ["HEV", "PROBLEM", 37, 40], ["human MDO1", "TEST", 51, 61], ["hydrolytic enzymes", "TEST", 74, 92], ["poly(ADP-ribose", "TREATMENT", 103, 118], ["specific poly(ADP-ribose)binding modules", "PROBLEM", 124, 164], ["human MDO1", "TREATMENT", 317, 327], ["SFV", "ANATOMY", 42, 45], ["active", "OBSERVATION_MODIFIER", 184, 190]]], ["The sites for two mutations in both proteins were selected so that by replacing highly conserved glycine residues (which flank the pocket) with a larger amino acid (tyrosine), the narrow binding pocket might become physically blocked (Fig. 4 ).", [["glycine", "CHEMICAL", 97, 104], ["amino acid", "CHEMICAL", 153, 163], ["tyrosine", "CHEMICAL", 165, 173], ["glycine", "CHEMICAL", 97, 104], ["amino acid", "CHEMICAL", 153, 163], ["tyrosine", "CHEMICAL", 165, 173], ["glycine", "AMINO_ACID", 97, 104], ["amino acid", "AMINO_ACID", 153, 163], ["tyrosine", "AMINO_ACID", 165, 173], ["two mutations in both proteins", "PROBLEM", 14, 44], ["conserved glycine residues", "TREATMENT", 87, 113], ["a larger amino acid (tyrosine", "TREATMENT", 144, 173], ["the narrow binding pocket", "PROBLEM", 176, 201], ["glycine residues", "OBSERVATION", 97, 113]]], ["In addition, some of the other conserved amino acids in SFV macro ligand-binding pocket were mutated (Fig. 1a) .", [["amino acids", "CHEMICAL", 41, 52], ["amino acids", "CHEMICAL", 41, 52], ["amino acids", "AMINO_ACID", 41, 52], ["SFV", "ORGANISM", 56, 59], ["SFV macro ligand-binding pocket", "PROTEIN", 56, 87], ["amino acids", "TREATMENT", 41, 52], ["binding pocket", "PROBLEM", 73, 87], ["amino acids", "OBSERVATION", 41, 52], ["binding pocket", "OBSERVATION", 73, 87]]], ["The mutant proteins were tested for ADPR-1\u2033P hydrolysis and for binding of ADP-ribose and poly(ADPribose).", [["ADP-ribose", "CHEMICAL", 75, 85], ["poly", "CHEMICAL", 90, 94], ["ADPribose", "CHEMICAL", 95, 104], ["ADP", "CHEMICAL", 75, 78], ["ribose", "CHEMICAL", 79, 85], ["poly(ADPribose)", "CHEMICAL", 90, 105], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 36, 42], ["ADP-ribose", "SIMPLE_CHEMICAL", 75, 85], ["poly(ADPribose", "SIMPLE_CHEMICAL", 90, 104], ["mutant proteins", "PROTEIN", 4, 19], ["ADPR", "PROTEIN", 36, 40], ["P", "DNA", 43, 44], ["The mutant proteins", "TEST", 0, 19], ["ADPR", "TEST", 36, 40], ["P hydrolysis", "TREATMENT", 43, 55], ["ADP", "PROBLEM", 75, 78], ["ribose and poly(ADPribose)", "TREATMENT", 79, 105]]], ["Several of the single-point mutations were sufficient to inactivate ADP-ribose binding and ADPR-1\u2033P hydrolysis.", [["ADP", "CHEMICAL", 68, 71], ["ribose", "CHEMICAL", 72, 78], ["ADP", "CHEMICAL", 68, 71], ["ribose", "CHEMICAL", 72, 78], ["ADPR-1\u2033P", "CHEMICAL", 91, 99], ["ADP-ribose", "SIMPLE_CHEMICAL", 68, 78], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 91, 99], ["the single-point mutations", "PROBLEM", 11, 37], ["ADP", "TEST", 68, 71], ["ribose binding", "PROBLEM", 72, 86], ["ADPR", "TEST", 91, 95], ["P hydrolysis", "TREATMENT", 98, 110]]], ["Mutations G182Y and G270Y in MDO1 inactivated ADP-ribose binding and ADPR-1\u2033P hydrolysis reactions, and the corresponding mutations in SFV macro (G32Y and G112Y) also totally abolished ADPR-1\u2033P hydrolysis ( Table 2 ).", [["ADP", "CHEMICAL", 46, 49], ["ADPR", "CHEMICAL", 185, 189], ["ADP", "CHEMICAL", 46, 49], ["ribose", "CHEMICAL", 50, 56], ["ADPR-1\u2033P", "CHEMICAL", 185, 193], ["ADP-ribose", "GENE_OR_GENE_PRODUCT", 46, 56], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 69, 75], ["SFV", "ORGANISM", 135, 138], ["ADPR", "SIMPLE_CHEMICAL", 185, 189], ["MDO1", "PROTEIN", 29, 33], ["P", "DNA", 76, 77], ["ADPR", "TEST", 69, 73], ["P hydrolysis reactions", "PROBLEM", 76, 98], ["the corresponding mutations", "PROBLEM", 104, 131], ["ADPR", "TEST", 185, 189]]], ["The ADP-ribose binding of SFV macro mutants was not tested, as no binding was detected for the wild-type protein.", [["ADP", "CHEMICAL", 4, 7], ["ribose", "CHEMICAL", 8, 14], ["ADP", "CHEMICAL", 4, 7], ["ribose", "CHEMICAL", 8, 14], ["ADP", "SIMPLE_CHEMICAL", 4, 7], ["ribose", "SIMPLE_CHEMICAL", 8, 14], ["SFV", "ORGANISM", 26, 29], ["SFV macro mutants", "PROTEIN", 26, 43], ["wild-type protein", "PROTEIN", 95, 112], ["The ADP", "TEST", 0, 7], ["ribose binding of SFV macro mutants", "PROBLEM", 8, 43], ["ribose binding", "OBSERVATION", 8, 22]]], ["Most macro domains contain a stretch of three glycines (residues 180-182 in MDO1), but SFV macro has an aspartate in the central position (Fig. 1a ).", [["aspartate", "CHEMICAL", 104, 113], ["aspartate", "CHEMICAL", 104, 113], ["MDO1", "GENE_OR_GENE_PRODUCT", 76, 80], ["aspartate", "SIMPLE_CHEMICAL", 104, 113], ["MDO1", "PROTEIN", 76, 80], ["SFV", "SPECIES", 87, 90], ["a stretch of three glycines", "TREATMENT", 27, 54], ["stretch", "OBSERVATION_MODIFIER", 29, 36], ["aspartate", "OBSERVATION_MODIFIER", 104, 113], ["central", "OBSERVATION_MODIFIER", 121, 128], ["position", "OBSERVATION_MODIFIER", 129, 137]]], ["An attempt to return to the consensus sequence by mutation of this aspartate to glycine further reduced the small ADPR-1\u2033P hydrolysis activity of SFV macro, and, for MDO1, an acidic residue (glutamate) was detrimental in this position ( Table 2) .", [["aspartate", "CHEMICAL", 67, 76], ["glycine", "CHEMICAL", 80, 87], ["glutamate", "CHEMICAL", 191, 200], ["aspartate", "CHEMICAL", 67, 76], ["glycine", "CHEMICAL", 80, 87], ["glutamate", "CHEMICAL", 191, 200], ["aspartate", "AMINO_ACID", 67, 76], ["glycine", "AMINO_ACID", 80, 87], ["SFV", "ORGANISM", 146, 149], ["MDO1", "SIMPLE_CHEMICAL", 166, 170], ["glutamate", "SIMPLE_CHEMICAL", 191, 200], ["consensus sequence", "DNA", 28, 46], ["P", "DNA", 121, 122], ["MDO1", "PROTEIN", 166, 170], ["SFV", "SPECIES", 146, 149], ["this aspartate to glycine", "TREATMENT", 62, 87], ["SFV macro", "TREATMENT", 146, 155], ["MDO1", "TREATMENT", 166, 170], ["an acidic residue", "PROBLEM", 172, 189], ["acidic residue", "OBSERVATION", 175, 189]]], ["Mutations in the other tested positions of SFV macro abolished the enzymatic activity of the protein ( Table 2) .Mutagenesis of the active siteNone of the mutations affected poly(ADP-ribose) binding (Table 2 ; two mutants are also illustrated in Fig. 3b ).", [["poly(ADP-ribose", "CHEMICAL", 174, 189], ["poly(ADP-ribose)", "CHEMICAL", 174, 190], ["SFV", "ORGANISM", 43, 46], ["poly(ADP-ribose) binding (Table 2", "GENE_OR_GENE_PRODUCT", 174, 207], ["Mutations", "PROBLEM", 0, 9], ["the mutations", "PROBLEM", 151, 164], ["ADP-ribose)", "TREATMENT", 179, 190], ["enzymatic activity", "OBSERVATION", 67, 85], ["active", "OBSERVATION_MODIFIER", 132, 138]]], ["This could be explained by the interaction of poly(ADP-ribose) with additional extensive sites on the surface of the macro domain outside of the deep pocket that binds monomeric ADP-ribose, as suggested.", [["surface", "ANATOMY", 102, 109], ["poly(ADP-ribose", "CHEMICAL", 46, 61], ["ADP-ribose", "CHEMICAL", 178, 188], ["poly(ADP-ribose)", "CHEMICAL", 46, 62], ["ADP", "CHEMICAL", 178, 181], ["ribose", "CHEMICAL", 182, 188], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 46, 61], ["surface", "CELLULAR_COMPONENT", 102, 109], ["ADP-ribose", "SIMPLE_CHEMICAL", 178, 188], ["macro domain", "PROTEIN", 117, 129], ["poly(ADP-ribose)", "TREATMENT", 46, 62], ["additional extensive sites", "TREATMENT", 68, 94], ["the deep pocket", "PROBLEM", 141, 156], ["monomeric ADP-ribose", "TREATMENT", 168, 188], ["could be explained", "UNCERTAINTY", 5, 23], ["extensive", "OBSERVATION_MODIFIER", 79, 88], ["sites", "OBSERVATION_MODIFIER", 89, 94], ["deep", "ANATOMY_MODIFIER", 145, 149], ["pocket", "ANATOMY_MODIFIER", 150, 156]]], ["6 However, it was surprising that none of the mutants could even noticeably reduce poly (ADP-ribose) binding, as examined by filter binding assay.", [["poly (ADP-ribose", "CHEMICAL", 83, 99], ["poly (ADP-ribose)", "CHEMICAL", 83, 100], ["ADP", "SIMPLE_CHEMICAL", 89, 92], ["poly (ADP-ribose) binding", "PROBLEM", 83, 108]]], ["For instance, mutating either of the glycines (G182 and G270 in MDO1) flanking the binding pocket to tyrosine residues totally abolished ADPribose binding, possibly by physically blocking the binding pocket.", [["tyrosine", "CHEMICAL", 101, 109], ["ADPribose", "CHEMICAL", 137, 146], ["tyrosine", "CHEMICAL", 101, 109], ["ADPribose", "CHEMICAL", 137, 146], ["tyrosine", "AMINO_ACID", 101, 109], ["ADPribose", "SIMPLE_CHEMICAL", 137, 146], ["MDO1", "PROTEIN", 64, 68], ["the binding pocket", "PROBLEM", 79, 97], ["tyrosine residues", "TREATMENT", 101, 118], ["ADPribose binding", "PROBLEM", 137, 154]]], ["Furthermore, combining these two mutations (G182Y + G270Y) did not have an effect on poly(ADP-ribose) binding (Fig. 3b) , even when the filter was washed under more stringent conditions (1 M NaCl) (not shown).", [["poly(ADP-ribose", "CHEMICAL", 85, 100], ["NaCl", "CHEMICAL", 191, 195], ["poly(ADP-ribose)", "CHEMICAL", 85, 101], ["NaCl", "CHEMICAL", 191, 195], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 85, 101], ["poly(ADP-ribose)", "TREATMENT", 85, 101], ["the filter", "TREATMENT", 132, 142]]], ["Thus, it seems that poly(ADP-ribose) binding is a relatively robust property of those macro domains that show an affinity for it.Subcellular localization of human macro proteinsThe macroH2A and BAL families of proteins are known to localize to the nucleus and to function in transcriptional regulation.", [["Subcellular", "ANATOMY", 129, 140], ["nucleus", "ANATOMY", 248, 255], ["poly(ADP-ribose", "CHEMICAL", 20, 35], ["poly(ADP-ribose)", "CHEMICAL", 20, 36], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 20, 36], ["human", "ORGANISM", 157, 162], ["macroH2A", "GENE_OR_GENE_PRODUCT", 181, 189], ["nucleus", "CELLULAR_COMPONENT", 248, 255], ["macro domains", "PROTEIN", 86, 99], ["human macro proteins", "PROTEIN", 157, 177], ["macroH2A and BAL families", "PROTEIN", 181, 206], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["poly(ADP-ribose) binding", "PROBLEM", 20, 44], ["The macroH2A", "TEST", 177, 189], ["BAL", "OBSERVATION", 194, 197], ["nucleus", "ANATOMY", 248, 255]]], ["8, 10, 14 As the virusencoded macro domain proteins function in theSubcellular localization of human macro proteinsADPR-1\u2033P hydrolysis was tested at 28\u00b0C and detected by TLC.", [["human", "ORGANISM", 95, 100], ["macro proteinsADPR-1", "GENE_OR_GENE_PRODUCT", 101, 121], ["C", "GENE_OR_GENE_PRODUCT", 152, 153], ["virusencoded macro domain proteins", "PROTEIN", 17, 51], ["human macro proteinsADPR", "PROTEIN", 95, 119], ["P", "DNA", 122, 123], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["the virusencoded macro domain proteins function", "TEST", 13, 60], ["proteinsADPR", "TEST", 107, 119], ["P hydrolysis", "TEST", 122, 134], ["TLC", "TEST", 170, 173], ["TLC", "ANATOMY", 170, 173]]], ["Hydrolysis activity was classified as moderate (++), poor (+), or none (\u2212).", [["Hydrolysis activity", "TEST", 0, 19]]], ["ADP-ribose binding was measured by isothermal titration calorimetry at 30\u00b0C. Binding of poly(ADP-ribose) and poly(A) was detected by filter binding assays with a 32 P-labeled ligand and classified as efficient (+) or inefficient (\u2212).", [["ADP", "CHEMICAL", 0, 3], ["ribose", "CHEMICAL", 4, 10], ["poly(ADP-ribose", "CHEMICAL", 88, 103], ["poly(A", "CHEMICAL", 109, 115], ["ADP", "CHEMICAL", 0, 3], ["ribose", "CHEMICAL", 4, 10], ["poly(ADP-ribose)", "CHEMICAL", 88, 104], ["poly(A)", "CHEMICAL", 109, 116], ["ADP-ribose", "SIMPLE_CHEMICAL", 0, 10], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 88, 103], ["poly(A", "SIMPLE_CHEMICAL", 109, 115], ["ADP-ribose binding", "PROBLEM", 0, 18], ["isothermal titration calorimetry", "TREATMENT", 35, 67], ["Binding of poly(ADP-ribose", "TREATMENT", 77, 103], ["ribose binding", "OBSERVATION", 4, 18]]], ["NB, nonbinding; ND, not determined. a Data from Egloff et al. 6 cytosol, we were interested to know whether some of their human counterparts would also reside in the cytosolic compartment.", [["cytosolic compartment", "ANATOMY", 166, 187], ["NB", "CANCER", 0, 2], ["cytosol", "ORGANISM_SUBSTANCE", 64, 71], ["human", "ORGANISM", 122, 127], ["cytosolic compartment", "CELLULAR_COMPONENT", 166, 187], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["ND", "PROBLEM", 16, 18], ["cytosolic compartment", "ANATOMY", 166, 187]]], ["We expressed MDO1, MDO2, and GDAP2 in HeLa cells as C-terminally myc-tagged or enhanced green fluorescent protein (EGFP)-tagged proteins.", [["HeLa cells", "ANATOMY", 38, 48], ["MDO1", "GENE_OR_GENE_PRODUCT", 13, 17], ["MDO2", "GENE_OR_GENE_PRODUCT", 19, 23], ["GDAP2", "GENE_OR_GENE_PRODUCT", 29, 34], ["HeLa cells", "CELL", 38, 48], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 88, 113], ["EGFP", "GENE_OR_GENE_PRODUCT", 115, 119], ["MDO1", "PROTEIN", 13, 17], ["MDO2", "PROTEIN", 19, 23], ["GDAP2", "PROTEIN", 29, 34], ["HeLa cells", "CELL_LINE", 38, 48], ["C-terminally myc-tagged", "PROTEIN", 52, 75], ["enhanced green fluorescent protein (EGFP)-tagged proteins", "PROTEIN", 79, 136], ["C-terminally myc-tagged", "PROBLEM", 52, 75]]], ["Two constructs, encoding either the full-length protein or the macro domain only, were made for each (see Materials and Methods).", [["full-length protein", "PROTEIN", 36, 55], ["macro domain", "PROTEIN", 63, 75]]], ["The myc antibodies failed to recognize the expressed proteins on Western blot analysis.", [["myc antibodies", "GENE_OR_GENE_PRODUCT", 4, 18], ["myc antibodies", "PROTEIN", 4, 18], ["The myc antibodies", "PROBLEM", 0, 18], ["blot analysis", "TEST", 73, 86], ["myc antibodies", "OBSERVATION", 4, 18]]], ["However, the macro proteins fused to EGFP were readily expressed, and proteins of the expected size were detected by Western blot analysis with EGFP antibodies (Fig. 5a) .", [["EGFP", "GENE_OR_GENE_PRODUCT", 37, 41], ["EGFP antibodies", "GENE_OR_GENE_PRODUCT", 144, 159], ["macro proteins", "PROTEIN", 13, 27], ["EGFP", "PROTEIN", 37, 41], ["EGFP antibodies", "PROTEIN", 144, 159], ["the macro proteins", "TEST", 9, 27], ["EGFP", "TEST", 37, 41], ["blot analysis", "TEST", 125, 138], ["EGFP antibodies", "TEST", 144, 159], ["size", "OBSERVATION_MODIFIER", 95, 99]]], ["In the case of full-length MDO1-EGFP, besides the protein of expected size (62 kDa), an additional smaller protein of \u223c 56 kDa-corresponding to roughly 29 kDa for the MDO1 portion when the mass of EGFP was subtracted-was also detected.", [["MDO1", "GENE_OR_GENE_PRODUCT", 27, 31], ["EGFP", "GENE_OR_GENE_PRODUCT", 32, 36], ["MDO1", "GENE_OR_GENE_PRODUCT", 167, 171], ["EGFP", "GENE_OR_GENE_PRODUCT", 197, 201], ["MDO1", "DNA", 27, 31], ["EGFP", "DNA", 32, 36], ["MDO1 portion", "PROTEIN", 167, 179], ["EGFP", "PROTEIN", 197, 201], ["the protein", "TEST", 46, 57], ["kDa", "TEST", 79, 82], ["an additional smaller protein", "TEST", 85, 114], ["the mass of EGFP", "PROBLEM", 185, 201], ["size", "OBSERVATION_MODIFIER", 70, 74], ["mass", "OBSERVATION", 189, 193]]], ["Similarly, two bands of \u223c 36 and \u223c 30 kDa were detected when MDO1myc was expressed and detected by anti-MDO1 antibodies (not shown).Subcellular localization of human macro proteinsFor immunofluorescence, HeLa cells were transfected with EGFP fusion constructs and, in the case of MDO1, also with myc fusion for detection by anti-MDO1 antibody.", [["Subcellular", "ANATOMY", 132, 143], ["HeLa cells", "ANATOMY", 204, 214], ["MDO1myc", "GENE_OR_GENE_PRODUCT", 61, 68], ["anti-MDO1 antibodies", "GENE_OR_GENE_PRODUCT", 99, 119], ["human", "ORGANISM", 160, 165], ["HeLa cells", "CELL", 204, 214], ["EGFP", "GENE_OR_GENE_PRODUCT", 237, 241], ["MDO1", "GENE_OR_GENE_PRODUCT", 280, 284], ["myc", "GENE_OR_GENE_PRODUCT", 296, 299], ["anti-MDO1 antibody", "GENE_OR_GENE_PRODUCT", 324, 342], ["MDO1myc", "PROTEIN", 61, 68], ["anti-MDO1 antibodies", "PROTEIN", 99, 119], ["human macro proteins", "PROTEIN", 160, 180], ["HeLa cells", "CELL_LINE", 204, 214], ["EGFP fusion constructs", "DNA", 237, 259], ["MDO1", "PROTEIN", 280, 284], ["anti-MDO1 antibody", "PROTEIN", 324, 342], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["two bands", "TEST", 11, 20], ["MDO1myc", "TEST", 61, 68], ["anti-MDO1 antibodies", "TEST", 99, 119], ["human macro proteins", "TEST", 160, 180], ["immunofluorescence", "TEST", 184, 202], ["HeLa cells", "PROBLEM", 204, 214], ["EGFP fusion constructs", "TREATMENT", 237, 259], ["myc fusion", "TREATMENT", 296, 306], ["anti-MDO1 antibody", "TEST", 324, 342], ["two", "OBSERVATION_MODIFIER", 11, 14], ["bands", "OBSERVATION_MODIFIER", 15, 20]]], ["The transfected cells were studied by immunofluorescence at 6 h and 18 h posttransfection.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["transfected cells", "CELL_LINE", 4, 21], ["The transfected cells", "PROBLEM", 0, 21], ["immunofluorescence", "TEST", 38, 56], ["transfected cells", "OBSERVATION", 4, 21]]], ["At both time points, MDO1 showed bright staining of specific and abundant organelles, which were confirmed as mitochondria, using anti-MDO1 antibody together with yellow fluorescent protein (YFP) linked to a mitochondrial localization signal (Fig. 5b) .", [["organelles", "ANATOMY", 74, 84], ["mitochondria", "ANATOMY", 110, 122], ["mitochondrial", "ANATOMY", 208, 221], ["MDO1", "SIMPLE_CHEMICAL", 21, 25], ["organelles", "CELLULAR_COMPONENT", 74, 84], ["mitochondria", "CELLULAR_COMPONENT", 110, 122], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 163, 189], ["YFP", "GENE_OR_GENE_PRODUCT", 191, 194], ["mitochondrial", "CELLULAR_COMPONENT", 208, 221], ["MDO1", "PROTEIN", 21, 25], ["anti-MDO1 antibody", "PROTEIN", 130, 148], ["yellow fluorescent protein", "PROTEIN", 163, 189], ["YFP", "PROTEIN", 191, 194], ["MDO1", "TEST", 21, 25], ["bright staining of specific and abundant organelles", "PROBLEM", 33, 84], ["anti-MDO1 antibody", "TEST", 130, 148], ["yellow fluorescent protein", "TEST", 163, 189], ["a mitochondrial localization signal", "TEST", 206, 241], ["bright staining", "OBSERVATION", 33, 48]]], ["This localization was identical independently of the vector used (EGFP fusion and myctagged).", [["EGFP", "GENE_OR_GENE_PRODUCT", 66, 70], ["EGFP fusion", "DNA", 66, 77], ["EGFP fusion", "TREATMENT", 66, 77]]], ["Notably, a faint staining of the mitochondria was also observed when untransfected HeLa cells were stained with anti-MDO1 antibodies (not shown), suggesting that endogenous MDO1 is The residues corresponding to the additionally mutated sites in SFV are also seen in this rendering: residues D10, N21, and N24 in the SFV sequence correspond to MDO1 D160, N171, and N174, respectively.Subcellular localization of human macro proteinsADPR-1\u2033P hydrolysis was tested at 28\u00b0C and detected by TLC.", [["mitochondria", "ANATOMY", 33, 45], ["HeLa cells", "ANATOMY", 83, 93], ["Subcellular", "ANATOMY", 383, 394], ["mitochondria", "CELLULAR_COMPONENT", 33, 45], ["HeLa cells", "CELL", 83, 93], ["anti-MDO1 antibodies", "GENE_OR_GENE_PRODUCT", 112, 132], ["MDO1", "GENE_OR_GENE_PRODUCT", 173, 177], ["SFV", "ORGANISM", 245, 248], ["N21", "GENE_OR_GENE_PRODUCT", 296, 299], ["N24", "GENE_OR_GENE_PRODUCT", 305, 308], ["SFV", "ORGANISM", 316, 319], ["human", "ORGANISM", 411, 416], ["macro proteinsADPR-1", "GENE_OR_GENE_PRODUCT", 417, 437], ["C", "GENE_OR_GENE_PRODUCT", 468, 469], ["untransfected HeLa cells", "CELL_LINE", 69, 93], ["anti-MDO1 antibodies", "PROTEIN", 112, 132], ["MDO1", "PROTEIN", 173, 177], ["MDO1", "PROTEIN", 343, 347], ["N174", "PROTEIN", 364, 368], ["human macro proteinsADPR", "PROTEIN", 411, 435], ["P", "DNA", 438, 439], ["human", "SPECIES", 411, 416], ["SFV", "SPECIES", 245, 248], ["human", "SPECIES", 411, 416], ["a faint staining of the mitochondria", "PROBLEM", 9, 45], ["untransfected HeLa cells", "PROBLEM", 69, 93], ["anti-MDO1 antibodies", "TEST", 112, 132], ["endogenous MDO1", "PROBLEM", 162, 177], ["The residues", "PROBLEM", 181, 193], ["the additionally mutated sites in SFV", "PROBLEM", 211, 248], ["N21", "TREATMENT", 296, 299], ["N24", "TREATMENT", 305, 308], ["human macro proteinsADPR", "TEST", 411, 435], ["P hydrolysis", "TEST", 438, 450], ["TLC", "TEST", 486, 489], ["faint", "OBSERVATION_MODIFIER", 11, 16], ["staining", "OBSERVATION", 17, 25], ["SFV", "ANATOMY", 245, 248], ["SFV", "ANATOMY", 316, 319], ["TLC", "ANATOMY", 486, 489]]], ["Hydrolysis activity was classified as moderate (++), poor (+), very weak (\u00b1), or none (\u2212).", [["Hydrolysis activity", "TEST", 0, 19], ["very weak (\u00b1)", "PROBLEM", 63, 76], ["moderate", "OBSERVATION_MODIFIER", 38, 46]]], ["ADP-ribose binding was measured by isothermal titration calorimetry at 30\u00b0C. Poly(ADP-ribose) binding was detected by filter binding assays with 32 P-labeled poly(ADP-ribose) and classified as efficient (+) or inefficient (\u2212).", [["ADP", "CHEMICAL", 0, 3], ["ribose", "CHEMICAL", 4, 10], ["Poly(ADP-ribose", "CHEMICAL", 77, 92], ["poly(ADP-ribose", "CHEMICAL", 158, 173], ["ADP", "CHEMICAL", 0, 3], ["ribose", "CHEMICAL", 4, 10], ["Poly(ADP-ribose)", "CHEMICAL", 77, 93], ["poly(ADP-ribose)", "CHEMICAL", 158, 174], ["ADP-ribose", "SIMPLE_CHEMICAL", 0, 10], ["Poly(ADP-ribose", "SIMPLE_CHEMICAL", 77, 92], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 158, 173], ["ADP-ribose binding", "PROBLEM", 0, 18], ["isothermal titration calorimetry", "TREATMENT", 35, 67], ["Poly(ADP-ribose) binding", "TREATMENT", 77, 101], ["labeled poly(ADP-ribose", "TREATMENT", 150, 173], ["ribose binding", "OBSERVATION", 4, 18]]], ["NB, nonbinding; ND, not determined. expressed and present in the mitochondria at low levels.Subcellular localization of human macro proteinsThe smaller band detected for MDO1 by Western blot analysis could indicate either translation initiation from the second in-frame methionine (Met83) in the MDO1 gene (yielding a 243-aa protein) or proteolytic cleavage of the full-length protein.", [["mitochondria", "ANATOMY", 65, 77], ["Subcellular", "ANATOMY", 92, 103], ["methionine", "CHEMICAL", 270, 280], ["methionine", "CHEMICAL", 270, 280], ["Met83", "CHEMICAL", 282, 287], ["NB", "CANCER", 0, 2], ["mitochondria", "CELLULAR_COMPONENT", 65, 77], ["human", "ORGANISM", 120, 125], ["MDO1", "GENE_OR_GENE_PRODUCT", 170, 174], ["methionine", "AMINO_ACID", 270, 280], ["Met83", "AMINO_ACID", 282, 287], ["MDO1", "GENE_OR_GENE_PRODUCT", 296, 300], ["human macro proteins", "PROTEIN", 120, 140], ["MDO1", "PROTEIN", 170, 174], ["MDO1 gene", "DNA", 296, 305], ["243-aa protein", "PROTEIN", 318, 332], ["full-length protein", "PROTEIN", 365, 384], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["ND", "PROBLEM", 16, 18], ["The smaller band", "PROBLEM", 140, 156], ["Western blot analysis", "TEST", 178, 199], ["proteolytic cleavage", "PROBLEM", 337, 357], ["the full-length protein", "TREATMENT", 361, 384], ["smaller", "OBSERVATION_MODIFIER", 144, 151], ["band", "OBSERVATION_MODIFIER", 152, 156]]], ["The localization of MDO1 in mitochondria led us to suspect the latter possibility, as it is common that mitochondrial import sequence is cleaved after transport to the mitochondria.", [["mitochondria", "ANATOMY", 28, 40], ["mitochondrial", "ANATOMY", 104, 117], ["mitochondria", "ANATOMY", 168, 180], ["MDO1", "GENE_OR_GENE_PRODUCT", 20, 24], ["mitochondria", "CELLULAR_COMPONENT", 28, 40], ["mitochondrial", "CELLULAR_COMPONENT", 104, 117], ["mitochondria", "CELLULAR_COMPONENT", 168, 180], ["MDO1", "PROTEIN", 20, 24], ["mitochondrial import sequence", "PROTEIN", 104, 133]]], ["The MDO1 protein sequence was analyzed with the MitoProt program, 31 which predicted export to the mitochondria with a probability of 0.99.", [["mitochondria", "ANATOMY", 99, 111], ["MDO1", "GENE_OR_GENE_PRODUCT", 4, 8], ["mitochondria", "CELLULAR_COMPONENT", 99, 111], ["MDO1 protein sequence", "DNA", 4, 25], ["The MDO1 protein sequence", "TEST", 0, 25]]], ["The predicted import sequence was 77 aa long, the cleavage of which would result in a mature protein of 248 aa in the mitochondria.", [["mitochondria", "ANATOMY", 118, 130], ["mitochondria", "CELLULAR_COMPONENT", 118, 130], ["mature protein", "PROTEIN", 86, 100], ["a mature protein", "TEST", 84, 100]]], ["To support the presence of a mitochondrial import sequence, we additionally expressed in HeLa cells a construct comprising the last 243 aa of MDO1.", [["mitochondrial", "ANATOMY", 29, 42], ["HeLa cells", "ANATOMY", 89, 99], ["mitochondrial", "CELLULAR_COMPONENT", 29, 42], ["HeLa cells", "CELL", 89, 99], ["MDO1", "GENE_OR_GENE_PRODUCT", 142, 146], ["mitochondrial import sequence", "PROTEIN", 29, 58], ["HeLa cells", "CELL_LINE", 89, 99], ["MDO1", "PROTEIN", 142, 146]]], ["Expression in this construct was initiated from the second in-frame methionine and resulted in an evenly distributed cytoplasmic protein (Fig. 5c) , which was sometimes concentrated in large aggregate-like structures at later time points (not shown), and no colocalization with the mitochondria was detected.", [["cytoplasmic", "ANATOMY", 117, 128], ["aggregate-like structures", "ANATOMY", 191, 216], ["mitochondria", "ANATOMY", 282, 294], ["methionine", "CHEMICAL", 68, 78], ["methionine", "CHEMICAL", 68, 78], ["methionine", "SIMPLE_CHEMICAL", 68, 78], ["cytoplasmic", "ORGANISM_SUBSTANCE", 117, 128], ["mitochondria", "CELLULAR_COMPONENT", 282, 294], ["cytoplasmic protein", "PROTEIN", 117, 136], ["Fig. 5c", "PROTEIN", 138, 145], ["methionine", "TREATMENT", 68, 78], ["an evenly distributed cytoplasmic protein", "PROBLEM", 95, 136], ["large aggregate-like structures", "PROBLEM", 185, 216], ["cytoplasmic protein", "OBSERVATION", 117, 136], ["concentrated", "OBSERVATION_MODIFIER", 169, 181], ["large", "OBSERVATION_MODIFIER", 185, 190], ["aggregate", "OBSERVATION_MODIFIER", 191, 200]]], ["Therefore, it is likely that MDO1 is initially expressed in the cells as a 325-aa protein, which is transported to the mitochondria and cleaved by mitochondrial enzymes to result in the shorter protein.Subcellular localization of human macro proteinsMDO2-EGFP and GDAP2-EGFP proteins showed an even distribution throughout the cytoplasm and nucleus (Fig. 5d and e) .", [["cells", "ANATOMY", 64, 69], ["mitochondria", "ANATOMY", 119, 131], ["mitochondrial", "ANATOMY", 147, 160], ["Subcellular", "ANATOMY", 202, 213], ["cytoplasm", "ANATOMY", 327, 336], ["nucleus", "ANATOMY", 341, 348], ["MDO1", "GENE_OR_GENE_PRODUCT", 29, 33], ["cells", "CELL", 64, 69], ["mitochondria", "CELLULAR_COMPONENT", 119, 131], ["mitochondrial", "CELLULAR_COMPONENT", 147, 160], ["human", "ORGANISM", 230, 235], ["MDO2", "GENE_OR_GENE_PRODUCT", 250, 254], ["EGFP", "GENE_OR_GENE_PRODUCT", 255, 259], ["GDAP2-EGFP", "GENE_OR_GENE_PRODUCT", 264, 274], ["cytoplasm", "ORGANISM_SUBSTANCE", 327, 336], ["nucleus", "CELLULAR_COMPONENT", 341, 348], ["MDO1", "PROTEIN", 29, 33], ["325-aa protein", "PROTEIN", 75, 89], ["mitochondrial enzymes", "PROTEIN", 147, 168], ["human macro proteins", "PROTEIN", 230, 250], ["MDO2", "PROTEIN", 250, 254], ["EGFP", "PROTEIN", 255, 259], ["GDAP2", "PROTEIN", 264, 269], ["EGFP proteins", "PROTEIN", 270, 283], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 230, 235], ["mitochondrial enzymes", "TEST", 147, 168], ["the shorter protein", "PROBLEM", 182, 201], ["human macro proteins", "TEST", 230, 250], ["MDO2", "TEST", 250, 254], ["EGFP", "TEST", 255, 259], ["GDAP2", "TEST", 264, 269], ["EGFP proteins", "TEST", 270, 283], ["is likely", "UNCERTAINTY", 14, 23], ["even distribution", "OBSERVATION", 294, 311], ["nucleus", "ANATOMY", 341, 348]]], ["This localization was identical for the full-length protein and the smaller macro core units fused to EGFP (not shown).", [["EGFP", "GENE_OR_GENE_PRODUCT", 102, 106], ["full-length protein", "PROTEIN", 40, 59], ["macro core units", "DNA", 76, 92], ["EGFP", "PROTEIN", 102, 106], ["the full-length protein", "TREATMENT", 36, 59], ["EGFP", "TEST", 102, 106], ["smaller", "OBSERVATION_MODIFIER", 68, 75]]], ["Thus, the localization of the proteins was not affected by the predicted Sec14 domain in GDAP2 or the \u223c 190aa unique sequence in the MDO2 C-terminus.", [["C", "CHEMICAL", 138, 139], ["Sec14", "GENE_OR_GENE_PRODUCT", 73, 78], ["GDAP2", "GENE_OR_GENE_PRODUCT", 89, 94], ["Sec14 domain", "PROTEIN", 73, 85], ["GDAP2", "PROTEIN", 89, 94], ["\u223c 190aa unique sequence", "PROTEIN", 102, 125], ["MDO2 C-terminus", "PROTEIN", 133, 148]]], ["Based on these results, MDO2 and GDAP2 are the first macro domain proteins to be found in the cytosol and the first macro domain proteins that could potentially be shuttling to and from the nucleus.DiscussionIn this study, we characterized the biochemical functions of small human macro domain proteins, which turned out to have rather distinct properties compared to one another.", [["cytosol", "ANATOMY", 94, 101], ["nucleus", "ANATOMY", 190, 197], ["MDO2", "GENE_OR_GENE_PRODUCT", 24, 28], ["GDAP2", "GENE_OR_GENE_PRODUCT", 33, 38], ["cytosol", "CELLULAR_COMPONENT", 94, 101], ["nucleus", "CELLULAR_COMPONENT", 190, 197], ["human", "ORGANISM", 275, 280], ["MDO2", "PROTEIN", 24, 28], ["GDAP2", "PROTEIN", 33, 38], ["macro domain proteins", "PROTEIN", 53, 74], ["macro domain proteins", "PROTEIN", 116, 137], ["small human macro domain proteins", "PROTEIN", 269, 302], ["human", "SPECIES", 275, 280], ["human", "SPECIES", 275, 280], ["MDO2", "TEST", 24, 28], ["GDAP2", "TREATMENT", 33, 38], ["the cytosol", "TEST", 90, 101], ["this study", "TEST", 211, 221], ["small human macro domain proteins", "PROBLEM", 269, 302], ["could potentially be", "UNCERTAINTY", 143, 163], ["nucleus", "ANATOMY", 190, 197], ["small", "OBSERVATION_MODIFIER", 269, 274]]], ["This study revealed new types of human macro domain proteins: two cytosolic/nuclear macro proteins MDO2 and GDAP2, one of which (GDAP2) contains the first macro domain binding poly(A), but not ADP-ribose derivatives.", [["cytosolic", "ANATOMY", 66, 75], ["nuclear", "ANATOMY", 76, 83], ["ADP", "CHEMICAL", 193, 196], ["ribose", "CHEMICAL", 197, 203], ["poly(A)", "CHEMICAL", 176, 183], ["ADP", "CHEMICAL", 193, 196], ["ribose", "CHEMICAL", 197, 203], ["human", "ORGANISM", 33, 38], ["nuclear", "CELLULAR_COMPONENT", 76, 83], ["MDO2", "GENE_OR_GENE_PRODUCT", 99, 103], ["GDAP2", "GENE_OR_GENE_PRODUCT", 108, 113], ["GDAP2", "GENE_OR_GENE_PRODUCT", 129, 134], ["poly(A)", "SIMPLE_CHEMICAL", 176, 183], ["ADP-ribose derivatives", "SIMPLE_CHEMICAL", 193, 215], ["human macro domain proteins", "PROTEIN", 33, 60], ["cytosolic/nuclear macro proteins", "PROTEIN", 66, 98], ["MDO2", "PROTEIN", 99, 103], ["GDAP2", "PROTEIN", 108, 113], ["GDAP2", "PROTEIN", 129, 134], ["macro domain", "PROTEIN", 155, 167], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["This study", "TEST", 0, 10], ["human macro domain proteins", "PROBLEM", 33, 60], ["GDAP2", "TREATMENT", 108, 113], ["ADP-ribose derivatives", "TREATMENT", 193, 215], ["new", "OBSERVATION_MODIFIER", 20, 23], ["ribose derivatives", "OBSERVATION", 197, 215]]], ["Furthermore, MDO1 was the first macro protein found to localize in mitochondria.", [["mitochondria", "ANATOMY", 67, 79], ["MDO1", "GENE_OR_GENE_PRODUCT", 13, 17], ["mitochondria", "CELLULAR_COMPONENT", 67, 79], ["MDO1", "PROTEIN", 13, 17], ["the first macro protein", "TEST", 22, 45]]], ["We also compared the viral macro domain proteins with their human homologs, expecting that the viral proteins would resemble some of their cellular counterparts and thus putatively influence the same cellular pathways.", [["cellular counterparts", "ANATOMY", 139, 160], ["cellular", "ANATOMY", 200, 208], ["human", "ORGANISM", 60, 65], ["cellular counterparts", "CELL", 139, 160], ["cellular", "CELL", 200, 208], ["viral macro domain proteins", "PROTEIN", 21, 48], ["human homologs", "PROTEIN", 60, 74], ["viral proteins", "PROTEIN", 95, 109], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["the viral proteins", "PROBLEM", 91, 109]]], ["However, the viral macro proteins from SFV, HEV, and SARS-CoV did not show a clear relatedness to any of the cellular proteins studied, but resembled each other in their biochemical properties.", [["cellular", "ANATOMY", 109, 117], ["SFV", "ORGANISM", 39, 42], ["HEV", "ORGANISM", 44, 47], ["SARS-CoV", "ORGANISM", 53, 61], ["cellular", "CELL", 109, 117], ["viral macro proteins", "PROTEIN", 13, 33], ["cellular proteins", "PROTEIN", 109, 126], ["SFV", "SPECIES", 39, 42], ["HEV", "SPECIES", 44, 47], ["SARS-CoV", "SPECIES", 53, 61], ["the viral macro proteins", "TEST", 9, 33], ["SFV", "TEST", 39, 42], ["HEV", "TEST", 44, 47], ["SARS-CoV", "TEST", 53, 61], ["the cellular proteins", "TEST", 105, 126], ["SFV", "ANATOMY", 39, 42]]], ["Based on this study, it seems likely that the functions of the macro domain proteins are more diversified than has been thought before.DiscussionThe human cytosolic macro proteins MDO2 and GDAP2 bound ADP-ribose monomer and poly(A), respectively, but did not bind poly(ADP-ribose).", [["cytosolic", "ANATOMY", 155, 164], ["ADP", "CHEMICAL", 201, 204], ["poly(A", "CHEMICAL", 224, 230], ["poly(ADP-ribose", "CHEMICAL", 264, 279], ["ADP", "CHEMICAL", 201, 204], ["ribose", "CHEMICAL", 205, 211], ["poly(A)", "CHEMICAL", 224, 231], ["poly(ADP-ribose)", "CHEMICAL", 264, 280], ["human", "ORGANISM", 149, 154], ["MDO2", "GENE_OR_GENE_PRODUCT", 180, 184], ["GDAP2", "GENE_OR_GENE_PRODUCT", 189, 194], ["ADP-ribose monomer", "SIMPLE_CHEMICAL", 201, 219], ["poly(A", "SIMPLE_CHEMICAL", 224, 230], ["ADP-ribose", "SIMPLE_CHEMICAL", 269, 279], ["macro domain proteins", "PROTEIN", 63, 84], ["human cytosolic macro proteins", "PROTEIN", 149, 179], ["MDO2", "PROTEIN", 180, 184], ["GDAP2", "PROTEIN", 189, 194], ["human", "SPECIES", 149, 154], ["human", "SPECIES", 149, 154], ["this study", "TEST", 9, 19], ["the macro domain proteins", "PROBLEM", 59, 84], ["GDAP2 bound ADP-ribose monomer and poly(A)", "TREATMENT", 189, 231], ["ADP-ribose", "TREATMENT", 269, 279], ["seems likely", "UNCERTAINTY", 24, 36], ["ribose monomer", "OBSERVATION", 205, 219]]], ["These proteins seem to reside also in the nucleus (EGFP-tagged proteins were detected in both the cytoplasm and the nucleus) and could potentially also participate in nuclear functions such as RNA processing, in addition to cytosolic metabolic/ signaling pathways.", [["nucleus", "ANATOMY", 42, 49], ["cytoplasm", "ANATOMY", 98, 107], ["nucleus", "ANATOMY", 116, 123], ["nuclear", "ANATOMY", 167, 174], ["cytosolic", "ANATOMY", 224, 233], ["nucleus", "CELLULAR_COMPONENT", 42, 49], ["EGFP", "GENE_OR_GENE_PRODUCT", 51, 55], ["cytoplasm", "ORGANISM_SUBSTANCE", 98, 107], ["nucleus", "CELLULAR_COMPONENT", 116, 123], ["nuclear", "CELLULAR_COMPONENT", 167, 174], ["EGFP", "PROTEIN", 51, 55], ["tagged proteins", "PROTEIN", 56, 71], ["These proteins", "TEST", 0, 14], ["tagged proteins", "TEST", 56, 71], ["RNA processing", "PROBLEM", 193, 207], ["cytosolic metabolic/ signaling pathways", "PROBLEM", 224, 263], ["nucleus", "ANATOMY", 42, 49], ["nucleus", "ANATOMY", 116, 123]]], ["The high binding affinity of MDO2 for ADP-ribose, its inability to bind poly (ADP-ribose), and its hydrolysis activity towards ADPR-1\u2033P are all properties that it shares with the yeast Poa1p (Table 1 ).", [["MDO2", "CHEMICAL", 29, 33], ["ADP-ribose", "CHEMICAL", 38, 48], ["poly (ADP-ribose", "CHEMICAL", 72, 88], ["MDO2", "CHEMICAL", 29, 33], ["ADP", "CHEMICAL", 38, 41], ["ribose", "CHEMICAL", 42, 48], ["poly (ADP-ribose)", "CHEMICAL", 72, 89], ["ADPR-1\u2033P", "CHEMICAL", 127, 135], ["MDO2", "SIMPLE_CHEMICAL", 29, 33], ["ADP-ribose", "SIMPLE_CHEMICAL", 38, 48], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 72, 88], ["ADPR-1\u2033P", "GENE_OR_GENE_PRODUCT", 127, 135], ["Table 1", "GENE_OR_GENE_PRODUCT", 192, 199], ["MDO2", "PROTEIN", 29, 33], ["ADPR", "PROTEIN", 127, 131], ["yeast Poa1p", "PROTEIN", 179, 190], ["yeast", "SPECIES", 179, 184], ["yeast", "SPECIES", 179, 184], ["ADP-ribose", "TREATMENT", 38, 48], ["ADP-ribose)", "TREATMENT", 78, 89]]], ["If mammalian cells harbor an enzymatic activity scavenging the ADPR-1\u2033P byproduct of tRNA splicing, this role could be fulfilled by MDO2, as previously suggested for Poa1p in yeast.", [["cells", "ANATOMY", 13, 18], ["mammalian cells", "CELL", 3, 18], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 63, 69], ["MDO2", "GENE_OR_GENE_PRODUCT", 132, 136], ["Poa1p", "GENE_OR_GENE_PRODUCT", 166, 171], ["mammalian cells", "CELL_TYPE", 3, 18], ["ADPR", "PROTEIN", 63, 67], ["MDO2", "PROTEIN", 132, 136], ["Poa1p", "PROTEIN", 166, 171], ["yeast", "SPECIES", 175, 180], ["yeast", "SPECIES", 175, 180], ["mammalian cells", "PROBLEM", 3, 18], ["tRNA splicing", "TREATMENT", 85, 98], ["Poa1p in yeast", "PROBLEM", 166, 180], ["tRNA splicing", "OBSERVATION", 85, 98]]], ["7 The unusual cytoplasmic splicing event of XBP-1 mRNA during the unfolded protein response caused by endoplasmic reticulum stress may also proceed via a tRNA-like pathway.", [["cytoplasmic", "ANATOMY", 14, 25], ["endoplasmic reticulum", "ANATOMY", 102, 123], ["cytoplasmic", "ORGANISM_SUBSTANCE", 14, 25], ["XBP-1", "GENE_OR_GENE_PRODUCT", 44, 49], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 102, 123], ["XBP-1 mRNA", "RNA", 44, 54], ["The unusual cytoplasmic splicing", "PROBLEM", 2, 34], ["XBP", "TEST", 44, 47], ["the unfolded protein response", "PROBLEM", 62, 91], ["endoplasmic reticulum stress", "PROBLEM", 102, 130], ["a tRNA", "TREATMENT", 152, 158], ["cytoplasmic splicing", "OBSERVATION", 14, 34], ["protein response", "OBSERVATION", 75, 91], ["endoplasmic reticulum stress", "OBSERVATION", 102, 130]]], ["32 Interestingly, disruption of the gene encoding MDO2 was suggested to be linked to a rare developmental disorder in one patient, 19 thus implying an important developmental role for this protein.", [["developmental disorder", "DISEASE", 92, 114], ["MDO2", "GENE_OR_GENE_PRODUCT", 50, 54], ["patient", "ORGANISM", 122, 129], ["MDO2", "PROTEIN", 50, 54], ["patient", "SPECIES", 122, 129], ["a rare developmental disorder", "PROBLEM", 85, 114], ["this protein", "TREATMENT", 184, 196]]], ["This could be related to ADP-ribose-mediated cellular signaling, as mono(ADP-ribosyl)ation has an important role in the signaling and metabolic pathways of eukaryotic cells (reviewed by Di Girolamo et al. 33 ).", [["cellular", "ANATOMY", 45, 53], ["cells", "ANATOMY", 167, 172], ["ADP-ribose", "CHEMICAL", 25, 35], ["ADP", "CHEMICAL", 73, 76], ["ribosyl", "CHEMICAL", 77, 84], ["ADP", "CHEMICAL", 25, 28], ["ribose", "CHEMICAL", 29, 35], ["mono(ADP-ribosyl)", "CHEMICAL", 68, 85], ["ADP", "SIMPLE_CHEMICAL", 25, 28], ["ribose", "SIMPLE_CHEMICAL", 29, 35], ["cellular", "CELL", 45, 53], ["mono(ADP-ribosyl", "SIMPLE_CHEMICAL", 68, 84], ["cells", "CELL", 167, 172], ["eukaryotic cells", "CELL_TYPE", 156, 172], ["ADP", "TEST", 25, 28], ["ribose-mediated cellular signaling", "PROBLEM", 29, 63], ["mono(ADP-ribosyl)ation", "TREATMENT", 68, 90], ["eukaryotic cells", "PROBLEM", 156, 172], ["cellular signaling", "OBSERVATION", 45, 63], ["eukaryotic cells", "OBSERVATION", 156, 172]]], ["Alternatively, accumulation of metabolic products such as ADPR-1\u2033P could lead to developmental disturbances.DiscussionGDAP2 was originally found in a search for ganglioside-induced neuronal differentiation factors, and its expression was found to be developmentally regulated in mouse brain.", [["neuronal", "ANATOMY", 181, 189], ["brain", "ANATOMY", 285, 290], ["ADPR-1\u2033", "CHEMICAL", 58, 65], ["ADPR-1\u2033", "CHEMICAL", 58, 65], ["ganglioside", "CHEMICAL", 161, 172], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 58, 64], ["DiscussionGDAP2", "GENE_OR_GENE_PRODUCT", 108, 123], ["ganglioside", "SIMPLE_CHEMICAL", 161, 172], ["neuronal", "CELL", 181, 189], ["mouse", "ORGANISM", 279, 284], ["brain", "ORGAN", 285, 290], ["ADPR", "PROTEIN", 58, 62], ["P", "DNA", 65, 66], ["DiscussionGDAP2", "PROTEIN", 108, 123], ["ganglioside-induced neuronal differentiation factors", "PROTEIN", 161, 213], ["mouse", "SPECIES", 279, 284], ["mouse", "SPECIES", 279, 284], ["metabolic products", "TREATMENT", 31, 49], ["ADPR", "TEST", 58, 62], ["developmental disturbances", "PROBLEM", 81, 107], ["ganglioside-induced neuronal differentiation factors", "PROBLEM", 161, 213], ["metabolic products", "OBSERVATION", 31, 49], ["neuronal differentiation", "OBSERVATION", 181, 205], ["brain", "ANATOMY", 285, 290]]], ["20 GDAP2 contains in its C-terminus a predicted Sec14 domain-a lipidbinding domain that is known to function in intracellular trafficking.", [["intracellular", "ANATOMY", 112, 125], ["GDAP2", "GENE_OR_GENE_PRODUCT", 3, 8], ["Sec14", "GENE_OR_GENE_PRODUCT", 48, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["GDAP2", "PROTEIN", 3, 8], ["C-terminus", "PROTEIN", 25, 35], ["Sec14 domain", "PROTEIN", 48, 60], ["lipidbinding domain", "PROTEIN", 63, 82], ["a lipidbinding domain", "PROBLEM", 61, 82], ["intracellular trafficking", "OBSERVATION", 112, 137]]], ["In our experiments, the inclusion of the Sec14 domain did not affect the subcellular localization of GDAP2 when the protein was overexpressed in HeLa cells.", [["subcellular", "ANATOMY", 73, 84], ["HeLa cells", "ANATOMY", 145, 155], ["Sec14", "GENE_OR_GENE_PRODUCT", 41, 46], ["GDAP2", "GENE_OR_GENE_PRODUCT", 101, 106], ["HeLa cells", "CELL", 145, 155], ["Sec14 domain", "PROTEIN", 41, 53], ["GDAP2", "PROTEIN", 101, 106], ["HeLa cells", "CELL_LINE", 145, 155], ["the protein", "TEST", 112, 123], ["HeLa cells", "OBSERVATION", 145, 155]]], ["However, it remains possible that, under specific circumstances, the Sec14 domain could have targeting effects on the protein.", [["Sec14", "GENE_OR_GENE_PRODUCT", 69, 74], ["Sec14 domain", "PROTEIN", 69, 81], ["the protein", "TEST", 114, 125]]], ["The GDAP2 macro did not possess the ability to interact with ADP-ribose and poly(ADP-ribose), but we demonstrated the binding of poly(A) (Fig. 3b and c) .", [["ADP-ribose", "CHEMICAL", 61, 71], ["poly(ADP-ribose", "CHEMICAL", 76, 91], ["ADP", "CHEMICAL", 61, 64], ["ribose", "CHEMICAL", 65, 71], ["poly(ADP-ribose)", "CHEMICAL", 76, 92], ["poly(A)", "CHEMICAL", 129, 136], ["GDAP2", "GENE_OR_GENE_PRODUCT", 4, 9], ["ADP-ribose", "SIMPLE_CHEMICAL", 61, 71], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 76, 91], ["c", "GENE_OR_GENE_PRODUCT", 150, 151], ["GDAP2", "PROTEIN", 4, 9], ["ADP-ribose and poly(ADP-ribose", "TREATMENT", 61, 91]]], ["Clarification of the nucleic acid binding properties and specificities of GDAP2 macro domain requires further studies.DiscussionMDO1 is a relatively potent ADP-ribose binding protein and is also able to bind poly(ADP-ribose) and to hydrolyze ADPR-1\u2033P (Table 1) .", [["nucleic acid", "CHEMICAL", 21, 33], ["DiscussionMDO1", "CHEMICAL", 118, 132], ["ADP", "CHEMICAL", 156, 159], ["ribose", "CHEMICAL", 160, 166], ["poly(ADP-ribose", "CHEMICAL", 208, 223], ["ADP", "CHEMICAL", 156, 159], ["ribose", "CHEMICAL", 160, 166], ["poly(ADP-ribose)", "CHEMICAL", 208, 224], ["ADPR-1\u2033P", "CHEMICAL", 242, 250], ["GDAP2", "GENE_OR_GENE_PRODUCT", 74, 79], ["DiscussionMDO1", "SIMPLE_CHEMICAL", 118, 132], ["ADP", "SIMPLE_CHEMICAL", 156, 159], ["ADP", "SIMPLE_CHEMICAL", 213, 216], ["GDAP2 macro domain", "PROTEIN", 74, 92], ["ADP-ribose binding protein", "PROTEIN", 156, 182], ["ADPR", "PROTEIN", 242, 246], ["the nucleic acid binding properties", "PROBLEM", 17, 52], ["GDAP2 macro domain", "PROBLEM", 74, 92], ["further studies", "TEST", 102, 117], ["ribose binding protein", "TREATMENT", 160, 182], ["bind poly(ADP-ribose)", "TREATMENT", 203, 224], ["hydrolyze ADPR", "TREATMENT", 232, 246]]], ["MDO1 is the first ADP-ribose binding protein that has been shown to localize in mitochondria.", [["mitochondria", "ANATOMY", 80, 92], ["ADP", "CHEMICAL", 18, 21], ["ADP", "CHEMICAL", 18, 21], ["ribose", "CHEMICAL", 22, 28], ["MDO1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ADP", "SIMPLE_CHEMICAL", 18, 21], ["mitochondria", "CELLULAR_COMPONENT", 80, 92], ["MDO1", "PROTEIN", 0, 4], ["ADP-ribose binding protein", "PROTEIN", 18, 44], ["ribose binding protein", "TREATMENT", 22, 44]]], ["The role of poly (ADP-ribosyl)ation in mitochondrial regulatory events has been under discussion (reviewed by Scovassi 34 ).", [["mitochondrial", "ANATOMY", 39, 52], ["poly (ADP-ribosyl)ation", "CHEMICAL", 12, 35], ["poly (ADP-ribosyl)", "CHEMICAL", 12, 30], ["poly (ADP-ribosyl", "SIMPLE_CHEMICAL", 12, 29], ["mitochondrial", "CELLULAR_COMPONENT", 39, 52], ["poly (ADP-ribosyl)ation", "TREATMENT", 12, 35]]], ["Recently, two newly discovered poly (ADP-ribose)-hydrolyzing PARG isoforms were detected in the mitochondria.", [["mitochondria", "ANATOMY", 96, 108], ["poly (ADP-ribose", "CHEMICAL", 31, 47], ["poly (ADP-ribose)", "CHEMICAL", 31, 48], ["poly (ADP-ribose)-hydrolyzing PARG", "GENE_OR_GENE_PRODUCT", 31, 65], ["mitochondria", "CELLULAR_COMPONENT", 96, 108], ["poly (ADP-ribose)-hydrolyzing PARG isoforms", "PROTEIN", 31, 74], ["poly (ADP-ribose", "TREATMENT", 31, 47], ["hydrolyzing PARG isoforms", "PROBLEM", 49, 74]]], ["35 Specific PARG activity was shown to be higher in the mitochondria than in the nucleus, although PARP activity in the mitochondria was low.", [["mitochondria", "ANATOMY", 56, 68], ["nucleus", "ANATOMY", 81, 88], ["mitochondria", "ANATOMY", 120, 132], ["PARG", "GENE_OR_GENE_PRODUCT", 12, 16], ["mitochondria", "CELLULAR_COMPONENT", 56, 68], ["nucleus", "CELLULAR_COMPONENT", 81, 88], ["PARP", "GENE_OR_GENE_PRODUCT", 99, 103], ["mitochondria", "CELLULAR_COMPONENT", 120, 132], ["PARG", "PROTEIN", 12, 16], ["PARP", "PROTEIN", 99, 103], ["Specific PARG activity", "TEST", 3, 25], ["PARP activity in the mitochondria", "PROBLEM", 99, 132], ["PARG activity", "OBSERVATION", 12, 25], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["nucleus", "ANATOMY", 81, 88], ["PARP activity", "OBSERVATION", 99, 112], ["low", "OBSERVATION_MODIFIER", 137, 140]]], ["35 This could indicate transport of poly(ADP-ribose) from the nucleus to the mitochondria.", [["nucleus", "ANATOMY", 62, 69], ["mitochondria", "ANATOMY", 77, 89], ["poly(ADP-ribose", "CHEMICAL", 36, 51], ["poly(ADP-ribose)", "CHEMICAL", 36, 52], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 36, 52], ["nucleus", "CELLULAR_COMPONENT", 62, 69], ["mitochondria", "CELLULAR_COMPONENT", 77, 89], ["transport of poly(ADP-ribose)", "TREATMENT", 23, 52], ["nucleus", "ANATOMY", 62, 69], ["mitochondria", "ANATOMY", 77, 89]]], ["In another study, nuclear-mitochondrial signaling was studied under apoptotic stress, and no poly(ADP-ribose) transport to the mitochondria was detected.", [["nuclear", "ANATOMY", 18, 25], ["mitochondrial", "ANATOMY", 26, 39], ["mitochondria", "ANATOMY", 127, 139], ["poly(ADP-ribose", "CHEMICAL", 93, 108], ["poly(ADP-ribose)", "CHEMICAL", 93, 109], ["nuclear", "CELLULAR_COMPONENT", 18, 25], ["mitochondrial", "CELLULAR_COMPONENT", 26, 39], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 93, 109], ["mitochondria", "CELLULAR_COMPONENT", 127, 139], ["another study", "TEST", 3, 16], ["apoptotic stress", "TEST", 68, 84], ["poly(ADP-ribose", "TREATMENT", 93, 108]]], ["36 Rather, it was proposed that ADP-ribose might serve as messenger molecule in the activation of mitochondrial apoptosis mechanisms after nuclear poly(ADP-ribosyl)ation.", [["mitochondrial", "ANATOMY", 98, 111], ["nuclear", "ANATOMY", 139, 146], ["ADP", "CHEMICAL", 32, 35], ["ribose", "CHEMICAL", 36, 42], ["poly(ADP-ribosyl", "CHEMICAL", 147, 163], ["ADP", "CHEMICAL", 32, 35], ["ribose", "CHEMICAL", 36, 42], ["poly(ADP-ribosyl)", "CHEMICAL", 147, 164], ["ADP-ribose", "SIMPLE_CHEMICAL", 32, 42], ["mitochondrial", "CELLULAR_COMPONENT", 98, 111], ["ADP-ribosyl)ation", "GENE_OR_GENE_PRODUCT", 152, 169], ["ADP-ribose", "TREATMENT", 32, 42], ["mitochondrial apoptosis mechanisms", "PROBLEM", 98, 132], ["nuclear poly(ADP-ribosyl)ation", "TREATMENT", 139, 169], ["mitochondrial apoptosis", "OBSERVATION", 98, 121]]], ["The localization of MDO1 in the mitochondria may support a role for ADP-ribosylation (either in polymeric or in monomeric form) also in the mitochondria, although the possibility of MDO1 functioning in ADPR-1\u2033P hydrolysis cannot be excluded.DiscussionThe viral macro domain proteins have been adopted as an essential part of viral genome, but are present only in a small subset of positive-strand RNA viruses that replicate in the cytosolic compartment.", [["mitochondria", "ANATOMY", 32, 44], ["mitochondria", "ANATOMY", 140, 152], ["cytosolic compartment", "ANATOMY", 431, 452], ["ADP", "CHEMICAL", 68, 71], ["ADP", "CHEMICAL", 68, 71], ["MDO1", "GENE_OR_GENE_PRODUCT", 20, 24], ["mitochondria", "CELLULAR_COMPONENT", 32, 44], ["ADP-ribosylation", "GENE_OR_GENE_PRODUCT", 68, 84], ["mitochondria", "CELLULAR_COMPONENT", 140, 152], ["MDO1", "GENE_OR_GENE_PRODUCT", 182, 186], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 202, 208], ["cytosolic compartment", "CELLULAR_COMPONENT", 431, 452], ["MDO1", "PROTEIN", 20, 24], ["P", "DNA", 209, 210], ["viral macro domain proteins", "PROTEIN", 255, 282], ["viral genome", "DNA", 325, 337], ["ADP-ribosylation", "TREATMENT", 68, 84], ["ADPR", "TEST", 202, 206], ["P hydrolysis", "TREATMENT", 209, 221], ["The viral macro domain proteins", "TEST", 251, 282], ["viral genome", "PROBLEM", 325, 337], ["positive-strand RNA viruses", "PROBLEM", 381, 408], ["cannot be excluded", "UNCERTAINTY", 222, 240], ["viral genome", "OBSERVATION", 325, 337], ["small", "OBSERVATION_MODIFIER", 365, 370], ["positive", "OBSERVATION_MODIFIER", 381, 389], ["strand RNA viruses", "OBSERVATION", 390, 408], ["cytosolic compartment", "OBSERVATION", 431, 452]]], ["It has been suggested that viral macro domains might function as poly(ADP-ribose)-binding modules.", [["poly(ADP-ribose", "CHEMICAL", 65, 80], ["poly(ADP-ribose)", "CHEMICAL", 65, 81], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 65, 81], ["viral macro domains", "PROTEIN", 27, 46], ["poly(ADP-ribose)-binding modules", "PROTEIN", 65, 97], ["viral macro domains", "PROBLEM", 27, 46], ["poly(ADP-ribose)-binding modules", "PROBLEM", 65, 97]]], ["6 The present study confirms that viral macro domain have substantial affinity for poly (ADP-ribose), but not for monomeric ADP-ribose.", [["poly (ADP-ribose", "CHEMICAL", 83, 99], ["ADP", "CHEMICAL", 124, 127], ["poly (ADP-ribose)", "CHEMICAL", 83, 100], ["ADP", "CHEMICAL", 124, 127], ["ribose", "CHEMICAL", 128, 134], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 83, 99], ["ADP-ribose", "SIMPLE_CHEMICAL", 124, 134], ["viral macro domain", "PROTEIN", 34, 52], ["The present study", "TEST", 2, 19], ["viral macro domain", "PROBLEM", 34, 52], ["poly (ADP-ribose", "TREATMENT", 83, 99], ["monomeric ADP-ribose", "PROBLEM", 114, 134], ["viral macro", "OBSERVATION", 34, 45]]], ["Poly(ADP-ribose) binding, coupled with poly(A)/ nucleic acid binding, further suggests that viral macro domains could have a role in viral RNA replication and/or transcription.", [["Poly(ADP-ribose", "CHEMICAL", 0, 15], ["poly(A", "CHEMICAL", 39, 45], ["nucleic acid", "CHEMICAL", 48, 60], ["Poly(ADP-ribose)", "CHEMICAL", 0, 16], ["poly(A)", "CHEMICAL", 39, 46], ["Poly(ADP-ribose", "SIMPLE_CHEMICAL", 0, 15], ["poly(A)", "SIMPLE_CHEMICAL", 39, 46], ["nucleic acid", "SIMPLE_CHEMICAL", 48, 60], ["poly(A)", "PROTEIN", 39, 46], ["viral macro domains", "PROTEIN", 92, 111], ["Poly(ADP-ribose) binding", "PROBLEM", 0, 24], ["poly(A)/ nucleic acid binding", "PROBLEM", 39, 68], ["viral macro domains", "PROBLEM", 92, 111], ["viral RNA replication", "TREATMENT", 133, 154]]], ["The macro domains of HEV and SFV can also bind poly(ADP-ribose) in the presence of a poly(A) competitor.", [["poly(ADP-ribose", "CHEMICAL", 47, 62], ["poly(ADP-ribose)", "CHEMICAL", 47, 63], ["poly(A)", "CHEMICAL", 85, 92], ["HEV", "ORGANISM", 21, 24], ["SFV", "ORGANISM", 29, 32], ["ADP-ribose", "SIMPLE_CHEMICAL", 52, 62], ["poly(A", "SIMPLE_CHEMICAL", 85, 91], ["poly(A) competitor", "PROTEIN", 85, 103], ["HEV", "SPECIES", 21, 24], ["SFV", "SPECIES", 29, 32], ["HEV and SFV", "TREATMENT", 21, 32], ["bind poly(ADP-ribose)", "TREATMENT", 42, 63], ["a poly(A) competitor", "TREATMENT", 83, 103], ["HEV", "OBSERVATION", 21, 24], ["SFV", "ANATOMY", 29, 32]]], ["This suggests that they could recruit poly(ADP-ribosyl)ated cellular factors to the replication complex while bound to RNA.", [["cellular", "ANATOMY", 60, 68], ["poly(ADP-ribosyl", "CHEMICAL", 38, 54], ["poly(ADP-ribosyl)", "CHEMICAL", 38, 55], ["poly(ADP-ribosyl)ated cellular factors", "GENE_OR_GENE_PRODUCT", 38, 76], ["poly(ADP-ribosyl)ated cellular factors", "PROTEIN", 38, 76], ["replication complex", "PROTEIN", 84, 103], ["RNA", "RNA", 119, 122], ["poly(ADP-ribosyl)ated cellular factors", "PROBLEM", 38, 76]]], ["It is also possible that the function of poly (ADP-ribose) binding would facilitate the disassembly of macro domain from the viral genome.", [["poly (ADP-ribose", "CHEMICAL", 41, 57], ["poly (ADP-ribose)", "CHEMICAL", 41, 58], ["poly (ADP-ribose)", "GENE_OR_GENE_PRODUCT", 41, 58], ["macro domain", "PROTEIN", 103, 115], ["viral genome", "DNA", 125, 137], ["poly (ADP-ribose) binding", "TREATMENT", 41, 66], ["macro domain", "PROBLEM", 103, 115], ["the viral genome", "PROBLEM", 121, 137], ["also possible", "UNCERTAINTY", 6, 19], ["viral genome", "OBSERVATION", 125, 137]]], ["This possibility could not be tested directly here because poly(ADP-ribose) could not be produced in amounts high enough to be tested in competition experiments against poly(A).", [["poly(ADP-ribose", "CHEMICAL", 59, 74], ["poly(A", "CHEMICAL", 169, 175], ["poly(ADP-ribose)", "CHEMICAL", 59, 75], ["poly(A)", "CHEMICAL", 169, 176], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 59, 74], ["poly(A", "SIMPLE_CHEMICAL", 169, 175], ["poly(ADP-ribose", "TREATMENT", 59, 74]]], ["Although the viral proteins can-to a higher or a lower extenthydrolyze ADPR-1\u2033P ( Fig. 2; Putics et al. 25, 37 ) , it is not easy to understand how this activity might be linked to the advancement of viral RNA replication.", [["ADPR-1\u2033P", "CHEMICAL", 71, 79], ["viral proteins", "PROTEIN", 13, 27], ["ADPR", "PROTEIN", 71, 75], ["the viral proteins", "TEST", 9, 27], ["a lower extenthydrolyze ADPR", "TREATMENT", 47, 75], ["viral RNA replication", "TREATMENT", 200, 221]]], ["This function has been also shown to be dispensable in a cell culture for coronavirus.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["coronavirus", "ORGANISM", 74, 85], ["a cell culture", "TEST", 55, 69], ["coronavirus", "PROBLEM", 74, 85]]], ["25 Whether poly (ADP-ribose) or poly(A) binding by viral macro domains is important for virus replication remains to be established.DiscussionOne possible pathway targeted by viral macro proteins involves a cellular protein called zinc-finger antiviral protein (ZAP), which has been shown to inhibit alphavirus growth in cell culture.", [["cellular", "ANATOMY", 207, 215], ["cell culture", "ANATOMY", 321, 333], ["poly (ADP-ribose", "CHEMICAL", 11, 27], ["poly(A", "CHEMICAL", 32, 38], ["poly (ADP-ribose)", "CHEMICAL", 11, 28], ["poly(A)", "CHEMICAL", 32, 39], ["zinc", "CHEMICAL", 231, 235], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 11, 27], ["poly(A)", "SIMPLE_CHEMICAL", 32, 39], ["cellular", "CELL", 207, 215], ["zinc-finger antiviral protein", "GENE_OR_GENE_PRODUCT", 231, 260], ["ZAP", "GENE_OR_GENE_PRODUCT", 262, 265], ["cell culture", "CELL", 321, 333], ["viral macro domains", "PROTEIN", 51, 70], ["viral macro proteins", "PROTEIN", 175, 195], ["cellular protein", "PROTEIN", 207, 223], ["zinc-finger antiviral protein", "PROTEIN", 231, 260], ["ZAP", "PROTEIN", 262, 265], ["poly (ADP-ribose)", "TREATMENT", 11, 28], ["poly(A) binding", "PROBLEM", 32, 47], ["viral macro domains", "PROBLEM", 51, 70], ["virus replication", "TREATMENT", 88, 105], ["viral macro proteins", "TEST", 175, 195], ["a cellular protein", "TEST", 205, 223], ["zinc", "TEST", 231, 235], ["alphavirus growth in cell culture", "PROBLEM", 300, 333]]], ["38,39 ZAP consists of repeated zinc-fingers, a TiPARP homology domain, a WWE domain, and a PARP-like domain.", [["zinc", "CHEMICAL", 31, 35], ["ZAP", "GENE_OR_GENE_PRODUCT", 6, 9], ["PARP", "GENE_OR_GENE_PRODUCT", 91, 95], ["ZAP", "PROTEIN", 6, 9], ["zinc-fingers", "PROTEIN", 31, 43], ["TiPARP homology domain", "PROTEIN", 47, 69], ["WWE domain", "PROTEIN", 73, 83], ["PARP-like domain", "PROTEIN", 91, 107], ["a TiPARP homology domain", "PROBLEM", 45, 69], ["a WWE domain", "PROBLEM", 71, 83], ["a PARP", "TEST", 89, 95], ["fingers", "ANATOMY", 36, 43]]], ["40 The zinc-finger domain of human ZAP was found to be sufficient for alphavirus inhibition; however, in a recent study, it was shown that the PARP-like domain increased the inhibition by fivefold.", [["zinc", "CHEMICAL", 7, 11], ["zinc", "CHEMICAL", 7, 11], ["human", "ORGANISM", 29, 34], ["ZAP", "GENE_OR_GENE_PRODUCT", 35, 38], ["PARP", "GENE_OR_GENE_PRODUCT", 143, 147], ["zinc-finger domain", "PROTEIN", 7, 25], ["human ZAP", "PROTEIN", 29, 38], ["PARP-like domain", "PROTEIN", 143, 159], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["human ZAP", "TREATMENT", 29, 38], ["alphavirus inhibition", "PROBLEM", 70, 91], ["a recent study", "TEST", 105, 119], ["the PARP", "PROBLEM", 139, 147], ["zinc", "OBSERVATION_MODIFIER", 7, 11], ["finger", "ANATOMY", 12, 18], ["human ZAP", "ANATOMY", 29, 38]]], ["In the same study, the PARP-like domain was also found to have been under positive evolutionary selection, unlike other ZAP domains.", [["PARP", "GENE_OR_GENE_PRODUCT", 23, 27], ["ZAP", "GENE_OR_GENE_PRODUCT", 120, 123], ["PARP", "PROTEIN", 23, 27], ["ZAP domains", "PROTEIN", 120, 131], ["the same study", "TEST", 3, 17], ["the PARP", "TEST", 19, 27], ["evolutionary selection", "OBSERVATION", 83, 105]]], ["40 Thus, SFV nsP3 and other viral macro proteins could aim to sequester ZAP, or other proteins modified by the putative PARP activity of ZAP, to prevent the normal function of ZAP and the inhibitory event.", [["SFV", "ORGANISM", 9, 12], ["nsP3", "GENE_OR_GENE_PRODUCT", 13, 17], ["ZAP", "GENE_OR_GENE_PRODUCT", 72, 75], ["PARP", "GENE_OR_GENE_PRODUCT", 120, 124], ["ZAP", "GENE_OR_GENE_PRODUCT", 137, 140], ["ZAP", "GENE_OR_GENE_PRODUCT", 176, 179], ["SFV nsP3", "PROTEIN", 9, 17], ["viral macro proteins", "PROTEIN", 28, 48], ["ZAP", "PROTEIN", 72, 75], ["PARP", "PROTEIN", 120, 124], ["ZAP", "PROTEIN", 137, 140], ["ZAP", "PROTEIN", 176, 179], ["SFV", "SPECIES", 9, 12], ["SFV nsP3", "PROBLEM", 9, 17], ["other viral macro proteins", "PROBLEM", 22, 48], ["ZAP", "TEST", 72, 75], ["other proteins", "PROBLEM", 80, 94], ["ZAP", "TREATMENT", 137, 140], ["SFV nsP3", "OBSERVATION", 9, 17], ["normal", "OBSERVATION", 157, 163]]], ["Also other cytosolic PARP-like proteins or proteins modified by these PARPs could interact with viral macro proteins, but even less is known about these proteins.", [["cytosolic", "ANATOMY", 11, 20], ["PARP-like proteins", "GENE_OR_GENE_PRODUCT", 21, 39], ["PARPs", "GENE_OR_GENE_PRODUCT", 70, 75], ["cytosolic PARP-like proteins", "PROTEIN", 11, 39], ["PARPs", "PROTEIN", 70, 75], ["viral macro proteins", "PROTEIN", 96, 116], ["other cytosolic PARP", "PROBLEM", 5, 25], ["proteins", "PROBLEM", 43, 51], ["these PARPs", "PROBLEM", 64, 75], ["viral macro proteins", "PROBLEM", 96, 116], ["cytosolic PARP", "OBSERVATION", 11, 25], ["viral macro proteins", "OBSERVATION", 96, 116]]], ["Altogether, 17 PARP-like proteins, some of which are likely to function in the cytosolic compartment, have been identified in humans.", [["cytosolic compartment", "ANATOMY", 79, 100], ["PARP", "GENE_OR_GENE_PRODUCT", 15, 19], ["humans", "ORGANISM", 126, 132], ["PARP", "PROTEIN", 15, 19], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["17 PARP-like proteins", "PROBLEM", 12, 33], ["17 PARP", "OBSERVATION_MODIFIER", 12, 19], ["like proteins", "OBSERVATION_MODIFIER", 20, 33], ["likely to", "UNCERTAINTY", 53, 62], ["cytosolic compartment", "OBSERVATION", 79, 100]]], ["41 Some of the already characterized PARP proteins have been shown to localize at least partly outside the nucleus, including PARP-3 and PARP-4, tankyrase-1 and tankyrase-2, and probably even PARP-1, the main PARP (reviewed by Vir\u00e1g 42 ).", [["nucleus", "ANATOMY", 107, 114], ["PARP", "GENE_OR_GENE_PRODUCT", 37, 41], ["nucleus", "CELLULAR_COMPONENT", 107, 114], ["PARP-3", "GENE_OR_GENE_PRODUCT", 126, 132], ["PARP-4", "GENE_OR_GENE_PRODUCT", 137, 143], ["tankyrase-1", "GENE_OR_GENE_PRODUCT", 145, 156], ["tankyrase-2", "GENE_OR_GENE_PRODUCT", 161, 172], ["PARP-1", "GENE_OR_GENE_PRODUCT", 192, 198], ["PARP", "GENE_OR_GENE_PRODUCT", 209, 213], ["PARP proteins", "PROTEIN", 37, 50], ["PARP-3", "PROTEIN", 126, 132], ["PARP-4", "PROTEIN", 137, 143], ["tankyrase-1", "PROTEIN", 145, 156], ["tankyrase-2", "PROTEIN", 161, 172], ["PARP-1", "PROTEIN", 192, 198], ["PARP", "PROTEIN", 209, 213], ["PARP proteins", "TEST", 37, 50], ["PARP", "TEST", 126, 130], ["PARP", "TEST", 137, 141], ["tankyrase", "TEST", 145, 154], ["tankyrase", "TEST", 161, 170], ["PARP", "TEST", 192, 196], ["nucleus", "ANATOMY", 107, 114], ["probably even", "UNCERTAINTY", 178, 191]]], ["Among the cellular macro domain proteins studied, only MDO1 was able to bind poly(ADP-ribose); however, due to its mitochondrial localization, MDO1 could only indirectly interact with the putative networks influenced by the viral macro proteins.", [["cellular", "ANATOMY", 10, 18], ["mitochondrial", "ANATOMY", 115, 128], ["poly(ADP-ribose", "CHEMICAL", 77, 92], ["poly(ADP-ribose)", "CHEMICAL", 77, 93], ["cellular", "CELL", 10, 18], ["MDO1", "GENE_OR_GENE_PRODUCT", 55, 59], ["poly(ADP-ribose)", "GENE_OR_GENE_PRODUCT", 77, 93], ["mitochondrial", "CELLULAR_COMPONENT", 115, 128], ["MDO1", "GENE_OR_GENE_PRODUCT", 143, 147], ["cellular macro domain proteins", "PROTEIN", 10, 40], ["MDO1", "PROTEIN", 55, 59], ["MDO1", "PROTEIN", 143, 147], ["viral macro proteins", "PROTEIN", 224, 244], ["the cellular macro domain proteins", "TEST", 6, 40], ["ADP-ribose", "TREATMENT", 82, 92], ["the viral macro proteins", "PROBLEM", 220, 244], ["macro domain", "OBSERVATION", 19, 31], ["viral macro proteins", "OBSERVATION", 224, 244]]], ["Thus, in contrast to our initial assumptions, it seems that functional studies of cellular macro proteins might not directly illuminate the functions of the related viral proteins.DiscussionWe show here that different macro domains can have a variety of binding properties, and that the binding of ADP-ribose monomer and polymer is not necessarily interrelated, as some of the examined proteins only bound one, but not the other, ligand.", [["cellular", "ANATOMY", 82, 90], ["ADP-ribose", "CHEMICAL", 298, 308], ["ADP", "CHEMICAL", 298, 301], ["ribose", "CHEMICAL", 302, 308], ["cellular", "CELL", 82, 90], ["ADP-ribose monomer", "SIMPLE_CHEMICAL", 298, 316], ["cellular macro proteins", "PROTEIN", 82, 105], ["viral proteins", "PROTEIN", 165, 179], ["cellular macro proteins", "PROBLEM", 82, 105], ["the related viral proteins", "PROBLEM", 153, 179], ["different macro domains", "PROBLEM", 208, 231], ["ADP-ribose monomer", "TREATMENT", 298, 316], ["viral proteins", "OBSERVATION", 165, 179], ["not necessarily", "UNCERTAINTY", 332, 347]]], ["These results are in accordance with experiments on the histone splicing variant mH2a1.1, which binds O-acetyl-ADP-ribose and ADP-ribose, but not poly (ADP-ribose).", [["O-acetyl-ADP-ribose", "CHEMICAL", 102, 121], ["ADP-ribose", "CHEMICAL", 126, 136], ["poly (ADP-ribose", "CHEMICAL", 146, 162], ["O-acetyl", "CHEMICAL", 102, 110], ["ADP", "CHEMICAL", 111, 114], ["ribose", "CHEMICAL", 115, 121], ["ADP", "CHEMICAL", 126, 129], ["ribose", "CHEMICAL", 130, 136], ["poly (ADP-ribose)", "CHEMICAL", 146, 163], ["histone", "GENE_OR_GENE_PRODUCT", 56, 63], ["O-acetyl-ADP-ribose", "SIMPLE_CHEMICAL", 102, 121], ["ADP-ribose", "SIMPLE_CHEMICAL", 126, 136], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 146, 162], ["histone", "PROTEIN", 56, 63], ["acetyl", "TREATMENT", 104, 110], ["ADP-ribose", "TREATMENT", 111, 121], ["ADP-ribose", "TREATMENT", 126, 136], ["poly (ADP-ribose)", "TREATMENT", 146, 163]]], ["43 The gene mH2A1 results in two differently spliced proteins, of which mH2A1.1 binds ADP-ribose, but mH2A1.2 does not.", [["ADP-ribose", "CHEMICAL", 86, 96], ["ADP", "CHEMICAL", 86, 89], ["ribose", "CHEMICAL", 90, 96], ["mH2A1", "GENE_OR_GENE_PRODUCT", 12, 17], ["mH2A1.1", "GENE_OR_GENE_PRODUCT", 72, 79], ["ADP-ribose", "SIMPLE_CHEMICAL", 86, 96], ["mH2A1", "DNA", 12, 17], ["mH2A1.1", "PROTEIN", 72, 79], ["mH2A1.2", "PROTEIN", 102, 109], ["The gene mH2A1", "TEST", 3, 17]]], ["The reported changes in the mH2A1.2 splicing variant were replacements of G223 and G224 by K and D, respectively, and a \u223c 90\u00b0flip in F348 stacking the adenine residue.", [["K", "CHEMICAL", 91, 92], ["adenine", "CHEMICAL", 151, 158], ["adenine", "CHEMICAL", 151, 158], ["mH2A1.2", "GENE_OR_GENE_PRODUCT", 28, 35], ["adenine", "SIMPLE_CHEMICAL", 151, 158], ["mH2A1.2 splicing variant", "DNA", 28, 52], ["replacements of G223", "TREATMENT", 58, 78], ["the adenine residue", "PROBLEM", 147, 166], ["adenine residue", "OBSERVATION", 151, 166]]], ["43 In GDAP2, the amino acids corresponding to G223 and G224 in histone mH2A1.1 are also replaced by larger amino acids, K82 and N83.", [["amino acids", "CHEMICAL", 17, 28], ["amino acids", "CHEMICAL", 107, 118], ["amino acids", "CHEMICAL", 17, 28], ["amino acids", "CHEMICAL", 107, 118], ["K82", "CHEMICAL", 120, 123], ["N83", "CHEMICAL", 128, 131], ["GDAP2", "GENE_OR_GENE_PRODUCT", 6, 11], ["amino acids", "AMINO_ACID", 17, 28], ["histone mH2A1.1", "GENE_OR_GENE_PRODUCT", 63, 78], ["amino acids", "AMINO_ACID", 107, 118], ["GDAP2", "PROTEIN", 6, 11], ["G223", "PROTEIN", 46, 50], ["G224", "PROTEIN", 55, 59], ["histone mH2A1.1", "PROTEIN", 63, 78], ["N83", "PROTEIN", 128, 131], ["the amino acids", "TEST", 13, 28], ["larger amino acids", "TEST", 100, 118], ["K82", "TEST", 120, 123], ["N83", "TREATMENT", 128, 131]]], ["In most macro domains, this region contains a stretch of three glycines (Fig. 1) .", [["a stretch of three glycines", "TREATMENT", 44, 71], ["most macro", "OBSERVATION_MODIFIER", 3, 13], ["stretch", "OBSERVATION_MODIFIER", 46, 53]]], ["We also observed in our experiments that mutating the last of the three glycines (G182 in MDO1) to tyrosine resulted in loss of ADP-ribose binding and ADPR-1\u2033P hydrolysis.", [["tyrosine", "CHEMICAL", 99, 107], ["ADP", "CHEMICAL", 128, 131], ["ribose", "CHEMICAL", 132, 138], ["ADPR", "CHEMICAL", 151, 155], ["tyrosine", "CHEMICAL", 99, 107], ["ADP", "CHEMICAL", 128, 131], ["ribose", "CHEMICAL", 132, 138], ["ADPR-1\u2033P", "CHEMICAL", 151, 159], ["MDO1", "GENE_OR_GENE_PRODUCT", 90, 94], ["tyrosine", "AMINO_ACID", 99, 107], ["ADP-ribose", "SIMPLE_CHEMICAL", 128, 138], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 151, 159], ["MDO1", "PROTEIN", 90, 94], ["tyrosine", "TREATMENT", 99, 107], ["loss of ADP-ribose binding", "PROBLEM", 120, 146], ["ADPR", "TEST", 151, 155], ["P hydrolysis", "TREATMENT", 158, 170], ["ribose binding", "OBSERVATION", 132, 146]]], ["It seems that the flexible glycine stretch at the edge of the binding pocket (aa 180-182 in MDO1; Fig. 4 ) is required for ADP-ribose binding.", [["glycine", "CHEMICAL", 27, 34], ["ADP", "CHEMICAL", 123, 126], ["ribose", "CHEMICAL", 127, 133], ["glycine", "CHEMICAL", 27, 34], ["ADP", "CHEMICAL", 123, 126], ["ribose", "CHEMICAL", 127, 133], ["glycine", "AMINO_ACID", 27, 34], ["ADP-ribose", "SIMPLE_CHEMICAL", 123, 133], ["the flexible glycine stretch", "TREATMENT", 14, 42], ["aa", "TEST", 78, 80], ["MDO1", "TEST", 92, 96], ["ADP-ribose binding", "PROBLEM", 123, 141], ["flexible", "OBSERVATION_MODIFIER", 18, 26], ["glycine stretch", "OBSERVATION", 27, 42], ["edge", "OBSERVATION_MODIFIER", 50, 54], ["binding pocket", "OBSERVATION", 62, 76], ["ribose binding", "OBSERVATION", 127, 141]]], ["The conservation of this stretch could be one hallmark for the binding of ADP-ribose-type ligands by selected macro domains.", [["ADP", "CHEMICAL", 74, 77], ["ribose", "CHEMICAL", 78, 84], ["ADP", "CHEMICAL", 74, 77], ["ribose", "CHEMICAL", 78, 84], ["ADP", "SIMPLE_CHEMICAL", 74, 77], ["macro domains", "PROTEIN", 110, 123], ["ADP", "TEST", 74, 77]]], ["In GDAP2, the glycine residue on the opposite side of the binding pocket (G270 in MDO1) has also been lost.DiscussionIn conclusion, it seems likely that most macro domain proteins have evolved to bind a variety of metabolites related to ADP-ribose, but some macro domains such as GDAP2 have evolved to a different direction to interact, for instance, with nucleic acids.", [["glycine", "CHEMICAL", 14, 21], ["ADP-ribose", "CHEMICAL", 237, 247], ["nucleic acids", "CHEMICAL", 356, 369], ["glycine", "CHEMICAL", 14, 21], ["ADP", "CHEMICAL", 237, 240], ["ribose", "CHEMICAL", 241, 247], ["GDAP2", "GENE_OR_GENE_PRODUCT", 3, 8], ["glycine", "AMINO_ACID", 14, 21], ["ADP", "SIMPLE_CHEMICAL", 237, 240], ["GDAP2", "GENE_OR_GENE_PRODUCT", 280, 285], ["nucleic acids", "SIMPLE_CHEMICAL", 356, 369], ["GDAP2", "PROTEIN", 3, 8], ["binding pocket", "PROTEIN", 58, 72], ["G270", "PROTEIN", 74, 78], ["MDO1", "PROTEIN", 82, 86], ["macro domain proteins", "PROTEIN", 158, 179], ["macro domains", "PROTEIN", 258, 271], ["GDAP2", "PROTEIN", 280, 285], ["the glycine residue", "PROBLEM", 10, 29], ["the binding pocket", "PROBLEM", 54, 72], ["most macro domain proteins", "PROBLEM", 153, 179], ["ADP", "TEST", 237, 240], ["ribose", "TREATMENT", 241, 247], ["some macro domains", "PROBLEM", 253, 271], ["nucleic acids", "TREATMENT", 356, 369], ["glycine residue", "OBSERVATION", 14, 29], ["binding pocket", "OBSERVATION", 58, 72], ["seems likely", "UNCERTAINTY", 135, 147]]], ["This divergence might perhaps not be so surprising, as it has been suggested that poly(ADP-ribose) could assume helical conformations similar to those of nucleic acids.", [["poly(ADP-ribose", "CHEMICAL", 82, 97], ["nucleic acids", "CHEMICAL", 154, 167], ["poly(ADP-ribose)", "CHEMICAL", 82, 98], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 82, 97], ["nucleic acids", "SIMPLE_CHEMICAL", 154, 167], ["poly(ADP-ribose)", "TREATMENT", 82, 98], ["helical conformations", "PROBLEM", 112, 133], ["nucleic acids", "TREATMENT", 154, 167], ["perhaps not be", "UNCERTAINTY", 22, 36]]], ["44 Very recently, PBZ, another poly(ADP-ribose) binding domain that consists of motifs (zinc-fingers) originally characterized for nucleic acid binding, was identified.", [["PBZ", "CHEMICAL", 18, 21], ["poly(ADP-ribose", "CHEMICAL", 31, 46], ["nucleic acid", "CHEMICAL", 131, 143], ["poly(ADP-ribose)", "CHEMICAL", 31, 47], ["zinc", "CHEMICAL", 88, 92], ["PBZ", "SIMPLE_CHEMICAL", 18, 21], ["ADP", "SIMPLE_CHEMICAL", 36, 39], ["nucleic acid", "SIMPLE_CHEMICAL", 131, 143], ["PBZ", "PROTEIN", 18, 21], ["poly(ADP-ribose) binding domain", "PROTEIN", 31, 62], ["zinc-fingers", "PROTEIN", 88, 100], ["PBZ", "TEST", 18, 21], ["another poly(ADP-ribose)", "TREATMENT", 23, 47], ["binding domain", "PROBLEM", 48, 62], ["nucleic acid binding", "PROBLEM", 131, 151], ["fingers", "ANATOMY", 93, 100], ["nucleic", "OBSERVATION", 131, 138], ["acid binding", "OBSERVATION", 139, 151]]], ["45Protein expression and purificationMacro domain encoding sequences derived from two viral genes, one yeast gene, and three human genes were cloned to a pHAT expression vector that encodes an N-terminal hexahistidine tag.", [["N", "CHEMICAL", 193, 194], ["45Protein", "GENE_OR_GENE_PRODUCT", 0, 9], ["human", "ORGANISM", 125, 130], ["pHAT", "GENE_OR_GENE_PRODUCT", 154, 158], ["45Protein", "PROTEIN", 0, 9], ["purificationMacro domain", "PROTEIN", 25, 49], ["viral genes", "DNA", 86, 97], ["yeast gene", "DNA", 103, 113], ["human genes", "DNA", 125, 136], ["pHAT expression vector", "DNA", 154, 176], ["N-terminal hexahistidine tag", "DNA", 193, 221], ["yeast", "SPECIES", 103, 108], ["human", "SPECIES", 125, 130], ["yeast", "SPECIES", 103, 108], ["human", "SPECIES", 125, 130], ["45Protein expression", "PROBLEM", 0, 20], ["purificationMacro domain encoding sequences", "TEST", 25, 68], ["two viral genes", "PROBLEM", 82, 97], ["a pHAT expression vector", "TREATMENT", 152, 176], ["an N-terminal hexahistidine tag", "TREATMENT", 190, 221], ["viral genes", "OBSERVATION", 86, 97], ["yeast gene", "OBSERVATION", 103, 113]]], ["46 The cloned regions, obtained by PCR and verified by sequencing, encoded the following amino acids: aa 775-960 from HEV open reading frame 1 protein (Burmese strain, described earlier 47 ); aa 1-167 or aa 1-328 from SFV nsP3 (prototype strain SFV4); aa 1-177 (entire protein) for S. cerevisiae Poa1p; aa 1-231 for Homo sapiens GDAP2; aa 83-325 for MDO1; and aa 1-243 for MDO2.", [["amino acids", "CHEMICAL", 89, 100], ["amino acids", "CHEMICAL", 89, 100], ["amino acids", "AMINO_ACID", 89, 100], ["HEV open reading frame 1", "GENE_OR_GENE_PRODUCT", 118, 142], ["SFV", "ORGANISM", 218, 221], ["nsP3", "GENE_OR_GENE_PRODUCT", 222, 226], ["S. cerevisiae", "ORGANISM", 282, 295], ["Homo sapiens", "ORGANISM", 316, 328], ["MDO2", "GENE_OR_GENE_PRODUCT", 373, 377], ["HEV open reading frame 1 protein", "PROTEIN", 118, 150], ["SFV nsP3", "PROTEIN", 218, 226], ["MDO1", "PROTEIN", 350, 354], ["MDO2", "PROTEIN", 373, 377], ["S. cerevisiae", "SPECIES", 282, 295], ["Homo sapiens", "SPECIES", 316, 328], ["S. cerevisiae", "SPECIES", 282, 295], ["Homo sapiens", "SPECIES", 316, 328], ["PCR", "TEST", 35, 38], ["amino acids", "TEST", 89, 100], ["aa", "TEST", 102, 104], ["HEV open reading frame", "TEST", 118, 140], ["Burmese strain", "TEST", 152, 166], ["aa", "TEST", 192, 194], ["aa", "TEST", 204, 206], ["SFV nsP3", "TEST", 218, 226], ["prototype strain SFV4", "TEST", 228, 249], ["aa", "TEST", 252, 254], ["entire protein", "TEST", 262, 276], ["aa", "TEST", 303, 305], ["Homo sapiens GDAP2", "TEST", 316, 334], ["aa", "TEST", 336, 338], ["MDO1", "TEST", 350, 354], ["aa", "TEST", 360, 362], ["MDO2", "PROBLEM", 373, 377]]], ["Clones for MDO1 (IRALp962M206) and GDAP2 (IRAKp961B043) were obtained from the RZPD German Resource Center for Genome Research (sequences correspond to the Entrez nucleotide database with accession numbers BC000270 and BC013132), and the clone for MDO2 was obtained from Origene (accession number NM_080676.5).", [["MDO1", "GENE_OR_GENE_PRODUCT", 11, 15], ["IRALp962M206", "GENE_OR_GENE_PRODUCT", 17, 29], ["GDAP2", "GENE_OR_GENE_PRODUCT", 35, 40], ["IRAKp961B043", "GENE_OR_GENE_PRODUCT", 42, 54], ["clone", "CELL", 238, 243], ["MDO2", "GENE_OR_GENE_PRODUCT", 248, 252], ["MDO1", "PROTEIN", 11, 15], ["IRALp962M206", "PROTEIN", 17, 29], ["GDAP2", "DNA", 35, 40], ["IRAKp961B043", "PROTEIN", 42, 54], ["MDO2", "PROTEIN", 248, 252]]], ["The POA1 gene was cloned in-house from S. cerevisiae, and Ser2 was mutated to Ala for cloning purposes.", [["Ala", "CHEMICAL", 78, 81], ["POA1", "GENE_OR_GENE_PRODUCT", 4, 8], ["S. cerevisiae", "ORGANISM", 39, 52], ["Ser2", "GENE_OR_GENE_PRODUCT", 58, 62], ["Ala", "AMINO_ACID", 78, 81], ["POA1 gene", "DNA", 4, 13], ["Ser2", "PROTEIN", 58, 62], ["S. cerevisiae", "SPECIES", 39, 52], ["S. cerevisiae", "SPECIES", 39, 52]]], ["HEV sequence was cloned to pHAT using SpeI and BamHI sites, and the others were cloned using NcoI and HindIII sites.", [["HEV", "ORGANISM", 0, 3], ["pHAT", "GENE_OR_GENE_PRODUCT", 27, 31], ["SpeI", "GENE_OR_GENE_PRODUCT", 38, 42], ["BamHI", "GENE_OR_GENE_PRODUCT", 47, 52], ["NcoI", "GENE_OR_GENE_PRODUCT", 93, 97], ["HindIII", "GENE_OR_GENE_PRODUCT", 102, 109], ["HEV sequence", "DNA", 0, 12], ["pHAT", "DNA", 27, 31], ["SpeI and BamHI sites", "DNA", 38, 58], ["NcoI and HindIII sites", "DNA", 93, 115], ["HEV", "SPECIES", 0, 3], ["HEV sequence", "TEST", 0, 12], ["SpeI and BamHI sites", "TREATMENT", 38, 58], ["NcoI and HindIII sites", "TREATMENT", 93, 115]]], ["Point mutations were made to the E. coli expression constructs of SFV nsP3 (328 aa) and human MDO1 (243 aa) using the XL mutagenesis kit (Promega) in accordance with the manufacturer's instructions.", [["E. coli", "ORGANISM", 33, 40], ["SFV", "ORGANISM", 66, 69], ["nsP3", "GENE_OR_GENE_PRODUCT", 70, 74], ["human", "ORGANISM", 88, 93], ["E. coli expression constructs", "DNA", 33, 62], ["SFV nsP3", "PROTEIN", 66, 74], ["human MDO1", "PROTEIN", 88, 98], ["E. coli", "SPECIES", 33, 40], ["human", "SPECIES", 88, 93], ["E. coli", "SPECIES", 33, 40], ["SFV", "SPECIES", 66, 69], ["human", "SPECIES", 88, 93], ["Point mutations", "PROBLEM", 0, 15], ["SFV nsP3", "TEST", 66, 74], ["human MDO1", "TREATMENT", 88, 98], ["the XL mutagenesis kit (Promega)", "TREATMENT", 114, 146], ["SFV nsP3", "ANATOMY", 66, 74]]], ["In nsP3, the following mutations were created: D10A, D31G, G32Y, N21A + N24A, G112Y; and in MDO1, the following mutations were created: G181E, G182Y, G270Y, and G182Y + G270Y.", [["nsP3", "GENE_OR_GENE_PRODUCT", 3, 7], ["MDO1", "GENE_OR_GENE_PRODUCT", 92, 96], ["nsP3", "PROTEIN", 3, 7], ["MDO1", "DNA", 92, 96]]], ["All constructs were fully sequenced.Protein expression and purificationProteins were expressed in E. coli BL21(DE3) and purified by nickel affinity chromatography (HiTrap; GE Healthcare) in 20 mM sodium phosphate (pH 8.0) and 0.5 M NaCl.", [["nickel", "CHEMICAL", 132, 138], ["sodium phosphate", "CHEMICAL", 196, 212], ["NaCl", "CHEMICAL", 232, 236], ["nickel", "CHEMICAL", 132, 138], ["sodium phosphate", "CHEMICAL", 196, 212], ["NaCl", "CHEMICAL", 232, 236], ["E. coli BL21", "ORGANISM", 98, 110], ["DE3", "GENE_OR_GENE_PRODUCT", 111, 114], ["nickel", "SIMPLE_CHEMICAL", 132, 138], ["sodium phosphate", "SIMPLE_CHEMICAL", 196, 212], ["E. coli BL21", "SPECIES", 98, 110], ["E. coli BL21", "SPECIES", 98, 110], ["DE3", "SPECIES", 111, 114], ["Protein expression", "TEST", 36, 54], ["purification", "TEST", 59, 71], ["Proteins", "TEST", 71, 79], ["E. coli BL21", "TEST", 98, 110], ["nickel affinity chromatography", "TEST", 132, 162], ["20 mM sodium phosphate", "TREATMENT", 190, 212], ["pH", "TEST", 214, 216], ["NaCl", "TREATMENT", 232, 236], ["E. coli BL21", "OBSERVATION", 98, 110]]], ["Protein binding was carried out in 20 mM imidazole, followed by washes with 40-100 mM imidazole and elution with 500 mM imidazole in sodium phosphate buffer.", [["imidazole", "CHEMICAL", 41, 50], ["imidazole", "CHEMICAL", 86, 95], ["imidazole", "CHEMICAL", 120, 129], ["sodium phosphate", "CHEMICAL", 133, 149], ["imidazole", "CHEMICAL", 41, 50], ["imidazole", "CHEMICAL", 86, 95], ["imidazole", "CHEMICAL", 120, 129], ["sodium phosphate", "CHEMICAL", 133, 149], ["imidazole", "SIMPLE_CHEMICAL", 41, 50], ["imidazole", "SIMPLE_CHEMICAL", 86, 95], ["imidazole", "SIMPLE_CHEMICAL", 120, 129], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 133, 156], ["Protein binding", "PROBLEM", 0, 15], ["20 mM imidazole", "TREATMENT", 35, 50], ["elution", "TREATMENT", 100, 107], ["500 mM imidazole in sodium phosphate buffer", "TREATMENT", 113, 156]]], ["Affinity purification was followed by ion exchange chromatography (Resource S; GE Healthcare) for MDO2.", [["Affinity purification", "TREATMENT", 0, 21], ["ion exchange chromatography", "TREATMENT", 38, 65], ["MDO2", "PROBLEM", 98, 102]]], ["The ion exchange chromatography was run in 20 mM Hepes and 100 mM NaCl, and the proteins were eluted with a NaCl gradient from 100 mM to 500 mM (1 ml/min for 15 min).", [["NaCl", "CHEMICAL", 66, 70], ["NaCl", "CHEMICAL", 108, 112], ["NaCl", "CHEMICAL", 66, 70], ["NaCl", "CHEMICAL", 108, 112], ["The ion exchange chromatography", "TEST", 0, 31], ["20 mM Hepes", "TREATMENT", 43, 54], ["100 mM NaCl", "TREATMENT", 59, 70], ["the proteins", "TEST", 76, 88], ["a NaCl gradient", "TEST", 106, 121]]], ["The proteins were stored in a protein storage buffer containing 25 mM Hepes (pH 8.0), 250 mM NaCl, 1 mM dithiothreitol (DTT), and 20% glycerol at \u221270\u00b0C. SARS-CoV macro protein was kindly provided by Dr. Bruno Canard (CNRS, Marseille, France).", [["NaCl", "CHEMICAL", 93, 97], ["dithiothreitol", "CHEMICAL", 104, 118], ["DTT", "CHEMICAL", 120, 123], ["glycerol", "CHEMICAL", 134, 142], ["SARS", "DISEASE", 153, 157], ["NaCl", "CHEMICAL", 93, 97], ["dithiothreitol", "CHEMICAL", 104, 118], ["DTT", "CHEMICAL", 120, 123], ["glycerol", "CHEMICAL", 134, 142], ["dithiothreitol", "SIMPLE_CHEMICAL", 104, 118], ["DTT", "SIMPLE_CHEMICAL", 120, 123], ["glycerol", "SIMPLE_CHEMICAL", 134, 142], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 153, 161], ["SARS-CoV macro protein", "PROTEIN", 153, 175], ["SARS-CoV", "SPECIES", 153, 161], ["a protein storage buffer", "TREATMENT", 28, 52], ["pH", "TEST", 77, 79], ["250 mM NaCl", "TREATMENT", 86, 97], ["1 mM dithiothreitol (DTT", "TREATMENT", 99, 123], ["20% glycerol", "TREATMENT", 130, 142], ["CoV macro protein", "TEST", 158, 175]]], ["30 Human macro protein encoding sequences were also cloned to vectors for expression in mammalian cell lines.", [["cell lines", "ANATOMY", 98, 108], ["Human", "ORGANISM", 3, 8], ["mammalian cell lines", "CELL", 88, 108], ["Human macro protein encoding sequences", "DNA", 3, 41], ["mammalian cell lines", "CELL_LINE", 88, 108], ["Human", "SPECIES", 3, 8], ["Human macro protein encoding sequences", "TREATMENT", 3, 41], ["mammalian cell lines", "TREATMENT", 88, 108], ["mammalian cell lines", "OBSERVATION", 88, 108]]], ["Two constructs, encoding either the full-length protein or a truncated derivative (macro domain with some flanking amino acids), were made for each protein.", [["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 115, 126], ["amino acids", "AMINO_ACID", 115, 126], ["full-length protein", "PROTEIN", 36, 55], ["truncated derivative", "PROTEIN", 61, 81], ["macro domain", "PROTEIN", 83, 95], ["flanking amino acids", "PROTEIN", 106, 126], ["the full-length protein", "TREATMENT", 32, 55], ["a truncated derivative (macro domain", "TREATMENT", 59, 95], ["some flanking amino acids", "TREATMENT", 101, 126]]], ["The MDO1 gene was cloned to pEGFP-N1 (EcoRI-AgeI; Clonetech) and pcDNA4/TO (EcoRI-XbaI; Invitrogen) to create a C-terminally myc-tagged (EQKLISEEDL) variant.", [["C", "CHEMICAL", 112, 113], ["MDO1", "GENE_OR_GENE_PRODUCT", 4, 8], ["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 28, 36], ["EcoRI-AgeI", "GENE_OR_GENE_PRODUCT", 38, 48], ["pcDNA4", "GENE_OR_GENE_PRODUCT", 65, 71], ["EcoRI-XbaI", "GENE_OR_GENE_PRODUCT", 76, 86], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 88, 98], ["EQKLISEEDL", "GENE_OR_GENE_PRODUCT", 137, 147], ["MDO1 gene", "DNA", 4, 13], ["pEGFP", "DNA", 28, 33], ["N1", "DNA", 34, 36], ["EcoRI", "DNA", 38, 43], ["AgeI", "DNA", 44, 48], ["Clonetech", "DNA", 50, 59], ["pcDNA4", "DNA", 65, 71], ["TO", "DNA", 72, 74], ["EcoRI", "DNA", 76, 81], ["XbaI", "DNA", 82, 86], ["C-terminally myc-tagged (EQKLISEEDL) variant", "PROTEIN", 112, 156], ["The MDO1 gene", "TREATMENT", 0, 13], ["pEGFP", "TEST", 28, 33], ["EcoRI", "TEST", 38, 43], ["EcoRI-XbaI", "TREATMENT", 76, 86], ["Invitrogen", "TREATMENT", 88, 98], ["a C-terminally myc-tagged (EQKLISEEDL) variant", "PROBLEM", 110, 156]]], ["Two different constructs were made for both vectors to express either the full-length (325 aa) protein or a 243-aa \"macro core unit\" (aa 83-325).", [["325 aa) protein", "PROTEIN", 87, 102], ["243-aa \"macro core unit", "DNA", 108, 131], ["Two different constructs", "TREATMENT", 0, 24]]], ["Corresponding constructs were made for GDAP2 and MDO2 (encoding aa 1-239 or aa 1-496, and aa 1-243 or aa 1-425, respectively) in pEGFP-N1 (MDO2: HindIII-SacII; GDAP2: SacI-SacII) and pcDNA4/ TO (GDAP2: EcoRI-XbaI).Enzyme assaysADPR-1\u2033P was produced from ADP-ribose-1\u20332\u2033 cyclic phosphate by cyclic phosphodiesterase (reagents were kindly provided by Dr. Witold Filipowicz, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland), and ADPR-1\u2033P hydrolysis activity of the proteins was detected essentially as previously described.", [["ADP", "CHEMICAL", 254, 257], ["cyclic phosphate", "CHEMICAL", 270, 286], ["cyclic phosphodiesterase", "CHEMICAL", 290, 314], ["assaysADPR-1\u2033P", "CHEMICAL", 221, 235], ["ADP-ribose-1\u20332\u2033 cyclic phosphate", "CHEMICAL", 254, 286], ["ADPR-1\u2033P", "CHEMICAL", 451, 459], ["GDAP2", "GENE_OR_GENE_PRODUCT", 39, 44], ["MDO2", "GENE_OR_GENE_PRODUCT", 49, 53], ["aa 1-239", "GENE_OR_GENE_PRODUCT", 64, 72], ["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 129, 137], ["HindIII-SacII", "GENE_OR_GENE_PRODUCT", 145, 158], ["GDAP2", "GENE_OR_GENE_PRODUCT", 160, 165], ["SacI-SacII", "GENE_OR_GENE_PRODUCT", 167, 177], ["pcDNA4", "GENE_OR_GENE_PRODUCT", 183, 189], ["EcoRI-XbaI", "GENE_OR_GENE_PRODUCT", 202, 212], ["ADP-ribose-1\u20332\u2033 cyclic phosphate", "SIMPLE_CHEMICAL", 254, 286], ["cyclic phosphodiesterase", "SIMPLE_CHEMICAL", 290, 314], ["ADPR-1", "GENE_OR_GENE_PRODUCT", 451, 457], ["GDAP2", "PROTEIN", 39, 44], ["MDO2", "PROTEIN", 49, 53], ["pEGFP", "DNA", 129, 134], ["N1", "DNA", 135, 137], ["SacII", "DNA", 153, 158], ["GDAP2", "DNA", 160, 165], ["SacI", "DNA", 167, 171], ["SacII", "DNA", 172, 177], ["pcDNA4", "DNA", 183, 189], ["TO", "DNA", 191, 193], ["GDAP2", "DNA", 195, 200], ["EcoRI", "DNA", 202, 207], ["XbaI", "DNA", 208, 212], ["Enzyme assaysADPR-1\u2033P", "DNA", 214, 235], ["GDAP2", "TEST", 39, 44], ["aa", "TEST", 76, 78], ["aa", "TEST", 90, 92], ["aa", "TEST", 102, 104], ["pEGFP", "TEST", 129, 134], ["HindIII", "TEST", 145, 152], ["SacII", "TEST", 153, 158], ["SacI", "TEST", 167, 171], ["Enzyme assaysADPR", "TEST", 214, 231], ["ADP", "TEST", 254, 257], ["ribose", "TEST", 258, 264], ["cyclic phosphate", "TREATMENT", 270, 286], ["cyclic phosphodiesterase", "TREATMENT", 290, 314], ["ADPR", "TREATMENT", 451, 455], ["the proteins", "TREATMENT", 483, 495]]], ["6 The proteins (15 \u03bcM) were incubated with 2.3 mM ADPR-1\u2033P [stored in 50 mM Tris (pH 7.0) and 0.1% Triton X-100] in the reaction mixture at pH 6.0 (1:1:1, protein storage buffer, ADPR-1\u2033P buffer, and 60 mM 4-morpholineethanesulfonic acid, pH 5.0) at 28\u00b0C for 1 h or 2 h.", [["Triton X-100", "CHEMICAL", 99, 111], ["4-morpholineethanesulfonic acid", "CHEMICAL", 206, 237], ["ADPR-1\u2033P", "CHEMICAL", 50, 58], ["Tris", "CHEMICAL", 76, 80], ["4-morpholineethanesulfonic acid", "CHEMICAL", 206, 237], ["ADPR-1\u2033P", "SIMPLE_CHEMICAL", 50, 58], ["Triton X-100", "SIMPLE_CHEMICAL", 99, 111], ["4-morpholineethanesulfonic acid", "SIMPLE_CHEMICAL", 206, 237], ["The proteins", "TEST", 2, 14], ["ADPR", "TEST", 50, 54], ["pH", "TEST", 82, 84], ["pH", "TEST", 140, 142], ["protein storage buffer", "TREATMENT", 155, 177], ["ADPR", "TEST", 179, 183], ["morpholineethanesulfonic acid", "TREATMENT", 208, 237], ["pH", "TEST", 239, 241]]], ["The longer incubation time was used for GDAP2 and in studies of mutants of the less active SFV nsP3.", [["GDAP2", "GENE_OR_GENE_PRODUCT", 40, 45], ["SFV", "ORGANISM", 91, 94], ["nsP3", "GENE_OR_GENE_PRODUCT", 95, 99], ["GDAP2", "PROTEIN", 40, 45], ["SFV nsP3", "PROTEIN", 91, 99], ["SFV", "SPECIES", 91, 94], ["The longer incubation time", "TREATMENT", 0, 26], ["GDAP2", "TREATMENT", 40, 45], ["the less active SFV nsP3", "PROBLEM", 75, 99], ["SFV nsP3", "OBSERVATION", 91, 99]]], ["The produced ADPribose was separated from the substrate by TLC on PEI-F cellulose plates in 0.15 M NaCl and 0.15 M sodium formate (pH 3.0), and detected under UV illumination.", [["ADPribose", "CHEMICAL", 13, 22], ["PEI-F cellulose", "CHEMICAL", 66, 81], ["NaCl", "CHEMICAL", 99, 103], ["sodium formate", "CHEMICAL", 115, 129], ["ADPribose", "CHEMICAL", 13, 22], ["PEI", "CHEMICAL", 66, 69], ["NaCl", "CHEMICAL", 99, 103], ["sodium formate", "CHEMICAL", 115, 129], ["ADPribose", "SIMPLE_CHEMICAL", 13, 22], ["PEI-F cellulose", "SIMPLE_CHEMICAL", 66, 81], ["sodium formate", "SIMPLE_CHEMICAL", 115, 129], ["PEI-F cellulose plates", "TREATMENT", 66, 88], ["NaCl", "TREATMENT", 99, 103], ["sodium formate", "TEST", 115, 129], ["pH", "TEST", 131, 133], ["UV illumination", "OBSERVATION", 159, 174]]], ["To determine the mass of the reaction product, 6 \u03bcl of the reaction mixture was run on reverse-phase HPLC with an RP-18 column (2.1 mm \u00d7 100 mm, Spherisorb C18, 5 \u03bcm, 120 \u00c5) over a linear gradient of 50 min at 180 \u03bcl/min [buffer 1: 0.2 M triethyl-ammoniumbicarbonate (pH 7); buffer 2: 50% acetonitrile].", [["triethyl-ammoniumbicarbonate", "CHEMICAL", 238, 266], ["acetonitrile", "CHEMICAL", 289, 301], ["triethyl-ammoniumbicarbonate", "CHEMICAL", 238, 266], ["acetonitrile", "CHEMICAL", 289, 301], ["triethyl-ammoniumbicarbonate", "SIMPLE_CHEMICAL", 238, 266], ["acetonitrile", "SIMPLE_CHEMICAL", 289, 301], ["the reaction mixture", "PROBLEM", 55, 75], ["HPLC", "TEST", 101, 105], ["an RP", "TEST", 111, 116], ["Spherisorb", "TEST", 145, 155], ["C18", "TEST", 156, 159], ["a linear gradient", "TEST", 179, 196], ["triethyl-ammoniumbicarbonate (pH", "TREATMENT", 238, 270], ["mass", "OBSERVATION", 17, 21]]], ["The peak fraction was studied with an Ultraflex TOF/TOF mass spectrometer (Bruker-Daltonik GmbH, Bremen, Germany) using alpha-cyano-4hydroxycinnamic acid matrix in linear negative mode.Enzyme assaysPARG activity was tested by incubating 140 pmol of macro domain or HeLa cell nuclear extract with 0.6 pmol (calculated as NAD + equivalents) of [ 32 P]poly(ADPribose) in 5 \u03bcl of glycohydrolase buffer [50 mM NaPO 4 (pH 7.4), 50 mM KCl, and 10 mM \u03b2-mercaptoethanol] for 20 min at 37\u00b0C. The reaction was stopped by adding 0.5 \u03bcl of 1% SDS, and products were analyzed on PEI-TLC with 0.3 M LiCl and 0.9 M acetic acid.", [["HeLa cell nuclear extract", "ANATOMY", 265, 290], ["alpha-cyano-4hydroxycinnamic acid", "CHEMICAL", 120, 153], ["NAD", "CHEMICAL", 320, 323], ["[ 32 P]poly", "CHEMICAL", 342, 353], ["ADPribose", "CHEMICAL", 354, 363], ["KCl", "CHEMICAL", 428, 431], ["\u03b2-mercaptoethanol", "CHEMICAL", 443, 460], ["PEI-TLC", "CHEMICAL", 565, 572], ["LiCl", "CHEMICAL", 584, 588], ["acetic acid", "CHEMICAL", 599, 610], ["alpha-cyano-4hydroxycinnamic acid", "CHEMICAL", 120, 153], ["NAD", "CHEMICAL", 320, 323], ["[ 32 P]poly(ADPribose)", "CHEMICAL", 342, 364], ["NaPO 4", "CHEMICAL", 405, 411], ["KCl", "CHEMICAL", 428, 431], ["\u03b2-mercaptoethanol", "CHEMICAL", 443, 460], ["SDS", "CHEMICAL", 530, 533], ["PEI", "CHEMICAL", 565, 568], ["LiCl", "CHEMICAL", 584, 588], ["acetic acid", "CHEMICAL", 599, 610], ["alpha-cyano-4hydroxycinnamic acid", "SIMPLE_CHEMICAL", 120, 153], ["Enzyme assaysPARG", "GENE_OR_GENE_PRODUCT", 185, 202], ["HeLa cell", "CELL", 265, 274], ["NAD +", "SIMPLE_CHEMICAL", 320, 325], ["[ 32 P]poly", "SIMPLE_CHEMICAL", 342, 353], ["ADPribose", "SIMPLE_CHEMICAL", 354, 363], ["glycohydrolase", "SIMPLE_CHEMICAL", 376, 390], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 443, 460], ["PEI", "SIMPLE_CHEMICAL", 565, 568], ["LiCl", "SIMPLE_CHEMICAL", 584, 588], ["0.9 M acetic acid", "SIMPLE_CHEMICAL", 593, 610], ["glycohydrolase", "PROTEIN", 376, 390], ["The peak fraction", "TEST", 0, 17], ["alpha-cyano", "TREATMENT", 120, 131], ["4hydroxycinnamic acid matrix", "TREATMENT", 132, 160], ["Enzyme assaysPARG activity", "TEST", 185, 211], ["macro domain", "TREATMENT", 249, 261], ["HeLa cell nuclear extract", "TREATMENT", 265, 290], ["NAD", "TEST", 320, 323], ["poly(ADPribose)", "TREATMENT", 349, 364], ["glycohydrolase buffer", "TREATMENT", 376, 397], ["50 mM NaPO", "TREATMENT", 399, 409], ["pH", "TEST", 413, 415], ["50 mM KCl", "TREATMENT", 422, 431], ["The reaction", "PROBLEM", 482, 494], ["1% SDS", "TREATMENT", 527, 533], ["PEI-TLC", "TREATMENT", 565, 572], ["0.3 M LiCl", "TREATMENT", 578, 588], ["0.9 M acetic acid", "TREATMENT", 593, 610], ["peak fraction", "OBSERVATION", 4, 17]]], ["The cleaved ADP-ribose was detected with BAS-1500 PhosphorImager (Fujifilm).ADP-ribose bindingIsothermal titration calorimetry binding assays were carried out at 30\u00b0C using a VP-ITC instrument (Microcal).", [["ADP-ribose", "CHEMICAL", 12, 22], ["ADP", "CHEMICAL", 76, 79], ["ribose", "CHEMICAL", 80, 86], ["ADP", "CHEMICAL", 12, 15], ["ribose", "CHEMICAL", 16, 22], ["ADP", "CHEMICAL", 76, 79], ["ribose", "CHEMICAL", 80, 86], ["ADP-ribose", "SIMPLE_CHEMICAL", 12, 22], ["ADP", "SIMPLE_CHEMICAL", 76, 79], ["The cleaved ADP-ribose", "TREATMENT", 0, 22], ["BAS", "TEST", 41, 44], ["ADP", "TEST", 76, 79], ["ribose binding", "TREATMENT", 80, 94], ["Isothermal titration calorimetry binding assays", "TEST", 94, 141], ["a VP-ITC instrument", "TREATMENT", 173, 192]]], ["Binding reactions were performed in 25 mM Hepes (pH 7.0) and 100 mM NaCl, using 25-45 \u03bcM protein and 350-500 \u03bcM ADP-ribose (Sigma) as the injected ligand.", [["NaCl", "CHEMICAL", 68, 72], ["ADP-ribose", "CHEMICAL", 112, 122], ["NaCl", "CHEMICAL", 68, 72], ["ADP", "CHEMICAL", 112, 115], ["ribose", "CHEMICAL", 116, 122], ["ADP-ribose", "SIMPLE_CHEMICAL", 112, 122], ["Sigma", "SIMPLE_CHEMICAL", 124, 129], ["Binding reactions", "PROBLEM", 0, 17], ["Hepes", "TEST", 42, 47], ["pH", "TEST", 49, 51], ["NaCl", "TEST", 68, 72], ["ADP-ribose (Sigma)", "TREATMENT", 112, 130]]], ["The binding assays were also performed in a stabilizing high-salt buffer of 25 mM Hepes (pH 7.0) and 500 mM NaCl, with SFV nsP3, GDAP2, and MDO1 as reference.", [["NaCl", "CHEMICAL", 108, 112], ["NaCl", "CHEMICAL", 108, 112], ["MDO1", "CHEMICAL", 140, 144], ["SFV", "ORGANISM", 119, 122], ["nsP3", "GENE_OR_GENE_PRODUCT", 123, 127], ["GDAP2", "GENE_OR_GENE_PRODUCT", 129, 134], ["MDO1", "SIMPLE_CHEMICAL", 140, 144], ["nsP3", "PROTEIN", 123, 127], ["GDAP2", "PROTEIN", 129, 134], ["MDO1", "PROTEIN", 140, 144], ["SFV", "SPECIES", 119, 122], ["The binding assays", "TEST", 0, 18], ["pH", "TEST", 89, 91], ["NaCl", "TEST", 108, 112], ["SFV nsP3", "TREATMENT", 119, 127], ["GDAP2", "TEST", 129, 134]]], ["Data analysis was conducted using Origin software (OriginLab).Poly(ADP-ribose) synthesisPoly(ADP-ribose) was synthesized by auto-ADP-ribosylation of PARP-1 as previously described.", [["Poly(ADP-ribose", "CHEMICAL", 62, 77], ["ADP-ribose", "CHEMICAL", 93, 103], ["Poly(ADP-ribose)", "CHEMICAL", 62, 78], ["ADP-ribose)", "CHEMICAL", 93, 104], ["auto-ADP", "CHEMICAL", 124, 132], ["Poly(ADP-ribose) synthesisPoly", "SIMPLE_CHEMICAL", 62, 92], ["ADP-ribose", "SIMPLE_CHEMICAL", 93, 103], ["auto-ADP", "SIMPLE_CHEMICAL", 124, 132], ["PARP-1", "GENE_OR_GENE_PRODUCT", 149, 155], ["auto-ADP", "PROTEIN", 124, 132], ["PARP-1", "PROTEIN", 149, 155], ["Data analysis", "TEST", 0, 13], ["Poly(ADP-ribose) synthesisPoly(ADP-ribose)", "TREATMENT", 62, 104], ["PARP", "PROBLEM", 149, 153]]], ["48 A 100-\u03bcl reaction mixture containing 500 ng of PARP-1 (Alexis), 2.5 \u03bcg of activated DNA (Sigma), and 150 \u03bcM NAD + , including 7.5 \u03bcCi of [ 32 P]NAD + (GE Healthcare), was incubated in 25 mM Tris (pH 8.0), 10 mM MgCl 2 , 0.5 mM DTT, and 100 mM NaCl.", [["NAD", "CHEMICAL", 111, 114], ["NAD", "CHEMICAL", 147, 150], ["MgCl", "CHEMICAL", 214, 218], ["DTT", "CHEMICAL", 230, 233], ["NaCl", "CHEMICAL", 246, 250], ["NAD +", "CHEMICAL", 111, 116], ["[ 32 P]NAD", "CHEMICAL", 140, 150], ["Tris", "CHEMICAL", 193, 197], ["MgCl 2", "CHEMICAL", 214, 220], ["DTT", "CHEMICAL", 230, 233], ["NaCl", "CHEMICAL", 246, 250], ["PARP-1", "GENE_OR_GENE_PRODUCT", 50, 56], ["Alexis", "SIMPLE_CHEMICAL", 58, 64], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["NAD +", "SIMPLE_CHEMICAL", 111, 116], ["[ 32 P]NAD +", "SIMPLE_CHEMICAL", 140, 152], ["DTT", "SIMPLE_CHEMICAL", 230, 233], ["PARP", "PROTEIN", 50, 54], ["\u03bcl reaction mixture", "TREATMENT", 9, 28], ["PARP", "TEST", 50, 54], ["NAD", "PROBLEM", 111, 114], ["Ci", "TEST", 134, 136], ["P", "TEST", 145, 146], ["NAD", "TEST", 147, 150], ["Tris", "TEST", 193, 197], ["pH", "TEST", 199, 201], ["100 mM NaCl", "TREATMENT", 239, 250]]], ["After 1 h at 24\u00b0C, the reaction mixture was used directly in a binding assay.", [["the reaction mixture", "TREATMENT", 19, 39], ["a binding assay", "TEST", 61, 76]]], ["Alternatively, to prepare purified poly(ADP-ribose), the reaction mixture was treated with proteinase K, and the proteinfree polymer was collected by phenol-chloroform extraction as previously described.", [["poly(ADP-ribose", "CHEMICAL", 35, 50], ["K", "CHEMICAL", 102, 103], ["phenol-chloroform", "CHEMICAL", 150, 167], ["poly(ADP-ribose)", "CHEMICAL", 35, 51], ["phenol", "CHEMICAL", 150, 156], ["chloroform", "CHEMICAL", 157, 167], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 35, 50], ["proteinase K", "GENE_OR_GENE_PRODUCT", 91, 103], ["proteinfree polymer", "SIMPLE_CHEMICAL", 113, 132], ["phenol", "SIMPLE_CHEMICAL", 150, 156], ["chloroform", "SIMPLE_CHEMICAL", 157, 167], ["proteinase K", "PROTEIN", 91, 103], ["purified poly(ADP-ribose", "TREATMENT", 26, 50], ["the reaction mixture", "PROBLEM", 53, 73], ["proteinase K", "TREATMENT", 91, 103], ["the proteinfree polymer", "TREATMENT", 109, 132], ["phenol-chloroform extraction", "TREATMENT", 150, 178]]], ["5 Poly(ADP-ribose) and poly(A) binding assay Poly(ADP-ribose) binding assay was performed essentially as previously described, 49 using either the polymer bound to PARP-1 or a protein-free preparation.", [["5 Poly(ADP-ribose", "CHEMICAL", 0, 17], ["poly(A", "CHEMICAL", 23, 29], ["Poly(ADP-ribose", "CHEMICAL", 45, 60], ["Poly(ADP-ribose)", "CHEMICAL", 2, 18], ["poly(A)", "CHEMICAL", 23, 30], ["Poly(ADP-ribose)", "CHEMICAL", 45, 61], ["5", "SIMPLE_CHEMICAL", 0, 1], ["Poly(ADP-ribose", "SIMPLE_CHEMICAL", 2, 17], ["poly(A)", "SIMPLE_CHEMICAL", 23, 30], ["ADP", "SIMPLE_CHEMICAL", 50, 53], ["PARP-1", "GENE_OR_GENE_PRODUCT", 164, 170], ["PARP-1", "PROTEIN", 164, 170], ["5 Poly(ADP-ribose", "TREATMENT", 0, 17], ["poly(A) binding assay Poly(ADP-ribose) binding assay", "TEST", 23, 75], ["PARP", "TEST", 164, 168], ["a protein-free preparation", "TREATMENT", 174, 200]]], ["Proteins (10 pmol, 100 pmol, or 1000 pmol) were blotted onto a nitrocellulose membrane using Minifold II slot blot apparatus (Schleichter and Schuell).", [["membrane", "ANATOMY", 78, 86], ["nitrocellulose", "CHEMICAL", 63, 77], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["Proteins", "TEST", 0, 8], ["a nitrocellulose membrane", "TREATMENT", 61, 86], ["Minifold II slot blot apparatus", "TREATMENT", 93, 124]]], ["The membrane was blocked for 1 h in TBS-T [10 mM Tris (pH 7.4), 150 mM NaCl, and 0.05% Tween] containing 5% nonfat milk powder.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 115, 119], ["NaCl", "CHEMICAL", 71, 75], ["Tris", "CHEMICAL", 49, 53], ["NaCl", "CHEMICAL", 71, 75], ["Tween", "CHEMICAL", 87, 92], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["TBS", "TEST", 36, 39], ["Tris", "TEST", 49, 53], ["pH", "TEST", 55, 57], ["NaCl", "TEST", 71, 75], ["5% nonfat milk powder", "TREATMENT", 105, 126]]], ["Subsequently, the membrane was incubated for 1 h with the poly(ADP-ribose) preparation (100 \u03bcl) diluted in 10 ml of TBS-T.", [["membrane", "ANATOMY", 18, 26], ["poly(ADP-ribose", "CHEMICAL", 58, 73], ["poly(ADP-ribose)", "CHEMICAL", 58, 74], ["membrane", "CELLULAR_COMPONENT", 18, 26], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 58, 73], ["the poly(ADP-ribose) preparation", "TREATMENT", 54, 86]]], ["The membrane was washed as described 5 and autoradiographed after drying.Poly(ADP-ribose) synthesisPoly(A) was labeled with 32 P using [\u03b3-32 P]ATP (GE Healthcare) and T4 polynucleotide kinase (New England Biolaboratories).", [["membrane", "ANATOMY", 4, 12], ["Poly(ADP-ribose", "CHEMICAL", 73, 88], ["ATP", "CHEMICAL", 143, 146], ["Poly(ADP-ribose)", "CHEMICAL", 73, 89], ["[\u03b3-32 P]ATP", "CHEMICAL", 135, 146], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["Poly(ADP-ribose) synthesisPoly", "SIMPLE_CHEMICAL", 73, 103], ["A", "SIMPLE_CHEMICAL", 104, 105], ["[\u03b3-32 P]ATP", "SIMPLE_CHEMICAL", 135, 146], ["T4 polynucleotide kinase", "GENE_OR_GENE_PRODUCT", 167, 191], ["Poly(ADP-ribose) synthesisPoly", "PROTEIN", 73, 103], ["T4 polynucleotide kinase", "PROTEIN", 167, 191], ["Poly(ADP-ribose)", "TREATMENT", 73, 89], ["ATP (GE Healthcare", "TREATMENT", 143, 161], ["T4 polynucleotide kinase", "TEST", 167, 191], ["New England Biolaboratories)", "TREATMENT", 193, 221], ["membrane", "OBSERVATION_MODIFIER", 4, 12]]], ["A 50-\u03bcl reaction mixture contained 4.2 \u03bcg poly(A) (Sigma), 140 nM ATP (corresponding to 24 \u03bcCi), 20 U of T4 polynucleotide kinase, and 4.8% polyethylene glycol 8000 in exchange buffer (0.1 mM spermidine, 5 mM DTT, 18 mM MgCl 2 , 0.1 mM ethylenediaminetetraacetic acid, and 50 mM imidazole-HCl, pH 7.0).", [["ATP", "CHEMICAL", 66, 69], ["polynucleotide", "CHEMICAL", 108, 122], ["polyethylene glycol 8000", "CHEMICAL", 140, 164], ["spermidine", "CHEMICAL", 192, 202], ["ethylenediaminetetraacetic acid", "CHEMICAL", 236, 267], ["imidazole-HCl", "CHEMICAL", 279, 292], ["poly(A)", "CHEMICAL", 42, 49], ["ATP", "CHEMICAL", 66, 69], ["polyethylene glycol", "CHEMICAL", 140, 159], ["spermidine", "CHEMICAL", 192, 202], ["DTT", "CHEMICAL", 209, 212], ["MgCl 2", "CHEMICAL", 220, 226], ["ethylenediaminetetraacetic acid", "CHEMICAL", 236, 267], ["imidazole", "CHEMICAL", 279, 288], ["HCl", "CHEMICAL", 289, 292], ["poly(A)", "SIMPLE_CHEMICAL", 42, 49], ["ATP", "SIMPLE_CHEMICAL", 66, 69], ["polyethylene glycol 8000", "SIMPLE_CHEMICAL", 140, 164], ["spermidine", "SIMPLE_CHEMICAL", 192, 202], ["DTT", "SIMPLE_CHEMICAL", 209, 212], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 236, 267], ["imidazole-HCl", "SIMPLE_CHEMICAL", 279, 292], ["T4 polynucleotide kinase", "PROTEIN", 105, 129], ["\u03bcl reaction mixture", "TEST", 5, 24], ["nM ATP", "TEST", 63, 69], ["\u03bcCi", "TEST", 91, 94], ["T4 polynucleotide kinase", "TEST", 105, 129], ["% polyethylene glycol", "TREATMENT", 138, 159], ["exchange buffer", "TREATMENT", 168, 183], ["spermidine", "TEST", 192, 202], ["DTT", "TEST", 209, 212], ["MgCl", "TEST", 220, 224], ["0.1 mM ethylenediaminetetraacetic acid", "TREATMENT", 229, 267], ["50 mM imidazole", "TREATMENT", 273, 288], ["pH", "TEST", 294, 296]]], ["The mixture was incubated for 45 min at 37\u00b0C, and then the reaction was stopped by adding 2 \u03bcl of 0.5 M ethylenediaminetetraacetic acid and incubating for 10 min at 70\u00b0C. Labeled poly(A) was purified with a Sephadex-25 column (PD-10; GE Healthcare), and binding assay was performed as described above for poly(ADP-ribose).Poly(ADP-ribose) synthesisFor competition binding assays, the amount of poly (ADP-ribose) in the protein-free purified preparation was calculated as NAD + equivalents, based on the specific activity of [ 32 P]NAD + and on the amount of 32 P in the product, as measured by liquid scintillation.", [["ethylenediaminetetraacetic acid", "CHEMICAL", 104, 135], ["poly(A", "CHEMICAL", 179, 185], ["poly(ADP-ribose", "CHEMICAL", 305, 320], ["Poly(ADP-ribose", "CHEMICAL", 322, 337], ["poly (ADP-ribose", "CHEMICAL", 394, 410], ["NAD", "CHEMICAL", 471, 474], ["NAD", "CHEMICAL", 531, 534], ["ethylenediaminetetraacetic acid", "CHEMICAL", 104, 135], ["poly(A)", "CHEMICAL", 179, 186], ["poly(ADP-ribose)", "CHEMICAL", 305, 321], ["Poly(ADP-ribose)", "CHEMICAL", 322, 338], ["poly (ADP-ribose)", "CHEMICAL", 394, 411], ["NAD +", "CHEMICAL", 471, 476], ["[ 32 P]NAD +", "CHEMICAL", 524, 536], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 104, 135], ["poly(A", "SIMPLE_CHEMICAL", 179, 185], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 305, 320], ["Poly(ADP-ribose", "SIMPLE_CHEMICAL", 322, 337], ["poly (ADP-ribose", "SIMPLE_CHEMICAL", 394, 410], ["NAD +", "SIMPLE_CHEMICAL", 471, 476], ["[ 32 P]NAD +", "SIMPLE_CHEMICAL", 524, 536], ["0.5 M ethylenediaminetetraacetic acid", "TREATMENT", 98, 135], ["a Sephadex-25 column (PD", "TREATMENT", 205, 229], ["binding assay", "TEST", 254, 267], ["poly(ADP-ribose)", "TREATMENT", 305, 321], ["Poly(ADP-ribose) synthesis", "TREATMENT", 322, 348], ["competition binding assays", "TEST", 352, 378], ["poly (ADP-ribose)", "TREATMENT", 394, 411], ["NAD", "PROBLEM", 531, 534]]], ["The proteincontaining membrane was incubated with 1500 pmol NAD + equivalents of poly(ADP-ribose) and 580 nmol of poly(A) in 10 ml of TBS-T for 1 h at room temperature, followed by washing, as before.", [["proteincontaining membrane", "ANATOMY", 4, 30], ["NAD", "CHEMICAL", 60, 63], ["poly(ADP-ribose", "CHEMICAL", 81, 96], ["poly(A", "CHEMICAL", 114, 120], ["NAD", "CHEMICAL", 60, 63], ["poly(ADP-ribose)", "CHEMICAL", 81, 97], ["poly(A)", "CHEMICAL", 114, 121], ["membrane", "CELLULAR_COMPONENT", 22, 30], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 81, 96], ["poly(A", "SIMPLE_CHEMICAL", 114, 120], ["NAD", "PROBLEM", 60, 63], ["poly(ADP-ribose)", "TREATMENT", 81, 97]]], ["For competition with ADP-ribose monomer, the membrane was preincubated in 10 ml of TBS-T with 3750 nmol of ADP-ribose for 10 min, then 1500 pmol NAD equivalents of purified and labeled poly(ADP-ribose) was added.", [["membrane", "ANATOMY", 45, 53], ["ADP-ribose", "CHEMICAL", 21, 31], ["ADP-ribose", "CHEMICAL", 107, 117], ["NAD", "CHEMICAL", 145, 148], ["poly(ADP-ribose", "CHEMICAL", 185, 200], ["ADP", "CHEMICAL", 21, 24], ["ribose", "CHEMICAL", 25, 31], ["ADP", "CHEMICAL", 107, 110], ["ribose", "CHEMICAL", 111, 117], ["NAD", "CHEMICAL", 145, 148], ["poly(ADP-ribose)", "CHEMICAL", 185, 201], ["ADP-ribose monomer", "SIMPLE_CHEMICAL", 21, 39], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["ADP-ribose", "SIMPLE_CHEMICAL", 107, 117], ["NAD", "SIMPLE_CHEMICAL", 145, 148], ["poly(ADP-ribose", "SIMPLE_CHEMICAL", 185, 200], ["ADP-ribose monomer", "TREATMENT", 21, 39], ["TBS", "TEST", 83, 86], ["ADP-ribose", "TREATMENT", 107, 117], ["labeled poly(ADP-ribose)", "TREATMENT", 177, 201], ["ribose monomer", "OBSERVATION", 25, 39]]], ["The mixture was incubated for 1 h, and the membrane was washed.Prediction of MDO1 structureStructure prediction for MDO1 was performed using the SARS-CoV macro domain as model (Protein Data Bank code FAV2).", [["membrane", "ANATOMY", 43, 51], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["MDO1", "GENE_OR_GENE_PRODUCT", 77, 81], ["MDO1", "GENE_OR_GENE_PRODUCT", 116, 120], ["MDO1", "PROTEIN", 77, 81], ["MDO1", "PROTEIN", 116, 120], ["SARS-CoV macro domain", "PROTEIN", 145, 166], ["Protein Data Bank code FAV2", "PROTEIN", 177, 204], ["SARS-CoV", "SPECIES", 145, 153], ["MDO1", "TEST", 116, 120], ["the SARS", "TEST", 141, 149]]], ["FAV2 was chosen for the model because its structure includes an ADP-ribose ligand.", [["ADP", "CHEMICAL", 64, 67], ["ADP", "CHEMICAL", 64, 67], ["ribose", "CHEMICAL", 68, 74], ["FAV2", "SIMPLE_CHEMICAL", 0, 4], ["ADP", "SIMPLE_CHEMICAL", 64, 67], ["FAV2", "PROTEIN", 0, 4], ["an ADP-ribose ligand", "TREATMENT", 61, 81], ["ribose ligand", "OBSERVATION", 68, 81]]], ["Alignment of MDO1 with FAV2 was obtained from Phyre \u2020 (E = 6.4 \u00d7 10 \u2212 18 ) and sent to SwissModel \u2021.", [["MDO1", "GENE_OR_GENE_PRODUCT", 13, 17], ["MDO1", "PROTEIN", 13, 17], ["FAV2", "DNA", 23, 27], ["FAV2", "TEST", 23, 27], ["Phyre", "TEST", 46, 51]]], ["The prediction obtained from SwissModel was used as the MDO1 structure model.Protein expression and detection in human cellsFor localization studies, the macro domain expression constructs (in pEGFP-N1 or pcDNA4/TO) were transfected into HeLa cells using Exgen (Fermentas) in accordance with the manufacturer's instructions.", [["cells", "ANATOMY", 119, 124], ["HeLa cells", "ANATOMY", 238, 248], ["human", "ORGANISM", 113, 118], ["cells", "CELL", 119, 124], ["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 193, 201], ["pcDNA4", "GENE_OR_GENE_PRODUCT", 205, 211], ["HeLa cells", "CELL", 238, 248], ["human cells", "CELL_TYPE", 113, 124], ["macro domain expression constructs", "DNA", 154, 188], ["pEGFP", "DNA", 193, 198], ["N1", "DNA", 199, 201], ["pcDNA4", "DNA", 205, 211], ["TO", "DNA", 212, 214], ["HeLa cells", "CELL_LINE", 238, 248], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["The prediction", "TEST", 0, 14], ["Protein expression", "TEST", 77, 95], ["detection in human cells", "PROBLEM", 100, 124], ["localization studies", "TEST", 128, 148], ["the macro domain expression constructs", "PROBLEM", 150, 188], ["pEGFP", "TEST", 193, 198], ["Exgen (Fermentas)", "TREATMENT", 255, 272], ["human cells", "OBSERVATION", 113, 124]]], ["For detection of mitochondria, the mitochondrial localization marker mt-YFP containing a mitochondrial localization signal fused to YFP (construct designed by Dr. A.Protein expression and detection in human cellsMiyawaki, Riken Brain Science Institute, Japan) was cotransfected with the macro domain construct.", [["mitochondria", "ANATOMY", 17, 29], ["mitochondrial", "ANATOMY", 35, 48], ["mitochondrial", "ANATOMY", 89, 102], ["cells", "ANATOMY", 207, 212], ["mitochondria", "CELLULAR_COMPONENT", 17, 29], ["mitochondrial", "CELLULAR_COMPONENT", 35, 48], ["mt-YFP", "GENE_OR_GENE_PRODUCT", 69, 75], ["mitochondrial", "CELLULAR_COMPONENT", 89, 102], ["YFP", "GENE_OR_GENE_PRODUCT", 132, 135], ["A.Protein", "GENE_OR_GENE_PRODUCT", 163, 172], ["human", "ORGANISM", 201, 206], ["cells", "CELL", 207, 212], ["mitochondrial localization marker mt", "PROTEIN", 35, 71], ["YFP", "PROTEIN", 72, 75], ["YFP", "PROTEIN", 132, 135], ["human cells", "CELL_TYPE", 201, 212], ["macro domain construct", "DNA", 287, 309], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206], ["mitochondria", "PROBLEM", 17, 29], ["human cells", "OBSERVATION", 201, 212]]], ["The cells were incubated at 37\u00b0C for 6 h or 18 h, fixed with 4% paraformaldehyde, and stained with an antibody (anti-MDO1, produced in-house against aa 83-325, as earlier described for HEV antibodies) 50 or detected directly by EGFP or YFP fluorescence.", [["cells", "ANATOMY", 4, 9], ["paraformaldehyde", "CHEMICAL", 64, 80], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 64, 80], ["MDO1", "GENE_OR_GENE_PRODUCT", 117, 121], ["HEV", "ORGANISM", 185, 188], ["EGFP", "GENE_OR_GENE_PRODUCT", 228, 232], ["YFP", "GENE_OR_GENE_PRODUCT", 236, 239], ["MDO1", "PROTEIN", 117, 121], ["HEV antibodies", "PROTEIN", 185, 199], ["YFP", "PROTEIN", 236, 239], ["HEV", "SPECIES", 185, 188], ["4% paraformaldehyde", "TREATMENT", 61, 80], ["an antibody", "TEST", 99, 110], ["anti-MDO1", "TEST", 112, 121], ["aa", "TEST", 149, 151], ["HEV antibodies", "TEST", 185, 199], ["YFP fluorescence", "TEST", 236, 252]]], ["In parallel, cells were collected in 1% SDS, and the proteins were separated by SDS-PAGE on 12% gels and detected by Western blot analysis with the appropriate antibodies (anti-MDO1 or anti-EGFP; kindly provided by Dr. Andres Merits, University of Tartu, Estonia) as described previously.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["MDO1", "GENE_OR_GENE_PRODUCT", 177, 181], ["antibodies", "PROTEIN", 160, 170], ["MDO1", "PROTEIN", 177, 181], ["anti-EGFP", "PROTEIN", 185, 194], ["the proteins", "TEST", 49, 61], ["blot analysis", "TEST", 125, 138], ["anti-MDO1", "TREATMENT", 172, 181], ["anti-EGFP", "TREATMENT", 185, 194]]]], "3369596169d731ab7396e4ba2f5c0d5b7f885be7": [["patients in the United States continue to be managed in coronary care units after primary percutaneous coronary intervention, there is a robust literature regarding the ability to triage STEMI patients safely and efficiently with low-risk features to non-ICU beds.", [["coronary", "ANATOMY", 56, 64], ["percutaneous", "ANATOMY", 90, 102], ["coronary", "ANATOMY", 103, 111], ["STEMI", "DISEASE", 187, 192], ["patients", "ORGANISM", 0, 8], ["coronary", "MULTI-TISSUE_STRUCTURE", 56, 64], ["coronary", "MULTI-TISSUE_STRUCTURE", 103, 111], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 0, 8], ["patients", "SPECIES", 193, 201], ["primary percutaneous coronary intervention", "TREATMENT", 82, 124], ["low-risk features", "PROBLEM", 230, 247], ["coronary", "ANATOMY", 56, 64], ["coronary", "ANATOMY", 103, 111]]], ["We review the various risk scores for STEMI triage and the data supporting their usage.", [["STEMI", "DISEASE", 38, 43], ["STEMI triage", "TEST", 38, 50], ["the data", "TEST", 55, 63]]], ["In summary, these findings support an approach to low-risk STEMI triage that does not come at the expense of quality patient care or outcomes, where up to two-thirds of patients with STEMI may be able to be safely managed without ICUlevel care. infarction, and ischemic time > 4 hr), with a score of 0-3 considered low risk, and a score \u22654 considered high risk, based on 30-day mortality rates, with a strong discriminatory capacity (c statistic: 0.907) (Figure 1) .", [["STEMI", "DISEASE", 59, 64], ["STEMI", "DISEASE", 183, 188], ["infarction", "DISEASE", 245, 255], ["patient", "ORGANISM", 117, 124], ["patients", "ORGANISM", 169, 177], ["patient", "SPECIES", 117, 124], ["patients", "SPECIES", 169, 177], ["STEMI", "TREATMENT", 183, 188], ["ICUlevel care", "TREATMENT", 230, 243], ["infarction", "PROBLEM", 245, 255], ["low risk", "PROBLEM", 315, 323], ["a score", "TEST", 329, 336], ["ischemic", "OBSERVATION_MODIFIER", 261, 269], ["low risk", "OBSERVATION_MODIFIER", 315, 323]]], ["In a validation cohort of 747 patients, 65% of STEMI patients were deemed low risk, with a mortality rate of 0.6% at 30 days.", [["STEMI", "DISEASE", 47, 52], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 53, 61], ["STEMI", "PROBLEM", 47, 52], ["a mortality rate", "TEST", 89, 105]]], ["5| CONTEMPORARY ASSESSMENT OF RISK TRIAGE MODELS FOR STEMIThe feasibility, effectiveness, and safety of utilizing such protocols have also been demonstrated in contemporary STEMI systems.| CONTEMPORARY ASSESSMENT OF RISK TRIAGE MODELS FOR STEMIRecently, a small retrospective study in 228 patients over 2 years (42% of all STEMI patients) reported no adverse effects after 3 days and 0 deaths at 1 year using the Cadillac Risk Score.", [["STEMI", "DISEASE", 173, 178], ["STEMI", "DISEASE", 323, 328], ["deaths", "DISEASE", 386, 392], ["patients", "ORGANISM", 289, 297], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 289, 297], ["patients", "SPECIES", 329, 337], ["such protocols", "TREATMENT", 114, 128], ["a small retrospective study", "TEST", 254, 281], ["small", "OBSERVATION_MODIFIER", 256, 261], ["no", "UNCERTAINTY", 348, 350]]], ["6 We recently reported the results of a larger prospective trial using the Zwolle Risk Score for STEMI patient triage.", [["STEMI", "DISEASE", 97, 102], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["a larger prospective trial", "TREATMENT", 38, 64], ["STEMI patient triage", "TEST", 97, 117]]], ["7 After initially validating the predictive ability of the score in 967 STEMI patients from our own retrospective data (death and major adverse cardiac events rates among low-risk patients of 0.2 and 0.9% at 30 days, respectively), the Zwolle Risk Score was incorporated into the electronic health record (EHR), adding out-of-hospital cardiac arrest as an automatic high-risk feature.| CONTEMPORARY ASSESSMENT OF RISK TRIAGE MODELS FOR STEMIThe EHR risk calculator was then prospectively applied to 549 STEMI patients, 62% (n = 266) of whom were determined to be low risk, with 62% of those (n = 177) treated per protocol, triaged to telemetry rather than CCU admission and targeted for early (<48 hr) hospital discharge.", [["cardiac", "ANATOMY", 144, 151], ["cardiac", "ANATOMY", 335, 342], ["STEMI", "DISEASE", 72, 77], ["death", "DISEASE", 120, 125], ["cardiac arrest", "DISEASE", 335, 349], ["STEMI", "DISEASE", 503, 508], ["patients", "ORGANISM", 78, 86], ["cardiac", "ORGAN", 144, 151], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 509, 517], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 509, 517], ["death", "PROBLEM", 120, 125], ["major adverse cardiac events", "PROBLEM", 130, 158], ["the Zwolle Risk Score", "TEST", 232, 253], ["STEMI", "TEST", 503, 508], ["telemetry", "TEST", 634, 643], ["cardiac", "ANATOMY", 335, 342], ["arrest", "OBSERVATION", 343, 349]]], ["The remainder included 109 low-risk patients triaged to the CCU and 176 high-risk STEMI patients.", [["STEMI", "DISEASE", 82, 87], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 88, 96]]], ["Reasons for low-risk STEMI triaged to the CCU were multifactorial but appeared to be mostly related to procedural complications or the potential for bleeding (2.5% for \"on protocol\" vs. 8.9% \"off protocol,\" p = .018).", [["STEMI", "DISEASE", 21, 26], ["bleeding", "DISEASE", 149, 157], ["low-risk STEMI", "PROBLEM", 12, 26], ["procedural complications", "PROBLEM", 103, 127], ["bleeding", "PROBLEM", 149, 157]]], ["At 30 days, lowrisk patients triaged to telemetry did extremely well, with shorter index hospital length of stay (LOS), markedly lower hospital costs, no inhospital mortality, and only one death at 30 days related to a stroke on admission.", [["death", "DISEASE", 189, 194], ["stroke", "DISEASE", 219, 225], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["telemetry", "TEST", 40, 49], ["markedly lower hospital costs", "PROBLEM", 120, 149], ["inhospital mortality", "PROBLEM", 154, 174], ["a stroke", "PROBLEM", 217, 225], ["no", "UNCERTAINTY", 151, 153], ["stroke", "OBSERVATION", 219, 225]]], ["These findings persisted at 1-year follow-up, with lower long-term mortality among the low-risk, on-protocol cohort (low-risk on-protocol, low-risk off-protocol, high risk: 2.3 vs. 6.4 vs. 17.1%, p < .001) (Figure 1 ).", [["lower long-term mortality", "PROBLEM", 51, 76]]], ["When used in conjunction with physician judgment, integration of the Zwolle Risk Score appropriately identifies STEMI patients who may be cared for in non-ICU settings, freeing these resources for critically ill patients who require ICU-level care.", [["STEMI", "DISEASE", 112, 117], ["critically ill", "DISEASE", 197, 211], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 212, 220], ["ICU-level care", "TREATMENT", 233, 247]]], ["A recent meta-analysis of five randomized clinical trials demonstrated that an early discharge strategy (\u22643 days) in selected low-risk STEMI patients significantly reduced LOS without an adverse effect on mortality or readmission rates.", [["STEMI", "DISEASE", 135, 140], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["A recent meta-analysis", "TEST", 0, 22], ["readmission rates", "TEST", 218, 235]]], ["8| CONCLUSIONWe believe that these findings support an approach to low-risk STEMI triage that does not come at the expense of quality of patient care or outcomes.", [["STEMI", "DISEASE", 76, 81], ["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144]]], ["Furthermore, during the current pandemic, we suggest that programmatic efforts utilizing this approach offer an evidence-based method of addressing the expected surge in the need for ICU beds.", [["this approach", "TREATMENT", 89, 102], ["ICU beds", "TREATMENT", 183, 191]]], ["Finally, we propose that in this time of crisis, it is important for programs and their cardiology leaders to consider supporting a newly developed consortium of institutions to collect prospective data on the impact of the rapid enactment of a standardized protocol for STEMI risk stratification.", [["STEMI", "DISEASE", 271, 276], ["crisis", "PROBLEM", 41, 47], ["prospective data", "TEST", 186, 202], ["a standardized protocol", "TREATMENT", 243, 266], ["STEMI risk stratification", "PROBLEM", 271, 296]]], ["We welcome sites and investigators to join us in this important endeavor.ORCIDJohn J. Lopez https://orcid.org/0000-0002-6727-3623ORCIDSorcha Allen https://orcid.org/0000-0002-7781-4139ORCIDTimothy D. Henry https://orcid.org/0000-0003-1123-0533", [["D. Henry", "SPECIES", 197, 205]]]], "PMC7321405": []}